WO2005123668A1 - Glucagon receptor antagonists, preparation and therapeutic uses - Google Patents

Glucagon receptor antagonists, preparation and therapeutic uses Download PDF

Info

Publication number
WO2005123668A1
WO2005123668A1 PCT/US2005/019901 US2005019901W WO2005123668A1 WO 2005123668 A1 WO2005123668 A1 WO 2005123668A1 US 2005019901 W US2005019901 W US 2005019901W WO 2005123668 A1 WO2005123668 A1 WO 2005123668A1
Authority
WO
WIPO (PCT)
Prior art keywords
benzoylamino
propionic acid
yloxy
biphenyl
butyl
Prior art date
Application number
PCT/US2005/019901
Other languages
French (fr)
Inventor
Scott Eugene Conner
Guoxin Zhu
Jianke Li
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK05757998.9T priority Critical patent/DK1758853T3/en
Priority to DE602005019043T priority patent/DE602005019043D1/en
Priority to EA200700027A priority patent/EA013003B1/en
Priority to PL05757998T priority patent/PL1758853T3/en
Priority to CN2005800194966A priority patent/CN1968921B/en
Priority to CA2569459A priority patent/CA2569459C/en
Priority to RSP-2010/0134A priority patent/RS51202B/en
Priority to US11/570,449 priority patent/US7816557B2/en
Priority to JP2007516542A priority patent/JP5000492B2/en
Priority to MXPA06014426A priority patent/MXPA06014426A/en
Priority to NZ551015A priority patent/NZ551015A/en
Priority to EP05757998A priority patent/EP1758853B1/en
Priority to BRPI0512058-6A priority patent/BRPI0512058A/en
Priority to AT05757998T priority patent/ATE455756T1/en
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Priority to AU2005254950A priority patent/AU2005254950B2/en
Publication of WO2005123668A1 publication Critical patent/WO2005123668A1/en
Priority to IL179599A priority patent/IL179599A/en
Priority to NO20070213A priority patent/NO341028B1/en
Priority to HK07108943.4A priority patent/HK1104174A1/en
Priority to HR20100148T priority patent/HRP20100148T1/en
Priority to US12/868,773 priority patent/US20100324140A1/en
Priority to AU2010246329A priority patent/AU2010246329A1/en
Priority to US13/013,280 priority patent/US8609892B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/65—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • This patent application claims the benefit of United States Provisional Patent Application No. 60/579,362 filed June 14, 2004.
  • This invention relates to compounds that are antagonists or inverse agonists of the glucagon receptor, and to pharmaceutical compositions thereof, and the uses of these compounds and compositions in the treatment of the human or animal body.
  • the present compounds show a high affinity and selective binding for the glucagon receptor, and as such are useful in the treatment of disorders responsive to the modulation of glucagon receptors, such as diabetic and other glucagon related metabolic disorders, and the like.
  • Glucagon is a key hormonal agent that, in cooperation with insulin, mediates homeostatic regulation of the amount of glucose in the blood. Glucagon primarily acts by stimulating certain cells (important among these are liver cells) to release glucose when blood glucose levels fall. The action of glucagon is opposite to that of insulin, which stimulates cells to take up and store glucose whenever blood glucose levels rise. Both glucagon and insulin are peptide hormones. Glucagon is produced in the alpha islet cells of the pancreas and insulin is produced in the beta islet cells. Glucagon exerts its action by binding to and activating its receptor, which is a member of the Glucagon-Secretin branch of the 7-transmembrane G-protein coupled receptor family.
  • the receptor functions by activating the adenylyl cyclase second messenger system resulting in an increase in cAMP levels.
  • the glucagon receptor or naturally occu ⁇ ing variants of the receptor, may possess intrinsic constitutive activity, invitro, as well as in vivo (i.e. activity in the absence of an agonist). Compounds acting as inverse agonists can inhibit this activity.
  • Diabetes mellitus is a common disorder of glucose metabolism. The disease is characterized by hyperglycemia and may be classified as type 1 diabetes, the insulin- dependent form, or type 2 diabetes, which is non-insulin-dependent in character. Subjects with type 1 diabetes are hyperglycemic and hypoinsulinemic, and the conventional treatment for this form of the disease is to provide insulin.
  • glucagon suppression or an action that antagonizes glucagon could be a useful adjunct to conventional treatment of hyperglycemia in diabetic patients.
  • glucagon can be suppressed by providing an antagonist or an inverse agonist, i.e. substances that inhibit or prevent constituitive, or glucagon-induced, glucagon receptor mediated responses.
  • an antagonist or an inverse agonist i.e. substances that inhibit or prevent constituitive, or glucagon-induced, glucagon receptor mediated responses.
  • Several publications disclose peptides that are stated to act as glucagon antagonists. Peptide antagonists of peptide hormones are often potent; however they are generally known not to be orally available because of degradation by physiological enzymes and poor distribution in vivo. Therefore, orally available non-peptide antagonists of peptide hormones are generally prefened.
  • the present invention provides such a contribution to the art based on the finding that a novel class of compounds has a high affinity, selective, and potent inhibitory activity at the glucagon receptor.
  • the present invention is distinct in the particular structures and their activities.
  • Y is -O- or -S-;
  • Q, D, X, and T independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein), or nitrogen (optionally substituted with oxygen), provided that no more than two of Q, D, X, and T are nitrogen;
  • RI is -H, -OH, or -halogen
  • R2 is -H or -(C ⁇ -C 3 ) alkyl (optionally substituted with 1 to 3 halogens);
  • R3 and R4 are independently - H, -halogen, -CN, -OH, -(C 1 -C 7 ) alkoxy, -(C 1 -C 7 ) alkyl(optionally substituted with 1 to 3 halogens), or -(C 2 -C 7 ) alkenyl;
  • R5 is selected from the group consisting of -H, -( -C 12 ) alkyl(optionally substituted with 1 to 3 halogens), -(C 3 -C 12 )cycloalkyl, -phenyl, -phenyl-phenyl-(C 1 -C 12 )alkyl, -aryl, -aryl-(C 1 -C 12 )alkyl, -heteroaryl, -heteroaryl-(C 1 -C 12 )alkyl, -(C 2 -C 12 )alkenyl, -(C 3 -C 12 )cycloalkenyl, -heterocycloalkyl, -aryl-(C 2 -C 10 )alkenyl, -heteroaryl-(C 2 -C 10 )alkenyl, -(C 2 -C 12 )alkynyl, -(C -C 12 )cycloal
  • RIO is selected from the group consisting of -H, halogen, -(CrC 12 )alkyl(optionally substituted with 1 to 3 halogens), -cycloalkyl, -aryl, -aryl-(C 1 -C 7 )alkyl, -heteroaryl, -heteroaryl -(C 1 -C 7 )alkyl, -(C -C 12 )alkenyl, -(C 3 -C 12 )cycloalkenyl, -aryl-(C 2 -C 1 o)alkenyl, -heteroaryl-(C 2 -C 1 o)alkenyl, -(C 2 -C 12 )alkynyl, -(C 3 -C 12 )cycloalkynyl, -aryl-(C 2 -C 12 )alkynyl, and -heteroaryl-(C 2 -C 12
  • A, G, and E independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein) or nitrogen, provided that no more than two of A, G, and E are nitrogen; provided however that wherein A is nitrogen, then R8, R9, and R14 are not attached to A, and provided that wherein G is nitrogen, then R8, R9, and R14 are not attached to G, and provided that wherein E is nitrogen, then R8, R9, and R14 are not attached to E,
  • zig-zag mark shows the point of attachment to the parent molecule, wherein m is an integer of 0, 1, 2, or 3, and when m is 0, men (CH 2 )m is a bond, and
  • R12 is independently at each occunence selected from the group consisting of -hydrogen, -( -C 7 ) alkyl(optionally substituted with 1 to 3 halogens), and -aryl;
  • R13 is independently at each occunence selected from the group consisting of -hydrogen, -halogen, -( ⁇ -Q ⁇ ) alkyl(optionally substituted with 1 to 3 halogens), phenyl, and -(C 2 -C 7 )alkenyl; and R14 is independently at each occunence -H, halogen, or -( -C7) alkyl (optionally substituted with 1 to 3 halogens).
  • the present invention provides compounds that are useful as glucagon receptor antagonists or inverse agonists.
  • the present invention further provides compounds that are selective antagonists or inverse agonists of the glucagon receptor over the GLP-1 receptor.
  • the present invention further provides a pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. Due to their interaction with the glucagon receptor, the present compounds are useful in the treatment of a wide range of conditions and disorders in which an interaction with the glucagon receptor is beneficial. These disorders and conditions are defined herein as "diabetic and other glucagon related metabolic disorders". One of skill in the art is able to identify "diabetic and other glucagon related metabolic disorders" by the involvement of glucagon receptor mediated signaling either in the pathophysiology of the disorder, or in the homeostatic response to the disorder.
  • the compounds may find use for example to prevent, treat, or alleviate, diseases or conditions or associated symptoms or sequelae, of the endocrinological system, the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, and the gastrointestinal system, while reducing and or eliminating one or more of the unwanted side effects associated with the cunent treatments.
  • Diabetic and other glucagon related metabolic disorders include, but are not limited to, diabetes, type 1 diabetes, type 2 diabetes, hyperglycemia, hyper insulinemia, beta-cell rest, improved beta-cell function by restoring first phase response, prandial hyperglycemia, preventing apoptosis, impaired fasting glucose (IFG), metabolic syndrome, hypoglycemia, hyper-/hypokalemia, normalizing glucagon levels, improved LDL/HDL ratio, reducing snacking, eating disorders, weight loss, polycystic ovarian syndrome (PCOS), obesity as a consequence of diabetes, latent autoimmune diabetes in adults (LAD A), insulitis, islet transplantation, pediatric diabetes, gestational diabetes, diabetic late complications, micro- /macroalbuminuria, nephropatl y, retinopathy, neuropathy, diabetic foot ulcers, reduced intestinal motility due to glucagon administration, short bowel syndrome, antidianheic, increasing gastric secretion, decreased blood flow, e
  • the present invention provides a compound of Formula I, or a pharmaceutical salt thereof, or a pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutical salt thereof, and a pharmaceutically acceptable canier, diluent, or excipient: for use in inhibiting the glucagon receptor; for use in inhibiting a glucagon receptor mediated cellular response in a mammal; for use in reducing the glycemic level in a mammal; for use in treating a disease arising from excessive glucagon; for use in treating diabetic and other glucagon related metabolic disorders in a mammal; and for use in treating diabetes, obesity, hyperglycemia, atheroscelerosis, ischemic heart disease, stroke, neuropathy, and wound healing.
  • the methods of this invention encompass a prophylactic and therapeutic administration of a compound of Formula I.
  • the present invention further provides the use of a compound of Formula I, or a pharmaceutical salt thereof for the manufacture of a medicament for inhibiting the glucagon receptor; for the manufacture of a medicament for inhibiting a glucagon receptor mediated cellular response in a mammal; for the manufacture of a medicament for reducing the glycemic level in a mammal; for the manufacture of a medicament for treating a disease arising from excessive glucagon; for the manufacture of a medicament for treating diabetic and other glucagon related metabolic disorders in a mammal; and for the manufacture of a medicament for preventing or treating diabetes, obesity, hyperglycemia, atheroscelerosis, ischemic heart disease, stroke, neuropathy, and improper wound healing.
  • the present invention further provides a method of treating conditions resulting from excessive glucagon in a mammal; a method of inhibiting the glucagon receptor in a mammal; a method of inhibiting a glucagon receptor mediated cellular response in a mammal; a method of reducing the glycemic level in a mammal; a method of treating diabetic and other glucagon related metabolic disorders in a mammal; a method of preventing or treating diabetes, obesity, hyperglycemia, atheroscelerosis, ischemic heart disease, stroke, neuropathy, and improper wound healing; said methods comprising administering to a mammal in need of such treatment a glucagon receptor-inhibiting amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutical salt thereof, and a pharmaceutically acceptable ca ⁇ ier, diluent, or excipient.
  • the present invention provides a pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient: adapted for use in inhibiting the glucagon receptor; adapted for use in inhibiting glucagon receptor mediated cellular responses; adapted for use in reducing the glycemic level in a mammal; adapted for use in treating diabetic and other glucagon related metabolic disorders in a mammal; and adapted for use in preventing or treating diabetes, obesity, hyperglycemia, atherosclerosis, ischemic heart disease, stroke, neuropathy, and wound healing.
  • the compound or salt of the present invention further provides a diagnostic agent for identifying patients having a defect in the glucagon receptor, as a therapy to increase gastric acid secretions, and to reverse intestinal hypomobility due to glucagon administration.
  • the invention also provides a method for the treatment of disorders or diseases, wherein a glucagon antagonistic action is beneficial, the method comprising administering to a subject in need thereof an effective amount of a compound according to the invention.
  • the present compounds are used for the preparation of a medicament for the treatment of any ghicagon-mediated conditions and diseases.
  • the present compounds are used for the preparation of a medicament for the treatment of hyperglycemia.
  • the present compounds are used for the preparation of a medicament for lowering blood glucose in a mammal.
  • the present compounds are effective in lowering the blood glucose, both in the fasting and the postprandial stage.
  • the present compounds are used for the preparation of a pharmaceutical composition for the treatment of IGT.
  • the present compounds are used for the preparation of a pharmaceutical composition for the treatment of type 2 diabetes.
  • the present compounds are used for the preparation of a pharmaceutical composition for the delaying or prevention of the progression from IGT to type 2 diabetes.
  • the present compounds are used for the preparation of a pharmaceutical composition for the delaying or prevention of the progression from non-insulin requiring type 2 diabetes to insulin requiring type 2 diabetes.
  • the present compounds are used for the preparation of a pharmaceutical composition for the treatment of type 1 diabetes. Such treatment is normally accompanied by insulin therapy.
  • the present compounds are used for the preparation of a pharmaceutical composition for the treatment of obesity.
  • the present compounds are used for the preparation of a pharmaceutical composition for the treatment of disorders of the lipid metabolism.
  • the present compounds are used for the preparation of a pharmaceutical composition for the treatment of an appetite regulation or energy expenditure disorder.
  • GLP-1 means glucagon-like peptide 1.
  • glucagon receptor means one or more receptors that interact specifically with glucagon to result in a biological signal.
  • GLP-1 receptor means one or more receptors that interact specifically with glucagon-like peptide 1 to result in a biological signal.
  • glucagon receptor antagonist means a compound of the present invention with the ability to block cAMP production in response glucagon.
  • glucagon receptor inverse agonist means a compound of the present invention with the ability to inhibit the constitutive activity of glucagon receptor.
  • selective antagonist or inverse agonist means a compound having greater affinity for the glucagon receptor as compared to the affinity for the GLP-1 receptor.
  • the general chemical terms have their usual meanings. For example; "Halogen” or “halo” means fluoro, chloro, bromo and iodo.
  • alkyl refers to those alkyl groups of a designated number of carbon atoms of either a straight or branched saturated configuration.
  • “(C ⁇ -C 3 ) alkyl” are one to three carbon atoms, such as methyl, ethyl, propyl, n-propyl, isopropyl, and the like and branched or isomeric forms thereof, and optionally may be substituted with one to three halogens or a designated number of substituents as set forth in the embodiments recited herein
  • “( -C 7 ) alkyl” are one to seven carbon atoms such as methyl, ethyl, propyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl, pentyl, isopentyl, hexyl, heptyl, and the like, and branched or isomeric forms thereof
  • (Ci-C 12 ) alkyl are one to twelve carbon atoms, such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, nonyl, decyl, and the like, and branched or isomeric forms thereof, and optionally may be substituted with one to three halogens or a designated number of substituents as set forth in the embodiments recited herein.
  • the term “(C 3 -C 12 ) cycloalkyl” refers to a saturated or partially saturated carbocycle containing one or more rings of from 3 to 12 carbon atoms, typically 3 to 7 carbon atoms optionally substituted with up to three halogens.
  • Examples of (C 3 -C 12 ) cycloalkyl include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, and the like.
  • “(C 3 -C 7 ) cycloalkyl” means a ring with three to seven carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, cycloheptyl, and the like, optionally substituted with up to three halogens.
  • (C 1 -C7) alkoxy represents an alkyl group of one to seven carbon atoms attached through an oxygen bridge, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentoxy, and the like, and may be optionally substituted with three halogens or a designated number of substituents as set forth in the embodiments recited herein.
  • (C 2 -C 7 ) alkenyl means hydrocarbon chains of the indiacted number of carbon atoms of either a straight or branched configuration having at least one carbon- carbon double bond which may occur at any point along the chain, such as ethenyl, propenyl, butenyl, pentenyl, vinyl, alkyl, 2-butenyl and the like, and may be optionally substituted with one to three halogens or a designated number of substituents as set forth in the embodiments recited herein.
  • (C 3 -C 12 ) cycloalkenyl refers to a partially saturated carbocycle containing one or more rings of from 3 to 12 carbon atoms, typically 3 to 7 carbon atoms optionally substituted with up to three halogens.
  • (C 2 - 2) alkynyl means a hydrocarbon chain of two to twelve carbon atoms of either a straight or branched configuration and having at least one carbon-carbon triple bond, which may occur at any point along the chain.
  • Example of alkynyl is acetylene.
  • Alkynyl as defined above may be optionally substituted with up to three halogens or the designated number of substituents as set forth in the embodiments recited herein.
  • (C 3 -Ci 2 ) cycloalkynyl refers to a carbocycle containing one or more rings of from 3 to 12 carbon atoms, typically 3 to 7 carbon atoms, having at least one carbon-carbon triple bond which may occur at any point along the chain or ring, optionally substituted with up to three halogens. Cycloalkynyl as defined above may be optionally substituted with the designated number of substituents as set forth in the embodiments recited herein.
  • aryl includes carbocyclic aromatic ring systems (e.g. phenyl), fused polycyclic aromatic ring systems (e.g.
  • Aryl as defined above may be optionally substituted with a designated number of substituents as set forth in the embodiments recited herein.
  • aryloxy refers to an aryl group which is linked to the parent molecule through an oxygen bridge.
  • heteroaryl group is an aryl ring system having at least one heteroatom such as nitrogen, sulfur, or oxygen, and includes monocyclic, bicyclic, or tricyclic aromatic rings of 5 to 14 carbon atoms containing one or more heteroatoms selected from the group consisting of O, N, and S.
  • heteroaryl as defined above may be optionally substituted with a designated number of substituents as set forth in the embodiments recited herein.
  • heteroaryl examples include furanyl, indolyl, thienyl (also refened to herein as "thiophenyl”) thiazolyl, imidazolyl, isoxazoyl, oxazoyl, pyrazoyl, pynolyl, pyrazinyl, pyridyl, pyrimidyl, pyrimidinyl and purinyl, cinnolinyl, benzofuranyl, benzothienyl, benzotriazoiyl, benzoxazolyl, quinoline, isoxazolyl, isoquinoline, and the like.
  • arylalkyl refers to an aryl group which is linked to the parent molecule through an alkyl moiety, and “arylalkyl” may be further optionally substituted with a designated number of substituents as set forth in the embodiments recited herein.
  • heterocycloalkyl refers to a non-aromatic ring which contains one or more oxygen, nitrogen or sulfur and includes a monocyclic, bicyclic or tricyclic non- aromatic ring of 5 to 14 carbon atoms containing one or more heteroatoms selected from O, N, or S.
  • substituents means that the groups in question are either unsubstituted or substituted with one or more of the substituents specified. When the groups in question are substituted with more than one substituent, the substituents may be the same or different. Furthermore, when using the terms “independently,” “independently are,” and “independently selected from” mean that the groups in question may be the same or different. Certain of the herein defined terms may occur more than once in the structural formulae, and upon such occunence each term shall be defined independently of the other.
  • patient includes human and non-human animals such as companion animals (dogs and cats and the like) and livestock animals. Livestock animals are animals raised for food production.
  • Ruminants or "cud-chewing" animals such as cows, bulls, heifers, steers, sheep, buffalo, bison, goats and antelopes are examples of livestock.
  • livestock include pigs and avians (poultry) such as chickens, ducks, turkeys and geese.
  • livestock include fish, shellfish and crustaceans raised in aquaculture.
  • exotic animals used in food production such as alligators, water buffalo and ratites (e.g., emu, rheas or ostriches).
  • the patient to be treated is preferably a mammal, in particular a human being.
  • a glucagon receptor mediated cellular response includes various responses by mammalian cells to glucagon stimulation or glucagon receptor activity.
  • glucagon receptor mediated cellular responses include but are not limited to, release of glucose from liver, or other cells, in response to glucagon stimulation or glucagon receptor activity.
  • glucagon receptor mediated cellular responses include but are not limited to, release of glucose from liver, or other cells, in response to glucagon stimulation or glucagon receptor activity.
  • One of ordinary skill in the art can readily identify other cellular responses mediated by glucagon receptor activity, for example by observing a change in the responsive cellular endpoint after contacting the cell with an effective dose of glucagon.
  • treatment include their generally accepted meanings, i.e., the management and care of a patient for the purpose of preventing, prohibiting, restraining, alleviating, ameliorating, slowing, stopping, delaying, or reversing the progression or severity of a disease, disorder, or pathological condition, described herein, including the alleviation or relief of symptoms or complications, or the cure or elimination of the disease, disorder, or condition.
  • Composition means a pharmaceutical composition and is intended to encompass a pharmaceutical product comprising the active ingredient(s) including compound(s) of Formula I, and the inert ingredient(s) that make up the canier.
  • compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable canier.
  • suitable solvent refers to any solvent, or mixture of solvents, inert to the ongoing reaction that sufficiently solubilizes the reactants to afford a medium within which to effect the desired reaction.
  • unit dosage form means physically discrete units suitable as unitary dosages for human subjects and other non-human animals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical carrier.
  • the present invention provides compounds of Formula I as described in detail herein. While all of the compounds of the present invention are useful, certain of the compounds are particularly interesting and are prefened.
  • X is carbon and RI 1 is attached to X and RI 1 is wherein the zig-zag mark shows the point of attachment to the parent molecule, and wherein A, G, and E independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein) or nitrogen, provided that no more than two of A, G, and E are nitrogen;
  • X is carbon and RI 1 is attached to X and RI 1 is , wherein the zig-zag mark shows the point of attachment to the parent molecule, and wherein A, G, and E independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein) or nitrogen, provided that no more than two of A, G, and E are nitrogen, and R8 and R9 are independently at each occunence selected from the group consisting of -hydrogen, -hydroxy, -CN, -nitro, -halo, -(C 1 -C 7 )alkyl(optionally substituted with 1 to 3 halogens), -(C 1 -C 7 )alkoxy, -(C 3 -C 7 )cycloalkyl, -aryl, -aryH ⁇ lkyl, -heteroaryl, -heteroaryl-(C 1 -C 7 )alkyl, -aryloxy, -C(O)R12,
  • X is carbon and RI 1 is attached to X and RI 1 is wherein the zig-zag mark shows the point of attachment to the parent molecule
  • A, G, and E independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein) or nitrogen, provided that no more than two of A, G, and E are nitrogen
  • R8 and R9 are independently at each occunence selected from the group consisting of -hydrogen, -hydroxy, -CN, -nitro, -halo, -(C 1 -C 7 )alkyl(optionally substituted with 1 to 3 halogens), -(C 1 -C 7 )alkoxy, and -(C 3 ⁇ C 7 )cycloalkyl,
  • R 8 and R9 are independently at each occunence selected from the group consisting of -hydrogen, -hydroxy, -CN, -nitro, -halo, -(C 1 -C 7 )alkyl(optionally substituted with 1 to 3 halogens), -(CrC 7 )alkoxy, -(C 3 -C 7 )cycloalkyl, -aryl, -aryl-(C 1 -C 7 )alkyl, -heteroaryl, -heteroaryl-(C ⁇ -C 7 )al yl, -aryloxy, -C(O)R12, -C(O)OR12, -OC(O)R12,
  • R8 and R9 are independently at each occunence selected from the group consisting of -hydrogen, -hydroxy, -CN, -nitro, -halo, -(C 1 -C 7 )alkyl(optionally substituted with 1 to 3 halogens), -(Ci-C 7 )alkoxy, and -(C 3 -C 7 )cycloalkyl,
  • R2 is hydrogen, 25. wherein R2 is -(d-C 3 ) alkyl(optionally substituted with 1 to 3 halogens),
  • R4 is halogen
  • R3 is selected from the group consisting of -( -C 7 ) alkoxy, -( -C 6 ) alkyl(optionally substituted with 1 to 3 halogens), and -(C 2 -C 7 ) alkenyl,
  • R4 is selected from the group consisting of -(C 1 -C 7 ) alkoxy, -( -C 7 ) alkyl(optionally substituted with 1 to 3 halogens), and -(C 2 -C 7 ) alkenyl,
  • R5 is selected from the group consisting of -H, -(C ⁇ -C 12 ) alkyl(optionally substituted with 1 to 3 halogens), -(C 3 -C 12 )cycloalkyl, -phenyl, -phenyl-phenyl-(C 1 -C 2 )alkyl, -aryl, -aryl-(C ⁇ -C ⁇ 2 )alkyl, -heteroaryl, -heteroaryl-(C ⁇ -C ⁇ 2 )alkyl, -(C 2 -C ⁇ 2 )alkenyl, -(C 3 -C 12 )cycloalkenyl, -heterocycloalkyl, -aryl-(C 2 -C ]0 )alkenyl, -heteroaryl-(C 2 -C 10 )alkenyl, -(C 2 -C 12 )alkynyl, -(C 3 -C
  • R5 is selected from the group consisting of -H, -(C ⁇ -C 12 ) alkyl(optionally substituted with 1 to 3 halogens), -(C 3 -C 12 )cycloalkyl, -phenyl, -phenyl-phenyl-(C 1 -C 12 )alkyl, -(C 2 -C 12 )alkenyl, -(C 3 -C 12 )cycloalkenyl, -heterocycloalkyl, -(C 2 -C I2 )alkynyl, and -(C 3 -C 12 )cycloalkynyl, 34.
  • R5 is selected from the group consisting of -(C1- 2 ) alkyl(optionally substituted with 1 to 3 halogens), and -(C 3 -C 12 )cycloalkyl, 35. wherein R6 and R7 are methyl, 36. wherein R6 and R7 form a six membered ring with the atoms to which they are attached, and the ring so formed may optionally contain up to two oxygens, and further the ring so formed may optionally be substituted with up to four , halogens, 37. wherein R8 is attached in the para postion and is tertbutyl or trifloromethyl, 38.
  • RIO is selected from the group consisting of -H, halogen, -(C ⁇ -Ci 2 )alkyl(optionally substituted with 1 to 3 halogens), -(C 3 -Ci2)cycloalkyl, -(C 2 -C 12 )alkenyl, -(C C ⁇ cycloalkenyl, -(C 2 -C 12 )alkynyl, -(C 3 -Cj 2 )cycloalkynyl, -aryl-(C 2 _C 12 )alkynyl, and -heteroaryl-(C 2 -C 12 )alkynyl, 39.
  • RIO is selected from the group consisting of -H, halogen, or -(C 1 -C ⁇ 2 )alkyl(optionally substituted with 1 to 3 halogens,
  • Another embodiment is a compound of Formula I or a pharmaceutically acceptable salt thereof wherein: Y is -O- or -S-; Q, D, X, and T independently represent carbon or nitrogen, provided that no more than two of Q, D, X, and T are nitrogen; RI is -H, -OH, or -halogen; R2 is -H or -(C 1 -C3) alkyl;
  • R3 and R4 are independently at each occunence selected from the group consisting of - H, -halogen, -CN, -OH, -(C1-C 7 ) alkoxy, -(C 1 -C 7 ) alkyl, -(C 2 -C 7 ) alkenyl;
  • R5 is selected from the group consisting of -H, -(C ⁇ -C ⁇ 2 ) alkyl, -(C 3 -C 12 )cycloalkyl, -phenyl, -phenyl-phenyl-(C 1 -C 12 )alkyl, -aryl, -aryl-(C 1 -C 1 2)alkyl, -heteroaryl, -heteroaryl-(C 1 -C 12 )alkyl, -(C 2 -C 12 )alkenyl, -(C 3 -C 12 )cycloalkenyl, -heterocycloalkyl, -aryl-(C 2 -C 10 )alkenyl, -heteroaryl-(C 2 -C 10 )alkenyl, -heteroaryl-(C 2 -C 10 )alkenyl, -(C 2 -C 12 )alkynyl, -(
  • -C 12 )alkyl -heteroaryl, -heteroaryl-( CrC 12 )alkyl, -heterocycloalkyl, -(C 2 - C 12 )alkenyl, -(C 3 -C 12 )cycloalkenyl, -aryl-(C 2 -C 10 )alkenyl, -heteroaryl-(C 2 - C 10 )alkenyl, -(C 2 -C 1 2)alkynyl, -(C 3 -C 12 ) cycloalkynyl, -aryl-(C 2 -C 12 )alkynyl, and -heteroaryl-(C 2 -C 12 )alkynyl, are each optionally substituted with from one to three substituents each independently selected from the group consisting of -hydrogen, -hydroxy, -cyano, -nitro, -halo, -oxo,
  • R6 and R7 are independently at each occunence selected from the group consisting of -H, -halogen, -hydroxy, -CN, -( -C 7 ) alkoxy, -(C 2 -C 7 )alkenyl, and -(C ⁇ -C 7 )alkyl, provided however that wherein D is nitrogen, then R6 or R7 are not attached to D, and provided that wherein T is nitrogen, then R6 or R7 are not attached to T, and provided that wherein Q is nitrogen, then R6 or R7 are not attached to Q, and provided that wherein X is nitrogen, then R6 or R7 are not attached to X; wherein R6 and R7 may optionally form a six membered ring with the atoms to which they are attached, and the ring so formed may optionally contain up to two oxygens, and further the ring so formed may optionally be substituted with up to four halogens;
  • R8 and R9 are independently at each occunence selected from the group consisting of -hydrogen, -hydroxy, -CN, -nitro, -halo, -(C 1 -C 7 )alkyl, -(C 3 -C 7 )cycloalkyl, -aryl, -aryl-(C 1 -C 7 )alkyl, -heteroaryl, -heteroaryl-(C 1 -C 7 )alkyl, -aryloxy, -C(O)R12, -COOR12, -OC(O)R12, -OS(O) 2 R12, -N(R12) 2 , -NR12C(O) R12, -NR12SO 2 R12, -SR12, -S(O)R12, -S(O) 2 R12, and -S(O) 2 N(R12) 2 ; and wherein -(C 1 -C 7 )alkyl,
  • zig-zag mark shows the point of attachment to the parent molecule
  • m is an integer of 0, 1, 2, or 3, and when m is 0 m is a bond, provided however that wherein D is nitrogen, then RI 1 is hot attached to D, and provided that wherein T is nitrogen, then Rll is not attached to T, and provided that wherein Q is nitrogen, then Rll is not attached to Q, and provided that wherein X is nitrogen, then Rll is not attached to X;
  • R12 is independently at each occunence selected from the group consisting of -hydrogen, -( -C 7 ) alkyl, and -aryl,
  • R13 is independently at each occunence selected from the group consisting of -hydrogen, -halogen, -( -C 7 ) alkyl, and -(C 2 -C 7 )alkenyl.
  • Another preferred embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: Y is -O- or -S-; Q, D, X, and T independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein) or nitrogen, provided that no more than two of Q, D, X, and T are nitrogen; RI is -H, -OH, or -halogen; R2 is -H or -(Ci-C 3 ) alkyl (optionally substituted with 1 to 3 halogens); R3 and R4 are independently - H, -halogen, -CN, -( -C 7 ) alkoxy, -( -C 7 ) alkyl(optionally substituted with 1 to 3 halogens), or -(C 2 -C 7 ) alkenyl; R5 is selected from the group consisting of -(Ci-C 12 ) alkyl(optionally substituted with 1 to 3 halogens),
  • R6 and R7 are independently at each occunence selected from the group consisting of -H, -halogen, -hydroxy, -CN, -( -C 7 ) alkoxy, -(C 2 -C 7 )alkenyl, -(C 1 -C 1 o)alkyl (optionally substituted with 1 to 3 halogens), -(C 3 -C 12 )cycloalkyl, tert-butoxyiminomethyl, l,3-dioxan-2-yl, hydroxymethyl, formyl, hydroxyiminomethyl, morphylino-4-yl-methyl, 4-methylpentyloxy, and pentyloxy; provided however that wherein D is nitrogen, then R6 or R7 are not attached to D, and provided that wherein T is nitrogen, then R6 or R7 are not attached to T, and provided that wherein Q is nitrogen, then R6 or R7 are not attached to Q, and provided that wherein X is nitrogen,
  • RIO is selected from the group consisting of -H, halogen, and -(C 1 -C 12 )alkyl(optionally substituted with 1 to 3 halogens); RI 1 is independently at each occunence selected from the group consisting of -H, -halogen,
  • the zig-zag mark shows the point of attachment to the parent molecule
  • A, G, and E independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein) or nitrogen, provided that no more than two of A, G, and E are nitrogen; provided however that wherein A is nitrogen, then R8, R9, and R14 are not attached to A, and provided that wherein G is nitrogen, then R8, R9, and R14 are not attached to G, and provided that wherein E is nitrogen, then R8, R9, and R14 are not attached to E, , wherein the zig-zag mark shows the point of attachment to the parent molecule, wherein m is an integer of 0, 1, 2, or 3, and when m is 0 then (CH 2 )m is a bond, and
  • R12 is independently at each occunence selected from the group consisting of -hydrogen, and -(C 1 -C 7 ) alkyl(optionally substituted with 1 to 3 halogens);
  • R13 is independently at each occunence selected from the group consisting of -hydrogen, -halogen, -( -C 7 ) alkyl(optionally substituted with 1 to 3 halogens), phenyl, and -(C 2 -C 7 )alkenyl; and
  • R14 is independently at each occunence -H, halogen, or -(C 1 -C 7
  • Another prefened embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: Y is -O- or -S-;
  • Q, D, X, and T independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein);
  • RI is -H, -OH, or -halogen
  • R2 is -H;
  • R3 and R4 are independently -H, -halogen, or -(C 1 -C 7 ) alkyl(optionally substituted with 1 to 3 halogens);
  • R5 is selected from the group consisting of -(C 1 -C 12 ) alkyl(optionally substituted with 1 to 3 halogens), and -(C 3 -C 12 )cycloalkyl(optionally substituted with 1 to 3 halogens);
  • R6 and R7 are independently at each occunence selected from the group consisting of -H, -halogen, -hydroxy, -CN, -(C 1 -C 7 ) alkoxy, -(C 2 -C 7 )alkenyl, -(C 1 -C 10 )alkyl (optionally substituted with 1 to 3 halogens), -(C 3 -C 12 )cycloalkyl, tert-butoxyiminomethyl, l,3-dioxan-2-yl, hydroxymethyl, formyl, hydroxyiminomethyl, morphylino-4-yl-methyl, 4-methylpentyloxy, and pentyloxy; provided however that wherein D is nitrogen, then R6 or R7 are not attached to D, and provided that wherein T is nitrogen, then R6 or R7 are not attached to T, and provided that wherein Q is nitrogen, then R6 or R7 are not attached to Q, and provided that wherein X is nitrogen
  • R8 and R9 are independently at each occunence selected from the group consisting of -hydrogen, -halogen, -(Ci-C 7 )alkyl(optionally substituted with 1 to 3 halogens), -(C 1 -C 7 )alkoxy, -(C 3 -C 7 )cycloalkyl, -C(O)R12, -COOR12, -OC(O)R12, -OS(O) 2 R12, -SR12, -S(O)R12, -S(O) 2 R12, and -O(C 2 -C 7 )alkenyl;
  • RIO is -H
  • RI 1 is independently at each occunence selected from the group consisting of -H, -halogen, and
  • R13 is independently at each occunence selected from the group consisting of -hydrogen, -halogen, -( -C7) alkyl(optionally substituted with 1 to 3 halogens), and -(C 2 -C 7 )alkenyl; and R14 is independently at each occunence -H, halogen, or -( -C 7 ) alkyl (optionally substituted with 1 to 3 halogens).
  • the term "stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures called configurations.
  • enantiomer refers to two stereoisomers whose molecules are nonsuperimposable minor images of one another.
  • chiral center refers to a carbon atom to which four different groups are attached.
  • diastereomers refers to stereoisomers which are not enantiomers.
  • two diastereomers which have a different configuration at only one chiral center are refened to herein as “epimers.”
  • racemate refers to a mixture of equal parts of enantiomers.
  • the compounds of the present invention may be chiral, and it is intended that any enantiomers, whether pure, partially purified, or racemic mixtures, are included within the scope of the invention. Furthermore, when a double bond or a fully or partially saturated ring system or more than one center of asymmetry or a bond with restricted rotatability is present in the molecule diastereomers may be formed. It is intended that any diastereomers, as separated, pure or partially purified diastereomers or mixtures thereof are included within the scope of the invention. Furthermore, some of the compounds of the present invention may exist in different tautomeric forms and it is intended that any tautomeric forms, which the compounds are able to form, are included within the scope of the present invention.
  • S sinister
  • S refers to that configuration of a chiral center with a counterclockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group.
  • the priority of groups is based upon their atomic number (in order of decreasing atomic number).
  • a partial list of priorities and a discussion of stereochemistry is contained in "Nomenclature of Organic Compounds: Principles and Practice", (J.H. Fletcher, et al., eds., 1974) at pages 103-120.
  • the designation " '"”” " refers to a bond that protrudes backward out of the plane of the page.
  • ⁇ * Afv refers to a bond wherein the stereochemistry is not defined.
  • the compounds of Formula I when existing as a diastereomeric mixture, may be separated into diastereomeric pairs of enantiomers by, for example, fractional crystallization from a suitable solvent, for example methanol or ethyl acetate or a mixture thereof.
  • the pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid as a resolving agent.
  • any enantiomer of a compound of Formula I may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known configuration or through enantioselective synthesis.
  • enantiomeric enrichment refers to the increase in the amount of one enantiomer as compared to the other.
  • the ee with respect to the first enantiomer is 40%.
  • the ee with respect to the first enantiomer is 80%.
  • An ee of greater than 90% is prefened, an ee of greater than 95% is most prefened and an ee of greater than 99%) is most especially prefened.
  • Enantiomeric enrichment is readily determined by one of ordinary skill in the art using standard techniques and procedures, such as gas or high performance liquid chromatography with a chiral column.
  • a compound indicated to be “isomer 1" will be the first isomer eluted from the chiral separation column and “isomer 2" will be the second.
  • pharmaceutical when used as an adjective means substantially non-toxic to living organisms.
  • pharmaceutical salt refers to salts of the compounds of Formula I, which are substantially non-toxic to living organisms. See, e.g., Berge, S.M, Bighley, L.D., and Monkhouse, D.C., "Pharmaceutical Salts," J. Pharm. Sci., 66:1, 1977.
  • the present invention also encompasses pharmaceutically acceptable salts of the present compounds.
  • Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts.
  • pharmaceutically acceptable acid addition salts are any hydrates that the present compounds are able to form.
  • the pharmaceutically acceptable salts comprise basic amino acid salts such as lysine, arginine and ornithine.
  • Typical pharmaceutical salts include those salts prepared by reaction of the compounds of Formula I, with an inorganic or organic acid or base. Such salts are known as acid addition or base addition salts respectively.
  • acid addition salt refers to a salt of a compound of Formula I, prepared by reaction of a compound of Formula I, with a mineral or organic acid.
  • acid addition salts see, e.g., Berge, S.M, Bighley, L.D., and Monkhouse, D.C., J. Pharm. Sci., 66:1, 1977. Since compounds of this invention can be basic in nature, they accordingly react with any of a number of inorganic and organic acids to form pharmaceutical acid addition salts.
  • the acid addition salts may be obtained as the direct products of compound synthesis.
  • the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.
  • Acids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids, such as p-toluenesulfonic acid, ethanesulfonic acid, methanesulfonic acid, oxalic acid, 7-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, tartaric acid, benzoic acid, acetic acid and the like.
  • Prefened pharmaceutical acid addition salts are those formed with mineral acids such as hydrochloric acid, hydrobromic acid, and sulfuric acid, and those formed with organic acids such as maleic acid, tartaric acid, and methanesulfonic acid.
  • Examples of such pharmaceutically acceptable salts thus are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-l,4-dioate, hexyne-l,6-dioate, benzoate, chlorobenzoate
  • base addition salt refers to a salt of a compound of Formula I, prepared by reaction of a compound of Formula I, with a mineral or organic base.
  • base addition salts see, e.g., Berge, S.M, Bighley, L.D., and Monkhouse, D.C., J. Pharm. Sci., 66:1, 1977.
  • Bases commonly employed to form pharmaceutical base addition salts are inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like.
  • Such bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate, and the like.
  • Examples of pharmaceutical base addition salts are the ammonium, lithium, potassium, sodium, calcium, magnesium, methylamino, diethylamino, ethylene diamino, cyclohexylamino, and ethanolamino salts, and the like of a compound of Formula I.
  • the potassium and sodium salt forms are particularly prefened.
  • the present invention also contemplates pharmaceutical base addition salts of compounds of Formula I.
  • the pharmaceutical salts of the invention are typically formed by reacting a compound of Formula I, with an equimolar or excess amount of acid or base.
  • the reactants are generally combined in a mutual solvent such as diethylether, tetrahydrofuran, methanol, ethanol, isopropanol, benzene, and the like for acid addition salts, or water, an alcohol or a chlorinated solvent such as dichloromethane for base addition salts.
  • the salts normally precipitate out of solution within about one hour to about ten days and can be isolated by filtration or other conventional methods. All pharmaceutically acceptable salts are contemplated in the present invention.
  • the compound or salt of the present invention may form a solvate with low molecular weight solvents.
  • the invention also encompasses prodrugs of the present compounds, which on administration undergo chemical conversion by metabolic processes before becoming pharmacologically active substances.
  • prodrugs will be functional derivatives of present compounds, which are readily convertible in vivo into a compound of the present invention.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
  • the present compounds are administered in combination with one or more further active substances in any suitable ratios.
  • Such further active substances may for example be selected from antidiabetics, antiobesity agents, antihypertensive agents, agents for the treatment of complications resulting from or associated with diabetes and agents for the treatment of complications and disorders resulting from or associated with obesity.
  • antidiabetics antiobesity agents, antihypertensive agents, agents for the treatment of complications resulting from or associated with diabetes and agents for the treatment of complications and disorders resulting from or associated with obesity.
  • the following listing sets out several groups of combinations. It will be understood that each of the agents named may be combined with other agents named to create additional combinations.
  • the present compounds may be administered in combination with one or more antidiabetics.
  • Suitable antidiabetic agents include insulin, insulin analogues and derivatives such as those disclosed in EP 792290 (Novo Nordisk A/S), for example N ⁇ B29 -tetradecanoyl des (B30) human insulin, EP 214 826 and EP 705 275 (Novo Nordisk A/S), for example Asp B28 human insulin, US 5,504,188 (Eli Lilly), for example Lys B28 Pro B29 human insulin, EP 368 187 (Aventis), for example Lantus®, which are all incorporated herein by reference, GLP-1 and GLP-1 derivatives such as those disclosed in WO 98/08871 (Novo Nordisk A/S), which is incorporated herein by reference, as well as orally active hypoglycemic agents.
  • EP 792290 Novo Nordisk A/S
  • N ⁇ B29 -tetradecanoyl des B30
  • EP 214 826 and EP 705 275 Novo Nordisk A/S
  • Asp B28 human insulin US
  • the orally active hypoglycemic agents preferably comprise imidazolines, sulphonylureas, biguanides, meglitinides, oxadiazolidinediones, thiazolidinediones, insulin sensitizers, insulin secretagogues, such as glimepiride, ⁇ -glucosidase inhibitors, agents acting on the ATP-dependent potassium channel of the ⁇ -cells for example potassium channel openers such as those disclosed in WO 97/26265, WO 99/03861 and WO 00/37474 (Novo Nordisk A S) which are incorporated herein by reference, or mitiglinide, or a potassium channel blocker, such as BTS-67582, nateglinide, glucagon antagonists such as those disclosed in WO 99/01423 and WO 00/39088 (Novo Nordisk A/S and Agouron Pharmaceuticals, Inc.), which are incorporated herein by reference, GLP-1 antagonists, DPP-IV (d
  • the present compounds are administered in combination with a sulphonylurea such as glibenclamide, glipizide, tolbautamide, chloropamidem, tolazamide, glimepride, glicazide and glyburide.
  • a sulphonylurea such as glibenclamide, glipizide, tolbautamide, chloropamidem, tolazamide, glimepride, glicazide and glyburide.
  • the present compounds are administered in combination with a biguanide for example metormin.
  • the present compounds are administered in combination with a meglitinide for example repaglinide or nateglinide.
  • the present compounds are administered in combination with a thiazolidinedione insulin sensitizer for example troglitazone, ciglitazone, piolitazone, rosiglitazone, isaglitazone, darglitazone, englitazone, CS-01 l/CI-1037 or T 174 or the compounds disclosed in WO 97/41097, WO 97/41119, WO 97/41120, WO 00/41121 and WO 98/45292 (Dr. Reddy's Research Foundation), which are incorporated herein by reference.
  • a thiazolidinedione insulin sensitizer for example troglitazone, ciglitazone, piolitazone, rosiglitazone, isaglitazone, darglitazone, englitazone, CS-01 l/CI-1037 or T 174 or the compounds disclosed in WO 97/41097, WO 97/41119, WO 97/41120,
  • the present compounds may be administered in combination with an insulin sensitizer for example such as GI 262570, YM-440, MCC-555, JTT-501, AR-H039242, KRP-297, GW-409544, CRE-16336, AR- H049020, LY510929, MBX-102, CLX-0940, GW-501516 or the compounds disclosed in WO 99/19313, WO 00/50414, WO 00/63191, WO 00/63192, WO 00/63193 such as ragaglitazar (NN 622 or (-)DRF 2725) (Dr. Reddy's Research Foundation) and WO
  • an insulin sensitizer for example such as GI 262570, YM-440, MCC-555, JTT-501, AR-H039242, KRP-297, GW-409544, CRE-16336, AR- H049020, LY510929, MBX-102, CLX-0940, GW-50
  • the present compounds are administered in combination with an ⁇ -glucosidase inhibitor for example voglibose, emiglitate, miglitol or acarbose.
  • an ⁇ -glucosidase inhibitor for example voglibose, emiglitate, miglitol or acarbose.
  • the present compounds are administered in combination with an agent acting on the ATP-dependent potassium channel of the ⁇ - cells for example tolbutamide, glibenclamide, glipizide, glicazide, BTS-67582 or repaglinide.
  • an agent acting on the ATP-dependent potassium channel of the ⁇ - cells for example tolbutamide, glibenclamide, glipizide, glicazide, BTS-67582 or repaglinide.
  • the present compounds may be administered in combination with nateglinide.
  • the present compounds are administered in combination with an antilipidemic agent or antihyperlipidemic agent for example cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, pitavastatin, rosuvastatin, probucol, dextrothyroxine, fenofibrate or atorvastin.
  • an antilipidemic agent or antihyperlipidemic agent for example cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, pitavastatin, rosuvastatin, probucol, dextrothyroxine, fenofibrate or atorvastin.
  • an antilipidemic agent or antihyperlipidemic agent for example cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin
  • the present compounds are administered in combination with more than one of the above-mentioned compounds for example in combination with metformin and a sulphonylurea such as glyburide; a sulphonylurea and acarbose; nateglinide and metformin; repaglinide and metformin, acarbose and metformin; a sulfonylurea, metformin and troghtazone; insulin and a sulfonylurea; insulin and metformin; insulin, metformin and a sulfonylurea; insulin and troghtazone; insulin and lovastatin; etc.
  • metformin and a sulphonylurea such as glyburide
  • a sulphonylurea and acarbose such as glyburide
  • a sulphonylurea and acarbose such as
  • the present compounds may be administered in combination with one or more antiobesity agents or appetite regulating agents.
  • agents may be selected from the group consisting of CART (***e amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melanocortin 4) agonists, MC3 (melanocortin 3) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, urocortin agonists, ⁇ 3 adrenergic agonists such as CL-316243, AJ-9677, GW-0604, LY362884, LY377267 or AZ-40140 MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte- concentrating hormone) antagonists, CCK (cholectaminophene
  • the antiobesity agent is dexamphetamine or amphetamine. In another embodiment the antiobesity agent is leptin. In another embodiment the antiobesity agent is fenfluramine or exfenfluramine. In still another embodiment the antiobesity agent is sibutramine. In a further embodiment the antiobesity agent is orlistat. In another embodiment the antiobesity agent is mazindol or phentermine. In still another embodiment the antiobesity agent is phendimetrazine, diethylpropion, fluoxetine, bupropion, topiramate or ecopipam. Furthermore, the present compounds may be administered in combination with one or more antihypertensive agents.
  • antihypertensive agents examples include ⁇ -blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, SCE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and ⁇ -blockers such as doxazosin, urapidil, prazosin and terazosin.
  • SCE angiotensin converting enzyme
  • benazepril such as benazepril, captopril, enalapril, fosinopril, lisino
  • the compounds of the present invention may be administered in combination with FAS inhibitors.
  • the compounds of the present invention may also be administered in combination with chemical uncouplers, hormone sensitive lipase inhibitor, imidazolines, 11- ⁇ - hydroxy steroid dehydrogenase inhibitors, lipoprotein lipase activator, AMPK activators, immunosuppresive drugs, nicotinamide, ASIS, anti-androgens or carboxypeptidase inhibitors.
  • any suitable combination of the compounds according to the invention with diet and/or exercise, one or more of the above-mentioned compounds and optionally one or more other active substances are considered to be within the scope of the present invention.
  • the compounds of Formula I can be prepared by one of ordinary skill in the art following a variety of procedures, some of which are illustrated in the procedures and schemes set forth below. The particular order of steps required to produce the compounds of Formula I is dependent upon the particular compound to being synthesized, the starting compound, and the relative liability of the substituted moieties.
  • Examples and Procedures can be determined by monitoring the progress of the reaction via conventional chromatographic techniques. Furthermore, it is prefened to conduct the reactions of the invention under an inert atmosphere, such as, for example, argon, or, particularly, nitrogen. Choice of solvent is generally not critical so long as the solvent employed is inert to the ongoing reaction and sufficiently solubilizes the reactants to effect the desired reaction.
  • the compounds are preferably isolated and purified before their use in subsequent reactions. Some compounds may crystallize out of the reaction solution during their formation and then collected by filtration, or the reaction solvent may be removed by extraction, evaporation, or decantation.
  • the intermediates and final products of Formula I may be further purified, if desired by common techniques such as recrystallization or chromatography over solid supports such as silica gel or alumina.
  • common techniques such as recrystallization or chromatography over solid supports such as silica gel or alumina.
  • solid supports such as silica gel or alumina.
  • substituents are compatible with all reaction conditions.
  • These compounds may be protected or modified at a convenient point in the synthesis by methods well known in the art.
  • the terms and abbreviations used in the instant Schemes, Preparations, Examples and Procedures have their normal meanings unless otherwise designated.
  • MS(FD) refers to field desorption mass spectrometry
  • MS(IS) refers to ion spray mass spectrometry
  • MS(FIA) refers to flow injection analysis mass spectrometry
  • MS(FAB) refers to fast atom bombardment mass spectrometry
  • MS(EI) refers to electron impact mass spectrometry
  • MS(ES) refers to electron spray mass spectrometry
  • UV refers to ultraviolet spectrometry
  • 1H NMR refers to proton nuclear magnetic resonance spectrometry.
  • IR refers to infra red spectrometry, and the absorption maxima listed for the IR spectra are only those of interest and not all of the maxima observed.
  • RT refers to room temperature.
  • DEAD refers to diethylazodicrboxylate.
  • Ph 3 refers to triphenylphosphine.
  • ADDP refers to 1,1 - (azodicarbonyl)dipiperidine.
  • PPBu 3 refers to tributylphosphine.
  • OTF refers to triflate.
  • LAH refers to lithium aluminum hydride.
  • DIBAL-H refers to diisobutylaluminum hydride.
  • K Bu refers to potassoium t-butoxide.
  • THF refers to tetrahydrofuran.
  • TBP refers to tributylphosphine.
  • EDCI refers to l-(3-dimethylaminopropyl)-3-ethylcarbodiamide hydrochloride.
  • DMAP dimethylaminopyridine.
  • HNMe(OMe) refers to N,N,dimethylhydroxyamine.
  • CDMT 2-chloro-4,6-dimethoxy-[l,3,5] triazine.
  • NMM refers to N-methyl morpholine.
  • DCM refers to dichloromethane.
  • DMSO dimethylsulfoxide.
  • ET 3 ⁇ refers to triethylamine.
  • DF dimethylformamide.
  • Et in a formula refers to ethyl, for example Et 2 0 refers to diethylether, and EtOAc refers to ethylacetate.
  • PyBOP refers to bromo-tris-pynolidino-phosphonium hexafluorophosphate.
  • Me refers to methyl as in MeOH which is methanol.
  • Pd/C refers to 10% palladium on carbon.
  • isomer 1 refers to the first isomer to be eluted in a chiral separation and isomer 2 refers to the second isomer to be eluted in a chiral separation.
  • Infrared spectra are recorded on a Perkin Elmer 781 spectrometer.
  • 13 C NMR are recorded on a Varian 400 MHz spectrometer at ambient temperature.
  • B L halide, mesylate, tosylate etc.
  • the alcohol intermediates A and C can be made by A) reduction of the ketone with or without chiral auxiliary or B) alkylation of aldehyde with an organometallic reagent, e.g. Grignard reagent.
  • biaryl phenol analogs can be made by a palladium catalyzed cross coupling reaction: Scheme 5
  • Racemic 4-(l-Hydroxy-butyl)-benzoic acid methyl ester This compound is made from 4-formyl-benzoic acid methyl ester and n-propylmagnesium chloride following the general method exemplified in Preparation 1.
  • Preparation s Racemic 4-(l-Hydroxy-2-methyl ⁇ propyl)-benzoic acid methyl ester
  • This compound is made from 4-formyl-benzoic acid methyl ester and isopropylmagnesium chloride following the general method exemplified in Preparation 1.
  • Racemic 4-(l-Hydroxy-pentyl)-benzoic acid methyl ester This compound is made from 4-formyl-benzoic acid methyl ester and n-butyl magnesium chloride following the general method exemplified in Preparation 1.
  • Preparation 5 Racemic 4-(l-Hydroxy-3-methyl-butyl)-benzoic acid methyl ester This compound is made from 4-formyl-benzoic acid methyl ester and isobutyhnagnesium chloride following the general method exemplified in Preparation 1.
  • Racemic 4-(l-Hydroxy-hexyl)-benzoic acid methyl ester This compound is made from 4-formyl-benzoic acid methyl ester and n- pentylmagnesium chloride following the general method exemplified in Preparation 1.
  • Preparation 7 Racemic 4-(l-Hydroxy-heptyl)-benzoic acid methyl ester
  • Step A N-Methoxy-N-methyl-terephthalamic acid methyl ester
  • a solution of Terephthalic acid monomethyl ester (5.4 g, 30 mmol) and 2- chloro-4,6-dimethoxy-[l,3,5]triazine (7.9 g, 45 mmol) in THF (300 mL) is added N- methyl morpholine (4.95 mL, 45 mmol), the mixture is stined at room temperature overnight. Additional N-methyl morpholine (4.95' mL, 45 mmol) is added, followed by the addition of O, N-dimethyl-hydroxylamine HCl salt (3.51 g, 45 mmol).
  • Step B 4-ButyryI-benzoic acid methyl ester
  • N-methoxy-N-methyl-terephthalamic acid methyl ester (4.56 g, 20.4 mmol) in THF (100 mL) is added PrMgCl (2.0M, 30.6 mmol) at 0 °C, the reaction is warmed to room temperature, stined overnight, quenched by NH 4 CI aqueous solution, extracted with ethyl acetate.
  • Step C Racemic 4-(l-Hydroxy-butyI)-benzoic acid methyl ester
  • 4-butyryl-benzoic acid methyl ester 400 mg, 1.94 mmol
  • THF 4 mL
  • sodium borohydride 110 mg, 2.9 mmol
  • the reaction mixture is quenched by acetic acid (0.5 mL) and water (10 mL), extracted with ethyl acetate.
  • Step A 3-(4-Formyl-benzoylamino)-propionic acid methyl ester
  • 4-Formyl-benzoic acid, CDMT, and 4-methylmorpholine are combined in anhydrous DCM under nitrogen.
  • the reaction is allowed to stir under nitrogen at room temperature overnight.
  • the amine is then added to the reaction mixture, and allowed to stir at room temperature.
  • Some water ( ⁇ 10% volume) is added to help solubility.
  • the reaction is monitored by HPLC, and upon complete consumption of the acid, the reaction is diluted with DCM.
  • the reaction is diluted with water and rinsed with IN HCl. Upon acidification, a white solid precipitated from the biphasic mixture. The solid was isolated by filtration and dried under vacuum to afford the titled compound.
  • Step B 3-(4-Formyl-benzoylamino)-propionic acid methyl ester
  • This compound is made by the general methods as exemplified in Preparation 10 using hexyl magnesium bromide as reagent.
  • Preparation 16 4'-Trifluoromethyl-biphenyl-4-ol 4-Bromophenol (5 g, 28.9 mmol), 4-trifluoromethyl phenyl boronic acid (6.59 g, 34.7 mmol), potassium carbonate (12 g, 86.7 mmol) and palladium acetate (0.324 g, 1.445 mmol) are placed in water (50 mL), and the resulting mixture is stined at room temperature over night under open air. The mixture is filtered through celite and extracted with ethyl acetate (3 x 200 ml).
  • Step A 2-(4-Benzyloxy-phenyl)-5-trifluoromethyl-pyridine
  • a mixture of 2-chloro-5 -trifluoromethy lpyridine (1.81 g, 10 mmol), 4- benzyloxyphenyl boronic acid (2.74 g, 12 mmol) and CsF (5.32 g, 35 mmol) in dioxane (40 mL) is degaseed and filled with nitrogen.
  • PdCl 2 (dppf) 200 mg
  • the mixture is cooled to room temperature, diluted with ethyl acetate (100 mL), filtered through a pad of Celite.
  • Step B 4-(5-Trifluoromethyl-pyridin-2-yI)-phenoI
  • 2-(4-Benzyloxy-phenyl)-5-trifluoromethyl-pyridine (2.55g) in ethanol (100 mL) and THF (25 mL) is added Pd/C (5%, 0.253 g), the mixture is stined under 60 psi of hydrogen overnight.
  • the catalyst is filtered off, concentration of the filtrate gave the title compound (1.25 g, 67.5%).
  • Racemic 4-(l-Hydroxy-3,3-dimethyl-butyI)-benzoic acid methyl ester This compound is made from 4-formyl-benzoic acid methyl ester and 3,3- dimethyl-butanemagnesium bromide following the general method exemplified in Preparation 1.
  • Preparation 20 Racemic 4-(Cyclopropyl-hydroxy-methyl)-benzoic acid methyl ester This compound is made from 4-formyl-benzoic acid methyl ester and Cyclopropyl magnesium bromide following the general method exemplified in Preparation 1.
  • Racemic 3-Fluoro-4-(l-hydroxy-3-methyl-butyl)-benzoic acid methyl ester This compound is made from 3-Fluoro-4-formyl-benzoic acid methyl ester and isobutylmagnesium bromide following the general method exemplified in Preparation 1.
  • Preparation 22 Racemic 3-Fluoro ⁇ 4-(l-hydroxy-heptyl)-benzoic acid methyl ester
  • Step A Dimethyl-thiocarbamic acid O-(4-bromo-3,5-dimethyl-phenyl) ester 4-Bromo-3 ,5 -dimethyl-phenol (10.0 g, 50.01 mmol) is dissolved into dry dioxane
  • Step B Dimethyl-thiocarbamic acid S-(4-bromo-3,5-dimethyl-phenyl) ester
  • Dimethyl-thiocarbamic acid O-(4-bromo-3,5-dimethyl-phenyl) ester (6.4 g, 22.3 mmol) is diluted with 50 mL of tetradecane and heated to reflux under nitrogen. The reaction is monitored by TLC until all the conversion was complete, approximately 20h. The reaction is allowed to cool to room temperature and then loaded onto silica gel column and purified using flash column chromatography, yielding 5.78 g, or 90% of the target product.
  • Step C 4-Bromo-3,5-dimethyl-benzenethiol Dimethyl-thiocarbamic acid S-(4-bromo-3,5-dimetnyl-phenyl) ester (5.78 g, 20.14 mmol) is diluted with methanol (50 mL) and sodium methoxide (4.75 mL of 4.25M in methanol, 20.14 mmol) is added. The reaction is heated to reflux under nitrogen and monitored by TLC. After complete conversion, 20 hours, the reaction is allowed to cool to room temperature. The reaction is neutralized with IN hydrochloric acid (7.5 mL) and diluted with ethyl acetate (150 mL).
  • the reaction is monitored by HPLC, and upon completion, allowed to cool to room temperature.
  • the reaction is diluted with ethyl acetate and Celite is added, followed by Water. This mixture is then filtered through a pad of Celite.
  • the solution is poured into a separatory funnel and the organic layer is washed with water and brine. The organic layer is dried over anhydrous sodium sulfate and concentrated.
  • the product is purified by flash column chromatography (5.6 g, 19.71 mmol).
  • Step B 5-Methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-ylamine
  • ethanol 50 mL
  • palladium 10%) on carbon (0.700 g, 20% by wt.).
  • the reaction is charged to 15 psi under a hydrogen atmosphere and allowed to stir for 4 hours.
  • the reaction is diluted with ethyl acetate and Celite is added, followed by water. This mixture is then filtered through a pad of celite.
  • Step C 5-Methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-ol 5-Methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-ylamine (2.74 g, 10.87 mmol) is suspended in hydrochloric acid (21.74 mL, 5N) and the solution is cooled to -15 °C in a brine/ice bath.
  • Step A 4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-propyI]-benzoic acid
  • 4-(l-hydroxy-propyl)-benzoic acid methyl ester 300 mg, 1.55 mmol
  • toluene 10 mL
  • l, -(azodicarbonyl)dipiperidine ADDP, 585 mg, 2.32 mmol
  • tributylphosphine (0.58 mL, 2.32 mmol
  • 4'-trifluoromethyl-biphenyl-4-ol 442 mg, 1.86 mmol.
  • the reaction mixture is warmed up to room temperature and stined overnight.
  • the mixture is loaded on silica gel, eluted with hexanes with a gradient from 0 % of ethyl acetate to 50 % of ethyl acetate giving 4- [l-(4 , -trifluoromethyl-biphenyl-4-yloxy)-propyl]-benzoic acid methyl ester.
  • the ester product is taken into ethanol (2 mL), treated with sodium hydroxide (5N aqueous, 1 mL) for 3 hours at room temperature.
  • the mixture is concentrated, diluted with ethyl acetate, acidified with 5 N HCl (1.1 mL), extracted with ethyl acetate.
  • Step B Racemic methyl 3-(4- ⁇ l-[6-(4-Trifluoromethyl-phenyl)-pyridin-3-yl]- heptyloxy ⁇ -benzoylamino)-propionoate
  • 4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-propyl]-benzoic acid 270 mg, 0.68 mmol
  • methylene chloride 7 mL
  • DMAP 5.0 mg
  • 3-amino-propionic acid methyl ester 141 mg, 1.01.
  • Racemic 3- ⁇ 4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-propyl]- benzoylamino ⁇ -propionic acid To a mixture of 3- ⁇ 4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-propyl]- benzoylamino ⁇ -propionic acid methyl ester (60 mg, 0.12 mmol) in methanol (2 mL) is added sodium hydroxide (5 N aqueous, 0.5 mL) and stined for 5 hours. The reaction mixture is concentrated and acidified by 5 N HCl (0.5 mL), extracted with ethyl acetate.
  • This compound is made by the general method exemplified in Example 1 using 4-
  • Example 4 Racemic 3- ⁇ 4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyI]- benzoylamino ⁇ -propionic acid This compound is made by the general method exemplified in Example 1 using 4- (l-hydroxy-4,4,4-trifluorobutyl)-benzoic acid methyl ester and 4'-tert-butyl-biphenyl-4-ol as starting materials. MS (ES): 526.2 [M+H] + .
  • Example 5 Racemic 3- ⁇ 4-[4,4,4-Trifluoro-l-(4 , -trifluoromethyl-biphenyl-4-yloxy)-butyl]- benzoylamino ⁇ -propionic acid
  • This compound is made by the general method exemplified in Example 1 using 4-
  • Example 11 Racemic 3- ⁇ 4-[l-(4-Cyclohexyl-phenoxy)-hexyl]-benzoylamino ⁇ -propionic acid This compound is made by the general method exemplified in Example 1 using 4- (l-hydroxy-hexyl)-benzoic acid methyl ester and 4-cyclohexylphenol as starting materials. MS (ES): 452.3 [M+H] + .
  • Example 12 Racemic 3- ⁇ 4-[l-(4-Benzyloxy-phenoxy)-hexyI]-benzoylamino ⁇ -propionic acid
  • This compound is made by the general method exemplified in Example 1 using 4-
  • Example 18 Racemic 3- ⁇ 4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-butyl]-benzoylamino ⁇ - propionic acid This compound is made by the general method exemplified in Example 1 using 4- (l-hydroxy-butyl)-benzoic acid methyl ester and 4'-trifluoromethyl-biphenyl-4-ol as starting materials.
  • Example 22 Racemic 3-(4- ⁇ 3-Methyl-l-[4-(6-trifluoromethyl-pyridin-3-yl)-phenoxy]-butyl ⁇ - benzoylamino)-propionic acid
  • This compound is made by the general method exemplified in Example 1 using 4-
  • Step A 4- [l-(4-Bromo-phenylsulfanyl)-3-m ethyl-butyl] -benzoic acid
  • 4-(l-hydroxy-3-methyl-butyl)-benzoic acid methyl ester (1240 mg, 5.59 mmol) in toluene (10 mL)
  • l,r-(azodicarbonyl)dipiperidine (ADDP, 2114 mg, 8.38 mmol) at 0 °C
  • tributylphosphine (2.09 mL, 8.38 mmol
  • 4-bromo-thiophenol (1267 mg, 6.7 mmol).
  • the reaction mixture is warmed up to room temperature and stined overnight.
  • the mixture is loaded on silica gel, eluted with hexanes with a gradient from 0 % of ethyl acetate to 50 % of ethyl acetate giving 4- [l-(4-bromo-phenylsulfanyl)-3 -methyl-butyl] -benzoic acid methyl ester.
  • 393 mg of the ester product is taken into ethanol (2 mL), treated with sodium hydroxide (5N aqueous, 1 mL) for 3 h at room temperature.
  • reaction mixture is stined at room temperature overnight, loaded on silica gel, eluted with eluted with hexanes with a gradient from 0 % of ethyl acetate to 100 % of ethyl acetate giving 3- ⁇ 4-[l-(4-Bromo- phenylsulfany ⁇ )-3 -methyl-butyl] -benzoy lamino ⁇ -propionic acid methyl ester (350 mg).
  • This compound is made by the general method as exemplified in Example 30 by resolving racemic 3- ⁇ 4-[l-(4-Benzyloxy-phenoxy)-hexyl]-benzoylamino ⁇ -propionic acid methyl ester on Chiralpak AD column (4.6 x 150 mm). MS (ES): 476.3 [M+H] + .
  • Example 32 3- ⁇ 4-[3-Methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]-benzoylamino ⁇ - propionic acid, Isomer 1 and Example 33 3- ⁇ 4-[3-Methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]-benzoylamino ⁇ - propionic acid, Isomer 2
  • Example 34 3- ⁇ 4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-propyl]-benzoylamino ⁇ -propionic acid, Isomer 1 and Example 35 3- ⁇ 4-[l-(4'-Trifluoromethyl-biphenyl-4-yIoxy)-propyl]-benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 36 3- ⁇ 4- [1 -(4' -tert-Butyl-biphenyl-4-yloxy)-propyl] -benzoylamino ⁇ -propionic acid, Isomer 1 and Example 37 3- ⁇ 4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-propyl]-benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 38 3- ⁇ 4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ -propionic cid, Isomer 1 and Example 39 3- ⁇ 4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 40 3- ⁇ 4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino ⁇ -propionic acid, Isomer 1 and Example 41 3- ⁇ 4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 42 3- ⁇ 4-[l-(4'-Trifluoromethyl-biphenyl-4-ylsuIfanyl)-heptyl]-benzoylamino ⁇ -propionic acid, Isomer 1 and Example 43 3- ⁇ 4-[l-(4'-Trifluoromethyl-biphenyl-4-ylsulfanyl)-heptyl]-benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 44 3- ⁇ 4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-pentyl]-benzoylamino ⁇ -propionic acid, Isomer 1 and Example 45 3- ⁇ 4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-pentyl]-benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 46 3- ⁇ 4-[2-Methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-benzoylamino ⁇ - propionic acid, Isomer 1 and Example 47 3- ⁇ 4-[2-Methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-benzoylamino ⁇ - propionic acid, Isomer 2
  • Example 48 3- ⁇ 4- [1 -(4 ' -Trifluoromethyl-biphenyl-4-yloxy)-pentyl] -benzoylamino ⁇ -propionic acid, Isomer 1 and Example 49 3- ⁇ 4- [1 -(4 ' -Trifluoromethyl-biphenyl-4-yloxy)-pentyl] -benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 52 3- ⁇ 4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-butyl]-benzoylamino ⁇ -propionic acid, Isomer 1 and Example 53 3- ⁇ 4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-butyl]-benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 54 3-(4- ⁇ l-[4'-(l-Fluoro-l-methyl-ethyl)-biphenyl-4-ylsulfanyl]-3-methyl-butyl ⁇ - benzoylamino)-propionic acid, Isomer 1 and Example 55 3-(4- ⁇ l-[4'-(l-Fluoro-l-methyl-ethyl)-biphenyl-4-ylsulfanyl]-3-methyl-butyl ⁇ - benzoylamino)-propionic acid, Isomer 2
  • Example 56 3-(4- ⁇ 3-Methyl-l-[4-(6-trifluoromethyl-pyridin-3-yl)-phenoxy]-butyl ⁇ - benzoylamino)-propionic acid, Isomer 1 and Example 57 3-(4- ⁇ 3-Methyl-l-[4-(6-trifluoromethyl-pyridin-3-yl)-phenoxy]-butyl ⁇ - benzoylamino)-propionic acid, Isomer 2
  • Example 58 3- ⁇ 4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-nonyl]-benzoylamino ⁇ -propionic acid, Isomer 1 and Example 59 3- ⁇ 4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-nonyl]-benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 60 3- ⁇ 4-[l-(4'-Ethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ -propionic acid, Isomer 1 and Example 61 3- ⁇ 4-[l-(4'-Ethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ -propionic acid, Isomer 2
  • Step A 3-(4-Formyl-benzoylamino)-propionic acid methyl ester 4-formyl-benzoic acid (20 g, 133 mmol), CDMT (24 g, 137 mmol), and 4-methyl- morpholine (15.4 mL, 140 mmol) are combined in anhydrous dichloromethane (DCM) (300 mL) under nitrogen. The reaction is allowed to stir under nitrogen at room temperature overnight. Beta-alanine methyl ester hydrochloride (20.4 g, (147 mmol) is then added to the reaction mixture, followed by 4-methylmorpholine (15.4 mL, 140 mmol), and allowed to stir at room temperature. Some water ( ⁇ 10% volume) is added to help solubility.
  • DCM dichloromethane
  • reaction is monitored by HPLC, and upon complete consumption of the acid, the reaction is diluted with DCM.
  • the reaction is diluted with water and extracted with IN HCl.
  • the organic layer is washed with water and brine, followed by drying over anhydrous sodium sulfate.
  • the solution is filtered and concentrated and further purified using flash column chromatography (30 g, 128 mmol).
  • Step B 3-[4-(l-Hydroxy-4,4-dimethyl-pentyl)-benzoylamino]-propionic acid methyl ester
  • a solution of 3-(4-Formyl-benzoylamino)-propionic acid methyl ester (4.8 g, 20.43 mmol) is dissolved in the anhydrous tetrahydrofuran (THF) (75 mL) and cooled to 0 °C under nitrogen.
  • 2,2-Dimethyl-butyl magnesium bromide (16.3 mL, 1.5M solution in THF, 24.5 mmol) is then added slowly to the solution by addition funnel. The reaction is allowed to stir at 0 °C for 1 hour and the ice bath is removed.
  • the reaction is monitored by TLC or HPLC to determine complete consumption of the aldehyde.
  • the reaction is cooled back down to 0 °C and 1.0N hydrogen chloride solution is dropped in to quench. •
  • the solids are dissolved with enough water and the solution is diluted with ether.
  • the two phases are separated and the organic layer is washed with brine, dried over anhydrous sodium sulfate and concentrated.
  • the alcohol (1.6 g, 4.98 mmol) is purified by column chromatography. Step C.
  • Tributylphosphine (TBP) (630 uL, 2.55 mmol) is added to the reaction mixture under nitrogen at 0 °C, followed by addition of l, -(azodicarbonyl)-dipi ⁇ eridine(ADDP) (643 mg, 2.55 mmol).
  • the reaction mixture is allowed to warm to room temperature and stined over night, the mixture is loaded on silica gel column. Chromatography gave the title compound (722 mg, 1.67 mmol).
  • Step D 3-(4- ⁇ l-[6-(4-tert-Butyl-phenyI)-pyridin-3-yloxy]-4,4-dimethyl-pentyl ⁇ - benzoylamino)-propionic acid methyl ester
  • 3- ⁇ 4-[l-(6-chloro-pyridin-3-yloxy)-4,4-dimethyl-pentyl]- benzoylamino ⁇ -propionic acid methyl ester (84 mg, 0.19 mmol) in toluene:water (1:1) (2 mL) is added palladium tetrakis triphenylphosphine (22.47 mg, 0.1 mol%), 4-tert- butylphenylboronic acid (58 mg, 0.39 mmol).
  • the reaction is purged with nitrogen and heated to reflux and the potassium fluoride (23 mg, 0.39 mmol) is added.
  • the reaction is monitored by HPLC, and upon completion, allowed to cool to room temperature.
  • the reaction is diluted with ethyl acetate and then Celite is added, followed by water. This mixture is then filtered through a pad of Celite.
  • the solution is separated in a seperatory funnel and the organic layer is washed with 0.1N sodium hydoxide, water, and brine. The organic layer is dried over anhydrous sodium sulfate and concentrated.
  • Step F 3-(4- ⁇ l-[6-(4-tert-Butyl-phenyl)-pyridin-3-yloxy]-4,4-dimethyl-pentyl ⁇ - benzoylamino)-propionic acid 3 -(4- ⁇ 1 - [6-(4-tert-Butyl-phenyl)-pyridin-3 -yloxy] -4,4-dimethyl-pentyl ⁇ - benzoylamino)-propionic acid methyl ester (isomer 1, 80 mg, 0.15 mmol) is dissolved in the tettahydrofuran (1 mL) and sodium hydroxide solution (5 M, 1.0 mL, 5 mmol) is added.
  • Example 65 Racemic 3-(4- ⁇ 3-Methyl-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-butyl ⁇ - benzoylamino)-propionic acid
  • This compound is made by the general method as exemplified in Example 62 using isobutylmagnesium chloride in step B and 4-trifluromethyl phenyl boronic acid in step D as starting materials, and without chiral separation in step E.
  • MS (ES): 499.3 [M-H] " the structure was also confirmed by proton NMR.
  • Example 68 Racemic 3-(4- ⁇ l-[6-(4-tert-Butyl-phenyl)-pyridin-3-yloxy]-4,4,4-trifluoro-butyl ⁇ - benzoylamino)-propionic acid
  • This compound is made by the general method as exemplified in Example 62 using 3,3,3-trifluropropylmagnesium chloride in step B and 4-tert-butylphenyl boronic acid in step D as starting materials.
  • MS (ES): 527.3 [M-H] " the structure was also confirmed by proton NMR.
  • Example 69 Racemic 3-(4- ⁇ 1 - [6-(4-tert-Butyl-phenyl)-pyridin-3-yloxy] -3-methyl-butyl ⁇ - benzoylamino)-propionic acid
  • Example 71 3-(4- ⁇ 1 - [6-(4-Trifluoromethyl-phenyl)-py ridin-3-yloxy] -heptyl ⁇ -benzoylamino)- propionic acid, Isomer 1 and Example 72 3-(4- ⁇ l-[6-(4-Trifluoromethyl-phenyl)-pyridm-3-yloxy]-heptyl ⁇ -benzoylamino)- propionic acid, Isomer 2
  • Step A 4-[l-(4-Bromo-phenylsulfanyl)-3-methyl-butyl]-benzoic acid
  • 4-(l-hydroxy-3-methyl-heptyl)-benzoic acid methyl ester 1760 mg, 7.04 mmol
  • toluene 70 mL
  • l,r-(azodicarbonyl)dipiperidine ADDP, 2664 mg, 10.56 mmol
  • tributylphosphine (2.63 mL, 8.38 mmol
  • 4-bromo-benzenethiol 1597 mg, 8.45 mmol.
  • the reaction mixture is warmed up to room temperature and stined overnight.
  • the mixture is loaded on silica gel, eluted with hexanes with a gradient from 0 % of ethyl acetate to 50 % of ethyl acetate giving 4-[l-(4-bromo-phenylsulfanyl)-heptyl]-benzoic acid methyl ester.
  • 1700 mg of the ester product is taken into ethanol (5 mL), treated with sodium hydroxide (5N aqueous, 2 mL) for 3 h at room temperature.
  • the mixture is concentrated, diluted with ethyl acetate, acidified with 5 N HCl (2 mL), and extracted with ethyl acetate.
  • Step B Racemic 3- ⁇ 4-[l-(4-Bromo-phenylsulfanyl)-3-methyl-heptyl]- benzoylamino ⁇ -propionic acid methyl ester
  • 4- [l-(4-bromo-phenylsulfanyl)-3-methyl-hepyl] -benzoic acid 1700 mg, 4.18 mmol
  • triethyl amine 1.75 mL, 12.53 mmol
  • DMAP 5.0 mg
  • 3-amino-propionic acid methyl ester 875 mg, 6.27 mmol
  • EDCI 2408 mg, 12.53 mmol
  • reaction mixture is stined at room temperature overnight, loaded on silica gel, eluted with eluted with hexanes with a gradient from 0 % of ethyl acetate to 100 % of ethyl acetate giving 3- ⁇ 4-[l-(4-bromo- phenylsulfanyl)-3-methyl-heptyl] -benzoylamino ⁇ -propionic acid methyl ester (1640 mg).
  • Example 82 Racemic 3- ⁇ 4-[l-(2',3'-dimethyl-biphenyl-4-ylsulfanyl)-heptyl]-benzoylamino ⁇ - propionic acid
  • Example 84 Racemic 3- ⁇ 4-[l-(3'-isopropyl-biphenyl-4-ylsulfanyl)-heptyl]-benzoylamino ⁇ - propionic acid
  • Example 86 Racemic 3- ⁇ 4-[l-(4'-pentyl-biphenyl-4-ylsulfanyl)-heptyl]-benzoylamino ⁇ -propionic acid
  • Example 87 Racemic 3- ⁇ 4-[l-(4'-cyclohexyl-biphenyl-4-ylsulfanyl)-heptyl]-benzoylamino ⁇ - propionic acid
  • Step 1 Racemic 3- ⁇ 4-[l-(4-AUyloxy-phenoxy)-heptyl]-benzoylamino ⁇ -propionic acid methyl ester (1.59 g, 3.51 mmol) and triphenyl-phosphine tetrakis palladium(203 mg, 0.18 mmol) are combined with anhydrous tetrahydrofuran (10 mL) in a round bottom flask under nitrogen. Diethyl amine (712 uL, 7.02 mmol) is added and the reaction is allowed to stir under nitrogen at room temperature. The reaction is monitored by HPLC, and upon complete conversion, the reaction is quenched with water.
  • Example 96 Racemic 3-(4- ⁇ l-[4-(4-ethyl-benzyloxy)-phenoxy]-heptyl ⁇ -benzoylamino)-propionic acid
  • Example 104 Racemic 3- ⁇ 4-[l-(3',5'-bistrifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ - propionic acid
  • This compound is made by the general method as exemplified in Example 1 using 4'-tert-butyl-biphenyl-4-ol and 4-(l-hydroxy-4,4-dimethyl-pentyl)-benzoic acid methyl ester in step A as starting materials.
  • Example 106 Racemic 3- ⁇ 4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylamino ⁇ -propionic acid This compound is made by the general method as exemplified in Example 1 using 4'-frifluoromethyl-biphenyl-4-ol and 4-(l-hydroxy-4,4-dimethyl-pentyl)-benzoic acid methyl ester in step A as starting materials. MS (ES): 526.2 [M-H] " .
  • Example 107 Racemic 3- ⁇ 4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-2-methyl-propyl]-benzoylamino ⁇ - propionic acid
  • This compound is made by the general method as exemplified in Example 109 by resolving racemic 3- ⁇ 4-[l-(3',5'-bistrifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino ⁇ -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm) eluted with Isopropyl Alcohol/Heptane (15 /85 ). MS (ES): 594.2 [M-H] " .
  • Example 111 3- ⁇ 4-[l-(4-tert-Butyl-phenoxy)-3-methyl-butyl]-benzoylamino ⁇ -propionic acid, i Isomer 1 and Example 112 3- ⁇ 4-[i-(4-tert-Butyl-phenoxy)-3-methyl-butyl]-benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 109 3- ⁇ 4-[l-(4-tert-Butyl-phenoxy)-3-methyl-butyl]-benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 115 3- ⁇ 4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]-benzoylamino ⁇ - propionic acid, Isomer 1 and Example 116 3- ⁇ 4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]-benzoylamino ⁇ - propionic acid, Isomer 2
  • Step A Racemic 4-[l-(4-Bromo-phenoxyI)-heptyl]-benzoic acid
  • 4-(l-hydroxy-heptyl)-benzoic acid methyl ester (1800 mg, 7.2 mmol) in toluene (72 mL)
  • l,r-(azodicarbonyl)dipiperidine (ADDP, 2725 mg, 10.8 mmol) at 0 °C
  • ADDP l,r-(azodicarbonyl)dipiperidine
  • tributylphosphine 2.69 mL, 10.8 mmol
  • 4-bromo-phenol 1503 mg, 8.64 mmol
  • the mixture is loaded on silica gel, eluted with hexanes with a gradient from 0 % of ethyl acetate to 50 % of ethyl acetate giving 4-[l-(4- bromo-phenoxyl)-heptyl] -benzoic acid methyl ester.
  • 1900 mg of the ester product is taken into ethanol (5 mL), treated with sodium hydroxide (5N aqueous, 2 mL) for 3 h at room temperature.
  • the mixture is concentrated, diluted with ethyl acetate, acidified with 5 N HCl (2 mL), and extracted with ethyl acetate.
  • Step B Racemic 3- ⁇ 4-[l-(4-Bromo-phenoxyl)-heptyl]-benzoylamino ⁇ -propionic acid methyl ester
  • 4- [l-(4-bromo-phenoxyl)-heptyl] -benzoic acid 1700 mg, 4.35 mmol
  • methylene chloride 43 mL
  • triethyl amine 1.82 mL, 13.4 mmol
  • DMAP 5.0 mg
  • 3-amino-propionic acid methyl ester 910 mg, 6.52 mmol
  • EDCI 2507 mg, 13.04 mmol
  • reaction mixture is stined at room temperature overnight, loaded on silica gel, eluted with eluted with hexanes with a gradient from 0 % of ethyl acetate to 100 % of ethyl acetate giving racemic 3- ⁇ 4-[l-(4- bromo-phenoxyl)-heptyl] -benzoylamino ⁇ -propionic acid methyl ester (1660 mg).
  • Step D 3- ⁇ 4-[l-(4'-Trifluoromethoxy-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ - propionic acid methyl ester, isomer 1 3- ⁇ 4-[l-(4-Bromo-phenoxyl)-heptyl]-benzoylamino ⁇ -propionic acid methyl ester (isomer 1, 100 mg, 0.21 mmol), potassium carbonate (85 mg, 0.63 mmol), 4-triflouromethoxylphenyl boronic acid (86 mg, 0.42 mmol) and tetrakis- (friphenylphosphine)palladium (24 mg, 0.021 mmol) are place in a flask.
  • This compound is made in a substantially similar manner as Example 117 using isomer 2 of 3- ⁇ 4-[l-(4-bromo-phenoxyl)-heptyl]-benzoylamino ⁇ -propionic acid methyl ester as starting material in step D.
  • Example 119 3- ⁇ 4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ -propionic acid, Isomer 1 or Example 120 3- ⁇ 4-[l-(4 , -Trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 121 3- ⁇ 4-[l-(2,2,3,3-Tetrafluoro-2,3-dihydro-benzo[l,4]dioxin-6-yloxy)-heptyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 122 3- ⁇ 4-[l-(2,2,3,3-Tetrafluoro-2,3-dihydro-benzo[l,4]dioxin-6-yloxy)-heptyl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • This compound is made by the general method as exemplified in Example 109 by resolving racemic 3- ⁇ 4-[l-(2,2,3,3 -tetrafluoro-2,3 -dihydro-benzo [ 1 ,4] dioxin-6-yloxy)- heptyl] -benzoylamino ⁇ -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm) eluted with Propyl Alcohol/Heptane (15 /85 ).
  • Example 123 3-(4- ⁇ l-[4-(4-Trifluoromethyl-phenoxy)-phenoxy]-heptyl ⁇ -benzoylamino)-propionic acid, Isomer 1 and Example 124 3-(4- ⁇ l-[4-(4-Trifluoromethyl-phenoxy)-phenoxy]-heptyl ⁇ -benzoylamino)-propionic acid, Isomer 2
  • Step A Racemic 4-[l-(4-Bromo-3,5-dimethyl-phenoxyl) ⁇ heptyl]-benzoic acid
  • 4-(l-hydroxy-heptyl)-benzoic acid methyl ester 1000 mg, 4.0 mmol
  • toluene 40 mL
  • l,r-(azodicarbonyl)dipiperidine ADDP, 1514mg, 6.0 mmol
  • tributylphosphine (1.49 mL, ⁇ .Ommol
  • 4- bromo-3,5-dimethyl-phenol 965 mg, 4.8 mmol
  • the reaction mixture is warmed up to room temperature and stined overnight.
  • the mixture is loaded on silica gel, eluted with hexanes with a gradient from 0 % of ethyl acetate to 50 % of ethyl acetate giving 4-[l-(4- bromo-phenoxyl)-heptyl] -benzoic acid methyl ester.
  • the ester product (1800 mg) is taken into ethanol (5 mL), treated with sodium hydroxide (5N aqueous, 5 mL) for 3 h at room temperature.
  • the mixture is concentrated, diluted with ethyl acetate, acidified with 5 N HCl (5 mL), extract with ethyl acetate.
  • the organic layers are dried and concentrated giving 4-[l-(4-bromo-3,5-dimethyl-phenoxyl)-heptyl]-benzoic acid (1790 mg).
  • Step B Racemic 3- ⁇ 4-[l-(4-Bromo-3,5-dimethyl-phenoxyl)-heptyl]-benzoylamino ⁇ - propionic acid methyl ester
  • 4-[l-(4-bromo-3,5-dimethyl-phenoxyl)-heptyl]-benzoic acid 17.90 mg, 4.27 mmol
  • methylene chloride 43 mL
  • triethyl amine (1.79 mL, 12.82 mmol)
  • DMAP 5.0 mg
  • 3-amino-propionic acid methyl ester 895 mg, 6.4 mmol
  • EDCI 2463 mg, 12.8 mmol
  • reaction mixture is stined at room temperature overnight, loaded on silica gel, eluted with eluted with hexanes with a gradient from 0 % of ethyl acetate to 100 % of ethyl acetate giving racemic 3- ⁇ 4-[l-(4- bromo-3,5-dimethyl-phenoxyl)-heptyl]-benzoylamino ⁇ -propionic acid methyl ester (945 mg).
  • Step C Racemic 3- ⁇ 4-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)- heptyl] -benzoylamino ⁇ -propionic acid 3 - ⁇ 4- [ 1 -(4-Bromo-3 ,5 -dimethyl-phenoxyl)-heptyl] -benzoylamino ⁇ -propionic acid methyl ester (isomer 1, 100 mg, 0.2 mmol), potassium flouride (35 mg, 0.6 mmol), 4- triflouromethoxylphenyl boronic acid (83 mg, 0.4 mmol) and tetrakis(triphenylphosphine)palladium (23 mg, 0.02mmol) are place in a flask.
  • Step D 3- ⁇ 4- [1 -(2,6-Dimethyl-4' -trifluoromethoxy-biphenyl-4-yloxy)-heptyl] - benzoylamino ⁇ -propionic acid
  • 3- ⁇ 4-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)- heptyl] -benzoylamino ⁇ -propionic acid methyl ester 105 mg
  • sodium hydroxide 5 N aqueous, 0.5 mL
  • Example 130 Racemic 3- ⁇ 4-[l-(2,6-Dimethyl-4'-tertbutyl-biphenyl-4-yloxy)-heptyl]- benzoylamino ⁇ -propionic acid
  • Step A 4-[l-(4'-tertbutyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoic acid
  • ADDP l,r-(azodicarbony ⁇ )dipiperidine
  • the reaction mixture is warmed up to room temperature and stined overnight.
  • the mixture is loaded on silica gel, eluted with hexanes with a gradient from 0 % of ethyl acetate to 50 % of ethyl acetate giving 4- [ 1 -(4'-tertbutyl-biphenyl-4-yloxy)-3 -methyl-butyl] -benzoic acid methyl ester.
  • the ester product is taken into ethanol (5 mL), treated with sodium hydroxide (5N aqueous, 1 mL) for 3 h at room temperature.
  • Step B 3- ⁇ 4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino ⁇ - 2(R)-hydroxy-propionic acid methyl ester
  • 4-[l-(4'-tertbutyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoic acid 120 mg
  • 4-[l-(4'-tertbutyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoic acid 120 mg
  • triethyl amine (0.12 mL, 0.87 mmol
  • DMAP 5 mg
  • 3-Amino-2( R)-hydroxy-propionic acid methyl ester (67.3 mg, 0.43 mmol)
  • EDCI 166 mg, 0.87 mmol
  • reaction mixture is stined at room temperature overnight, loaded on silica gel, eluted with eluted with hexanes with a gradient from 0 % of ethyl acetate to 100 % of ethyl acetate giving 3- ⁇ 4- [ 1 -(4'-tert-butyl-biphenyl-4-yloxy)-3 -methyl-butyl] -benzoylamino ⁇ -2(R)-hydroxy- propionic acid methyl ester (60 mg).
  • Step C 3- ⁇ 4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino ⁇ - 2(R)-hydroxy-propionic acid
  • methanol 2-mL
  • sodium hydroxide 5 N aqueous, 0.5 mL
  • Example 132 3- ⁇ 4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino ⁇ -2(S)- hydroxy-propionic acid This compound is made in a substantially similar manner as Example 131 using 3- amino-2( S)-hydroxy-propionic acid methyl ester as reagent in step B. MS (ES): 504.2 [M+H] + .
  • Example 133 3- ⁇ 4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino ⁇ -2(S)- hydroxy-propionic acid This compound is made in a substantially similar manner as Example 131 using 3- amino-2( S)-hydroxy-propionic acid methyl ester as reagent in step B. MS (ES): 504.2 [M+H] + .
  • Example 133 3- ⁇ 4-[l-(4'-tert-Butyl
  • This compound is made in a substantially similar manner as Example 117 using isomer 1 of 3- ⁇ 4- [l-(4-bromo-phenoxy)-butyl] -benzoylamino ⁇ -propionic acid methyl ester and 4-isobutylphenylbronic acid as starting materials in step D.
  • Example 135 Racemic 3- ⁇ 4-[l-(6-chloro-pyridin-3-yloxy)-4,4,4-trifluoro-butyl]-benzoylamino ⁇ - propionic acid
  • the title compound is prepared in a manner substantially similar to Example 62 starting from 3- ⁇ 4-[l-(6-chloro-pyridin-3-yloxy)-4,4,4-trifluoro-butyl]-benzoylamino ⁇ - propionic acid methyl ester.
  • MS 429.2 [M-H] " .
  • Example 136 3- ⁇ 4-[l-(4'-Acetyl-biphenyl-4-yloxy)-butyl]-benzoylamino ⁇ -propionic acid, Isomer 1
  • This compound is made in a substantially similar manner as Example 117 using isomer 1 of 3- ⁇ 4-[l-(4-bromo-phenoxy)-butyl]-benzoylamino ⁇ -propionic acid methyl ester and 4-acetylphenylboronic acid as starting materials in step D.
  • This compound is made in a substantially similar manner as Example 117 using isomer 1 of3- ⁇ 4-[l -(4-bromo-phenoxy)-butyl] -benzoylamino ⁇ -propionic acid methyl ester and 2', 3', 4'-trifluorophenylboronic acid as starting materials in step D.
  • This compound is made in a substantially similar manner as Example 117 using isomer 1 of 3- ⁇ 4- [l-(4-bromo-phenoxy)-butyl] -benzoy lamino ⁇ -propionic acid methyl ester and 2', 4'-dimethoxyphenylboronic acid as starting materials in step D.
  • Example 141 3- ⁇ 4-[l-(4'-t-butyl-biphenyl-4-yloxy)-hexyl]-benzoylamino ⁇ -propionic acid, Isomer 1 and Example 142 3- ⁇ 4-[l-(4'-t-butyl-biphenyl-4-yloxy)-hexyl]-benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 143 3- ⁇ 4-[l-(4'-pentylphenyl-4-yloxy)-hexyl]-benzoylamino ⁇ -propionic acid, Isomer 1 and Example 144 3- ⁇ 4-[l-(4'-pentylphenyl-4-yloxy)-hexyl]-benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 145 3-(4- ⁇ l-[4-(l-Methyl-l-phenyl-ethyl)-phenoxy]-heptyl ⁇ -benzoylamino)-propionic acid, Isomer 1 and Example 146 3-(4- ⁇ l-[4-(l-Methyl-l-phenyl-ethyl)-phenoxy]-heptyl ⁇ -benzoylamino)-propionic acid, Isomer 2
  • This compound is made in a substantially similar manner to Example 117 using isomer 1 of 3- ⁇ 4- [l-(4-bromo-phenoxy)-heptyl] -benzoylamino ⁇ -propionic acid methyl ester and 4-trifluoromethoxy-phenylboronic acid as starting materials in step D.
  • Example 151 3- ⁇ 4-[Cyclopropyl-(4'-trifluoromethyl-biphenyl-4-yloxy)-methyl]-benzoylamino ⁇ - propionic acid, Isomer 1 and Example 152 3- ⁇ 4-[Cyclopropyl-(4'-trifluoromethyl-biphenyl-4-yloxy)-methyl]-benzoylamino ⁇ - propionic acid, Isomer 2
  • This compound is made in a substantially similar manner to Example 117 using isomer l of3- ⁇ 4-[l -(4-bromo-phenoxy)-heptyl] -benzoylamino ⁇ -propionic acid methyl ester and 4-chlorophenylboronic acid as starting materials in step D.
  • Example 156 3- ⁇ 4-[l-(4'-tert-Butyl-2-methyl-biphenyl-4-yloxy)-3-methyl-butyl]-3-fluoro- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 157 3- ⁇ 4-[l-(4'-tert-Butyl-2-methyl-biphenyl-4-yloxy)-3-methyl-butyl]-3-fluoro- benzoylamino ⁇ -propionic acid, Isomer 2 These compounds are made by the general method exemplified in Example 30 by resolving racemic 3- ⁇ 4-[l-(4'-tert-butyl-2-methyl-biphenyl-4-yloxy)-3-methyl-butyl]-3- fluoro-benzoy lamino ⁇ -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm).
  • Example 160 3- ⁇ 3-Fluoro-4-[l-(2-methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 161 3- ⁇ 3-Fluoro-4-[l-(2-methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • These compounds are made by the general method exemplified in Example 30 by resolving racemic 3 - ⁇ 3 -fluoro-4- [ 1 -(2-methyl-4 , -trifluoromethyl-biphenyl-4-yloxy)- heptyl] -benzoylamino ⁇ -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm).
  • Example 164 3- ⁇ 4- [1 -(4' -tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-heptyl] -benzoylamino ⁇ - propionic acid, Isomer 1 and Example 165 3- ⁇ 4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ - propionic acid, Isomer 2
  • Example 166 3- ⁇ 4-[l-(4'-tert-Butyl-2-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ -propionic acid, Isomer 1 and Example 167 3- ⁇ 4-[l-(4'-tert-Butyl-2-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 168 3- ⁇ 4-[l-(2-Methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ - propionic acid, Isomer 1 and Example 169 3- ⁇ 4-[l-(2-Methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ - propionic acid, Isomer 2
  • Example 170 3- ⁇ 4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 171 3- ⁇ 4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 172 3- ⁇ 4- [1 -(4 ' -Isopropyl-2-methyl-biphenyl-4-yloxy)-heptyl] -benzoylaminoj-propionic acid, Isomer 1 and Example 173 3- ⁇ 4-[l-(4'-IsopropyI-2-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ -propionic acid, Isomer 2
  • These compounds are made by the general method exemplified in Example 30 by resolving racemic 3 - ⁇ 4- [ 1 -(4'-isopropyl-2-methyl-biphenyl-4-yloxy)-heptyl] - benzoylamino ⁇ -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm).
  • Example 178 3- ⁇ 4-[l-(2,6-Dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino ⁇ -propionic acid, Isomer 1 and Example 179 3- ⁇ 4- [1 -(2,6-Dimethyl-biphenyl-4-yloxy)-3-methyl-butyl] -benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 180 3- ⁇ 4-[l-(4'-Ethyl-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino ⁇ - propionic acid, Isomer 1 and Example 181 3- ⁇ 4-[l-(4'-Ethyl-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino ⁇ - propionic acid, Isomer 2
  • These compounds are made by the general method exemplified in Example 30 by resolving racemic 3- ⁇ 4-[l-(4'-ethyl-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino ⁇ -propionic acid methyl ester on Chiralcel OJ column (4.6 x 250 mm).
  • Example 182 3- ⁇ 4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 183 3- ⁇ 4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 184 3- ⁇ 4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ - propionic acid, Isomer 1 and Example 185 3- ⁇ 4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-heptyI]-benzoylamino ⁇ - propionic acid, Isomer 2
  • Example 186 3- ⁇ 4-[l-(4'-tert-Buryl-2-trifluoromethyl-biphenyl-4-yloxy)-pentyl]-benzoylamino ⁇ - propionic acid, Isomer 1 and Example 187 3- ⁇ 4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-pentyl]-benzoylamino ⁇ - propionic acid, Isomer 2
  • Example 188 3- ⁇ 4- [1 -(4 ' -tert-Butyl-2-trifluoromethyl-biphenyl-4-y loxy)-2-methyl-propyl] - benzoylamino ⁇ -propionic acid, Isomer 1 and Example 189 3- ⁇ 4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 30 shows that resolving racemic 3- ⁇ 4-[l-(4'-tert-butyl-2-trifluoromethyl-biphenyl-4-yloxy)-2-methyl- propyl] -benzoylamino ⁇ -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm).
  • Example 190 3- ⁇ 4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 191 3- ⁇ 4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 192 3- ⁇ 4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 193 3- ⁇ 4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • These compounds are made by the general method exemplified in Example 30 by resolving racemic 3- ⁇ 4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4-dimethyl- pentyl] -benzoylamino ⁇ -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm).
  • Example 196 3- ⁇ 4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yIoxy)-2-methyl-propyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 197 3- ⁇ 4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 198 3- ⁇ 4- [1 -(2-Ethyl-4' -trifluoromethyl-biphenyl-4-yloxy)-heptyl] -benzoylamino ⁇ - propionic acid, Isomer 1 and Example 199 3- ⁇ 4-[l-(2-Ethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ - propionic acid, Isomer 2
  • Example 200 3- ⁇ 4-[l-(4'-Chloro-2,6-dimethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 201 3- ⁇ 4-[l-(4'-Chloro-2,6-dimethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • These compounds are made by the general method exemplified in Example 30 by resolving racemic 3- ⁇ 4-[l-(4'-chloro-2,6-dimethyl-biphenyl-4-yloxy)-4,4-dimethyl- pentyl] -benzoylamino ⁇ -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm).
  • Example 202 3- ⁇ 4- [1 -(4' -tert-Butyl-2,6-dimethyl-biphenyl-4-y loxy)-2-methyl-propyl] - benzoylamino ⁇ -propionic acid, Isomer 1 and Example 203 3- ⁇ 4- [1 -(4' -tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl] - benzoylaminoj-propionic acid, Isomer 2
  • Example 204 3- ⁇ 4-[2-Methyl-l-(2-methyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-propyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 205 3- ⁇ 4- [2-Methyl-l -(2-methy 1-4 ' -trifluoromethoxy-biphenyl-4-yloxy)-propyl] - benzoy!amino ⁇ -propionic acid, Isomer 2
  • Example 30 3- ⁇ 4-[2-methyl-l -(2-methyl-4'-trifluoromethoxy-biphenyl-4-yloxy)- propyl] -benzoylamino ⁇ -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm).
  • Example 206 3- ⁇ 4-[l-(2-Chloro-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino ⁇ - propionic acid, Isomer 1 and Example 207 3- ⁇ 4-[l-(2-Chloro-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino ⁇ - propionic acid, Isomer 2
  • Example 208 3- ⁇ 4- [1 -(2-Chloro-4' -trifluoromethyl-bipheny l-4-yloxy)-3-methyl-buty 1] - benzoylamino ⁇ -propionic acid, Isomer 1 and Example 209 3- ⁇ 4-[l-(2-Chloro-4'-trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 30 These compounds are made by the general method exemplified in Example 30 by resolving racemic 3- ⁇ 4-[l-(2-chloro-4'-trifluoromethyl-biphenyl-4-yloxy)-3-methyl- butyl] -benzoylamino ⁇ -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm).
  • Example 210 3- ⁇ 4-[2-Methyl-l-(2-methyl-4 , -trifluoromethyl-biphenyl-4-yloxy)-propyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 211 3- ⁇ 4-[2-Methyl-l-(2-methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 212 3-(4- ⁇ 3-Methyl-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-butyl ⁇ - benzoylamino)-propionic acid, Isomer 1 and Example 213 3-(4- ⁇ 3-Methyl-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-butyl ⁇ - benzoylamino)-propionic acid, Isomer 2
  • Example 30 These compounds are made by the general method exemplified in Example 30 by resolving racemic 3 -(4- ⁇ 3 -methyl-1 -[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3- yloxy]-butyl ⁇ -benzoylamino)-propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm).
  • Example 214 3-(4- ⁇ l-[6-(4-Isopropyl-phenyl)-5-methyl-pyridin-3-yloxy]-3-methyl-butyl ⁇ - benzoylamino)-propionic acid, Isomer 1 and Example 215 3-(4- ⁇ l-[6-(4-Isopropyl-phenyl)-5-methyl-pyridin-3-yloxy]-3-methyl-butyl ⁇ - benzoylamino)-propionic acid, Isomer 2
  • Example 216 3-(3-Fluoro-4- ⁇ 3-methyl-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-butyl ⁇ - benzoylamino)-propionic acid, Isomer 1 and Example 217 3-(3-Fluoro-4- ⁇ 3-methyl-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-butyl ⁇ - benzoyIamino) ⁇ propionic acid, Isomer 2
  • Example 218 3-(4- ⁇ 3-MethyI-l-[4-(5-trifluoromethyl-pyridin-2-yl)-phenoxy]-butyl ⁇ - benzoylamino)-propionic acid, Isomer 1 and Example 219 3-(4- ⁇ 3-Methyl-l-[4-(5-trifluoromethyl-pyridin-2-yI)-phenoxy]-butyl ⁇ - benzoylamino)-propionic acid, Isomer 2
  • Example 220 3- ⁇ 4-[l-(4-tert-Butyl-phenoxy)-3-methyl-butyI]-benzoyIamino ⁇ -propionic acid, Isomer 1 and Example 221 3- ⁇ 4-[l-(4-tert-Butyl-phenoxy)-3-methyl-butyl]-benzoyIamino ⁇ -propionic acid, Isomer 2
  • Example 222 2-Hydroxy-3- ⁇ 4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ - propionic acid, Isomer 1 and Example 223 2-Hydroxy-3- ⁇ 4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ - propionic acid, Isomer 2
  • Example 224 2-Hydroxy-3- ⁇ 4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ - propionic acid, Isomer 1 and Example 225 2-Hydroxy-3- ⁇ 4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ - propionic acid, Isomer 2
  • Example 226 3-(4- ⁇ l-[4-(l,l,3,3-Tetramethyl-butyl)-phenoxy]-heptyl ⁇ -benzoylamino)-propionic acid, Isomer 1 and Example 227 3-(4- ⁇ l-[4-(l,l,3,3-Tetramethyl-bu yl)-phenoxy]-heptyl ⁇ -benzoylamino)-propionic acid, Isomer 2
  • Example 228 3- ⁇ 4-[l-(2,2,3,3-Tetrafluoro-2,3-dihydro-benzo[l,4]dioxin-6-yloxy)-heptyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 229 3- ⁇ 4.[l.(2,2,3,3-Tetrafluoro-2,3-dihydro-benzo[l,4]dioxin-6-yloxy)-heptyl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 230 3- ⁇ 4-[l-(2,6-DimethyI-4'-trifluoromethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 231 3- ⁇ 4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 232 3- ⁇ 4-[l-(4'-tert-Buryl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 233 3- ⁇ 4-[l-(4 , -tert-Buryl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 30 3- ⁇ 4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl- butyl] -benzoylamino ⁇ -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm).
  • Example 234 3- ⁇ 4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 235 3- ⁇ 4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 236 3-(4- ⁇ 3,3-Dimethyl-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- butyl ⁇ -benzoylamino)-propionic acid, Isomer 1 and Example 237 3-(4- ⁇ 3,3-Dimethyl-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- butyl ⁇ -benzoylamino)-propionic acid, Isomer 2
  • Example 30 These compounds are made by the general method exemplified in Example 30 by resolving racemic 3 -(4- ⁇ 3 ,3 -dimethyl- 1 - [5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin- 3-yloxy]-butyl ⁇ -benzoylamino)-propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm).
  • Example 240 3- ⁇ 4-[l-(4'-Isopropyl-2-methyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino ⁇ - propionic acid, Isomer 1 and Example 241 3- ⁇ 4-[l-(4'-Isopropyl-2-methyI-biphenyl-4-yloxy)-3-methyl-butyI]-benzoylamino ⁇ - propionic acid, Isomer 2
  • These compounds are made by the general method exemplified in Example 30 by resolving racemic 3 - ⁇ 4- [ 1 -(4' ⁇ isopropyl-2-methyl-biphenyl-4-yloxy)-3 -methyl-butyl] - benzoylamino ⁇ -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm).
  • Example 248 3- ⁇ 4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino ⁇ -2-hydroxy-propionic acid, Isomer 1. and Example 249 3- ⁇ 4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino ⁇ -2-hydroxy-propionic acid, Isomer 2
  • This compound is made in a manner substantially similar to Example 117 using isomer 1 of 3- ⁇ 4-[l -(4-bromo-3,5-dimethyl-phenoxy)-3-methyl-butyl]-benzoylamino ⁇ - propionic acid methyl ester and 4-isopropylphenylboronic acid as starting materials in step D.
  • Example 254 3- ⁇ 4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 255 3- ⁇ 4- [1 -(2,6-Dimethyl-4' -trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl] - benzoylaminoj-propionic acid, Isomer 2
  • These compounds are made by the general method as exemplified in Example 30 by resolving racemic 3- ⁇ 4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3- methyl-butyl] -benzoylamino ⁇ -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm).
  • This compound is made by the general method as exemplified in Example 1 using
  • This compound is made by the general method as exemplified in Example 1 using 3 -(4-hydroxymethyl-benzoic acid methyl ester and 4'-trifluoromethyl-2,6-dimethyl- * biphenyl-4-ol as starting materials.
  • Example 264 Racemic 3- ⁇ 4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-ethyl]- benzoylamino ⁇ -propionic acid
  • This compound is made by the general method as exemplified in Example 1 using 4-(l-hydroxy-ethyl)-benzoic acid methyl ester and 4'-trifluoromethyl-2,6-dimethyl- bi ⁇ henyl-4-ol as starting materials.
  • Example 265 Racemic 3- ⁇ 4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-ethyl]-benzoylamino ⁇ - propionic acid
  • This compound is made by the general method as exemplified in Example 1 using 3-fluoro-4-(l-hydroxy-3-methyl-butyl)-benzoic acid methyl ester and 6-(4- trifluoromethyl-phenyl)-pyridin-3-ol as starting materials.
  • Example 267 Racemic 3-(4- ⁇ l-[4-(l,l,3,3-Tetramethyl-butyl)-phenoxy]-heptyl ⁇ -benzoylamino)- propionic acid This compound is made by the general method as exemplified in Example 1 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-(l,l,3,3-tetramethyl-butyl)-phenol as starting materials. MS (ES): 494.2 [M-H] " .
  • Example 268 Racemic 3-(4- ⁇ 3-Methyl-l-[4-(5-trifluoromethyl-pyridin-2-yl)-phenoxy]-butyl ⁇ - benzoylamino)-propionic acid
  • This compound is made by the general method as exemplified in Example 1 using
  • Example 270 Racemic 3- ⁇ 4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino ⁇ -2-hydroxy-propionic acid
  • This compound is made by the general method as exemplified in Example 1 using 4-(l-hydroxy-3,3-dimethyl-butyl)-benzoic acid methyl ester and 4'-tert-butyl-2,6- dimethyl-biphenyl-4-ol as starting materials.
  • Example 273 Chiral 3- ⁇ 4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyI-4-yloxy)-3-methyl-butyl]- benzoylamino ⁇ -2-hydroxy-propionic acid, Isomer 1
  • This compound is made by the general method as exemplified in Example 1 using chiral 4-(l-hydroxy-3-methyl-butyl)-benzoic acid methyl ester and 2,6-dimethyl-4'- trifluoromethyl-biphenyl-4-ol as starting materials.
  • Example 274 Racemic 3- ⁇ 4-[l-(4-Bromo-3-[l,3]dioxan-2-yl-phenoxy)-3-methyl-butyl]- benzoylamino ⁇ -propionic acid
  • This compound is made by the general method as exemplified in Example 1 using
  • Example 276 Racemic 3- ⁇ 4-[l-(4'-tert-ButyI-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino ⁇ -2- hydroxy-propionic acid This compound is made by the general method as exemplified in Example 1 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 4' -tertbutyl-biphenol as starting materials. MS (ES): 504.2 [M+H] + .
  • Example 277 Racemic 3- ⁇ 4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino ⁇ -2- hydroxy-propionic acid
  • Example 280 Racemic 2-Hy droxy-3- ⁇ 4- [l-(4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl] - benzoylamino ⁇ -propionic acid
  • Example 282 Racemic 3- ⁇ 4-[l-(4'-Isopropyl-2-methyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino ⁇ -propionic acid This compound is made by the general method as exemplified in Example 1 using 4-(l-hydroxy-3-methyl-butyl)-benzoic acid methyl ester and 4'-isopropyl-2-methyl- biphenyl-4-ol as starting materials.
  • This compound is made by the general method as exemplified in Example 1 using
  • This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-4,4-dimethyl-pentyl)-benzoic acid methyl ester and 6-chloro-5- methyl-pyridin-3-ol as reagents in step A and 4-trifluoromethylphenyl boronic acid in step C as starting materials.
  • Example 293 Racemic 3-(4- ⁇ 4,4-Dimethyl-l- [5-methyl-6-(4-trifluoromethoxy-phenyI)-pyridin-3- yloxy]-pentyl ⁇ -benzoylamino)-propionic acid
  • This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-4,4-dimethyl-pentyl)-benzoic acid methyl ester and 6-chloro-5- methyl-pyridin-3-ol as reagents in step A and 4-trifluoromethoxyphenyl boronic acid in step C as starting materials.
  • This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-3-methyl-butyl)-benzoic acid methyl ester and 4-bromo-benzene-l,3- diol as reagents in step A and 4-isopropylphenyl boronic acid in step C as starting materials.
  • Example 306 Racemic 3- ⁇ 4-[l-(2-[l,3]Dioxan-2-yl-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino ⁇ -propionic acid
  • This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 4-bromo-3- [l,3]dioxan-2-yl-phenol as reagents in step A and 4-isopropylphenyl boronic acid in step C as starting materials.
  • This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 2-bromo-5 ⁇ hydroxy- benzaldehyde O-tert-butyl-oxime as reagents in step A and 4-trifluoromethylphenyl boronic acid in step C as starting materials.
  • Example 309 Racemic 3- ⁇ 4-[l-(2,6-Dimethyl-biphenyl-4-yloxy)-3-methyl-buryl]-benzoylamino ⁇ - propionic acid
  • Tins compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 3-bromo-phenol as reagents in step A and 4-isopropyl-phenyl boronic acid in step C as starting materials.
  • Example 342 Racemic 3- ⁇ 4-[3-Methyl-l-(4'-trifluoromethoxy-biphenyl-3-yloxy)-butyl]- benzoylamino ⁇ -propionic acid
  • Step A 4-[l-(4-Bromo-3-[l,3]dioxan-2-yl-phenoxy)-3-methyl-butyl]-benzoic acid methyl ester
  • 4-( 1 -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester (1600 mg, 7.21 mmol) in toluene (72 mL) is added l, -(azodicarbonyl)dipiperidine (ADDP, 2728 mg, 10.81 mmol) at 0°C, followed by the additions of tributylphosphine (2.69 mL, 10.81 mmol) and 4-bromo-3-[l,3]dioxan-2-yl-phenol (2240 mg, 8.65 mmol).
  • the reaction mixture is warmed up to room temperature and stined overnight.
  • the mixture is loaded on silica gel, eluted with hexanes with a gradient from 0 % of ethyl
  • Step B 4-[l-(4-Bromo-3-[l,3]dioxan-2-yl-phenoxy)-3-methyl-butyl]-benzoic acid
  • 4-[l-(4-bromo-3-[l,3]dioxan-2-yl-phenoxy)-3-methyl-butyl]- benzoic acid methyl ester (1000 mg) in methanol (20 mL) is added sodium hydroxide (5
  • Step C 3- ⁇ 4-[l-(4-Bromo-3-[l,3]dioxan-2-yl-phenoxy)-3-methyl-butyl]- benzoylaminoj-propionic acid methyl ester
  • 4-[l-(4-bromo-3-[l,3]dioxan-2-yl-phenoxy)-3-methyl-butyl]- benzoic acid 940 mg, 2.09 mmol
  • methylene chloride 21 mL
  • DMAP 5.0 mg
  • 3-Amino-propionic acid methyl ester hydrochloride (438 mg, 3.14 mmol)
  • EDCI (1207 mg, 6.28mmol
  • Step D 3- ⁇ 4-[l-(2-[l,3]Dioxan-2-yl-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylaminoj-propionic acid methyl ester 3 - ⁇ 4- [ 1 -(4-Bromo-3 -[1,3] dioxan-2-yl-phenoxy)-3 -methyl-butyl] -benzoylamino ⁇ - propionic acid methyl ester (560 mg, 1.05 mmol), potassium Fluoride (183 mg, 3.15 mmol), 4-isopropylphenyl boronic acid (344 mg, 2.1 mmol) and tetrakis(triphenylphosphine)palladium (121 mg, 0.105 mmol) are placed in a flask.
  • Step E Racemic 3- ⁇ 4-[l-(2-Formyl-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoy laminoj-propionic acid methyl ester, and
  • Step A 4-[l-(6-Chloro-5-methyl-pyridin-3-yloxy)-3,3-dimethyl-butyl]-benzoic acid methyl ester
  • 4-(l -hydroxy-3 ,3 -dimethyl-butyl)-benzoic acid methyl ester 450 mg, 1.91 mmol
  • l,r-(azodicarbonyl)dipiperidine ADDP, 722 mg, 2.86 mmol
  • tributylphosphine (0.71 mL, 2.86 mmol
  • 6-chloro-5-methyl-pyridin-3-ol 327 mg, 2.29 mmol.
  • the reaction mixture is warmed up to room temperature and stined overnight.
  • the mixture is loaded on silica gel, eluted with hexanes with a gradient from 0 % of ethyl acetate to 50 % of ethyl acetate giving the titled compound (440 mg).
  • Step B 4-[l-(6-Chloro-5-methyl-pyridin-3-yloxy)-3,3-dimethyl-butyl]-benzoic acid
  • methanol 30 mL
  • sodium hydroxide 5 N aqueous, 2 mL
  • stined 5 h
  • the reaction mixture is concentrated and acidified by 5 N HCl (2 mL), extracted with ethyl acetate. Combined organic layers are washed with water and brine, dried over sodium sulfate.
  • Step C 3- ⁇ 4-[l-(6-Chloro-5-methyl-pyridin-3-yloxy)-3,3-dimethyl-butyl]- benzoylamino ⁇ -propionic acid methyl ester
  • 4-[l-(6-chloro-5-methyl-pyridin-3-yloxy)-3,3-dimethyl-butyl]- benzoic acid (414 mg, 1.19 mmol) in methylene chloride (12 mL) is added triethyl amine (0.
  • Step F 3-(4- ⁇ 3,3-Dimethyl-l-[5-methyl-l-oxy-6-(4-trifluoromethoxy-phenyl)- pyridin-3-yloxy] -butyl ⁇ -benzoylamino)-propionic acid
  • 3 -(4- ⁇ 3, 3 -Dimethyl- 1 -[5-methyl-6-(4-trifluoromethoxy- phenyl)-pyridin-3-yloxy] -butyl ⁇ -benzoylamino)-propionic acid methyl ester 200 mg, 0.36mmol
  • chloroform 20 mL
  • mCPBA 247 mg, 1.43mmol
  • Step A 4-[l-(4-Bromo-3,5-dimethyl-phenoxy)-2-methyl-propyl]-benzoic acid methyl ester
  • 4-(l-hydroxy-2-methyl-propyl)-benzoic acid methyl ester 5000 mg, 24.04 mmol
  • toluene 240 mL
  • l,r-(azodicarbonyl)dipiperidine ADDP
  • Step B 4-[l-(4-Bromo-3,5-dimethyl-phenoxy)-2-methyl-propyl]-benzoic acid methyl ester, isomers 1 and 2
  • the racemic 4- [ 1 -(4-bromo-3 ,5 -dimethyl-phenoxy)-2-methyl-propyl] -benzoic acid methyl ester was resolved on a Chiralcel OJ-H column (4.6 x 150 mm). Eluted with Methanol/DMEA (98/2) and concentrated the fractions to provide a purified enantiomer ester (isomer 1, 98.4 % ee, isomer 2, >99% ee).
  • Step C 4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]-benzoic acid methyl ester, isomer 1
  • Step D 4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]-benzoic acid, isomers 1 To the solution of isomer 1 of 4-[l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-
  • Step E 2-Hydroxy-3- ⁇ 4-[l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl- propyl]-benzoylamino ⁇ -propionic acid methyl ester, isomer 1
  • methylene chloride 4 mL
  • triethyl amine 0.15mL, 1.08 mmol
  • DMAP 5.0 mg
  • 3-Amino-2-hydroxy-propionic acid methyl ester 83 mg, 0.54 mmol
  • EDCI 208 mg, 1.08 mmol
  • reaction mixture is stined at room temperature overnight, loaded on silica gel, eluted with eluted with hexanes with a gradient from 0 % of ethyl acetate to 100 % of ethyl acetate giving the titled compound (150mg).
  • Example 351 2-Hydroxy-3- ⁇ 4-[l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • Step A Racemic 4-[l-(4-Bromo-3,5-dimethyl-phenyIsulfanyl)-5,5,5-trifluoro- pentyl] -benzoic acid methyl ester
  • 4-bromo-3,5-dimethyl-benzenethiol 0.572 g, 2.26 mmol
  • R,S 4-(5,5,5-trifluoro-l-hydroxy-penty ⁇ )-benzoic acid methyl ester (0.500 g, 1.81 mmol) in toluene(10 mL) is degassed and filled with nitrogen three times.
  • Tributylphosphine (0.670 mL, 2.72 mmol) is added to the reaction mixture under nitrogen at 0 °C, followed by addition of l,r-(azodicarbonyl)-dipiperidine (0.685 g, 2.72 mmol). The reaction mixture is allowed to warm to room temperature and stined overnight, the mixture is concentrated and purified by flash column chromatography (0.424 g, 0.89 mmol). Step B.
  • the reaction is allowed to stir under nitrogen at room temperature overnight.
  • the beta alanine ethyl ester hydrochloride (0.0695 g, 0.450 mmol) and 4-methylmorpholine (0.100 mL, 0.860 mmol) is added to the reaction mixture and allowed to stir at room temperature. Some water ( ⁇ 10% volume) is added to help solubility.
  • the reaction is monitored by HPLC, and upon complete consumption of the acid, the reaction is diluted with dichloromethane. The reaction is diluted with water and rinsed with IN hydrochloric acid. Upon acidification, the two layers are separated. The organic layer is washed with brine, dried over anhydrous sodium sulfate, and concentrated.
  • Step D Racemic 3- ⁇ 4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)- 5,5,5-trifluoro-pentyl]-benzoylamino ⁇ -propionic acid ethyl ester
  • To a solution of racemic 3- ⁇ 4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-5,5,5- trifluoro-pentyl] -benzoylamino ⁇ -propionic acid ethyl ester (0.200 g, 0.360 mmol) in toluene(2 mL) is added palladium tetrakis triphenylphosphine (0.0267 g, 0.020 mmol), 4- trifluoromethyl phenyl boronic acid(0.135 g, 0.720 mmol
  • Step A Racemic 4-[l-(4-Bromo-phenoxy)-5,5,5-trifluoro-pentyl]-benzoic acid methyl ester
  • a solution of the 4-bromo-phenol (2.36 g, 13.61 mmol) and (R,S) 4-(5,5,5- trifluoro-l-hydroxy-pentyl)-benzoic acid methyl ester (3.00 g, 10.89 mmol) in toluene (50 mL) is degassed and filled with nitrogen three times.
  • Tributylphosphine (4.03 mL, 16.34 mmol) is added to the reaction mixture under nitrogen at 0°C, followed by addition of l, -(azodicarbonyl)-dipiperidine (4.12 g, 16.34 mmol).
  • the reaction mixture is allowed to warm to room temperature and stined overnight; the mixture is concentrated and purified by flash column chromatography (3.0 g, 6.96 mmol).
  • Step B Racemic 4-[l-(4-Bromo-phenoxy)-5,5,5-trifluoro-pentyl]-benzoic acid
  • Racemic 4-[l-(4-bromo-phenoxy)-5,5,5-trifluoro-pentyl]-benzoic acid methyl ester (7.80 g, 18.1 mmol) is dissolved in the tetrahydrofuran (75 mL) and sodium hydroxide(25 mL, 5N) is added. The reaction is heated to reflux under nitrogen. The reaction is monitored by HPLC, and upon complete conversion, the reaction is neutralized with hydrochloric acid (25 mL, 5N) and diluted with diethyl ether and water.
  • Step C Racemic 3- ⁇ 4-[l-(4-Bromo-phenoxy)-5,5,5-trifluoro-pentyl]-benzoylamino ⁇ - propionic acid methyl ester Racemic 4-[l-(4-bromo-phenoxy)-5,5,5-trifluoro-pentyl]-benzoic acid (7.46 g, 17.89 mmol), 2-chloro-4,6-dimethoxy-l,3,5-triazine (3.23 g, 18.43 mmol) and 4- methylmorpholine (2.07 mL, 18.78 mmol) are combined in anhydrous dichloromethane (100 mL) under nitrogen.
  • the reaction is purged with nitrogen three times and heated to reflux under nitrogen.
  • the reaction is monitored by HPLC, and upon completion, allowed to cool to room temperature.
  • the reaction is diluted with ethyl acetate and celite is added, followed by water. This mixture is then filtered through a pad of celite.
  • the solution is poured into a separatory funnel and the organic layer is washed with water and brine. The organic layer is dried over anhydrous sodium sulfate and concentrated.
  • the product is purified by flash column chromatography (1.78 g, 3.24 mmol).
  • Racemic 3- ⁇ 4-[l-(2,4,6-tri-t-butyl-phenoxy)-5,5,5-trifluoro-pentyl]- benzoylamino ⁇ -propionic acid methyl ester To a solution of racemic 3-(4- ⁇ 5,5,5-Trifluoro-l-[4-(4,4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl)-phenoxy] -pentyl ⁇ -benzoylamino)-propionic acid methyl ester(0.300 g, 0.550 mmol) in toluene(3.0 mL) is added palladium tetrakis triphenylphosphine(0.0316 g, 0.030 mmol), 2-bromo-l ,3,5-tri-tert-butyl-benzene (0.353 g, 1.09 mmol), and potassium fluoride(0.063 g, 1.09 mmol).
  • the reaction is purged with nitrogen three times and heated to reflux under nitrogen. At reflux, water (1.0 mL) is added to the reaction and the reaction is allowed to reflux under nitrogen. The reaction is monitored by HPLC, and upon completion, allowed to cool to room temperature. The reaction is diluted with ethyl acetate and celite is added, followed by water. This mixture is then filtered through a pad of celite. The solution is poured into a separatory funnel and the organic layer is washed with water and brine. The organic layer is dried over anhydrous sodium sulfate and concentrated. The product is purified by flash column chromatography (0.333 g, 0.500 mmol).
  • Step F Racemic 3- ⁇ 4-[l-(2,4,6-tri-t-butyl-phenoxy)-5,5,5-trifluoro-pen yl]- benzoylamino ⁇ -propionic acid Racemic 3- ⁇ 4-[l-(2,4,6-tri-t-butyl-phenoxy)-5,5,5-trifluoro-pentyl]- berizoy lamino ⁇ -propionic acid methyl ester (0.333 g, 0.500 mmol) is dissolved in tehahydrofuran(3.0 mL) and sodium hydroxide(3.0 mL, 5N) is added.
  • Example 360 3-(4- ⁇ 5,5,5-trifluoro-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- pentyl ⁇ -benzoylamino)-propionic acid, Isomer 1 and Example 361 3-(4- ⁇ 5,5,5-trifluoro-l-[5-methyl-6-(4-trifluoromethyl-phenyI)-pyridin-3-yloxy]- pentyl ⁇ -benzoylamino)-propionic acid, Isomer 2
  • Example 362 Racemic 3-(4- ⁇ l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-pentyl ⁇ - benzoy!amino)-propionic acid
  • Example 363 Racemic 3- ⁇ 4-[l-(4'-tert-buryl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-5,5,5-trifluoro- pentyl] -benzoylamino ⁇ -propionic acid
  • Example 358 The title compound is prepared in a manner substantially similar to Example 358 starting from 3- ⁇ 4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-5,5,5-trifluoro-pentyl]- benzoylamino ⁇ -propionic acid methyl ester and 4-tert-butyl phenyl boronic acid. MS: , . 584.2 [M-H] " .
  • Example 364 Racemic 3- ⁇ 4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-5,5,5-trifluoro-pentyl]- benzoylamino ⁇ -propionic acid
  • Example 358 The title compound is prepared in a manner substantially similar to Example 358 starting from 3- ⁇ 4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-5,5,5-trifluoro-pentyl]- benzoylamino ⁇ -propionic acid methyl ester. MS: 531.2 [M-H] " .
  • Example 365 Racemic 3-(4- ⁇ 5,5,5-trifluoro-l- [5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3- yloxy] -penryl ⁇ -benzoylamino)-propionic acid
  • the title compound is prepared in a manner substantially similar to Example 1 starting from 4-(5,5,5-trifluoro-l-hydroxy-pentyl)-benzoic acid methyl ester and 5- methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-ol (Preparation 34).
  • Example 366 Racemic 3-(4- ⁇ 4,4,4-trifluoro-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3- yloxy]-butyl ⁇ -benzoylamino)-propionic acid
  • Example 367 3- ⁇ 4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-3-methyl-butyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 368 3- ⁇ 4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-3-methyl-butyI]- benzoyIamino ⁇ -propionic acid, Isomer 2
  • the title compound is prepared in a manner substantially similar to Example 358 starting from enatiomerically purified 3- ⁇ 4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-3- methyl-butyl] -benzoylamino ⁇ -propionic acid methyl ester and 4-trifluoromethyl phenyl boronic acid.
  • Example 369 3- ⁇ 4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-3-methyl-butyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 370 3- ⁇ 4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-3-methyl-butyl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • the title compound is prepared in a manner substantially similar to Example 367 starting from 3 - ⁇ 4- [ 1 -(4-bromo-3 ,5-dimethyl-phenylsulfanyl)-3 -methyl-butyl] - benzoylamino ⁇ -propionic acid methyl ester and 4-tert-butyl phenyl boronic acid.
  • Example 371 3- ⁇ 4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-4,4,4-trifluoro-butyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 372 3- ⁇ 4-[i-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-4,4,4-trifluoro-buryl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 373 3- ⁇ 4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-4,4,4-trifluoro-butyl]-benzoylamino ⁇ - propionic acid, Isomer 1 and Example 374 3- ⁇ 4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-4,4,4-trifluoro-butyl]-benzoylamino ⁇ - propionic acid, Isomer 2
  • Example 375 3- ⁇ 4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-3-methyl-butyl]-benzoylamino ⁇ - propionic acid, Isomer 1 and Example 376 3- ⁇ 4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-3-methyl-butyl]-benzoylamino ⁇ - propionic acid, Isomer 2
  • Example 377 3- ⁇ 4-[l-(2,6-dimethyl-4 , -trifluoromethyl-biphenyl-4-yloxy)-5,5,5-trifluoro-pentyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 378 3- ⁇ 4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-5,5,5-trifluoro-pentyl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 2 The title compounds are prepared in a manner substantially similar to Example 1 starting from 4-(6,6,6-trifluoro-l-hydroxy-hexyl)-benzoic acid methyl ester and 4'-tert- butyl-2,6-dimethyl-biphenyl-4-ol.
  • the isomers are resovled by methods described herein or known to one skilled in the art.
  • Example 381 Racemic 3- ⁇ 4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-4,4,4- trifluoro-butyl]-benzoylamino ⁇ -propionic acid
  • the title compound is prepared in a manner substantially similar to Example 358 starting from 3- ⁇ 4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-4,4,4-trifluoro-butyl]- benzoylamino ⁇ -propionic acid methyl ester and 4-trifluoromethyl phenyl boronic acid.
  • Example 383 The title compound is prepared in a manner substantially similar to Example 358 starting from 3- ⁇ 4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-4,4,4-trifluoro-butyl]- benzoylamino ⁇ -propionic acid methyl ester and 4-tert-butyl phenyl boronic acid. MS: 570.2 [M-H] " .
  • the title compound is prepared in a manner substantially similar to Example 358 starting from 3- ⁇ 4- [ 1 -(4-bromo-3 ,5-dimethyl-phenylsulfanyl)-3 -methyl-butyl] - benzoylamino ⁇ -propionic acid methyl ester and 4-trifluoromethyl phenyl boronic acid.
  • Example 384 Racemic 3- ⁇ 4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-3-methyl-butyl]- benzoylaminoj-propionic acid
  • the title compound is prepared in a manner substantially similar to Example 358 starting from 3 - ⁇ 4-[ 1 -(4-bromo-3 ,5-dimethyl-phenylsulfanyl)-3 -methyl-butyl] - benzoylamino ⁇ -propionic acid methyl ester and 4-tert-butyl phenyl boronic acid.
  • MS: 530.2 [M-H] " MS: 530.2 [M-H] " .
  • Example 386 Racemic 3- ⁇ 4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-3-methyl-butyl]- benzoylamino ⁇ -propionic acid
  • Example 358 The title compound is prepared in a manner substantially similar to Example 358 starting from 3 - ⁇ 4- [ 1 -(4-bromo-3 ,5 -dimethyl-phenylsulfanyl)-3 -methyl-butyl] - benzoylamino ⁇ -propionic acid methyl ester. MS: 477.2 [M-H] " .
  • Example 387 3- ⁇ 4-[l-(2,6-dimethyI-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ - propionic acid, Isomer 1 and Example 388 3- ⁇ 4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ - propionic acid, Isomer 2
  • Example 2 The title compounds are prepared in a manner substantially similar to Example 1 starting from 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4'-tert-butyl-2,6- dimethyl-biphenyl-4-ol. The isomers are resovled by methods described herein or known to one skilled in the art. Isomer 1 MS: 554.3 [M-H] " ; Isomer 2 MS: 554.3 [M-H] " .
  • Example 389 3- ⁇ 4-[3-methyl-l-(2,2',4'-trichloro-biphenyl-4-yloxy)-butyl]-benzoylamino ⁇ - propionic acid, Isomer 1 and Example 390 3- ⁇ 4-[3-methyl-l-(2,2',4'-trichloro-biphenyl-4-yloxy)-buryl]-benzoylamino ⁇ - propionic acid, isomer 2
  • Example 391 3- ⁇ 4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 392 3- ⁇ 4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 2 The title compounds are prepared in a manner substantially similar to Example 1 starting from 4-(4,4,4-trifluoro-l-hychOxy-butyl)-benzoic acid methyl ester and 2,6- dimethyl-4'-trifluoromethyl-biphenyl-4-ol.
  • the isomers are resovled by methods described herein or known to one skilled in the art.
  • Example 393 3- ⁇ 4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-buryl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 394 3- ⁇ 4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyI]- benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 395 3- ⁇ 4-[5,5,5-trifluoro-l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-pentyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 396 3- ⁇ 4-[5,5,5-trifluoro-l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-pentyl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • Example 128 The title compound is prepared in a manner substantially similar to Example 128 starting from 3- ⁇ 4-[l-(4-bromo-3,5-dimethyl-phenoxy)-5,5,5-trifluoro-pentyl]- benzoylamino ⁇ -propionic acid methyl ester and 4-isopropyl phenyl boronic acid. MS: 554.2 [M-H] " .
  • Example 398 3- ⁇ 4- [1 -(2,6 ⁇ dimethyl-4' -trifluoromethyl-biphenyl-4-yloxy)-5-methyl-hexyl] - benzoylamino ⁇ -propionic acid, Isomer 1 and Example 399 3- ⁇ 4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-5-methyl-hexyl]- benzoylamino ⁇ -propionic acid, Isomer 2
  • the title compounds are prepared in a manner substantially similar to Example 1 starting from 4-(l-hydroxy-5-methyl-hexyl)-benzoic acid methyl ester and 2,6-dimethyl- 4'-trifluoromethyl-biphenyl-4-ol.
  • Example 402 3-(4- ⁇ l 7 [6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-5-methyl-hexyl ⁇ -benzoylamino)- propionic acid, Isomer 1 and Example 403 3-(4- ⁇ 1 - [6-(4-tert-butyl-phenyl)-py ridin-3-yloxy] -5-methyl-hexyl ⁇ -benzoylamino)- propionic acid, Isomer 2
  • the title compounds are prepared in a manner substantially similar to Example 62 starting from 3 - ⁇ 4- [ 1 -(6-chloro-pyridin-3 -yloxy)-5 -methyl-hexyl] -benzoylamino ⁇ - propionic acid methyl ester and 4-tert-butyl phenyl boronic acid.
  • Example 405 Racemic 3- ⁇ 4-[l-(6-chloro-pyridin-3-yloxy)-5-methyl-hexyl]-benzoylamino ⁇ - propionic acid metliyl ester and 4-trifluoromethyl phenyl boronic acid.
  • Racemic 3- ⁇ 4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-5-methyl-hexyl]- benzoylamino ⁇ -propionic acid The title compound is prepared in a manner substantially similar to Example 1 starting from 4-(l-hydroxy-5-methyl-hexyl)-benzoic acid methyl ester and 2,6-dimethyl- 4'-trifluoromethyl-biphenyl-4-ol. MS: 554.2 [M-H] " .
  • Example 407 Racemic 3-(4- ⁇ l-[6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-5-methyl-hexyl ⁇ - benzoylamino)-propionic acid
  • Example 408 Racemic 3- ⁇ 4-[5-methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-hexyl]- benzoylamino ⁇ -propionic acid
  • Example 409 Racemic 3- ⁇ 4-[l-(4'-tert-butyl-biphenyl-4-yloxy)-5-methyl-hexyl]-benzoylamino ⁇ - propionic acid
  • the title compound is prepared in a manner substantially similar to Example 1 starting from 4-(l-hydroxy-5-methyl-hexyl)-benzoic acid methyl ester and 4'-tert-butyl- biphenyl-4-ol.
  • Example 410 3-(4- ⁇ l-[6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-5,5,5-trifluoro-pentyl ⁇ - benzoylamino)-propionic acid, Isomer 1 and Example 411 3-(4- ⁇ l-[6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-5,5,5-trifluoro-pentyl ⁇ - benzoylamino)-propionic acid, Isomer 2
  • Example 412 3-(4- ⁇ l-[6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-4,4,4-trifluoro-butyl ⁇ - benzoylamino)-propionic acid, Isomer 1 and Example 413 3-(4- ⁇ l-[6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-4,4,4-trifluoro-butyl ⁇ - benzoylamino)-propionic acid, Isomer 2
  • Example 414 Racemic 3- ⁇ 4-[(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-cyclohexyl-methyl]- benzoylamino ⁇ -propionic acid
  • Example 415 Racemic 3- ⁇ 4- [l-(4 ' -tert-butyl-2,6-dimethyl-biphenyl-4-y loxy)-4,4,4-trifluoro-buty 1] - benzoylamino ⁇ -propionic acid
  • Example 416 3- ⁇ 4-[4,4,4-trifluoro-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]-benzoylamino ⁇ - propionic acid, Isomer 1 and Example 417 3- ⁇ 4-[4,4,4-trifluoro-l-(4'-trifluoromethyI-biphenyI-4-yIoxy)-butyl]-benzoylamino ⁇ - propionic acid, Isomer 2
  • the title compounds are prepared in a manner substantially similar to Example 1 starting from 4-(4,4,4-trifluoro-l-hydroxy-butyl)-benzoic acid methyl ester and 4'- trifluoromethyl-biphenyl-4-ol.
  • Example 419 Racemic 3-(4- ⁇ 5,5,5-trifluoro-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- pentyl ⁇ -benzoylamino)-propionic acid
  • Example 62 The title compound is prepared in a manner substantially similar to Example 62 starting from 4-[l-(6-chloro-pyridin-3-yloxy)-5,5,5-trifluoro-pentyl]-benzoic acid methyl ester and 4-trifluoromethyl phenyl boronic acid. MS: 553.3 [M-H] " .
  • Example 420 Racemic 3-(4- ⁇ [6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-cyclohexyl-methyl ⁇ - benzoylamino)-propionic acid
  • the title compoxind is prepared in a manner substantially similar to Example 62 starting from 4- [(6-chloro-pyridin-3-yloxy)-cyclohexyl-methyl] -benzoic acid methyl ester and 4-tert-butyl phenyl boronic acid.
  • MS: 513.2 [M-H] " MS: 513.2 [M-H] " .
  • Example 422 Racemic 3- ⁇ 4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4,4-trifluoro- butyl]-benzoylamino ⁇ -propionic acid
  • Example 423 Racemic 3-(4- ⁇ cyclohexyl-[6-(4-isopropyl-phenyl)-pyridin-3-yIoxy]-methyl ⁇ - benzoylamino)-propionic acid
  • Example 424 Racemic 3- ⁇ 4-[cyclohexyl-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-methyI]- benzoylamino ⁇ -propionic acid
  • Example 425 Racemic 3- ⁇ 4- [4,4,4-trifluoro-l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-butyl] - benzoyIamino ⁇ -propionic acid
  • Example 426 3- ⁇ 4-[cyclohexyl-(4 , -trifluoromethyl-biphenyl-4-yloxy)-methyl]-benzoylamino ⁇ - propionic acid, Isomer 1 and Example 427 3- ⁇ 4-[cyclohexyl-(4'-trifluoromethyl-biphenyl-4-yloxy)-methyl]-benzoylamino ⁇ - propionic acid, Isomer 2
  • Example 428 3- ⁇ 4-[5,5,5-trifluoro-l-(4'-isopropyl-biphenyl-4-yloxy)-pentyl]-benzoylamino ⁇ - propionic acid, Isomer 1 and Example 429 3- ⁇ 4-[5,5,5-trifluor ⁇ l-(4'-isopropyl-biphenyl-4-yloxy)-pentyl]-benzoylamino ⁇ - propionic acid, Isomer 2
  • Example 430 Racemic 3- ⁇ 4- [(4' -tert-butyl-biphenyl-4-yloxy)-cy clohexyl-methyl] -benzoylamino ⁇ - propionic acid
  • Example 431 Racemic 3- ⁇ 4-[5,5,5-trifluoro-l-(2 , -3'-fluoro-4 , -trifluoromethyl-biphenyl-4-yloxy)- pentyl] -benzoylamino ⁇ -propionic acid
  • Example 432 Racemic 3- ⁇ 4-[cyclohexyl-(4'-trifluoromethyl-biphenyl-4-yloxy)-methyl]- benzoylamino ⁇ -propionic acid
  • the title compound is prepared in a manner substantially similar to Example 128 starting from 3 - ⁇ 4- [(4-bromo-phenoxy)-cyclohexyl-methyl] -benzoylamino ⁇ -propionic acid methyl ester and 4-trifluoromethyl phenyl boronic acid. MS: 524.3 [M-H] " .
  • Example 433 Racemic 3- ⁇ 4-[5,5,5-trifluoro-l-(4'-isopropyl-biphenyl-4-yloxy)-pentyl]- benzoylamino ⁇ -propionic acid
  • the title compound is prepared in a manner substantially similar to Example 128 starting from 3 - ⁇ 4- [ 1 -(4-bromo-phenoxy)-5 ,5 ,5 -trifluoro-pentyl] -benzoylamino ⁇ - propionic acid methyl ester and 4-isopropyl phenyl boronic acid.
  • MS 526.2 [M-H] " .
  • Example 434 Racemic 3- ⁇ 4-[l-(4'-ethyl-biphenyl-4-yloxy)-5,5,5-trifluoro-pentyl]-benzoylamino ⁇ - propionic acid
  • Example 435 Racemic 3- ⁇ 4-[5,5,5-trifluoro-l-(3'-fluoro-4'-trifluoromethyl-biphenyl-4-yloxy)- pentyl] -benzoylaminoj-propionic acid
  • the title compound is prepared in a manner substantially similar to Example 359 starting from 3-(4- ⁇ 5,5,5-trifluoro-l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- phenoxy]-pentyl ⁇ -benzoylamino)-propionic acid methyl ester and 4-bromo-2-fluoro-l- frifluoromethyl-benzene. MS: 570.2 [M-H] " .
  • Example 436 Racemic 3- ⁇ 4-[l-(2,4,6-triisopropyl-phenoxy)-5,5,5-trifluoro-pentyl]-benzoylamino ⁇ - propionic acid
  • the title compound is prepared in a manner substantially similar to Example 359 starting from 3-(4- ⁇ 5,5,5-trifluoro-l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- phenoxy]-pentyl ⁇ -benzoylamino)-propionic acid methyl ester and 2-bromo- 1,3,5- triisopropyl-benzene.
  • MS 610.2 [M-H] " .
  • Example 437 Racemic 3- ⁇ 4-[l-(2,3,4,5,6-pentamethyI-phenoxy)-5,5,5-trifluoro-pentyl]- benzoylamino ⁇ -propionic acid
  • Example 438 Racemic 3- ⁇ 4-[l-(2,4,6-tri-t-butyl-phenoxy)-5,5,5-trifluoro-pentyl]-benzoylamino ⁇ - propionic acid
  • Example 439 Racemic 3- ⁇ 4-[l-(3,5-dimethyl-phenoxy)-5,5,5-trifluoro-pentyl]-benzoylamino ⁇ - propionic acid
  • Example 440 3- ⁇ 4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-5,5,5-trifluoro-pentyl]- benzoylamino ⁇ -propionic acid, Isomer 1 and Example 441 3- ⁇ 4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyI-4-yloxy)-5,5,5-trifluoro-pentyI]- benzoylamino ⁇ -propionic acid, isomer 2
  • Example 443 Racemic 3- ⁇ 4-[l -(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-5,5,5-trifluoro- pentyl]-benzoylamino ⁇ -propionic acid
  • Example 444 Racemic 3-(4- ⁇ l-[4-(4-methyl-pentyloxy)-phenoxy]-heptyl ⁇ -benzoylamino)-propionic acid
  • Example 445 Racemic 3- ⁇ 4-[l-(4-pentyloxy-phenoxy)-heptyl]-benzoylamino ⁇ -propionic acid
  • Example 446 3- ⁇ 4-[5,5,5-trifluoro-l-(4 , -trifluoromethyl-biphenyl-4-yloxy)-pentyl]-benzoylamino ⁇ - propionic acid, Isomer 1 and Example 447
  • the title compound is prepared in a manner substantially similar to Example 128 starting from 3 - ⁇ 4- [ 1 -(4-bromo-phenoxy)-5 ,5 ,5 -trifluoro-pentyl] -benzoylamino ⁇ - propionic acid methyl ester and 4-trifluoromethyl phenyl boronic acid.
  • Example 450 3- ⁇ 4-[l-(4'-tert-butyl-biphenyl-4-yloxy)-5,5,5-trifluoro-pentyl]-benzoylamino ⁇ - propionic acid, Isomer 1 and Example 451 3- ⁇ 4-[l-(4'-tert-butyl-biphenyl-4-yloxy)-5,5,5-trifluoro-pentyl]-benzoylamino ⁇ - propionic acid, Isomer 2
  • Example 452 3-(4- ⁇ l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-hexyl ⁇ -benzoylamino)- propionic acid, Isomer 1 and Example 453 3-(4- ⁇ l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-hexyl ⁇ -benzoylamino)- propionic acid, Isomer 2
  • the title compounds are prepared in a manner substantially similar to Example 62 starting from 3 - ⁇ 4- [l-(6-chloro-pyridin-3-yloxy)-hexyl] -benzoylamino ⁇ -propionic acid methyl ester and 4-trifluoromethyl phenyl boronic acid.
  • Example 456 Racemic 3- ⁇ 4-[5,5,5-trifluoro-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-pentyl]- benzoylamino ⁇ -propionic acid
  • Example 457 Racemic 3- ⁇ 4-[l-(4'-tert-butyl-biphenyl-4-yloxy)-5,5,5-trifluoro-pentyl]- benzoylamino ⁇ -propionic acid
  • Example 458 Racemic 3- ⁇ 4-[l-(4-bromo-phenoxy)-5,5,5-trifluoro-pentyl]-benzoylamino ⁇ - propionic acid
  • Example 459 Racemic 3- ⁇ 4-[l-(4-hydroxy-phenoxy)-heptyl]-benzoylamino ⁇ -propionic acid
  • Example 460 3- (4- [1 -(2,6-Dimethyl-4' -trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl] - benzoylamino ⁇ -propionic acid, isomer 1
  • Example 461 3- ⁇ 4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino ⁇ -propionic acid, isomer 1
  • Example 462 3- ⁇ 4-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ - propionic acid, isomer 1
  • Example 463 3- ⁇ 4-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ - propionic acid, isomer 1
  • Example 463 3- ⁇ 4-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-heptyl]-benzoylamino ⁇ - propionic acid, isomer 1
  • the compound of Formula I is preferably formulated in a unit dosage form prior to administration. Therefore, yet another embodiment of the present invention is a pharmaceutical composition comprising a compound of Formula I and one or more pharmaceutically acceptable earners, diluents or excipients.
  • the present pharmaceutical compositions are prepared by known procedures using well-known and readily available ingredients.
  • the active ingredient (Formula I compound) will usually be mixed with a canier, or diluted by a canier, or enclosed within a canier which may be in the form of a capsule, sachet, paper or other container.
  • the canier When the canier serves as a diluent, it may be a solid, semisolid or liquid material that acts as a vehicle, excipient, or medium for the active ingredient.
  • the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosol (as a solid or in a liquid medium), soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
  • Suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpynolidone, cellulose, water syrup, methyl cellulose, methyl and propylhydroxybenzoates, talc, magnesium stearate and mineral oil.
  • the formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents.
  • compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient.
  • the compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimize the therapeutic effects, i.e., antihistaminic activity and the like.
  • Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.
  • Liquid form preparations include solutions, suspensions and emulsions.
  • Liquid form preparations may also include solutions for intranasal administration.
  • Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier such as inert compressed gas, e.g. nitrogen.
  • a pharmaceutically acceptable carrier such as inert compressed gas, e.g. nitrogen.
  • a low melting wax such as a mixture of fatty acid glycerides such as cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein by stirring or similar mixing.
  • the molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration, Such liquid forms include solutions, suspensions and emulsions.
  • the compounds of the invention may also be deliverable transdermally.
  • the transdermal compositions may take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as a re conventional in the art for this purpose.
  • the compound is administered orally.
  • the pharmaceutical preparation is in a unit dosage form.
  • the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose.
  • the quantity of the inventive active composition in a unit dose of preparation may be generally varied or adjusted from about 0.01 milligrams to about 1,000 milligrams, preferably from about 0.01 to about 950 milligrams, more preferably from about 0.01 to about 500 milligrams, and typically from about 1 to about 250 milligrams, according to the particular application.
  • the actual dosage employed may be varied depending upon the patient's age, sex, weight and severity of the condition being treated. Such techniques are well known to those skilled in the art.
  • the human oral dosage form containing the active ingredients can be administered 1 or 2 times per day.
  • glucagon plays an important role in glucose homeostasis.
  • Compounds of Formula I are effective as antagonists or inverse agonists of the glucagon receptor, and thus inhibit the activity of the glucagon receptor. More particularly, these compounds are selective antagonists or inverse agonists of the glucagon receptor. As selective antagonists or inverse agonists, the compounds of Formula I are useful in the treatment of diseases, disorders, or conditions responsive to the inactivation of the glucagon receptor, including but not limited to diabetic and other glucagon related disorder. It is postulated that selective antagonists or inverse agonists of the glucagon receptor will lower plasma glucose levels and thus prevent or treat diabetic and other glucagon related metabolic disorders.
  • Binding of compounds to the glucagon receptor may be determined in a competition binding assay using the cloned human glucagon receptor, and selectivity against the hGlpl receptor.
  • Antagonism may be determined as the ability of the compounds to inhibit the amount of cAMP formed in in the assay in the presence of 5 nM glucagon.
  • the receptor binding assay used cloned human glucagon receptor (Lok S, Kuijper JL, Jelinek LJ, Kramer JM, Whitmore TE, Sprecher CA, Mathewes S, Grant FJ, Biggs SH, Rosenberg GB, et al.Gene 140 (2), 203-209 (1994)) isolated from 293HEK membranes.
  • the hGlucR cDNA was subcloned into the expression plasmid phD (Trans-activated expression of fully gamma-carboxylated recombinant human protein C, an antithrombotic factor.
  • This plasmid DNA was transfected into 293 HEK cells and selected with 200 ug/mL Hygromycin. Crude plasma membranes are prepared using cells from suspension culture. The cells are lysed on ice in hypotonic buffer containing 25 mM Tris HCL, pH 7.5, 1 mM ⁇ MgC12, DNAsel, 20 u/mL, and Roche Complete Inhibitors-without EDTA. The cell suspension is homogenized with a glass dounce homogenizer using a Teflon pestle for 25 strokes. The homogenate is centrifuged at 4 degrees C at 1800 x g for 15 mins.
  • the supernate is collected and the pellet is resuspended in hypotonic buffer and rehomogenized.
  • the mixture is centrifuged at 1800 x g for 15 mins.
  • the second supernate is combined with the first supernate.
  • the combined supemates are recentrifuged at 1800 x g for 15 mins to clarify.
  • the clarified supernate is transfened to high speed tubes and centrifuged at 25000 x g for 30 minutes at 4 degrees C.
  • the membrane pellet is resuspended in homogenization buffer and stored as frozen aliquots at -80 degree C freezer until needed.
  • Glucagon is radioiodinated by I-125-lactoperoxidase procedure and purified by reversed phase HPLC at Perkin-Elmer/NEN (NEX207). The specific activity is 2200 Ci/mmol. Kd determination is performed by homologous competition instead of saturation binding due to high propanol content in the 1-125 glucagon material. The Kd is estimated to be 3 nM and is used to calculate Ki values for all compounds tested. The binding assays are carried out using a Scintillation Proximity Assay
  • the binding buffer contains 25 mM Hepes, pH 7.4, 2.5 mM CaC12, 1 mM MgC12, 0.1% fatty acid free BSA, (ICN), 0.003% tween-20, and Roche Complete Inhibitors without EDTA.
  • Glucagon is dissolved in 0.01 N HCl at 1 mg/mL and immediately frozen at -80 degrees C in 30 ul aliquots. The glucagon aliquot is diluted and used in binding assays within an hour. Test compounds are dissolved in DMSO and serially diluted in DMSO.
  • Glucagon -Like - Peptide 1 (Glpl-R) Receptor Binding Assay
  • the receptor binding assay used cloned human glucagon-like peptide 1 receptor (hGlpl-R). (Graziano MP, Hey PJ, Borkowski D, Chicchi GG, Strader CD, Biochem Biophys Res Commun. 1993 Oct 15;196(l):141-6) isolated from 293HEK membranes.
  • the hGlpl-R cDNA was subcloned into the expression plasmid phD (Trans-activated expression of fully gamma-carboxylated recombinant human protein C, an antithrombotic factor. Grinnell, B.W., Berg, D.T., Walls, J. and Yan, S.B. Bio/Technology 5: 1189- 1192 (1987)).
  • This plasmid DNA was transfected into 293 HEK cells and selected with 200 ug/mL Hygromycin. Crude plasma membrane is prepared using cells from suspension culture.
  • the cells are lysed on ice in hypotonic buffer containing 25 mM Tris HCl, pH 7.5, 1 mM MgC12, DNAse, 20 u/mL, and Roche Complete Inhibitors without EDTA.
  • the cell suspension is homogenized with a glass dounce homogenizer using a Teflon pestle for 25 strokes.
  • the homogenate is centrifuged at 4 degrees C at 1800 x g for 15 mins.
  • the supernate is collected and the pellet is resuspended in hypotonic buffer and rehomogenized.
  • the mixture is centrifuged at 1800 x g for 15 mins.
  • the second supernate is combined with the first supernate.
  • the combined supemates are recentrifuged at 1800 x g for 15 mins to clarify.
  • the clarified supernate is transfened to high speed tubes and centrifuged at 25000 x g for 30 minutes at 4 degrees C.
  • the membrane pellet is resuspended in homogenization buffer and stored as frozen aliquots in -80 degree C freezer until use.
  • Glucagaon-like peptide 1 (Glp-1) is radioiodinated by the I-125-lactoperoxidase procedure and purified by reversed phase HPLC at Perkin-Elmer/NEN (NEX308). The specific activity is 2200 Ci/mmol.
  • Kd determination is performed by homologous competition instead of saturation binding due to high propanol content in the 1-125 Glp-1 material.
  • the Kd is estimated to be 3 nM and is used to calculate Ki values for all compounds tested.
  • the binding assays are canied out using a Scintillation Proximity Assay (Amersham) with wheat germ agglutinin (WGA) beads previously blocked with 1% fatty acid free BSA (ICN).
  • the binding buffer contains 25 mM Hepes, pH 7.4, 2.5 mM CaC12, 1 mM MgC12, 0.1% fatty acid free BSA, (ICN), 0.003% rween-20, and Roche Complete Inhibitors without EDTA.
  • Glucagon-like peptide 1 is dissolved in PBS at 1 mg/mL and immediately frozen at -80 degrees C in 30 ul aliquots. The glucagon-like peptide aliquot is diluted and used in binding assays within an hour. Test compounds are dissolved in DMSO and serially diluted in DMSO. 10 ul diluted compounds or DMSO is transfened into Corning 3632, opaque clear bottom assay plates containing 90 ul assay binding buffer or cold glucagon-like peptide 1 (NSB at 1 uM final).
  • Glucagon-Stimulated cAMP Functional Antagonist Assay uses the same cloned human glucagon receptor cell line isolated for the hGlucR binding assay described above. Cells are stimulated with a mixture of an EC80 dose of glucagon in the presence of compound. The cAMP generated within the cell is quantitated using an Amplified Luminescent Proximity Homogeneous Assay, Alpha Screen, from Perkin Elmer (6760625R).
  • cAMP within the cell competes for binding of biotinylated cAMP from the kit to a coated anti-cAMP antibody Acceptor bead and a strepavidin coated Donor bead. As the cAMP level within the cell increases, a disruption of the Acceptor bead-biotinlyated cAMP -Donor bead complex occurs and decreases the signal.
  • Glucagon is dissolved in 0.01 N HCl at 1 mg/mL and immediately frozen at -80 degrees C in 30 ul aliquots. The glucagon aliquot is diluted and used in the functional assay within an hour.
  • Cells are harvested from sub-confluent tissue culture dishes with Enzyme-Free Cell Dissociation Solution, (Specialty Media 5-004-B). The cells are pelleted at low speed and washed 3 times with assay buffer [25 mM Hepes in HBSS-with Mg and Ca (GIBCO, 14025-092) with 0.1% Fatty Acid Free BSA (ICN)] then diluted to a final concentration of 250,000 cells per mL.
  • assay buffer 25 mM Hepes in HBSS-with Mg and Ca (GIBCO, 14025-092) with 0.1% Fatty Acid Free BSA (ICN)
  • Compounds are serially diluted into DMSO then diluted into assay buffer with a 3X concentration of glucagon and 3% DMSO.
  • the EC80 of glucagon is pre-determined from a full glucagon dose response and represents the dose at which glucagons produces an 80% of the maximal glucagon response.
  • a mixture of biotinylated cAMP (1 unit/well final) from the Alpha Screen Kit and 3X IBMX (1500 uM) is prepared in Assay Buffer.
  • the functional assay is performed in 96 well, low- volume, white, poylstyrene Costar Plates (3688).
  • the biotinylated cAMP/IBMX mixture 0.02 mLs, is placed into each well, followed by addition of 0.02 mLs of glucagon dose response, cAMP standard curve, or compound/glucagon mixtures.
  • the reaction is started by addition of 0.02 mLs of cells (5000/well final).
  • Lysis Buffer 10 mM Hepes, pH 7.4, 1% NP40, and 0.01% fatty acid free BSA (ICN) containing 1 unit each well of Acceptor and Donor beads from the Alpha Screen Kit. Lysis Buffer addition is performed under a green light to prevent bleaching of the detection beads. The plates are wrapped in foil and left to equilibrate overnight at room temperature. The plates are read on a Packard FusionTM- D Instrument. Alpha screen units are converted to pmoles cAMP generated per well based upon the cAMP standard curve.
  • the pmoles cAMP produced in the presence of compound are converted to % of a maximal response with the EC80 dose of glucagon alone. With each experiment, the dose of glucagon needed to produce a 50% response of pmoles cAMP is determined.
  • the compounds according to the invention preferably have a Ki value of no greater than 50 ⁇ M as determined by the Glucagon Receptor (hGlucR) Binding Assay disclosed herein. More preferably, the compounds according to the invention have a Ki value of less than 5 ⁇ M, preferably of less than 500 nM and even more prefened of less than 100 nM as determined by the Glucagon Receptor (hGlucR) Binding Assay disclosed herein. Generally, the compounds according to the invention show a higher affinity for the glucagon receptor compared to the GLP-1 receptor, and preferably have a higher binding affinity to the glucagon receptor than to the GLP-1 receptor. The results are given below for the indicated compound. Table 1:

Abstract

The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

Description

GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES This patent application claims the benefit of United States Provisional Patent Application No. 60/579,362 filed June 14, 2004. This invention relates to compounds that are antagonists or inverse agonists of the glucagon receptor, and to pharmaceutical compositions thereof, and the uses of these compounds and compositions in the treatment of the human or animal body. The present compounds show a high affinity and selective binding for the glucagon receptor, and as such are useful in the treatment of disorders responsive to the modulation of glucagon receptors, such as diabetic and other glucagon related metabolic disorders, and the like. Glucagon is a key hormonal agent that, in cooperation with insulin, mediates homeostatic regulation of the amount of glucose in the blood. Glucagon primarily acts by stimulating certain cells (important among these are liver cells) to release glucose when blood glucose levels fall. The action of glucagon is opposite to that of insulin, which stimulates cells to take up and store glucose whenever blood glucose levels rise. Both glucagon and insulin are peptide hormones. Glucagon is produced in the alpha islet cells of the pancreas and insulin is produced in the beta islet cells. Glucagon exerts its action by binding to and activating its receptor, which is a member of the Glucagon-Secretin branch of the 7-transmembrane G-protein coupled receptor family. The receptor functions by activating the adenylyl cyclase second messenger system resulting in an increase in cAMP levels. The glucagon receptor, or naturally occuπing variants of the receptor, may possess intrinsic constitutive activity, invitro, as well as in vivo (i.e. activity in the absence of an agonist). Compounds acting as inverse agonists can inhibit this activity. Diabetes mellitus is a common disorder of glucose metabolism. The disease is characterized by hyperglycemia and may be classified as type 1 diabetes, the insulin- dependent form, or type 2 diabetes, which is non-insulin-dependent in character. Subjects with type 1 diabetes are hyperglycemic and hypoinsulinemic, and the conventional treatment for this form of the disease is to provide insulin. However, in some patients with type 1 or type 2 diabetes, absolute or relative elevated glucagon levels have been shown to contribute to the hyperglycemic state. Both in healthy control animals as well as in animal models of type 1 and type 2 diabetes, removal of circulating glucagon with selective and specific antibodies has resulted in reduction of the glycemic level. Mice with a homozygous deletion of the glucagon receptor exhibit increased glucose tolerance. Also, inhibition of glucagon receptor expression using antisense oligonucleotides ameliorates diabetic syndrome in db/db mice. These studies suggest that glucagon suppression or an action that antagonizes glucagon could be a useful adjunct to conventional treatment of hyperglycemia in diabetic patients. The action of glucagon can be suppressed by providing an antagonist or an inverse agonist, i.e. substances that inhibit or prevent constituitive, or glucagon-induced, glucagon receptor mediated responses. Several publications disclose peptides that are stated to act as glucagon antagonists. Peptide antagonists of peptide hormones are often potent; however they are generally known not to be orally available because of degradation by physiological enzymes and poor distribution in vivo. Therefore, orally available non-peptide antagonists of peptide hormones are generally prefened. A number of publications have appeared in recent years reporting non-peptide agents that act at the glucagon receptor, h spite of the number of treatments for diseases that involve glucagon, the cunent therapies suffer from one or more inadequacies, including poor or incomplete efficacy, unacceptable side effects, and contraindications for certain patient populations. Thus, there remains a need for an improved treatment using alternative or improved pharmaceutical agents that modulate glucagon receptor activity and treat the diseases that could benefit from glucagon receptor modulation. The present invention provides such a contribution to the art based on the finding that a novel class of compounds has a high affinity, selective, and potent inhibitory activity at the glucagon receptor. The present invention is distinct in the particular structures and their activities. SUMMARY OF THE INVENTION The present invention provides a compound structurally represented by Formula I:
Figure imgf000003_0001
R11 ( I ) or a pharmaceutically acceptable salt thereof wherein:
Y is -O- or -S-;
Q, D, X, and T independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein), or nitrogen (optionally substituted with oxygen), provided that no more than two of Q, D, X, and T are nitrogen;
RI is -H, -OH, or -halogen;
R2 is -H or -(Cι-C3) alkyl (optionally substituted with 1 to 3 halogens);
R3 and R4 are independently - H, -halogen, -CN, -OH, -(C1-C7) alkoxy, -(C1-C7) alkyl(optionally substituted with 1 to 3 halogens), or -(C2-C7) alkenyl;
R5 is selected from the group consisting of -H, -( -C12) alkyl(optionally substituted with 1 to 3 halogens), -(C3-C12)cycloalkyl, -phenyl, -phenyl-phenyl-(C1-C12)alkyl, -aryl, -aryl-(C1-C12)alkyl, -heteroaryl, -heteroaryl-(C1-C12)alkyl, -(C2-C12)alkenyl, -(C3-C12)cycloalkenyl, -heterocycloalkyl, -aryl-(C2-C10)alkenyl, -heteroaryl-(C2-C10)alkenyl, -(C2-C12)alkynyl, -(C -C12)cycloalkynyl, -aryl-( C2-C12)alkynyl, and -heteroaryl-(C2-C12)alkynyl, and wherein -(C\- C12)alkyl, ~(C3-C12)cycloalkyl, -phenyl, -phenyl-phenyl-(C1-C12)alkyl, -aryl, -aryl-(C1-C12)alkyl, -heteroaryl, -heteroaryl-(C1-C12)alkyl, -heterocycloalkyl, -(C2- C12)alkenyl, -(C3-C12)cycloalkenyl, -aryl-(C2-C10)alkenyl, -heteroaryl-(C2-C10)alkenyl, -(C2-C12)alkynyl, -(C3-C12) cycloalkynyl, -aryl-(C2-C12)alkynyl, -heteroaryl-(C2-C12)alkynyl, are each optionally substituted with from one to three substituents each independently selected from the group consisting of -hydrogen, -hydroxy, -cyano, -nitro, -halo, -oxo, -(C1-C7)alkyl (optionally substituted with 1 to 3 halogens), -(C1-C7)alkyl-COOR12, -(C C7)alkoxy, -(C3-C7)cycloalkyl, -C(O)R12, -COOR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O)R12, -NR12SO2R12, -SR12, -S(O)R12, -S(O)2R12, and -S(O)2N(R12)2; R6 and R7 are independently at each occunence selected from the group consisting of -H, -halogen, -hydroxy, -CN, -( -C7) alkoxy, -(C2-C7)alkenyl, -(C1-C10)alkyl (optionally substituted with 1 to 3 halogens), ~(C -C12)cycloalkyl, tert-butoxyiminomethyl, l,3-dioxan-2-yl, hydroxymethyl, formyl, hydroxyiminomethyl, morphylino-4-yl-methyl, 4-methylpentyloxy, and pentyloxy; provided however that wherein D is nitrogen, then R6 or R7 are not attached to D, and provided that wherein T is nitrogen, then R6 or R7 are not attached to T, and provided that wherein Q is nitrogen, then R6 or R7 are not attached to Q, and provided that wherein X is nitrogen, then R6 or R7 are not attached to X; wherein R6 and R7 may optionally form a six membered ring with the atoms to which they are attached, and the ring so formed may optionally contain up to two oxygens, and further the ring so formed may optionally be substituted with up to four halogens; R8 and R9 are independently at each occunence selected from the group consisting of -hydrogen, -hydroxy, -CN, -nitro, -halo, -(Ci-C7)alkyl(optionally substituted with 1 to 3 halogens), -(C1-C7)alkoxy, -(C3-C7)cycloalkyl, -aryl, -aryl-(C1-C7)alkyl, -heteroaryl, -heteroaryl-(C1-C7)alkyl, -aryloxy, -C(O)R12, ~C(O)OR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O) R12, -NR12SO2 R12, -SR12, -S(O)R12, -S(O)2R12, -O(C2-C7)alkenyl, and -S(O)2N(R12)2; and wherein -(Cι-C7)alkyl, -(C1-C7)alkoxy, -(C3-C7)cycloalkyl, -aryl, -aryl-(C1-C7)alkyl, -heteroaryl, -heteroaryl-(C1-C7)alkyl, -aryloxy, and -O(C2-C7)alkenyl are each optionally substituted with from one to three substituents independently selected from the group consisting of -hydrogen, -hydroxy, -cyano, -nitro, -halo, -oxo, -(Cι-C7)alkyl, -(C1-C7)alkyl-C(O)OR12, -(C1-C7)alkoxyl, -(C3-C7)cycloalkyl, -heterocycloalkyl, -C(O)R12, -C(O)OR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O)R12, -NR12SO2 R12, -SR12, -S(O)R12, -S(O)2R12, and -S(O)2N(R12)2;
RIO is selected from the group consisting of -H, halogen, -(CrC12)alkyl(optionally substituted with 1 to 3 halogens), -cycloalkyl, -aryl, -aryl-(C1-C7)alkyl, -heteroaryl, -heteroaryl -(C1-C7)alkyl, -(C -C12)alkenyl, -(C3-C12)cycloalkenyl, -aryl-(C2-C1o)alkenyl, -heteroaryl-(C2-C1o)alkenyl, -(C2-C12)alkynyl, -(C3-C12)cycloalkynyl, -aryl-(C2-C12)alkynyl, and -heteroaryl-(C2-C12)alkynyl; Rll is independently at each occunence selected from the group consisting of -H, -halogen,
Figure imgf000006_0001
, wherein the zig-zag mark shows the point of attachment to the parent molecule, wherein A, G, and E independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein) or nitrogen, provided that no more than two of A, G, and E are nitrogen; provided however that wherein A is nitrogen, then R8, R9, and R14 are not attached to A, and provided that wherein G is nitrogen, then R8, R9, and R14 are not attached to G, and provided that wherein E is nitrogen, then R8, R9, and R14 are not attached to E,
Figure imgf000006_0002
, wherein the zig-zag mark shows the point of attachment to the parent molecule, wherein m is an integer of 0, 1, 2, or 3, and when m is 0, men (CH2)m is a bond, and
Figure imgf000006_0003
, wherein the zig-zag mark shows the point of attachment to the parent molecule, provided however that wherein D is nitrogen, then RI 1 is not attached to D, and provided that wherein T is nitrogen, then Rll is not attached to T, and provided that wherein Q is nitrogen, then Rll is not attached to Q, and provided that wherein X is nitrogen, then Rll is not attached to X; R12 is independently at each occunence selected from the group consisting of -hydrogen, -( -C7) alkyl(optionally substituted with 1 to 3 halogens), and -aryl;
R13 is independently at each occunence selected from the group consisting of -hydrogen, -halogen, -( \-Qη) alkyl(optionally substituted with 1 to 3 halogens), phenyl, and -(C2-C7)alkenyl; and R14 is independently at each occunence -H, halogen, or -( -C7) alkyl (optionally substituted with 1 to 3 halogens). The present invention provides compounds that are useful as glucagon receptor antagonists or inverse agonists. The present invention further provides compounds that are selective antagonists or inverse agonists of the glucagon receptor over the GLP-1 receptor. The present invention further provides a pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. Due to their interaction with the glucagon receptor, the present compounds are useful in the treatment of a wide range of conditions and disorders in which an interaction with the glucagon receptor is beneficial. These disorders and conditions are defined herein as "diabetic and other glucagon related metabolic disorders". One of skill in the art is able to identify "diabetic and other glucagon related metabolic disorders" by the involvement of glucagon receptor mediated signaling either in the pathophysiology of the disorder, or in the homeostatic response to the disorder. Thus, the compounds may find use for example to prevent, treat, or alleviate, diseases or conditions or associated symptoms or sequelae, of the endocrinological system, the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, and the gastrointestinal system, while reducing and or eliminating one or more of the unwanted side effects associated with the cunent treatments. "Diabetic and other glucagon related metabolic disorders" include, but are not limited to, diabetes, type 1 diabetes, type 2 diabetes, hyperglycemia, hyper insulinemia, beta-cell rest, improved beta-cell function by restoring first phase response, prandial hyperglycemia, preventing apoptosis, impaired fasting glucose (IFG), metabolic syndrome, hypoglycemia, hyper-/hypokalemia, normalizing glucagon levels, improved LDL/HDL ratio, reducing snacking, eating disorders, weight loss, polycystic ovarian syndrome (PCOS), obesity as a consequence of diabetes, latent autoimmune diabetes in adults (LAD A), insulitis, islet transplantation, pediatric diabetes, gestational diabetes, diabetic late complications, micro- /macroalbuminuria, nephropatl y, retinopathy, neuropathy, diabetic foot ulcers, reduced intestinal motility due to glucagon administration, short bowel syndrome, antidianheic, increasing gastric secretion, decreased blood flow, erectile dysfunction, glaucoma, post surgical stress, ameliorating organ tissue injury caused by reperfusion of blood flow after ischemia, ischemic heart damage, heart insufficiency, congestive heart failure, stroke, myocardial infarction, arcythmia, premature death, anti-apoptosis, wound healing, impaired glucose tolerance (IGT), insulin resistance syndromes, syndrome X, hyperlipidemia, dyslipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, arteriosclerosis including atherosclerosis, glucagonomas, acute pancreatitis, cardiovascular diseases, hypertension, cardiac hypertrophy, gastrointestinal disorders, obesity, diabetes as a consequence of obesity, diabetic dyslipidemia, etc. hi addition, the present invention provides a compound of Formula I, or a pharmaceutical salt thereof, or a pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutical salt thereof, and a pharmaceutically acceptable canier, diluent, or excipient: for use in inhibiting the glucagon receptor; for use in inhibiting a glucagon receptor mediated cellular response in a mammal; for use in reducing the glycemic level in a mammal; for use in treating a disease arising from excessive glucagon; for use in treating diabetic and other glucagon related metabolic disorders in a mammal; and for use in treating diabetes, obesity, hyperglycemia, atheroscelerosis, ischemic heart disease, stroke, neuropathy, and wound healing. Thus, the methods of this invention encompass a prophylactic and therapeutic administration of a compound of Formula I. The present invention further provides the use of a compound of Formula I, or a pharmaceutical salt thereof for the manufacture of a medicament for inhibiting the glucagon receptor; for the manufacture of a medicament for inhibiting a glucagon receptor mediated cellular response in a mammal; for the manufacture of a medicament for reducing the glycemic level in a mammal; for the manufacture of a medicament for treating a disease arising from excessive glucagon; for the manufacture of a medicament for treating diabetic and other glucagon related metabolic disorders in a mammal; and for the manufacture of a medicament for preventing or treating diabetes, obesity, hyperglycemia, atheroscelerosis, ischemic heart disease, stroke, neuropathy, and improper wound healing. The present invention further provides a method of treating conditions resulting from excessive glucagon in a mammal; a method of inhibiting the glucagon receptor in a mammal; a method of inhibiting a glucagon receptor mediated cellular response in a mammal; a method of reducing the glycemic level in a mammal; a method of treating diabetic and other glucagon related metabolic disorders in a mammal; a method of preventing or treating diabetes, obesity, hyperglycemia, atheroscelerosis, ischemic heart disease, stroke, neuropathy, and improper wound healing; said methods comprising administering to a mammal in need of such treatment a glucagon receptor-inhibiting amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutical salt thereof, and a pharmaceutically acceptable caπier, diluent, or excipient. In addition, the present invention provides a pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient: adapted for use in inhibiting the glucagon receptor; adapted for use in inhibiting glucagon receptor mediated cellular responses; adapted for use in reducing the glycemic level in a mammal; adapted for use in treating diabetic and other glucagon related metabolic disorders in a mammal; and adapted for use in preventing or treating diabetes, obesity, hyperglycemia, atherosclerosis, ischemic heart disease, stroke, neuropathy, and wound healing. The compound or salt of the present invention further provides a diagnostic agent for identifying patients having a defect in the glucagon receptor, as a therapy to increase gastric acid secretions, and to reverse intestinal hypomobility due to glucagon administration. The invention also provides a method for the treatment of disorders or diseases, wherein a glucagon antagonistic action is beneficial, the method comprising administering to a subject in need thereof an effective amount of a compound according to the invention. In another embodiment of the invention, the present compounds are used for the preparation of a medicament for the treatment of any ghicagon-mediated conditions and diseases. In another embodiment of the invention, the present compounds are used for the preparation of a medicament for the treatment of hyperglycemia. In yet another embodiment of the invention, the present compounds are used for the preparation of a medicament for lowering blood glucose in a mammal. The present compounds are effective in lowering the blood glucose, both in the fasting and the postprandial stage. In still another embodiment of the invention, the present compounds are used for the preparation of a pharmaceutical composition for the treatment of IGT. In a further embodiment of the invention, the present compounds are used for the preparation of a pharmaceutical composition for the treatment of type 2 diabetes. In yet a further embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the delaying or prevention of the progression from IGT to type 2 diabetes. In yet another embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the delaying or prevention of the progression from non-insulin requiring type 2 diabetes to insulin requiring type 2 diabetes. In a further embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the treatment of type 1 diabetes. Such treatment is normally accompanied by insulin therapy. In yet a further embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the treatment of obesity. In still a further embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the treatment of disorders of the lipid metabolism. In still another embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the treatment of an appetite regulation or energy expenditure disorder. In a further embodiment of the invention, treatment of a patient with the present compounds is combined with diet and/or exercise. DETAILED DESCRIPTION OF THE INVENTION General terms used in the description of compounds, compositions, and methods herein described, bear their usual meanings. Throughout the instant application, the following terms have the indicated meanings: "GLP-1" means glucagon-like peptide 1. The term "glucagon receptor" means one or more receptors that interact specifically with glucagon to result in a biological signal. The term "GLP-1 receptor" means one or more receptors that interact specifically with glucagon-like peptide 1 to result in a biological signal. The term "glucagon receptor antagonist" means a compound of the present invention with the ability to block cAMP production in response glucagon. The term "glucagon receptor inverse agonist" means a compound of the present invention with the ability to inhibit the constitutive activity of glucagon receptor. The term "selective" antagonist or inverse agonist means a compound having greater affinity for the glucagon receptor as compared to the affinity for the GLP-1 receptor. In the general formulae of the present document, the general chemical terms have their usual meanings. For example; "Halogen" or "halo" means fluoro, chloro, bromo and iodo. The term "alkyl," unless otherwise indicated, refers to those alkyl groups of a designated number of carbon atoms of either a straight or branched saturated configuration. "(Cι-C3) alkyl" are one to three carbon atoms, such as methyl, ethyl, propyl, n-propyl, isopropyl, and the like and branched or isomeric forms thereof, and optionally may be substituted with one to three halogens or a designated number of substituents as set forth in the embodiments recited herein, "( -C7) alkyl" are one to seven carbon atoms such as methyl, ethyl, propyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl, pentyl, isopentyl, hexyl, heptyl, and the like, and branched or isomeric forms thereof, and optionally may be substituted with one to three halogens or a designated number of substituents as set forth in the embodiments recited herein, and "( - o) alkyl" are one to ten carbon atoms, such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, nonyl, decyl, and the like, and branched or isomeric forms thereof, and optionally may be substituted with one to three halogens or a designated number of substituents as set forth in the embodiments recited herein. "(Ci-C12) alkyl" are one to twelve carbon atoms, such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, nonyl, decyl, and the like, and branched or isomeric forms thereof, and optionally may be substituted with one to three halogens or a designated number of substituents as set forth in the embodiments recited herein. The term "(C3-C12) cycloalkyl" refers to a saturated or partially saturated carbocycle containing one or more rings of from 3 to 12 carbon atoms, typically 3 to 7 carbon atoms optionally substituted with up to three halogens. Examples of (C3-C12) cycloalkyl include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, and the like. "(C3-C7) cycloalkyl" means a ring with three to seven carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, cycloheptyl, and the like, optionally substituted with up to three halogens. The term "(C1-C7) alkoxy" represents an alkyl group of one to seven carbon atoms attached through an oxygen bridge, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentoxy, and the like, and may be optionally substituted with three halogens or a designated number of substituents as set forth in the embodiments recited herein. The terms "(C2-C7) alkenyl", "(C2-C10) alkenyl", "(C2-C10) alkylenyl", "(C2-C12) alkenyl", or "(C2-C12) alkylenyl" means hydrocarbon chains of the indiacted number of carbon atoms of either a straight or branched configuration having at least one carbon- carbon double bond which may occur at any point along the chain, such as ethenyl, propenyl, butenyl, pentenyl, vinyl, alkyl, 2-butenyl and the like, and may be optionally substituted with one to three halogens or a designated number of substituents as set forth in the embodiments recited herein. The term "(C3-C12) cycloalkenyl " refers to a partially saturated carbocycle containing one or more rings of from 3 to 12 carbon atoms, typically 3 to 7 carbon atoms optionally substituted with up to three halogens. The term "(C2- 2) alkynyl" means a hydrocarbon chain of two to twelve carbon atoms of either a straight or branched configuration and having at least one carbon-carbon triple bond, which may occur at any point along the chain. Example of alkynyl is acetylene. Alkynyl as defined above may be optionally substituted with up to three halogens or the designated number of substituents as set forth in the embodiments recited herein. The term "(C3-Ci2) cycloalkynyl" refers to a carbocycle containing one or more rings of from 3 to 12 carbon atoms, typically 3 to 7 carbon atoms, having at least one carbon-carbon triple bond which may occur at any point along the chain or ring, optionally substituted with up to three halogens. Cycloalkynyl as defined above may be optionally substituted with the designated number of substituents as set forth in the embodiments recited herein. The term "aryl" includes carbocyclic aromatic ring systems (e.g. phenyl), fused polycyclic aromatic ring systems (e.g. naphthyl and anthracenyl), and aromatic ring systems fused to carbocyclic non-aromatic ring systems (e.g., 1,2,3,4- tetrahydronaphthyl). "Aryl" as defined above may be optionally substituted with a designated number of substituents as set forth in the embodiments recited herein. The term "aryloxy" refers to an aryl group which is linked to the parent molecule through an oxygen bridge. The term "heteroaryl" group, as used herein, is an aryl ring system having at least one heteroatom such as nitrogen, sulfur, or oxygen, and includes monocyclic, bicyclic, or tricyclic aromatic rings of 5 to 14 carbon atoms containing one or more heteroatoms selected from the group consisting of O, N, and S. The "heteroaryl" as defined above may be optionally substituted with a designated number of substituents as set forth in the embodiments recited herein. Examples of heteroaryl are, but are not limited to, furanyl, indolyl, thienyl (also refened to herein as "thiophenyl") thiazolyl, imidazolyl, isoxazoyl, oxazoyl, pyrazoyl, pynolyl, pyrazinyl, pyridyl, pyrimidyl, pyrimidinyl and purinyl, cinnolinyl, benzofuranyl, benzothienyl, benzotriazoiyl, benzoxazolyl, quinoline, isoxazolyl, isoquinoline, and the like. The term "arylalkyl" refers to an aryl group which is linked to the parent molecule through an alkyl moiety, and "arylalkyl" may be further optionally substituted with a designated number of substituents as set forth in the embodiments recited herein. The term "heterocycloalkyl" refers to a non-aromatic ring which contains one or more oxygen, nitrogen or sulfur and includes a monocyclic, bicyclic or tricyclic non- aromatic ring of 5 to 14 carbon atoms containing one or more heteroatoms selected from O, N, or S. The term "optionally substituted," or "optional substituents," as used herein, means that the groups in question are either unsubstituted or substituted with one or more of the substituents specified. When the groups in question are substituted with more than one substituent, the substituents may be the same or different. Furthermore, when using the terms "independently," "independently are," and "independently selected from" mean that the groups in question may be the same or different. Certain of the herein defined terms may occur more than once in the structural formulae, and upon such occunence each term shall be defined independently of the other. The term "patient" includes human and non-human animals such as companion animals (dogs and cats and the like) and livestock animals. Livestock animals are animals raised for food production. Ruminants or "cud-chewing" animals such as cows, bulls, heifers, steers, sheep, buffalo, bison, goats and antelopes are examples of livestock. Other examples of livestock include pigs and avians (poultry) such as chickens, ducks, turkeys and geese. Yet other examples of livestock include fish, shellfish and crustaceans raised in aquaculture. Also included are exotic animals used in food production such as alligators, water buffalo and ratites (e.g., emu, rheas or ostriches). The patient to be treated is preferably a mammal, in particular a human being. The term "a glucagon receptor mediated cellular response" includes various responses by mammalian cells to glucagon stimulation or glucagon receptor activity. For example "glucagon receptor mediated cellular responses," include but are not limited to, release of glucose from liver, or other cells, in response to glucagon stimulation or glucagon receptor activity. One of ordinary skill in the art can readily identify other cellular responses mediated by glucagon receptor activity, for example by observing a change in the responsive cellular endpoint after contacting the cell with an effective dose of glucagon. The terms "treatment", "treating" and "treat", as used herein, include their generally accepted meanings, i.e., the management and care of a patient for the purpose of preventing, prohibiting, restraining, alleviating, ameliorating, slowing, stopping, delaying, or reversing the progression or severity of a disease, disorder, or pathological condition, described herein, including the alleviation or relief of symptoms or complications, or the cure or elimination of the disease, disorder, or condition. "Composition" means a pharmaceutical composition and is intended to encompass a pharmaceutical product comprising the active ingredient(s) including compound(s) of Formula I, and the inert ingredient(s) that make up the canier. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable canier. The term "suitable solvent" refers to any solvent, or mixture of solvents, inert to the ongoing reaction that sufficiently solubilizes the reactants to afford a medium within which to effect the desired reaction. The term "unit dosage form" means physically discrete units suitable as unitary dosages for human subjects and other non-human animals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical carrier. In one embodiment, the present invention provides compounds of Formula I as described in detail herein. While all of the compounds of the present invention are useful, certain of the compounds are particularly interesting and are prefened. The following listing sets out several groups of prefened compounds. It will be understood that each of the listings may be combined with other listings to create additional groups of prefened embodiments. 1. wherein Y is -O-, 2. wherein Y is -S-, 3. wherein D, Q, X, and T are carbon(substituted with hydrogen or the optional substituents as indicated herein), 4. wherein RI, R2, R3, R4 and RIO are hydrogen, 5. wherein X is carbon and RI 1 is attached to X, 6. wherein D is carbon and Rll is attached to D,
7. wherein X is carbon and RI 1 is attached to X and RI 1 is
Figure imgf000015_0001
wherein the zig-zag mark shows the point of attachment to the parent molecule, and wherein A, G, and E independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein) or nitrogen, provided that no more than two of A, G, and E are nitrogen;
8. wherein X is carbon and RI 1 is attached to X and RI 1 is
Figure imgf000015_0002
, wherein the zig-zag mark shows the point of attachment to the parent molecule, and wherein A, G, and E independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein) or nitrogen, provided that no more than two of A, G, and E are nitrogen, and R8 and R9 are independently at each occunence selected from the group consisting of -hydrogen, -hydroxy, -CN, -nitro, -halo, -(C1-C7)alkyl(optionally substituted with 1 to 3 halogens), -(C1-C7)alkoxy, -(C3-C7)cycloalkyl, -aryl, -aryH ^^lkyl, -heteroaryl, -heteroaryl-(C1-C7)alkyl, -aryloxy, -C(O)R12, -C(O)OR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O)R12, -N R12SO2 R12, -SR12, -S(O)R12, -S(O)2 R12, and -S(O)2N(R12)2, 9. wherein X is carbon and RI 1 is attached to X and RI 1 is
Figure imgf000016_0001
wherein the zig-zag mark shows the point of attachment to the parent molecule, and wherein A, G, and E independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein) or nitrogen, provided that no more than two of A, G, and E are nitrogen, and R8 and R9 are independently at each occunence selected from the group consisting of -hydrogen, -hydroxy, -CN, -nitro, -halo, -(C1-C7)alkyl(optionally substituted with 1 to 3 halogens), -(C1-C7)alkoxy, and -(C3~C7)cycloalkyl,
10. wherein X is carbon and RI 1 is attached to X and RI 1 is
Figure imgf000016_0002
wherein the zig-zag mark shows the point of attachment to the parent molecule, and wherein A, G, and E are carbon (substituted with hydrogen or the optional substituents as indicated herein),
11. wherein X is carbon and R 11 is attached to X and R 11 is
Figure imgf000016_0003
wherein the zig-zag mark shows the point of attachment to the parent molecule, and wherein A, G, and E are carbon(substituted with hydrogen or the optional substituents as indicated herein), and R8 and R9 are independently at each occunence selected from the group consisting of -hydrogen, -hydroxy, -CN, -nitro, -halo, -(C1-C7)alkyl(optionally substituted with 1 to 3 halogens), -(CrC7)alkoxy, -(C3-C7)cycloalkyl, -aryl, -aryl-(C1-C7)alkyl, -heteroaryl, -heteroaryl-(Cι-C7)al yl, -aryloxy, -C(O)R12, -C(O)OR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O)R12, -N R12SO2 R12, -SR12, -S(O)R12, -S(O)2 R12, and -S(O)2N(R12)2, 12. wherein X is carbon and RI 1 is attached to X and RI 1 is
Figure imgf000017_0001
, wherein the zig-zag mark shows the point of attachment to the parent molecule, and wherein A, G, and E are carbon(substituted with hydrogen or the optional substituents as indicated herein), and R8 and R9 are independently at each occunence selected from the group consisting of -hydrogen, -hydroxy, -CN, -nitro, -halo, -(C1-C7)alkyl(optionally substituted with 1 to 3 halogens), -(Ci-C7)alkoxy, and -(C3-C7)cycloalkyl,
13. wherein one of D, X, Q or T is nitrogen,
14. wherein D is nitrogen, 15. wherein X is nitrogen,
16. wherein Q is nitrogen,
17. wherein T is nitrogen,
18. wherein two of D, X, Q and T are nitrogen,
19. wherein D and T are nitrogen, 20. wherein Q and X are nitrogen,
21. wherein RI is hydrogen,
22. wherein RI is -OH,
23. wherein RI is halogen,
24. wherein R2 is hydrogen, 25. wherein R2 is -(d-C3) alkyl(optionally substituted with 1 to 3 halogens),
26. wherein R3 is hydrogen,
27. wherein R3 is halogen,
28. wherein R4 is hydrogen,
29. wherein R4 is halogen, 30. wherein R3 is selected from the group consisting of -( -C7) alkoxy, -( -C6) alkyl(optionally substituted with 1 to 3 halogens), and -(C2-C7) alkenyl,
31. wherein R4 is selected from the group consisting of -(C1-C7) alkoxy, -( -C7) alkyl(optionally substituted with 1 to 3 halogens), and -(C2-C7) alkenyl,
32. R5 is selected from the group consisting of -H, -(Cι-C12) alkyl(optionally substituted with 1 to 3 halogens), -(C3-C12)cycloalkyl, -phenyl, -phenyl-phenyl-(C1-C 2)alkyl, -aryl, -aryl-(Cι-Cι2)alkyl, -heteroaryl, -heteroaryl-(Cι-Cι2)alkyl, -(C2-Cι2)alkenyl, -(C3-C12)cycloalkenyl, -heterocycloalkyl, -aryl-(C2-C]0)alkenyl, -heteroaryl-(C2-C10)alkenyl, -(C2-C12)alkynyl, -(C3-C12)cycloalkynyl, -aryl-(C2-Ci2)alkynyl, and -heteroaryl-( C2-Ci2)alkynyl, 33. R5 is selected from the group consisting of -H, -(Cι-C12) alkyl(optionally substituted with 1 to 3 halogens), -(C3-C12)cycloalkyl, -phenyl, -phenyl-phenyl-(C1-C12)alkyl, -(C2-C12)alkenyl, -(C3-C12)cycloalkenyl, -heterocycloalkyl, -(C2-CI2)alkynyl, and -(C3-C12)cycloalkynyl, 34. R5 is selected from the group consisting of -(C1- 2) alkyl(optionally substituted with 1 to 3 halogens), and -(C3-C12)cycloalkyl, 35. wherein R6 and R7 are methyl, 36. wherein R6 and R7 form a six membered ring with the atoms to which they are attached, and the ring so formed may optionally contain up to two oxygens, and further the ring so formed may optionally be substituted with up to four , halogens, 37. wherein R8 is attached in the para postion and is tertbutyl or trifloromethyl, 38. RIO is selected from the group consisting of -H, halogen, -(Cι-Ci2)alkyl(optionally substituted with 1 to 3 halogens), -(C3-Ci2)cycloalkyl, -(C2-C12)alkenyl, -(C C^cycloalkenyl, -(C2-C12)alkynyl, -(C3-Cj2)cycloalkynyl, -aryl-(C2_C12)alkynyl, and -heteroaryl-(C2-C12)alkynyl, 39. RIO is selected from the group consisting of -H, halogen, or -(C1-Cι2)alkyl(optionally substituted with 1 to 3 halogens,
Another embodiment is a compound of Formula I or a pharmaceutically acceptable salt thereof wherein: Y is -O- or -S-; Q, D, X, and T independently represent carbon or nitrogen, provided that no more than two of Q, D, X, and T are nitrogen; RI is -H, -OH, or -halogen; R2 is -H or -(C1-C3) alkyl;
R3 and R4 are independently at each occunence selected from the group consisting of - H, -halogen, -CN, -OH, -(C1-C7) alkoxy, -(C1-C7) alkyl, -(C2-C7) alkenyl;
R5 is selected from the group consisting of -H, -(Cι-Cι2) alkyl, -(C3-C12)cycloalkyl, -phenyl, -phenyl-phenyl-(C1-C12)alkyl, -aryl, -aryl-(C1-C12)alkyl, -heteroaryl, -heteroaryl-(C1-C12)alkyl, -(C2-C12)alkenyl, -(C3-C12)cycloalkenyl, -heterocycloalkyl, -aryl-(C2-C10)alkenyl, -heteroaryl-(C2-C10)alkenyl, -(C2-C12)alkynyl, -(C3-C12)cycloalkynyl, -aryl-( C2-C!2)alkynyl, and -heteroaryl-( C2~C12)alkynyl, and wherein -(Ci- Cι2)alkyl, -(C3-C12)cycloalkyl, -phenyl, -phenyl-phenyl-(C1-C12)alkyl, -aryl, -aryl- (C!-C12)alkyl, -heteroaryl, -heteroaryl-( CrC12)alkyl, -heterocycloalkyl, -(C2- C12)alkenyl, -(C3-C12)cycloalkenyl, -aryl-(C2-C10)alkenyl, -heteroaryl-(C2- C10)alkenyl, -(C2-C12)alkynyl, -(C3-C12) cycloalkynyl, -aryl-(C2-C12)alkynyl, and -heteroaryl-(C2-C12)alkynyl, are each optionally substituted with from one to three substituents each independently selected from the group consisting of -hydrogen, -hydroxy, -cyano, -nitro, -halo, -oxo, -(Cι-C7)alkyl, -(C1-C7)alkyl-COOR12, -(Ci- C7)alkoxy, -(C3-C7)cycloalkyl, -aryloxy, -aryl, -aryl-(C1-C7)alkyl, - heteroaryl,-heterocycloalkyl, -C(O)R12, -COOR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O)R12, -NR12SO2R12, -SR12, -S(O)R12, -S(O)2R12, and -S(O)2N(R12)2;
R6 and R7 are independently at each occunence selected from the group consisting of -H, -halogen, -hydroxy, -CN, -( -C7) alkoxy, -(C2-C7)alkenyl, and -(Cι-C7)alkyl, provided however that wherein D is nitrogen, then R6 or R7 are not attached to D, and provided that wherein T is nitrogen, then R6 or R7 are not attached to T, and provided that wherein Q is nitrogen, then R6 or R7 are not attached to Q, and provided that wherein X is nitrogen, then R6 or R7 are not attached to X; wherein R6 and R7 may optionally form a six membered ring with the atoms to which they are attached, and the ring so formed may optionally contain up to two oxygens, and further the ring so formed may optionally be substituted with up to four halogens;
R8 and R9 are independently at each occunence selected from the group consisting of -hydrogen, -hydroxy, -CN, -nitro, -halo, -(C1-C7)alkyl,
Figure imgf000020_0001
-(C3-C7)cycloalkyl, -aryl, -aryl-(C1-C7)alkyl, -heteroaryl, -heteroaryl-(C1-C7)alkyl, -aryloxy, -C(O)R12, -COOR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O) R12, -NR12SO2 R12, -SR12, -S(O)R12, -S(O)2 R12, and -S(O)2N(R12)2; and wherein -(C1-C7)alkyl, -(Ci-C7)alkoxy, -(C3-C7)cycloalkyl, -aryl, -aryl-(C1-C7)alkyl, -heteroaryl, -heteroaryl-(C1-C7)alkyl, -aryloxy, are each optionally substituted with from one to three substituents independently selected from the group consisting of -hydrogen, -hydroxy, -cyano, -nitro, -halo, -oxo, -(Cι-C7)alkyl, -(Cι-C7)alkyl-COOR12, -(C1-C7)alkoxyl, -(C3-C7)cycloalkyl, -aryloxy, -aryl, -aryl-(C1-C7)alkyl, -heteroaryl, -heterocycloalkyl, -C(O)R12, -COOR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O)R12, -NR12SO2 R12, -SR12, -S(O)R12, -S(O)2R12, and -S(O)2N(R12)2; RIO is selected from the group consisting of -H, -(C1-C12)alkyl, -cycloalkyl, -aryl, -aryl-(C1-C7)alkyl, -heteroaryl, -heteroaryl- (C1-C7)alkyl, -(C2-C12)alkenyl, -(C3-C12)cycloalkenyl, -aryl-(C2-C10)alkenyl, -heteroaryl-(C2-C1o)alkenyl, -(C2-Cj2)alkynyl, -(C3-Ci2)cycloalkynyl, -aryl-(C2-C12)alkynyl, and -heteroaryl-(C2-C!2)alkynyl, and wherein -(Ci- C12)alkyl, -cycloalkyl, -aryl, -aryl-(C1-C7)alkyl, -heteroaryl, -heteroaryl -(Ci- C7)alkyl, -(C2-C12)alkenyl, -(C3-C12)cycloalkenyl, -aryl-(C2-C10)alkenyl, -heteroaryl-(C2-C10)alkenyl, -(C2-C12)alkynyl, -(C3-C12)cycloalkynyl, -aryl-(C2- C12)alkynyl, and -heteroaryl-(C2-C12)alkynyl, are each optionally substituted with from one to three substituents each independently selected from the group consisting of -hydrogen, -hydroxy, -cyano, -nitro, -halo, -oxo, -(CrC7)alkyl, -( - C7)alkyl-COOR12, -(C1-C7)alkoxyl, -(C3-C7)cycloalkyl, -aryloxy, -aryl, -aryl-Cr C7 alkyl, -heteroaryl, -heterocycloalkyl, -C(O)R12, -COOR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O)R12, -NR12SO2 R12, -SR12, -S(O)R12, -S(O)2R12, and -S(O)2N(R12)2; Rll is idependently at each occurrence selected from the group consisting of -H,
Figure imgf000021_0001
, wherein the zig-zag mark shows the point of attachment to the parent molecule, wherein A, G, and E independently represent carbon or nitrogen, provided that no more than two of A, G, and E are nitrogen; provided however that wherein A is nitrogen, then R8 or R9 are not attached to A, and provided that wherein G is nitrogen, then R8 or R9 are not attached to G, and provided that wherein E is nitrogen, then R8 or R9 are not attached to E;
Figure imgf000021_0002
, wherein the zig-zag mark shows the point of attachment to the parent molecule, wherein m is an integer of 0, 1, 2, or 3, and when m is 0 m is a bond, provided however that wherein D is nitrogen, then RI 1 is hot attached to D, and provided that wherein T is nitrogen, then Rll is not attached to T, and provided that wherein Q is nitrogen, then Rll is not attached to Q, and provided that wherein X is nitrogen, then Rll is not attached to X; R12 is independently at each occunence selected from the group consisting of -hydrogen, -( -C7) alkyl, and -aryl,
R13 is independently at each occunence selected from the group consisting of -hydrogen, -halogen, -( -C7) alkyl, and -(C2-C7)alkenyl.
Another preferred embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: Y is -O- or -S-; Q, D, X, and T independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein) or nitrogen, provided that no more than two of Q, D, X, and T are nitrogen; RI is -H, -OH, or -halogen; R2 is -H or -(Ci-C3) alkyl (optionally substituted with 1 to 3 halogens); R3 and R4 are independently - H, -halogen, -CN, -( -C7) alkoxy, -( -C7) alkyl(optionally substituted with 1 to 3 halogens), or -(C2-C7) alkenyl; R5 is selected from the group consisting of -(Ci-C12) alkyl(optionally substituted with 1 to 3 halogens), -(C3-Cι2)cycloalkyl, -phenyl, -phenyl-phenyl-(C1-C12)alkyl, -(C2-C12)alkenyl, -(C3-C12)cycloalkenyl, -heterocycloalkyl, -(C2-C12)alkynyl, and -(C3-C12)cycloalkynyl, and wherein -( -C^alkyl, -(C3-C12)cycloalkyl, -phenyl, -phenyl-phenyl-(C1-C12)alkyl, -heterocycloalkyl, -(C2-C12)alkenyl, -(C3-C12)cycloalkenyl, -(C2-C12)alkynyl, and -(C3-C12)cycloalkynyl, are each optionally substituted with from one to three substituents each independently selected from the group consisting of -hydrogen, -hydroxy, -cyano, -nitro, -halo, -oxo, -(Cι-C7)alkyl (optionally substituted with 1 to 3 halogens);
R6 and R7 are independently at each occunence selected from the group consisting of -H, -halogen, -hydroxy, -CN, -( -C7) alkoxy, -(C2-C7)alkenyl, -(C1-C1o)alkyl (optionally substituted with 1 to 3 halogens), -(C3-C12)cycloalkyl, tert-butoxyiminomethyl, l,3-dioxan-2-yl, hydroxymethyl, formyl, hydroxyiminomethyl, morphylino-4-yl-methyl, 4-methylpentyloxy, and pentyloxy; provided however that wherein D is nitrogen, then R6 or R7 are not attached to D, and provided that wherein T is nitrogen, then R6 or R7 are not attached to T, and provided that wherein Q is nitrogen, then R6 or R7 are not attached to Q, and provided that wherein X is nitrogen, then R6 or R7 are not attached to X; wherein R6 and R7 may optionally form a six membered ring with the atoms to which they are attached, and the ring so formed may optionally contain up to two oxygens, and further the ring so formed may optionally be substituted with up to four halogens; R8 and R9 are independently at each occunence selected from the group consisting of -hydrogen, -hydroxy, -CN, -nitro, -halo, -(C1-C7)alkyl(oρtionally substituted with 1 to 3 halogens), -(C1-C7)alkoxy, -(C3-C7)cycloalkyl, -C(O)R12, -C(O)OR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O) R12, -NR12SO2 R12, -SR12, -S(O)R12, -S(O)2R12, -O(C2-C7)alkenyl, and -S(O)2N(R12)2; and wherein -(C!-C7)alkyl, -(C C7)alkoxy, -(C3-C7)cycloalkyl, and -O(C2-C7)alkenyl are each optionally substituted with from one to three substituents independently selected from the group consisting of -hydrogen, -hydroxy, -cyano, -nitro, -halo, -oxo, and -(Cι-C7)alkyl
RIO is selected from the group consisting of -H, halogen, and -(C1-C12)alkyl(optionally substituted with 1 to 3 halogens); RI 1 is independently at each occunence selected from the group consisting of -H, -halogen,
Figure imgf000023_0001
, wherein the zig-zag mark shows the point of attachment to the parent molecule, wherein A, G, and E independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein) or nitrogen, provided that no more than two of A, G, and E are nitrogen; provided however that wherein A is nitrogen, then R8, R9, and R14 are not attached to A, and provided that wherein G is nitrogen, then R8, R9, and R14 are not attached to G, and provided that wherein E is nitrogen, then R8, R9, and R14 are not attached to E,
Figure imgf000024_0001
, wherein the zig-zag mark shows the point of attachment to the parent molecule, wherein m is an integer of 0, 1, 2, or 3, and when m is 0 then (CH2)m is a bond, and
Figure imgf000024_0002
, wherein the zig-zag mark shows the point of attachment to the parent molecule, provided however that wherein D is nitrogen, then Rll is not attached to D, and provided that wherein T is nitrogen, then RI 1 is not attached to T, and provided that wherein Q is nitrogen, then RI 1 is not attached to Q, and provided that wherein X is nitrogen, then RI 1 is not attached to X; R12 is independently at each occunence selected from the group consisting of -hydrogen, and -(C1-C7) alkyl(optionally substituted with 1 to 3 halogens); R13 is independently at each occunence selected from the group consisting of -hydrogen, -halogen, -( -C7) alkyl(optionally substituted with 1 to 3 halogens), phenyl, and -(C2-C7)alkenyl; and R14 is independently at each occunence -H, halogen, or -(C1-C7) alkyl (optionally substituted with 1 to 3 halogens).
Another prefened embodiment is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: Y is -O- or -S-;
Q, D, X, and T independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein);
RI is -H, -OH, or -halogen;
R2 is -H; R3 and R4 are independently -H, -halogen, or -(C1-C7) alkyl(optionally substituted with 1 to 3 halogens); R5 is selected from the group consisting of -(C1-C12) alkyl(optionally substituted with 1 to 3 halogens), and -(C3-C12)cycloalkyl(optionally substituted with 1 to 3 halogens);
R6 and R7 are independently at each occunence selected from the group consisting of -H, -halogen, -hydroxy, -CN, -(C1-C7) alkoxy, -(C2-C7)alkenyl, -(C1-C10)alkyl (optionally substituted with 1 to 3 halogens), -(C3-C12)cycloalkyl, tert-butoxyiminomethyl, l,3-dioxan-2-yl, hydroxymethyl, formyl, hydroxyiminomethyl, morphylino-4-yl-methyl, 4-methylpentyloxy, and pentyloxy; provided however that wherein D is nitrogen, then R6 or R7 are not attached to D, and provided that wherein T is nitrogen, then R6 or R7 are not attached to T, and provided that wherein Q is nitrogen, then R6 or R7 are not attached to Q, and provided that wherein X is nitrogen, then R6 or R7 are not attached to X;
R8 and R9 are independently at each occunence selected from the group consisting of -hydrogen, -halogen, -(Ci-C7)alkyl(optionally substituted with 1 to 3 halogens), -(C1-C7)alkoxy, -(C3-C7)cycloalkyl, -C(O)R12, -COOR12, -OC(O)R12, -OS(O)2R12, -SR12, -S(O)R12, -S(O)2R12, and -O(C2-C7)alkenyl;
RIO is -H;
RI 1 is independently at each occunence selected from the group consisting of -H, -halogen, and
Figure imgf000025_0001
, wherein the zig-zag mark shows the point of attachment to the parent molecule, wherein A, G, and E independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein), provided however that wherein A is nitrogen, then R8, R9, and R14 are not attached to A, and provided that wherein G is nitrogen, then R8, R9, and R14 are not attached to G, and provided that wherein E is nitrogen, then R8, R9, and R14 are not attached to E; R12 is independently at each occunence selected from the group consisting of -hydrogen, and -(C C?) alkyl(optionally substituted with 1 to 3 halogens); R13 is independently at each occunence selected from the group consisting of -hydrogen, -halogen, -( -C7) alkyl(optionally substituted with 1 to 3 halogens), and -(C2-C7)alkenyl; and R14 is independently at each occunence -H, halogen, or -( -C7) alkyl (optionally substituted with 1 to 3 halogens). As used herein, the term "stereoisomer" refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures called configurations. As used herein, the term "enantiomer" refers to two stereoisomers whose molecules are nonsuperimposable minor images of one another. The term "chiral center" refers to a carbon atom to which four different groups are attached. As used herein, the term "diastereomers" refers to stereoisomers which are not enantiomers. In addition, two diastereomers which have a different configuration at only one chiral center are refened to herein as "epimers." The terms "racemate," "racemic mixture" or "racemic modification" refer to a mixture of equal parts of enantiomers. The compounds of the present invention may be chiral, and it is intended that any enantiomers, whether pure, partially purified, or racemic mixtures, are included within the scope of the invention. Furthermore, when a double bond or a fully or partially saturated ring system or more than one center of asymmetry or a bond with restricted rotatability is present in the molecule diastereomers may be formed. It is intended that any diastereomers, as separated, pure or partially purified diastereomers or mixtures thereof are included within the scope of the invention. Furthermore, some of the compounds of the present invention may exist in different tautomeric forms and it is intended that any tautomeric forms, which the compounds are able to form, are included within the scope of the present invention. Thus, as one skilled in the art knows, certain aryls may exist in tautomeric forms. The invention also includes tautomers, enantiomers and other stereoisomers of the compounds of Formula I. Such variations are contemplated to be within the scope of the invention. The terms "R" and "S" are used herein as commonly used in organic chemistry to denote specific configuration of a chiral center. The term "R" (rectus) refers to that configuration of a chiral center with a clockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group. The term "S" (sinister) refers to that configuration of a chiral center with a counterclockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group. The priority of groups is based upon their atomic number (in order of decreasing atomic number). A partial list of priorities and a discussion of stereochemistry is contained in "Nomenclature of Organic Compounds: Principles and Practice", (J.H. Fletcher, et al., eds., 1974) at pages 103-120. The designation " """^ " refers to a bond that protrudes forward out of the plane of the page. The designation " '""" " refers to a bond that protrudes backward out of the plane of the page. The designation " ~*Afv " refers to a bond wherein the stereochemistry is not defined. The compounds of Formula I, when existing as a diastereomeric mixture, may be separated into diastereomeric pairs of enantiomers by, for example, fractional crystallization from a suitable solvent, for example methanol or ethyl acetate or a mixture thereof. The pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid as a resolving agent. Alternatively, any enantiomer of a compound of Formula I may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known configuration or through enantioselective synthesis. The term "enantiomeric enrichment" as used herein refers to the increase in the amount of one enantiomer as compared to the other. A convenient method of expressing the enantiomeric enrichment achieved is the concept of enantiomeric excess, or "ee," which is found using the following equation: ee = E1 - E2 X 100 E + E2 . wherein E1 is the amount of the first enantiomer and E2 is the amount of the second enantiomer. Thus, if the initial ratio of the two enantiomers is 50:50, such as is present in a racemic mixture, and an enantiomeric enrichment sufficient to produce a final ratio of 70:30 is achieved, the ee with respect to the first enantiomer is 40%. However, if the final ratio is 90:10, the ee with respect to the first enantiomer is 80%. An ee of greater than 90% is prefened, an ee of greater than 95% is most prefened and an ee of greater than 99%) is most especially prefened. Enantiomeric enrichment is readily determined by one of ordinary skill in the art using standard techniques and procedures, such as gas or high performance liquid chromatography with a chiral column. Choice of the appropriate chiral column, eluent and conditions necessary to effect separation of the enantiomeric pair is well within the knowledge of one of ordinary skill in the art. In addition, the specific stereoisomers and enantiomers of compounds of Formula I, can be prepared by one of ordinary skill in the art utilizing well known techniques and processes, such as those disclosed by J. Jacques, et al., "Enantiomers. Racemates, and Resolutions," John Wiley and Sons, Inc., 1981, and E.L. Eliel and S.H. Wilen," Stereochemistry of Organic Compounds." (Wiley-Interscience 1994), and European Patent Application No. EP-A-838448, published April 29, 1998. Examples of resolutions include recrystallization techniques or chiral chromatography. Unless otherwise indicated, a compound indicated to be "isomer 1" will be the first isomer eluted from the chiral separation column and "isomer 2" will be the second. In general, the term "pharmaceutical" when used as an adjective means substantially non-toxic to living organisms. For example, the term "pharmaceutical salt" as used herein, refers to salts of the compounds of Formula I, which are substantially non-toxic to living organisms. See, e.g., Berge, S.M, Bighley, L.D., and Monkhouse, D.C., "Pharmaceutical Salts," J. Pharm. Sci., 66:1, 1977. The present invention also encompasses pharmaceutically acceptable salts of the present compounds. Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts. Also intended as pharmaceutically acceptable acid addition salts are any hydrates that the present compounds are able to form. Furthermore, the pharmaceutically acceptable salts comprise basic amino acid salts such as lysine, arginine and ornithine. Typical pharmaceutical salts include those salts prepared by reaction of the compounds of Formula I, with an inorganic or organic acid or base. Such salts are known as acid addition or base addition salts respectively. These pharmaceutical salts frequently have enhanced solubility characteristics compared to the compound from which they are derived, and thus are often more amenable to formulation as liquids or emulsions. The term "acid addition salt" refers to a salt of a compound of Formula I, prepared by reaction of a compound of Formula I, with a mineral or organic acid. For exemplification of pharmaceutical acid addition salts see, e.g., Berge, S.M, Bighley, L.D., and Monkhouse, D.C., J. Pharm. Sci., 66:1, 1977. Since compounds of this invention can be basic in nature, they accordingly react with any of a number of inorganic and organic acids to form pharmaceutical acid addition salts. The acid addition salts may be obtained as the direct products of compound synthesis. In the alternative, the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent. Acids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids, such as p-toluenesulfonic acid, ethanesulfonic acid, methanesulfonic acid, oxalic acid, 7-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, tartaric acid, benzoic acid, acetic acid and the like. Prefened pharmaceutical acid addition salts are those formed with mineral acids such as hydrochloric acid, hydrobromic acid, and sulfuric acid, and those formed with organic acids such as maleic acid, tartaric acid, and methanesulfonic acid. Examples of such pharmaceutically acceptable salts thus are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-l,4-dioate, hexyne-l,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxybutyrate, glycollate, tartrate, methanesulfonate, propanesulfonate, naphthalene- 1 -sulfonate, naphthalene-2-sulfonate, mandelate and the like. The skilled artisan would appreciate that some compounds of Formula I, may be acidic in nature and accordingly react with any of a number of inorganic and organic bases to form pharmaceutical base addition salts. The term "base addition salt" refers to a salt of a compound of Formula I, prepared by reaction of a compound of Formula I, with a mineral or organic base. For exemplification of pharmaceutical base addition salts see, e.g., Berge, S.M, Bighley, L.D., and Monkhouse, D.C., J. Pharm. Sci., 66:1, 1977. Bases commonly employed to form pharmaceutical base addition salts are inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like. Such bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate, and the like. Examples of pharmaceutical base addition salts are the ammonium, lithium, potassium, sodium, calcium, magnesium, methylamino, diethylamino, ethylene diamino, cyclohexylamino, and ethanolamino salts, and the like of a compound of Formula I. The potassium and sodium salt forms are particularly prefened. The present invention also contemplates pharmaceutical base addition salts of compounds of Formula I. The pharmaceutical salts of the invention are typically formed by reacting a compound of Formula I, with an equimolar or excess amount of acid or base. The reactants are generally combined in a mutual solvent such as diethylether, tetrahydrofuran, methanol, ethanol, isopropanol, benzene, and the like for acid addition salts, or water, an alcohol or a chlorinated solvent such as dichloromethane for base addition salts. The salts normally precipitate out of solution within about one hour to about ten days and can be isolated by filtration or other conventional methods. All pharmaceutically acceptable salts are contemplated in the present invention. The compound or salt of the present invention may form a solvate with low molecular weight solvents. Such solvates are also contemplated as being within the scope of the present invention. The invention also encompasses prodrugs of the present compounds, which on administration undergo chemical conversion by metabolic processes before becoming pharmacologically active substances. In general, such prodrugs will be functional derivatives of present compounds, which are readily convertible in vivo into a compound of the present invention. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985. In a further aspect of the invention the present compounds are administered in combination with one or more further active substances in any suitable ratios. Such further active substances may for example be selected from antidiabetics, antiobesity agents, antihypertensive agents, agents for the treatment of complications resulting from or associated with diabetes and agents for the treatment of complications and disorders resulting from or associated with obesity. The following listing sets out several groups of combinations. It will be understood that each of the agents named may be combined with other agents named to create additional combinations. Thus, in a further embodiment of the invention the present compounds may be administered in combination with one or more antidiabetics. Suitable antidiabetic agents include insulin, insulin analogues and derivatives such as those disclosed in EP 792290 (Novo Nordisk A/S), for example NεB29-tetradecanoyl des (B30) human insulin, EP 214 826 and EP 705 275 (Novo Nordisk A/S), for example AspB28 human insulin, US 5,504,188 (Eli Lilly), for example LysB28 ProB29 human insulin, EP 368 187 (Aventis), for example Lantus®, which are all incorporated herein by reference, GLP-1 and GLP-1 derivatives such as those disclosed in WO 98/08871 (Novo Nordisk A/S), which is incorporated herein by reference, as well as orally active hypoglycemic agents. The orally active hypoglycemic agents preferably comprise imidazolines, sulphonylureas, biguanides, meglitinides, oxadiazolidinediones, thiazolidinediones, insulin sensitizers, insulin secretagogues, such as glimepiride, α-glucosidase inhibitors, agents acting on the ATP-dependent potassium channel of the β-cells for example potassium channel openers such as those disclosed in WO 97/26265, WO 99/03861 and WO 00/37474 (Novo Nordisk A S) which are incorporated herein by reference, or mitiglinide, or a potassium channel blocker, such as BTS-67582, nateglinide, glucagon antagonists such as those disclosed in WO 99/01423 and WO 00/39088 (Novo Nordisk A/S and Agouron Pharmaceuticals, Inc.), which are incorporated herein by reference, GLP-1 antagonists, DPP-IV (dipeptidyl peptidase-IV) inhibitors, PTPase (protein tyrosine phosphatase) inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis and/or glycogenolysis, glucose uptake modulators, activators of glucokinase (GK) such as those disclosed in WO 00/58293, WO 01/44216, WO 01/83465, WO 01/83478, WO 01/85706, WO 01/85707, and WO 02/08209 (Hoffman-La Roche) or those disclosed in WO 03/00262, WO 03/00267 and WO 03/15774 (AstraZeneca), which are incorporated herein by reference, GSK-3 (glycogen synthase kinase-3) inhibitors, compounds modifying the lipid metabolism such as antilipidemic agents such as HMG CoA inhibitors (statins), compounds lowering food intake, PPAR (Peroxisome proliferator-activated receptor) ligands including the PPAR-alpha, PPAR- gamma and PPAR-delta substypes, and RXR (retinoid X receptor) agonists, such as ALRT-268, LG-1268 or LG-1069 In another embodiment, the present compounds are administered in combination with insulin or an insulin analogue or derivative, such as NεB29-tetradecanoyl des (B30) human insulin, AspB28 human insulin, LysB28 ProB29 human insulin, Lantus®, or a mix- preparation comprising one or more of these. In a further embodiment of the invention the present compounds are administered in combination with a sulphonylurea such as glibenclamide, glipizide, tolbautamide, chloropamidem, tolazamide, glimepride, glicazide and glyburide. In another embodiment of the invention the present compounds are administered in combination with a biguanide for example metormin. In yet another embodiment of the invention the present compounds are administered in combination with a meglitinide for example repaglinide or nateglinide. In still another embodiment of the invention the present compounds are administered in combination with a thiazolidinedione insulin sensitizer for example troglitazone, ciglitazone, piolitazone, rosiglitazone, isaglitazone, darglitazone, englitazone, CS-01 l/CI-1037 or T 174 or the compounds disclosed in WO 97/41097, WO 97/41119, WO 97/41120, WO 00/41121 and WO 98/45292 (Dr. Reddy's Research Foundation), which are incorporated herein by reference. In still another embodiment of the invention the present compounds may be administered in combination with an insulin sensitizer for example such as GI 262570, YM-440, MCC-555, JTT-501, AR-H039242, KRP-297, GW-409544, CRE-16336, AR- H049020, LY510929, MBX-102, CLX-0940, GW-501516 or the compounds disclosed in WO 99/19313, WO 00/50414, WO 00/63191, WO 00/63192, WO 00/63193 such as ragaglitazar (NN 622 or (-)DRF 2725) (Dr. Reddy's Research Foundation) and WO
00/23425, WO 00/23415, WO 00/23451, WO 00/23445, WO 00/23417, WO 00/23416, WO 00/63153, WO 63196, WO 00/63209, WO 00/63190 and WO 00/63189 (Novo Nordisk A/S), which are incorporated herein by reference. In a further embodiment of the invention the present compounds are administered in combination with an α-glucosidase inhibitor for example voglibose, emiglitate, miglitol or acarbose. In another embodiment of the invention the present compounds are administered in combination with an agent acting on the ATP-dependent potassium channel of the β- cells for example tolbutamide, glibenclamide, glipizide, glicazide, BTS-67582 or repaglinide. In yet another embodiment of the invention the present compounds may be administered in combination with nateglinide. In still another embodiment of the invention the present compounds are administered in combination with an antilipidemic agent or antihyperlipidemic agent for example cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, pitavastatin, rosuvastatin, probucol, dextrothyroxine, fenofibrate or atorvastin. In still another embodiment of the invention the present compounds are administered in combination with compounds lowering food intake. In another embodiment of the invention, the present compounds are administered in combination with more than one of the above-mentioned compounds for example in combination with metformin and a sulphonylurea such as glyburide; a sulphonylurea and acarbose; nateglinide and metformin; repaglinide and metformin, acarbose and metformin; a sulfonylurea, metformin and troghtazone; insulin and a sulfonylurea; insulin and metformin; insulin, metformin and a sulfonylurea; insulin and troghtazone; insulin and lovastatin; etc. In a further embodiment of the invention the present compounds may be administered in combination with one or more antiobesity agents or appetite regulating agents. Such agents may be selected from the group consisting of CART (***e amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melanocortin 4) agonists, MC3 (melanocortin 3) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, urocortin agonists, β3 adrenergic agonists such as CL-316243, AJ-9677, GW-0604, LY362884, LY377267 or AZ-40140 MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte- concentrating hormone) antagonists, CCK (cholecystoldnin) agonists, serotonin re-uptake inhibitors such as fluoxetine, seroxat or citalopram, serotonin and noradrenaline re-uptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT (serotonin) agonists, bombesin agonists, galanin antagonists, growth hormone, growth factors such as prolactin or placental lactogen, growth hormone releasing compounds, TRH (thyreotropin releasing hormone) agonists, UCP 2 or 3 (uncoupling protein 2 or 3) modulators, leptin agonists, DA agonists (bromocriptin, doprexin), lipase/amylase inhibitors, PPAR (peroxisome proliferator-activated receptor) modulators, RXR (retinoid X receptor) modulators, TR β agonists, AGRP (Agouti related protein) inhibitors, H3 histamine antagonists, opioid antagonists (such as naltrexone), exendin-4, GLP-1 and ciliary neurotrophic factor (such as axokine), cannaboid receptor antagonist for example CB-1 (such as rimonabanf). In another embodiment the antiobesity agent is dexamphetamine or amphetamine. In another embodiment the antiobesity agent is leptin. In another embodiment the antiobesity agent is fenfluramine or exfenfluramine. In still another embodiment the antiobesity agent is sibutramine. In a further embodiment the antiobesity agent is orlistat. In another embodiment the antiobesity agent is mazindol or phentermine. In still another embodiment the antiobesity agent is phendimetrazine, diethylpropion, fluoxetine, bupropion, topiramate or ecopipam. Furthermore, the present compounds may be administered in combination with one or more antihypertensive agents. Examples of antihypertensive agents are β-blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, SCE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and α-blockers such as doxazosin, urapidil, prazosin and terazosin. Further reference can be made to Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995. The compounds of the present invention may be administered in combination with FAS inhibitors. The compounds of the present invention may also be administered in combination with chemical uncouplers, hormone sensitive lipase inhibitor, imidazolines, 11-β- hydroxy steroid dehydrogenase inhibitors, lipoprotein lipase activator, AMPK activators, immunosuppresive drugs, nicotinamide, ASIS, anti-androgens or carboxypeptidase inhibitors. It should be understood that any suitable combination of the compounds according to the invention with diet and/or exercise, one or more of the above-mentioned compounds and optionally one or more other active substances are considered to be within the scope of the present invention. The compounds of Formula I, can be prepared by one of ordinary skill in the art following a variety of procedures, some of which are illustrated in the procedures and schemes set forth below. The particular order of steps required to produce the compounds of Formula I is dependent upon the particular compound to being synthesized, the starting compound, and the relative liability of the substituted moieties. The reagents or starting materials are readily available to one of skill in the art, and to the extent not commercially available, are readily synthesized by one of ordinary skill in the art following standard procedures commonly employed in the art, along with the various procedures and schemes set forth below. The following Schemes, Preparations, Examples and Procedures are provided to better elucidate the practice of the present invention and should not be interpreted in any way as to limit the scope of the same. Those skilled in the art will recognize that various modifications may be made while not departing from the spirit and scope of the invention. All publications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains. The optimal time for performing the reactions of the Schemes, Preparations,
Examples and Procedures can be determined by monitoring the progress of the reaction via conventional chromatographic techniques. Furthermore, it is prefened to conduct the reactions of the invention under an inert atmosphere, such as, for example, argon, or, particularly, nitrogen. Choice of solvent is generally not critical so long as the solvent employed is inert to the ongoing reaction and sufficiently solubilizes the reactants to effect the desired reaction. The compounds are preferably isolated and purified before their use in subsequent reactions. Some compounds may crystallize out of the reaction solution during their formation and then collected by filtration, or the reaction solvent may be removed by extraction, evaporation, or decantation. The intermediates and final products of Formula I may be further purified, if desired by common techniques such as recrystallization or chromatography over solid supports such as silica gel or alumina. The skilled artisan will appreciate that not all substituents are compatible with all reaction conditions. These compounds may be protected or modified at a convenient point in the synthesis by methods well known in the art. The terms and abbreviations used in the instant Schemes, Preparations, Examples and Procedures have their normal meanings unless otherwise designated. For example, as used herein, the following terms have the meanings indicated: "eq" refers to equivalents; "N" refers to normal or normality, "M" refers to molar or molarity, "g" refers to gram or grams, "mg" refers to milligrams; "L" refers to liters; "mL" refers to milliliters; "μL" refers to microliters; "mol" refers to moles; "mmol" refers to millimoles; "psi" refers to pounds per square inch; "min" refers to minutes; "h" or "hr" refers to hours; "°C" refers to degrees Celsius; "TLC" refers to thin layer chromatography; "HPLC" refers to high performance liquid chromatography; "Rf" refers to retention factor; "Rt" refers to retention time; "δ"refers to part per million down-field from tetramethylsilane; "MS" refers to mass spectrometry, Observed Mass indicates [M+H] unless indicated otherwise. "MS(FD)" refers to field desorption mass spectrometry, "MS(IS)" refers to ion spray mass spectrometry, "MS(FIA)" refers to flow injection analysis mass spectrometry, "MS(FAB)" refers to fast atom bombardment mass spectrometry, "MS(EI)" refers to electron impact mass spectrometry, "MS(ES)" refers to electron spray mass spectrometry, "UV" refers to ultraviolet spectrometry, "1H NMR" refers to proton nuclear magnetic resonance spectrometry. In addition, "IR" refers to infra red spectrometry, and the absorption maxima listed for the IR spectra are only those of interest and not all of the maxima observed. "RT" refers to room temperature. "DEAD" refers to diethylazodicrboxylate. "PPh3" refers to triphenylphosphine. "ADDP" refers to 1,1 - (azodicarbonyl)dipiperidine. "PPBu3" refers to tributylphosphine. "OTF" refers to triflate. "LAH" refers to lithium aluminum hydride. "DIBAL-H" refers to diisobutylaluminum hydride. "KO Bu" refers to potassoium t-butoxide. "THF" refers to tetrahydrofuran. "TBP" refers to tributylphosphine. "EDCI" refers to l-(3-dimethylaminopropyl)-3-ethylcarbodiamide hydrochloride. "DMAP" refers to dimethylaminopyridine. "HNMe(OMe)" refers to N,N,dimethylhydroxyamine. "CDMT" refers to 2-chloro-4,6-dimethoxy-[l,3,5] triazine. "NMM" refers to N-methyl morpholine. "DCM" refers to dichloromethane. "DMSO" refers to dimethylsulfoxide. "ET3Ν" refers to triethylamine. "DMF" refers to dimethylformamide. "Et" in a formula refers to ethyl, for example Et20 refers to diethylether, and EtOAc refers to ethylacetate. "PyBOP" refers to bromo-tris-pynolidino-phosphonium hexafluorophosphate. "Me" refers to methyl as in MeOH which is methanol. "Pd/C" refers to 10% palladium on carbon. Unless otherwise indicated, isomer 1 refers to the first isomer to be eluted in a chiral separation and isomer 2 refers to the second isomer to be eluted in a chiral separation. Infrared spectra are recorded on a Perkin Elmer 781 spectrometer. 1H NMR spectra are recorded on a Varian 400 MHz spectrometer at ambient temperature. Data are reported as follows: chemical shift in ppm from internal standard tetramethylsilane on the δ scale, multiplicity (b = broad, s = singlet, d - doublet, t = triplet, q = quartet, qn = quintet and m = multiplet), integration, coupling constant (Hz) and assignment. 13C NMR are recorded on a Varian 400 MHz spectrometer at ambient temperature. Chemical shifts are reported in ppm from tetramethylsilane on the δ scale, with the solvent resonance employed as the internal standard (CDC13 at 77.0 ppm and DMSO-d6 at 39.5 ppm). Combustion analyses are performed by Eli Lilly & Company Microanalytical Laboratory. High resolution mass spectra are obtained on VG ZAB 3F or VG 70 SE spectrometers. Analytical thin layer chromatography is performed on EM Reagent 0.25 mm silica gel 60- F plates. Visualization is accomplished with UV light. GENERAL SCHEMES Compounds of the present invention have been formed as specifically described in the examples. Further, many compounds are prepared as more generally using a) alkylation of a alcohol, phenol or thiophenol with a halide, b) a Mitsunobu protocol (O. Mitsunobu, 1981 Synthesis, pi); c) and other methods known to the skilled artisan. Alternative synthesis methods may also be effective and known to the skilled artisan. Unless otherwise indicated, all variables, such as Y', RI' to R15', etc., are as defined for analogous variables (RI to R15, etc.) in the summary of the invention, and otherwise as defined herein. For example, an intermediate like A is alkylated with an alkylating agent B in the presence of a base (e.g. NaH, K2CO3, Cs2CO3 etc.). Hydrolysis in the presence of aqueous NaOH or LiOH gave the acid product. Scheme 1
Figure imgf000038_0001
B L = halide, mesylate, tosylate etc.
Figure imgf000038_0002
Alternatively, an intermediate like A is coupled with an alcohol C under Mitsunobu reaction condition (DEAD/PPh3, ADDP/PBu3 etc.). Hydrolysis in the presence of aqueous NaOH or LiOH gave the acid product: Scheme 2
Figure imgf000038_0003
B
Figure imgf000038_0004
Under certain circumstances, the synthetic sequence can be altered, where an intermediate like D is coupled with an aryl boronic acid or ester under Suzuki reaction conditions (Pd catalyst, base). Hydrolysis in the presence of aqueous NaOH or Li OH gave the acid product: Scheme 3
Figure imgf000039_0001
X = Cl, Br, I, OTf etc.
Figure imgf000039_0002
The alcohol intermediates A and C can be made by A) reduction of the ketone with or without chiral auxiliary or B) alkylation of aldehyde with an organometallic reagent, e.g. Grignard reagent. Scheme 4
Figure imgf000039_0003
The biaryl phenol analogs can be made by a palladium catalyzed cross coupling reaction: Scheme 5
Figure imgf000040_0001
M = B(OR')2, SnR'4 The enantiomeric purifiedproducts are prepared either through A) chiral chromatography or B) Mitsunobu coupling between a phenol or thiophenol and a chiral alcohol that can be prepared using the methods known to the art. PREPARATIONS AND EXAMPLES The Examples provided herein are illustrative of the invention claimed herein and are not intended to limit the scope of the claimed invention in any way. Names of the preparations and examples are derived using ChemDraw. Infrared spectra are recorded on a Perkin Elmer 781 spectrometer. IH NMR spectra are recorded on a Varian 400 MHz spectrometer at ambient temperature. Data are reported as follows: chemical shift in ppm from internal standard tetramethylsilane on the (scale, multiplicity (b = broad, s = singlet, d = doublet, t = triplet, q = quartet, qn = quintet and m = multiplet), integration, coupling constant (Hz) and assignment. 13C NMR are recorded on a Varian 400 MHz spectrometer at ambient temperature. Chemical shifts are reported in ppm from tetramethylsilane on the (scale, with the solvent resonance employed as the internal standard (CDC13 at 77.0 ppm and DMSO-d6 at 39.5 ppm). Combustion analyses are performed by Eli Lilly & Company Microanalytical Laboratory. High resolution mass spectra are obtained on VG ZAB 3F or VG 70 SE spectrometers. Analytical thin layer chromatography is performed on EM Reagent 0.25 mm silica gel 60- F plates. Visualization is accomplished with UV light. Preparation 1 Racemic 4-(l-Hydroxy~propyl)-benzoic acid methyl ester
Figure imgf000040_0002
To a solution of 4-formyl-benzoic acid methyl ester (3.0 g, 18.3 mmol) in THF (10 mL) at 0 °C is added ethylmagnesium bromide (2M, 10 mL). After stining at room temperature for 2 hours, it is quenched with saturated ammonium chloride, extracted with EtOAc. The organic is concentrated to give the titled compound as colorless oil: 2.2 g (62 %).
The following compounds are made in a similar manner: Preparation 2 Racemic 4-(l-Hydroxy-butyl)-benzoic acid methyl ester
Figure imgf000041_0001
This compound is made from 4-formyl-benzoic acid methyl ester and n-propylmagnesium chloride following the general method exemplified in Preparation 1. Preparation s Racemic 4-(l-Hydroxy-2-methyl~propyl)-benzoic acid methyl ester
Figure imgf000041_0002
This compound is made from 4-formyl-benzoic acid methyl ester and isopropylmagnesium chloride following the general method exemplified in Preparation 1. Preparation 4 Racemic 4-(l-Hydroxy-pentyl)-benzoic acid methyl ester
Figure imgf000041_0003
This compound is made from 4-formyl-benzoic acid methyl ester and n-butyl magnesium chloride following the general method exemplified in Preparation 1. Preparation 5 Racemic 4-(l-Hydroxy-3-methyl-butyl)-benzoic acid methyl ester
Figure imgf000041_0004
This compound is made from 4-formyl-benzoic acid methyl ester and isobutyhnagnesium chloride following the general method exemplified in Preparation 1. Preparation 6 Racemic 4-(l-Hydroxy-hexyl)-benzoic acid methyl ester
Figure imgf000042_0001
This compound is made from 4-formyl-benzoic acid methyl ester and n- pentylmagnesium chloride following the general method exemplified in Preparation 1. Preparation 7 Racemic 4-(l-Hydroxy-heptyl)-benzoic acid methyl ester
Figure imgf000042_0002
This compound is made from 4-formyl-benzoic acid methyl ester and n-hexylmagnesium chloride following the general method of Preparation 1. Preparation 8 Racemic 4-(l-Hydroxy-4,4-dimethyl~pentyl)-benzoic acid methyl ester
Figure imgf000042_0003
This compound is made from 4-formyl-benzoic acid methyl ester and 4,4- dimethylpentylmagnesium bromide following the general method of Preparation 1. Preparation 9 Racemic 4-(l -Hydrox ~butyl)-benzoic acid methyl ester
Figure imgf000042_0004
Step A. N-Methoxy-N-methyl-terephthalamic acid methyl ester To a solution of Terephthalic acid monomethyl ester (5.4 g, 30 mmol) and 2- chloro-4,6-dimethoxy-[l,3,5]triazine (7.9 g, 45 mmol) in THF (300 mL) is added N- methyl morpholine (4.95 mL, 45 mmol), the mixture is stined at room temperature overnight. Additional N-methyl morpholine (4.95' mL, 45 mmol) is added, followed by the addition of O, N-dimethyl-hydroxylamine HCl salt (3.51 g, 45 mmol). The reaction mixture is stined overnight, and filtered through celite. The filtrate was concentrated and purified by column chromatography on silica gel (hexane/ethyl acetate) giving the title compound (6.8 g). Step B. 4-ButyryI-benzoic acid methyl ester To a solution of N-methoxy-N-methyl-terephthalamic acid methyl ester (4.56 g, 20.4 mmol) in THF (100 mL) is added PrMgCl (2.0M, 30.6 mmol) at 0 °C, the reaction is warmed to room temperature, stined overnight, quenched by NH4CI aqueous solution, extracted with ethyl acetate. The combined organic layers are washed with brine, dried over sodium sulfate, concentrate. Column chromatography on silica gel gives the title compound (1 g, 23.7 %). Step C. Racemic 4-(l-Hydroxy-butyI)-benzoic acid methyl ester To a solution of 4-butyryl-benzoic acid methyl ester (400 mg, 1.94 mmol) in ethanol (5 mL) and THF (4 mL) is added sodium borohydride (110 mg, 2.9 mmol), the mixture is stined at room temperature for 2 h. The reaction mixture is quenched by acetic acid (0.5 mL) and water (10 mL), extracted with ethyl acetate. Combined organic layers are washed with brine and dried over sodium sulfate. Concentration and column chromatography on silica gel gives the title compound (370 mg). Preparation 10 Racemic 3-[4-(l-Hydroxy-nonyl)-benzoylamino]-propionic acid methyl ester
Figure imgf000043_0001
Step A. 3-(4-Formyl-benzoylamino)-propionic acid methyl ester 4-Formyl-benzoic acid, CDMT, and 4-methylmorpholine are combined in anhydrous DCM under nitrogen. The reaction is allowed to stir under nitrogen at room temperature overnight. The amine is then added to the reaction mixture, and allowed to stir at room temperature. Some water (<10% volume) is added to help solubility. The reaction is monitored by HPLC, and upon complete consumption of the acid, the reaction is diluted with DCM. The reaction is diluted with water and rinsed with IN HCl. Upon acidification, a white solid precipitated from the biphasic mixture. The solid was isolated by filtration and dried under vacuum to afford the titled compound. , Step B. Racemic 3-[4-(l-Hydroxy-nonyl)-benzoylamino]-propionic acid methyl ester To a solution of 3-(4-formyl-benzoylamino)-propionic acid methyl ester (1.2 g, 5 mmol) in THF (10 mL) at 0 °C is added ethylmagnesium bromide (2M, 1.1 mL). After stining at room temperature for 2 hours, it is quenched with saturated ammonium chloride, extracted with EtOAc. The organic is concentrated to give the titled compound as colorless oil: 270 mg (15 %).
The following compound is made in a substantially similar manner: Preparation 11 Racemic 3-[4-(4,4,4-Trifluoro-l-hydroxy-butyl)-benzoylamino]-propionic acid methyl ester
Figure imgf000044_0001
This compound is made by the general method exemplified in Preparation 10 using 3,3,3-trifluoropropylmagnesium bromide. Preparation 12 Racemic 3-[4-(l-Hydroxy-4,4-dimethyl-pentyl)-benzoylamino]-propionic acid methyl ester
Figure imgf000044_0002
This compound is made by the general method exemplified in Preparation 10 using 2,2-dimethylbutylmagnesium bromide. Preparation 13 Racemic 3-[4-(l-Hydroxy-butyl)-benzoylamino]-propionic acid methyl ester
Figure imgf000044_0003
This compound is made by the general method exemplified in Preparation 10 using n-propylmagnesium bromide. Preparation 14 Racemic 3-[4-(l-Hydroxy-3-methyl~butyl)-benzoylamino]-propionic acid methyl ester
Figure imgf000045_0001
This compound is made by the general methods as exemplified in Preparation 10 using isobutyl magnesium bromide as reagent. Preparation 15 Racemic 3-[4-(l-Hydroxy-heptyl)~benzoylamino]-propionic acid methyl ester
Figure imgf000045_0002
This compound is made by the general methods as exemplified in Preparation 10 using hexyl magnesium bromide as reagent. Preparation 16 4'-Trifluoromethyl-biphenyl-4-ol
Figure imgf000045_0003
4-Bromophenol (5 g, 28.9 mmol), 4-trifluoromethyl phenyl boronic acid (6.59 g, 34.7 mmol), potassium carbonate (12 g, 86.7 mmol) and palladium acetate (0.324 g, 1.445 mmol) are placed in water (50 mL), and the resulting mixture is stined at room temperature over night under open air. The mixture is filtered through celite and extracted with ethyl acetate (3 x 200 ml). The combined organic layers are washed with water, IN HCl, water, brine, dried (MgSO4), concentrated and chromatographed to yield the title compound as a white solid (6.0 g, 87%). The following compound is made in a substantially similar manner: Preparation 17 4'-tert-Butyl-biphenyl-4-ol
Figure imgf000045_0004
This compound is made by the general method exemplified in Preparation 16 using 4-tert-butyl phenyl boronic acid as reagent. Preparation 18 4-(5-Trifluoromethyl-pyridin-2-yl)~phenol
Figure imgf000046_0001
Step A. 2-(4-Benzyloxy-phenyl)-5-trifluoromethyl-pyridine A mixture of 2-chloro-5 -trifluoromethy lpyridine (1.81 g, 10 mmol), 4- benzyloxyphenyl boronic acid (2.74 g, 12 mmol) and CsF (5.32 g, 35 mmol) in dioxane (40 mL) is degaseed and filled with nitrogen. PdCl2(dppf) (200 mg) is added under nitrogen, the reaction mixture is heated at 105 °C overnight. The mixture is cooled to room temperature, diluted with ethyl acetate (100 mL), filtered through a pad of Celite. The filtrate is concentrated and the residue is purified by column chromatography on silica gel giving the title compound (2.55g, 77.4 %). Step B. 4-(5-Trifluoromethyl-pyridin-2-yI)-phenoI To a solution of 2-(4-Benzyloxy-phenyl)-5-trifluoromethyl-pyridine (2.55g) in ethanol (100 mL) and THF (25 mL) is added Pd/C (5%, 0.253 g), the mixture is stined under 60 psi of hydrogen overnight. The catalyst is filtered off, concentration of the filtrate gave the title compound (1.25 g, 67.5%). Preparation 19 Racemic 4-(l-Hydroxy-3,3-dimethyl-butyI)-benzoic acid methyl ester
Figure imgf000046_0002
This compound is made from 4-formyl-benzoic acid methyl ester and 3,3- dimethyl-butanemagnesium bromide following the general method exemplified in Preparation 1. Preparation 20 Racemic 4-(Cyclopropyl-hydroxy-methyl)-benzoic acid methyl ester
Figure imgf000046_0003
This compound is made from 4-formyl-benzoic acid methyl ester and Cyclopropyl magnesium bromide following the general method exemplified in Preparation 1. Preparation 21 Racemic 3-Fluoro-4-(l-hydroxy-3-methyl-butyl)-benzoic acid methyl ester
Figure imgf000047_0001
This compound is made from 3-Fluoro-4-formyl-benzoic acid methyl ester and isobutylmagnesium bromide following the general method exemplified in Preparation 1. Preparation 22 Racemic 3-Fluoro~4-(l-hydroxy-heptyl)-benzoic acid methyl ester
Figure imgf000047_0002
This compound is made from 3-Fluoro-4-formyl-benzoic acid methyl ester and hexylmagnesium bromide following the general method exemplified in Preparation 1. Preparation 23 4-Bromo-3-[l,3]dioxan-2-yl-phenol
Figure imgf000047_0003
To the solution of 2-bromo-5-methoxy-benzaldehyde (10g, 46.5 mmol) at -78°C is added BBr3 (25g, 93.75 mmol) and allowed to warm to room temperature. After 2h, the reaction is quenched with water and extracted with ethyl acetate. The combined organic layers are washed with water, brine, dried over MgSO4, concentrated and purified by column chromatography to afford 3.6g of 2-bromo-5-hydroxy-benzaldehyde. To the solution of 2-bromo-5-hydroxy-benzaldehyde (1.45 g, 7.2mmol in benzene (30ml) and THF (6ml) is added 1,3-propanediol (2.74g, 36mmol) and TsOH (37mg, 0.22mmol). The mixture is refluxed for 24. After cooling down, the solvent is evaporated. The residue is loaded on silica and purified by column chromatography to afford the titled compound (2.3g) as brown oil. Preparation 24 6-Chloro-5-methyl-pyridin-3~ol
Figure imgf000047_0004
2-Chloro-3-methyl-5-nitro-pyridine (2g, 11.6 mmol) and SnCl2»(H2O)2 (7.86g, 34.8 mmol) are refluxed in MeOH overnight. After cooled down, the mixture is diluted with ethyl acetate, washed with water, brine, dried over MgSO , concentrated and purified by column chromatography to afford 6-chloro-5-methyl-pyridin-3-ylamine (1.7g). To the solution of 6-chloro-5-methyl-pyridin-3-ylamine (1.7g, 11.6 mmol) in IN HCl is added the solution of NaNO2 (960mg, 13.92mmol) in water (10ml) slowly at 0 °C. After the addition, the solution is stined for 20min and then heated to 90 °C for 30min. The solution is cooled down, quenched with K2CO3, extracted with ether, dried over MgSO4, and purified by column chromatography to afford the titled compound (560mg) as a yellow solid. Preparation 25 4'-Isopropyl-2-methyl-biphenyl-4-ol
Figure imgf000048_0001
4-Bromo-3-methylphenol (1.87 g, 10 mmol), 4-isopropyl phenyl boronic acid (2.0 g, 12 mmol), potassium carbonate (4.1 g, 30 mmol) and palladium acetate (0.112 g, 0.5 mmol) are placed in water (100 mL). And the resulting mixture is stined at room temperature over night under open air. The mixture is filtered through Celite and extracted with ethyl acetate (3 x 200 ml). The combined organic layers are washed with water, IN HCl, water, brine, dried (MgSO4), concentrated and chromatographed to yield the title compound as a white solid (1.9g). Preparation 26 2-Bromo-5-hydroxy-benzaldehyde
Figure imgf000048_0002
To 2-bromo-5-methoxy-benzaldehyde (lOg, 31.25mmol) in dichloromethane (30ml) at -78 °C is added BB 3 (25g, 93.75mmol) and allowed to warm to room temperature. After 2h, the reaction is quenched with water and extracted with ethyl acetate. The combined organic layers are washed with water, brine, dried and purified by the column chromatography to afford 3.6g of the titled compound. Preparation 27 2-Bromo-5-hydroxy~benzaldehyde O-tert-butyl-oxime
Figure imgf000049_0001
To the solution of 2-bromo-5-hydroxy-benzaldehyde (402mg, 2mmol) in methanol (10ml) is added O-tert-butyl-hydroxylamine hydrochloride (125mg, lOmmol). The mixture is stined at room temperature overnight. The resulting mixture is diluted with ethyl acetate, washed with brine, dried over MgSO4, and evaporated to afford the titled compound (360mg) as colorless oil. Preparation 28 4-Bromo-3,5-dimethyl-benzenethiol
Figure imgf000049_0002
Step A. Dimethyl-thiocarbamic acid O-(4-bromo-3,5-dimethyl-phenyl) ester 4-Bromo-3 ,5 -dimethyl-phenol (10.0 g, 50.01 mmol) is dissolved into dry dioxane
(200 mL) and combined with 4-dimethylamino pyridine (1.0 g, 5.2 mmol), triethylamine
(12.77 mL, 100.1 mmol), and dimethylamino-thiocarbomoyl chloride (7.69 g, 62.51 mmol). The reaction is heated to reflux under nitrogen. The reaction is monitored by TLC until all of the phenol is consumed, approximately 20h. After cooling to room temperature, the reaction is diluted with ethyl acetate (200 mL). Water (75 mL) is added and the two layers are separated. The organic layer is washed with brine (75mL) then dried-over anhydrous sodium sulfate. The solvent is removed and the residue is purified by column chromatography, (6.4 g or 55% yield).
Step B. Dimethyl-thiocarbamic acid S-(4-bromo-3,5-dimethyl-phenyl) ester Dimethyl-thiocarbamic acid O-(4-bromo-3,5-dimethyl-phenyl) ester (6.4 g, 22.3 mmol) is diluted with 50 mL of tetradecane and heated to reflux under nitrogen. The reaction is monitored by TLC until all the conversion was complete, approximately 20h. The reaction is allowed to cool to room temperature and then loaded onto silica gel column and purified using flash column chromatography, yielding 5.78 g, or 90% of the target product.
Step C. 4-Bromo-3,5-dimethyl-benzenethiol Dimethyl-thiocarbamic acid S-(4-bromo-3,5-dimetnyl-phenyl) ester (5.78 g, 20.14 mmol) is diluted with methanol (50 mL) and sodium methoxide (4.75 mL of 4.25M in methanol, 20.14 mmol) is added. The reaction is heated to reflux under nitrogen and monitored by TLC. After complete conversion, 20 hours, the reaction is allowed to cool to room temperature. The reaction is neutralized with IN hydrochloric acid (7.5 mL) and diluted with ethyl acetate (150 mL). The two phases are separated and the organic layer is washed with water (75 mL), then brine (75 mL). The organic layer is dried over anhydrous sodium sulfate, concentrated and loaded onto silica gel column. The title compound is purified using flash column chromatography, yielding 4.0g, or 92%. Preparation 29 (R,S) 4-(5,5,5-Trifluoro-l-hydroxy-pentyl)-benzoic acid methyl ester
Figure imgf000050_0001
This compound is made following the general method exemplified in Preparation
1 using 4-formyl-benzoic acid methyl ester and l,l,l-trifluoro-butane-4-magnesium bromide. Preparation 30 (R,S) 3-[4-(Cyclohexyl-hydroxy-methyl)-benzoylamino]-propionic acid methyl ester
Figure imgf000050_0002
This compound is made by the general method exemplified in Preparation 10 using 3-(4-formyl-benzoylamino)-propionic acid methyl ester and cyclohexylmagnesium bromide. Preparation 31 (R,S) 3-[4-(l-Hydroxy-5-methyl-hexyl)-benzoylamino]-propionic acid methyl ester
Figure imgf000051_0001
This compound is made by the general method exemplified in Preparation 10 using 3-(4-formyl-benzoylamino)-propionic acid methyl ester and 4-methy lpentane-1- magnesiumbromide. Preparation 32 4'-tert-ButyI-2,6-dimethyl-biphenyI-4-ol
Figure imgf000051_0002
This compound is made by the general method as exemplified in Preparation 16 using 4-bromo-3,5-dknethyl-phenol and 4-tert-butyl phenyl boronic acid as reagents. Preparation 33 2,6-DimethyI-4'-trifluoromethyI-biphenyl-4-ol
Figure imgf000051_0003
This compound is made by the general method as exemplified in Preparation 16 using 4-bromo-3,5-dimethyl-phenol and 4-trifuoromethyl phenyl boronic acid as reagents. Preparation 34 5-Methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-ol
Figure imgf000051_0004
Step A. 3-Methyl-5-nitro-2-(4-trifluoromethyl-phenyl)-pyridine To a solution of 2-chloro-3-methyl-5-nitro-pyridine(5.0 g, 28,73 mmol) in toluene(50 mL) is added palladium tetrakis triphenylphosphine(l .66 g, 1.44 mmol), 4- trifluoromethy 1 phenyl boronic acid(10.92 g, 57.46 mmol), and potassium fluoride (3.34g, 57.46 mmol). The reaction is purged with nitrogen three times and heated to reflux under nitrogen. At reflux, water (25 mL) is added to the reaction and the reaction is allowed to reflux under nitrogen. The reaction is monitored by HPLC, and upon completion, allowed to cool to room temperature. The reaction is diluted with ethyl acetate and Celite is added, followed by Water. This mixture is then filtered through a pad of Celite. The solution is poured into a separatory funnel and the organic layer is washed with water and brine. The organic layer is dried over anhydrous sodium sulfate and concentrated. The product is purified by flash column chromatography (5.6 g, 19.71 mmol).
Step B. 5-Methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-ylamine To a solution of the 3-methyl-5-nitro-2-(4-trifluoromethyl-phenyl)-pyridine(3.5 g, 10.56 mmol) in ethanol(50 mL) is added palladium (10%) on carbon (0.700 g, 20% by wt.). The reaction is charged to 15 psi under a hydrogen atmosphere and allowed to stir for 4 hours. The reaction is diluted with ethyl acetate and Celite is added, followed by water. This mixture is then filtered through a pad of celite. The solution is concentrated, diluted with ethyl acetate, poured into a separatory funnel and the organic layer is washed with water and brine. The organic layer is dried over anhydrous sodium sulfate and concentrated. The product is used directly in the next step (2.74 g, 10.87 mmol). Step C. 5-Methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-ol 5-Methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-ylamine (2.74 g, 10.87 mmol) is suspended in hydrochloric acid (21.74 mL, 5N) and the solution is cooled to -15 °C in a brine/ice bath. Sodium nitrate (0.9 g, 13.04 mmol) in water (10 mL) is added slowly to the mixture. The reaction is allowed to stir at -15 °C for ten minutes after complete addition. Hexafluorophosphoric acid (5 mL, 21.74 mmol of a 60% wt. solution in water) is added slowly to the mixture. The resulting slurry is filtered, rinsed with cold water, methanol, and diethyl ether, and dried under vacuum. This solid is added in small portions to a round bottom containing acetic acid (10 mL) at 105°C. This solution is cooled to room temperature then treated with sodium hydroxide (25 mL, 5N) for 30 min. The pH of this solution is adjusted to 6 with hydrochloric acid, extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate, then filtered and concentrated to provide the title product (2.2 g, 8.69 mmol). Preparation 35 6-(4-tert-Butyl-phenyl)-5-methyl-pyridin-3-ol
Figure imgf000052_0001
This compound is made by the general method exemplified in Preparation 16 using 2-chloro-3-methyl-5-nitro-pyridine and 4-tbutyl phenyl boronic acid. Example 1 Racemic 3-{4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-propyl]-benzoylamino}- propionic acid
Figure imgf000053_0001
Step A. 4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-propyI]-benzoic acid To a solution of 4-(l-hydroxy-propyl)-benzoic acid methyl ester (300 mg, 1.55 mmol) in toluene (10 mL) is added l, -(azodicarbonyl)dipiperidine (ADDP, 585 mg, 2.32 mmol) at 0 °C, followed by the addition of tributylphosphine (0.58 mL, 2.32 mmol) and 4'-trifluoromethyl-biphenyl-4-ol (442 mg, 1.86 mmol). The reaction mixture is warmed up to room temperature and stined overnight. The mixture is loaded on silica gel, eluted with hexanes with a gradient from 0 % of ethyl acetate to 50 % of ethyl acetate giving 4- [l-(4,-trifluoromethyl-biphenyl-4-yloxy)-propyl]-benzoic acid methyl ester. The ester product is taken into ethanol (2 mL), treated with sodium hydroxide (5N aqueous, 1 mL) for 3 hours at room temperature. The mixture is concentrated, diluted with ethyl acetate, acidified with 5 N HCl (1.1 mL), extracted with ethyl acetate. The organic layers are dried and concentrated giving 4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]- benzoic acid (570 mg). Step B. Racemic methyl 3-(4-{l-[6-(4-Trifluoromethyl-phenyl)-pyridin-3-yl]- heptyloxy}-benzoylamino)-propionoate To a mixture of 4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-propyl]-benzoic acid (270 mg, 0.68 mmol) in methylene chloride (7 mL) are added triethyl amine (0.28 mL, 2.03 mmol), DMAP (5.0 mg), 3-amino-propionic acid methyl ester (141 mg, 1.01. mmol) and EDCI (389 mg, 2.03 mmol) at room temperature. The reaction mixture is stined at room temperature overnight, loaded on silica gel, eluted with eluted with hexanes with a gradient from 0 % of ethyl acetate to 100 % of ethyl acetate giving 3-{4-[l-(4'- trifluoromethyl-biphenyl-4-yloxy)-propyl]-benzoylammo}-propionic acid methyl ester (215 mg). Step C. Racemic 3-{4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-propyl]- benzoylamino}-propionic acid To a mixture of 3-{4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-propyl]- benzoylamino}-propionic acid methyl ester (60 mg, 0.12 mmol) in methanol (2 mL) is added sodium hydroxide (5 N aqueous, 0.5 mL) and stined for 5 hours. The reaction mixture is concentrated and acidified by 5 N HCl (0.5 mL), extracted with ethyl acetate. Combined organic layers are washed with water and brine, dried over sodium sulfate. Concentration gives the title compound (54 mg). MS (ES): 472.2 [M+H]+. Example 2 Racemic 3-{4-[3-Methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]- benzoylamino}-propionic acid
Figure imgf000054_0001
This compound is made by the general method exemplified in Example 1 using 4- (l-hydroxy-3-methylbutyl)-benzoic acid methyl ester and 4,-trifluoromethyl-biphenyl-4- ol as starting materials. MS (ES): 500.2 [M+H]+. Example 3 Racemic 3-{4-[l-(4-tert-Butyl-phenoxy)-3-methyl-butyl]-benzoylamino}-propionic acid
Figure imgf000054_0002
This compound is made by the general method exemplified in Example 1 using 4-
(l-hydroxy-3-methylbutyl)-benzoic acid methyl ester and 4-tert-butyl-phenol as starting materials. MS (ES): 412.3 [M+H]+. Example 4 Racemic 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyI]- benzoylamino}-propionic acid
Figure imgf000055_0001
This compound is made by the general method exemplified in Example 1 using 4- (l-hydroxy-4,4,4-trifluorobutyl)-benzoic acid methyl ester and 4'-tert-butyl-biphenyl-4-ol as starting materials. MS (ES): 526.2 [M+H]+. Example 5 Racemic 3-{4-[4,4,4-Trifluoro-l-(4,-trifluoromethyl-biphenyl-4-yloxy)-butyl]- benzoylamino}-propionic acid
Figure imgf000055_0002
This compound is made by the general method exemplified in Example 1 using 4- (1 -hydroxy-4,4,4-trifluorobutyl)-benzoic acid methyl ester and 4'-trifluoromethyl- biphenyl-4-ol as starting materials. MS (ES): 538.3 [M+H]+. Example 6 Racemic 3-{4-[(4-Bromo-phenyl)-(4'-tert-buryl-biphenyl-4-yloxy)-methyl]- benzoy!amino}-propionic acid
Figure imgf000055_0003
This compound is made by the general method exemplified in Example 1 using 4- (l-hydroxy-l-(4-bromophenyl)-methyl)-benzoic acid methyl ester and 4'-tbutyl-biphenyl- 4-ol as starting materials. MS (ES): 585.0. Example 7 Racemic 3-{4-[2-Methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]- benzoylamino}-propionic acid
Figure imgf000055_0004
This compound is made by the general method exemplified in Example 1 using 4- (l-hydroxy-2-methylpropyl)-benzoic acid methyl ester and 4'-trifluoromethyl-biphenyl-4- ol as starting materials. MS (ES): 486.2 [M+H]+. Example 8 Racemic 3- {4- [1 -(4 ' -tert-Butyl-biphenyl-4-yloxy)-propyl] -benzoylamino}-propionic acid
Figure imgf000056_0001
This compound is made by the general method exemplified in Example 1 using 4- (l-hydroxy-propyl)-benzoic acid methyl ester and 4'-tert-butyl-biphenyl-4-ol as starting materials. MS (ES): 458.3 [M-H]". Example 9 Racemic 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid
Figure imgf000056_0002
This compound is made by the general method exemplified in Example 1 using 4-
(l-hydroxy-heptyl)-benzoic acid methyl ester and 4'-tert-butyl-biphenyl-4-ol as starting materials. MS (ES): 516.3 [M+H]+. Example 10 Racemic 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}- propionic acid
Figure imgf000056_0003
This "compound is made by the general method exemplified in Example 1 using 4- (l-hydroxy-3-methylbutyl)-benzoic acid methyl ester and 4'-tbutyl-biphenyl-4-ol as starting materials. MS (ES): 488.3 [M+H]+. Example 11 Racemic 3-{4-[l-(4-Cyclohexyl-phenoxy)-hexyl]-benzoylamino}-propionic acid
Figure imgf000057_0001
This compound is made by the general method exemplified in Example 1 using 4- (l-hydroxy-hexyl)-benzoic acid methyl ester and 4-cyclohexylphenol as starting materials. MS (ES): 452.3 [M+H]+. Example 12 Racemic 3-{4-[l-(4-Benzyloxy-phenoxy)-hexyI]-benzoylamino}-propionic acid
Figure imgf000057_0002
This compound is made by the general method exemplified in Example 1 using 4- (l-hydroxy-hexyl)-benzoic acid methyl ester and 4-benzyloxyphenol as starting materials. MS (ES): 476.2 [M+H]+. Example 13 Racemic 3-[4-(l-Phenoxy-hexyl)-benzoyIamino]-propionic acid
Figure imgf000057_0003
This compound is made by the general method exemplified in Example 1 using 4- (l-hydroxy-hexyl)-benzoic acid methyl ester and phenol as starting materials. MS (ES): 370.3 [M+H]+. Example 14 Racemic 3-{4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid
Figure imgf000057_0004
This compound is made by the general method exemplified in Example 1 using 4- (l-hydroxy-heptyl)-benzoic acid methyl ester and 4'-trifluoromethyl-biphenyl-4-ol as starting materials. MS (ES): 528.2 [M+H]+. Example 15 Racemic 3-{4-[l-(4'-Trifluoromethyl-biphenyl-4-ylsulfanyl)-heptyl]-benzoylamino}- propionic acid
Figure imgf000058_0001
This compound is made by the general method exemplified in Example 1 using 4- (l-hydroxy-heptyl)-benzoic acid methyl ester and 4'-trifluoromethyl-biphenyl-4- mercaptol as starting materials. MS (ES): 542.2 [M-H]". Example 16 Racemic 3-{4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-pentyl]-benzoylamino}- propionic acid
Figure imgf000058_0002
This compound is made by the general method exemplified in Example 1 using 4-
(1 -hydroxy -pentyl)-benzoic acid methyl ester and 4'-trinuoromethyl-biphenyl-4-ol as starting materials. MS (ES): 498.2 [M-H]". Example 17 Racemic 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-pentyl]-benzoylamino}-propionic acid
Figure imgf000058_0003
This compound is made by the general method exemplified in Example 1 using 4- (l-hydroxy-pentyl)-benzoic acid methyl ester and 4'-tbutyl-biphenyl-4-ol as starting materials. MS (ES): 486.3 [M-H]-. Example 18 Racemic 3-{4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-butyl]-benzoylamino}- propionic acid
Figure imgf000059_0001
This compound is made by the general method exemplified in Example 1 using 4- (l-hydroxy-butyl)-benzoic acid methyl ester and 4'-trifluoromethyl-biphenyl-4-ol as starting materials. MS (ES): 486.2 [M+H]+. Example 19 Racemic 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-butyl]-benzoylamino}-propionic acid
Figure imgf000059_0002
This compound is made by the general method exemplified in Example 1 using 4- (l-hydroxy-butyl)-benzoic acid methyl ester and 4'-tert-butyl-biphenyl-4-ol as starting materials. MS (ES): 475.2 [M+H]+. Example 20 Racemic 3-{4-[3-Methyl-l-(4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-butyl]- benzoylamino}-propionic acid
Figure imgf000059_0003
This compound is made by the general method exemplified in Example 1 using 4- (l-hydroxy-3-methylbutyl)-benzoic acid methyl ester and 4'-trifluoromethyl-biphenyl-4- mercaptol as starting materials. MS (ES): 515.3 [M-H]-. Example 21 Racemic 3-{4-[l-(4?-Trifluoromethyl-biphenyl-4-yloxy)-nonyl]-benzoylamino}- propionic acid
Figure imgf000059_0004
This compound is made by the general method exemplified in Example 1 using 4- (l-hydroxy-nonyl)-benzoic acid methyl ester and 4'-trifluoromethyl-biphenyl-4-mercaptol as starting materials. MS (ES): 554.2 [M-H]". Example 22 Racemic 3-(4-{3-Methyl-l-[4-(6-trifluoromethyl-pyridin-3-yl)-phenoxy]-butyl}- benzoylamino)-propionic acid
Figure imgf000060_0001
This compound is made by the general method exemplified in Example 1 using 4- (l-hydroxy-3-methylbutyl)-benzoic acid methyl ester and 4-(6-Trifluoromethyl-pyridin- 3-yl)-phenol as starting materials. MS (ES): 500.3 [M-H]". Example 23 Racemic 3-(4-{2-Methyl-l-[4-(6-trifluoromethyl-pyridin-3-yl)-phenoxy]-propyl}- benzoylamino)-propionic acid
Figure imgf000060_0002
This compound is made by the general method exemplified in Example 1 using 4-
(l-hydroxy-2-meihylpropyl)-benzoic acid methyl ester and 4-(6-Trifluoromethyl-pyridin- 3-yl)-phenol as starting materials. MS (ES): 487.3 [M+H]+. Example 24 Racemic 3-(4-{l-[4'-trifluoromethoxy-biphenyl-4-ylsulfanyl]-3-methyl-butyl}- benzoylamino)-propionic acid
Figure imgf000060_0003
Step A. 4- [l-(4-Bromo-phenylsulfanyl)-3-m ethyl-butyl] -benzoic acid To a solution of 4-(l-hydroxy-3-methyl-butyl)-benzoic acid methyl ester (1240 mg, 5.59 mmol) in toluene (10 mL) is added l,r-(azodicarbonyl)dipiperidine (ADDP, 2114 mg, 8.38 mmol) at 0 °C, followed by the additions of tributylphosphine (2.09 mL, 8.38 mmol) and 4-bromo-thiophenol (1267 mg, 6.7 mmol). The reaction mixture is warmed up to room temperature and stined overnight. The mixture is loaded on silica gel, eluted with hexanes with a gradient from 0 % of ethyl acetate to 50 % of ethyl acetate giving 4- [l-(4-bromo-phenylsulfanyl)-3 -methyl-butyl] -benzoic acid methyl ester. 393 mg of the ester product is taken into ethanol (2 mL), treated with sodium hydroxide (5N aqueous, 1 mL) for 3 h at room temperature. The mixture is concentrated, diluted with ethyl acetate, acidified with 5 N HCl (1.1 mL), extracted with ethyl acetate. The organic layers are dried and concentrated giving 4- [l-(4-bromo-phenylsulfanyl)-3 -methyl-butyl] - benzoic acid (379 mg). Step B. Racemic 3-{4-[l-(4-Bromo-phenylsulfanyl)-3-methyl-butyl]-benzoylamino}- propionic acid methyl ester To a mixture of 4-[l-(4-bromo-phenylsulfanyl)-3-methyl-butyl]-benzoic acid (379 mg, 1 mmol) in methylene chloride (10 mL) are added triethyl amine (0.42 mL, 3 mmol), DMAP (5.0 mg), 3-amino-propionic acid methyl ester (209 mg, 1.5 mmol) and EDCI (577 mg, 3.0 mmol) at room temperature. The reaction mixture is stined at room temperature overnight, loaded on silica gel, eluted with eluted with hexanes with a gradient from 0 % of ethyl acetate to 100 % of ethyl acetate giving 3-{4-[l-(4-Bromo- phenylsulfanyι)-3 -methyl-butyl] -benzoy lamino }-propionic acid methyl ester (350 mg). Step C. Racemic 3-{4-[3-Methyl-l-(4'-trifluoromethoxy-biphenyl-4-ylsulfanyl)- butyl]-benzoylamino}-propionic acid methyl ester 3 - {4- [ 1 -(4-bromo-phenylsulfanyl)-3 -methyl-butyl] -benzoylamino } -propionic acid methyl ester (350 mg, 0.75 mmol), potassium carbonate (311 mg, 2.25 mmol), 4- triflouromethoxylphenyl boronic acid (311 mg, 1.5 mmol) and tetrakis- (triphenylphosphine)palladium (87 mg, 0.075 mmol) are place in a flask. After the reaction is purged with N2 for several times, THF/H2O (20ml/5ml) is added. The resulting solution is refluxed overnight, loaded on silica gel, eluted with hexane and ethyl acetate to give 3- {4- [3 -Methyl- 1 -(4'-trifluoromethoxy-biphenyl-4-ylsulfanyl)-butyl]- benzoylamino} -propionic acid methyl ester (294 mg) as a yellow solid. Step D. Racemic 3-(4-{l-[4'-(l-Fluoro-ethoxy)-biphenyl-4-ylsulfanyl]-3-methyl- butyl}-benzoylamino)-propionic acid To a mixture of 3-{4-[3-Methyl-l-(4'-trifluoromethoxy-biphenyl-4-ylsulfanyl)- butyl] -benzoylamino} -propionic acid methyl ester (20 mg) in methanol (2 mL) is added sodium hydroxide (5 N aqueous, 0.5 mL) and stined for 5 h. The reaction mixture is concentrated and acidified by 5 N HCl (0.5 mL), extracted with ethyl acetate. Combined organic layers are washed with water and brine, dried over sodium sulfate. Concentration gives the title compound (18 mg). MS (ES): 531.2 [M-H]".
The following compounds are made in a substantially substantially similar manner: Example 25 Racemic 3-{4-[l-(3',4'-dimethyl-biphenyl-4-ylsulfanyl)-3-methyl-butyl]- benzoylamino}-propionic acid
Figure imgf000062_0001
This compound is made by the general method as exemplified in Example 24 using 3,4-dimethylphenyl boronic acid as starting material in step C. MS (ES): 477.2 [M+H]+. Example 26 Racemic 3-{4-[l-(4'-cyano-biphenyl-4-ylsulfanyl)-3-methyl-butyl]-benzoylamino}- propionic acid
Figure imgf000062_0002
This compound is made by the general method as exemplified in Example 24 using 4-cyanophenyl boronic acid as starting material in step C. MS (ES): 472.2 [M+H]+. Example 27
Racemic 3-{4-[l-(4'-Isobutyl-biphenyl-4-ylsulfanyl)-3-methyl-butyl]-benzoylamino}- propionic acid
Figure imgf000062_0003
This compound is made by the general method as exemplified in Example 24 using 4-isobutylphenyl boronic acid in step C. MS (ES): 505.2 [M+H]+. Example 28 Racemic 3-(4-{l-[4-(6-Methoxy-pyridin-3-yl)-phenylsulfanyl]-3-methyI-butyl}- benzoylamino)-propionic acid
Figure imgf000063_0001
This compound is made by the general method as exemplified in Example 24 using 4-methoxy-pyridin-3-yl boronic acid as starting material in step C. MS (ES): 480.2 [M+H]+. Example 29 Racemic 3-{4-[l-(4'-Ethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid
Figure imgf000063_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-bromophenol as reagents in step A and 4-ethylρhenyl boronic acid in step C. MS (ES): 488.3 [M+H]+. Example 30 3-{4-[l-(4-Benzyloxy-phenoxy)-hexyl]-benzoylamino}-propionic acid, Isomer 1
Figure imgf000063_0003
Chiral Separation: The racemic 3-{4-[l-(4-Benzyloxy-phenoxy)-hexyι]- benzoylamino} -propionic acid methyl ester was resolved on a Chiralpak AD column (4.6 x 150 mm). Eluted with Isopropyl Alcohol/Heptane (30/70) and concentrated the fractions to provide a purified enantiomer ester (isomer 1, 100 % ee). Hydrolysis of the purified enantiomer of the ester provided the title compound as a white solid. MS (ES): 476.3 [M+H]+. The following enantiomerically purifiedcompounds were obtained by substantially similar chiral separation using Chiralpak AD column (4.6 x 150 mm) or Chiralcel OJ column (4.6 x 250 mm): Example 31 3-{4-[l-(4-Benzyloxy-phenoxy)-hexyl]-benzoylamino}-propionic acid, Isomer 2
Figure imgf000064_0001
This compound is made by the general method as exemplified in Example 30 by resolving racemic 3-{4-[l-(4-Benzyloxy-phenoxy)-hexyl]-benzoylamino}-propionic acid methyl ester on Chiralpak AD column (4.6 x 150 mm). MS (ES): 476.3 [M+H]+. Example 32 3-{4-[3-Methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]-benzoylamino}- propionic acid, Isomer 1 and Example 33 3-{4-[3-Methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000064_0002
These compounds are made by the general method as exemplified in Example 30 by resolving racemic 3-{4-[3-methyl-l-(4'-trifiuoromethyl-biphenyl-4-yloxy)-butyl]- benzoylamino} -propionic acid methyl ester on Chiralpak AD column (4.6 x 150 mm). Isomer 1 MS (ES): 500.3 [M+H]+. Isomer 2 MS (ES): 500.3 [M+H]+. Example 34 3-{4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-propyl]-benzoylamino}-propionic acid, Isomer 1 and Example 35 3-{4-[l-(4'-Trifluoromethyl-biphenyl-4-yIoxy)-propyl]-benzoylamino}-propionic acid, Isomer 2
Figure imgf000065_0001
These compounds are made by the general method as exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]- benzoylamino} -propionic acid methyl ester on Chiralpak AD column (4.6 x 150 mm). Isomer 1 MS (ES): 470.2 [M-H]". Isomer 2 MS (ES): 470.2 [M-H]". Example 36 3- {4- [1 -(4' -tert-Butyl-biphenyl-4-yloxy)-propyl] -benzoylamino} -propionic acid, Isomer 1 and Example 37 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-propyl]-benzoylamino}-propionic acid, Isomer 2
Figure imgf000065_0002
These compounds are made by the general method as exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-tert-butyl-biphenyl-4-yloxy)-propyl]-benzoylamino}- propionic acid methyl ester on Chiralpak AD column (4.6 x 150 mm). Isomer 1 MS (ES): 458.3 [M-H]". Isomer 2 MS (ES): 458.3 [M-H]". Example 38 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic cid, Isomer 1 and Example 39 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid, Isomer 2
Figure imgf000066_0001
These compounds are made by the general method as exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-tert-butyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid methyl ester on Chiralpak AD column (4.6 x 150 mm). Isomer 1 MS (ES): 516.3 [M+H]+. Isomer 2 MS (ES): 516.3 [M+H]+. Example 40 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}-propionic acid, Isomer 1 and Example 41 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}-propionic acid, Isomer 2
Figure imgf000066_0002
These compounds are made by the general method as exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-tert-butyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid methyl ester on Chiralpak AD column (4.6 x 150 mm). Isomer 1 MS (ES): 488.3 [M+H]+. Isomer 2 MS (ES): 488.3 [M+H]+. Example 42 3-{4-[l-(4'-Trifluoromethyl-biphenyl-4-ylsuIfanyl)-heptyl]-benzoylamino}-propionic acid, Isomer 1 and Example 43 3-{4-[l-(4'-Trifluoromethyl-biphenyl-4-ylsulfanyl)-heptyl]-benzoylamino}-propionic acid, Isomer 2
Figure imgf000067_0001
These compounds are made by the general method as exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-Trifluoromethyl-biphenyl-4-ylsulfanyl)-heptyl]- benzoylamino} -propionic acid methyl ester on Chiralcel OD column (4.6 x 150 mm). Isomer 1 MS (ES): 543.2 [M-H]". Isomer 2 MS (ES): 543.2 [M-H]". Example 44 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-pentyl]-benzoylamino}-propionic acid, Isomer 1 and Example 45 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-pentyl]-benzoylamino}-propionic acid, Isomer 2
Figure imgf000067_0002
These compounds are made by the general method as exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-pentyl]-benzoylamino}- propionic acid methyl ester on Chiralpak AD column (4.6 x 150 mm). Isomer 1 MS (ES): 489.44 [M+H]+. Isomer 2 MS (ES): 489.44 [M+H]+. Example 46 3-{4-[2-Methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-benzoylamino}- propionic acid, Isomer 1 and Example 47 3-{4-[2-Methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000068_0001
These compounds are made by the general method as exemplified in Example 30 by resolving racemic 3-{4-[2-Methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]- benzoylamino} -propionic acid methyl ester on Chiralpak AD column (4.6 x 150 mm). Isomer 1 MS (ES): 486.2 [M+H]+, Isomer 2 MS (ES): 486.2 [M+H]+. Example 48 3- {4- [1 -(4 ' -Trifluoromethyl-biphenyl-4-yloxy)-pentyl] -benzoylamino} -propionic acid, Isomer 1 and Example 49 3- {4- [1 -(4 ' -Trifluoromethyl-biphenyl-4-yloxy)-pentyl] -benzoylamino}-propionic acid, Isomer 2
Figure imgf000068_0002
This compound is made by the general method as exemplified in Example 30 by resolving racemic 3 - {4- [ 1 -(4'-trifluoromethyl-biphenyl-4-yloxy)-pentyl] -benzoylamino } - propionic acid methyl ester on Chiralcel OJ column (4.6 x 150 mm). Isomer 1 MS (ES):
501.2 [M+H]+. Isomer 2 MS (ES): 501.2 [M+H]+. Example 50 3-{4-[l-(4'-Trifluoromethyl-biphenyl-4-yIoxy)-butyl]-benzoylamino}-propionic acid, Isomer 1 and Example 51
3-{4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-butyl]-benzoylamino}-propionic acid, Isomer 2
Figure imgf000069_0001
These compounds are made by the general method as exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]- benzoylamino} -propionic acid methyl ester on Chiralcel OJ column (4.6 x 150 mm). Isomer 1 MS (ES): 486.2 [M+H]+. Isomer 2 MS (ES): 486.2 [M+H]+. Example 52 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-butyl]-benzoylamino}-propionic acid, Isomer 1 and Example 53 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-butyl]-benzoylamino}-propionic acid, Isomer 2
Figure imgf000069_0002
These compounds are made by the general method as exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-tert-butyl-biphenyl-4-yloxy)-butyl]-benzoylamino}- propionic acid methyl ester on Chiralpak AD column (4.6 x 150 mm). Isomer 1 MS (ES): 475.2 [M+H . Isomer 2 MS (ES): 475.2 [M+H]+. Example 54 3-(4-{l-[4'-(l-Fluoro-l-methyl-ethyl)-biphenyl-4-ylsulfanyl]-3-methyl-butyl}- benzoylamino)-propionic acid, Isomer 1 and Example 55 3-(4-{l-[4'-(l-Fluoro-l-methyl-ethyl)-biphenyl-4-ylsulfanyl]-3-methyl-butyl}- benzoylamino)-propionic acid, Isomer 2
Figure imgf000070_0001
These compounds are made by the general method as exemplified in Example 30 by resolving racemic 3-(4-{l-[4'-(l-fluoro-l-methyl-ethyl)-biphenyl-4-ylsulfanyl]-3- methyl-butyl} -benzoylamino)-propionic acid methyl ester on Chiralpak AD column (4.6 x 150 mm). Isomer 1 MS (ES): 517.3 [M+H]+. Isomer 2 MS (ES): 517.3 [M+H]+. Example 56 3-(4-{3-Methyl-l-[4-(6-trifluoromethyl-pyridin-3-yl)-phenoxy]-butyl}- benzoylamino)-propionic acid, Isomer 1 and Example 57 3-(4-{3-Methyl-l-[4-(6-trifluoromethyl-pyridin-3-yl)-phenoxy]-butyl}- benzoylamino)-propionic acid, Isomer 2
Figure imgf000070_0002
These compounds are made by the general method as exemplified in Example 30 by resolving racemic 3-(4-{3-methyl-l-[4-(6-trifluoromethyl-pyridin-3-yl)-phenoxy]- butyl}-benzoylamino)-propionic acid methyl ester on Chiralpak AD column (4.6 x 150 mm). Isomer 1 MS (ES): 501.2 [M+H]+. Isomer 2 MS (ES): 501.2 [M+H]+. Example 58 3-{4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-nonyl]-benzoylamino}-propionic acid, Isomer 1 and Example 59 3-{4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-nonyl]-benzoylamino}-propionic acid, Isomer 2
Figure imgf000071_0001
These compounds are made by the general method as exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-nonyl]- benzoylamino} -propionic acid methyl ester on Chiralpak AD column (4.6 x 150 mm). Isomer 1 MS (ES): 554.2 [M-H]". Isomer 2 MS (ES): 554.2 [M-H]". Example 60 3-{4-[l-(4'-Ethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid, Isomer 1 and Example 61 3-{4-[l-(4'-Ethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid, Isomer 2
Figure imgf000071_0002
These compounds are made by the general method as exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-ethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid methyl ester on Chiralpak AD column (4.6 x 150 mm). Isomer 1 MS (ES): 488.3 [M+H]+. Isomer 2 MS (ES): 488.3 [M+H]+. Example 62 3-(4-{l-[6-(4-tert-Butyl-phenyl)-pyridin-3-yloxy]-4,4-dimethyl-pentyl}- benzoylamino)-propionic acid, Isomer 1
Figure imgf000072_0001
Step A. 3-(4-Formyl-benzoylamino)-propionic acid methyl ester 4-formyl-benzoic acid (20 g, 133 mmol), CDMT (24 g, 137 mmol), and 4-methyl- morpholine (15.4 mL, 140 mmol) are combined in anhydrous dichloromethane (DCM) (300 mL) under nitrogen. The reaction is allowed to stir under nitrogen at room temperature overnight. Beta-alanine methyl ester hydrochloride (20.4 g, (147 mmol) is then added to the reaction mixture, followed by 4-methylmorpholine (15.4 mL, 140 mmol), and allowed to stir at room temperature. Some water (<10% volume) is added to help solubility. The reaction is monitored by HPLC, and upon complete consumption of the acid, the reaction is diluted with DCM. The reaction is diluted with water and extracted with IN HCl. The organic layer is washed with water and brine, followed by drying over anhydrous sodium sulfate. The solution is filtered and concentrated and further purified using flash column chromatography (30 g, 128 mmol).
Step B. 3-[4-(l-Hydroxy-4,4-dimethyl-pentyl)-benzoylamino]-propionic acid methyl ester A solution of 3-(4-Formyl-benzoylamino)-propionic acid methyl ester (4.8 g, 20.43 mmol) is dissolved in the anhydrous tetrahydrofuran (THF) (75 mL) and cooled to 0 °C under nitrogen. 2,2-Dimethyl-butyl magnesium bromide (16.3 mL, 1.5M solution in THF, 24.5 mmol) is then added slowly to the solution by addition funnel. The reaction is allowed to stir at 0 °C for 1 hour and the ice bath is removed. The reaction is monitored by TLC or HPLC to determine complete consumption of the aldehyde. The reaction is cooled back down to 0 °C and 1.0N hydrogen chloride solution is dropped in to quench. • The solids are dissolved with enough water and the solution is diluted with ether. The two phases are separated and the organic layer is washed with brine, dried over anhydrous sodium sulfate and concentrated. The alcohol (1.6 g, 4.98 mmol) is purified by column chromatography. Step C. 3-{4-[l-(6-Chloro-pyridin-3-yloxy)-4,4-dimethyl-pentyl]-benzoylamino}- propionic acid methyl ester 3-[4-(l-Hydroxy-4,4-dimethyl-pentyl)-benzoylamino]-propionic acid methyl ester (546 mg, 1.7 mmol) and 6-chloro-pyridin-3-ol (270 mg, 2.09 mmol) are combined in anhydrous toluene (10 mL), degassed, filled with nitrogen for 3 times, and cooled in an ice bath. Tributylphosphine (TBP) (630 uL, 2.55 mmol) is added to the reaction mixture under nitrogen at 0 °C, followed by addition of l, -(azodicarbonyl)-dipiρeridine(ADDP) (643 mg, 2.55 mmol). The reaction mixture is allowed to warm to room temperature and stined over night, the mixture is loaded on silica gel column. Chromatography gave the title compound (722 mg, 1.67 mmol).
Step D. 3-(4-{l-[6-(4-tert-Butyl-phenyI)-pyridin-3-yloxy]-4,4-dimethyl-pentyl}- benzoylamino)-propionic acid methyl ester To a solution of 3-{4-[l-(6-chloro-pyridin-3-yloxy)-4,4-dimethyl-pentyl]- benzoylamino} -propionic acid methyl ester (84 mg, 0.19 mmol) in toluene:water (1:1) (2 mL) is added palladium tetrakis triphenylphosphine (22.47 mg, 0.1 mol%), 4-tert- butylphenylboronic acid (58 mg, 0.39 mmol). The reaction is purged with nitrogen and heated to reflux and the potassium fluoride (23 mg, 0.39 mmol) is added. The reaction is monitored by HPLC, and upon completion, allowed to cool to room temperature. The reaction is diluted with ethyl acetate and then Celite is added, followed by water. This mixture is then filtered through a pad of Celite. The solution is separated in a seperatory funnel and the organic layer is washed with 0.1N sodium hydoxide, water, and brine. The organic layer is dried over anhydrous sodium sulfate and concentrated. The 5-(4-{l-[6- (4-tert-butyl-phenyl)-pyridin-3-yloxy]-4,4-dimethyl-pentyl}-phenyl)-5-oxo-pentanoic acid methyl ester (80 mg, 0.15 mmol) is purified by flash column chromatography. Step E. Chiral separation The racemic 3-(4-{ l-[6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-4,4-dimethyl- pentyl}-phenyl)-5-oxo-pentanoic acid methyl ester is resolved on a Chiralpak AD-H column (4.6 x 150 mm). Eluted with Isopropyl Alcohol/Heptane (30/70) and concentrated the fractions to provide a purified enantiomer ester (isomer 1, 98.6 % ee). Step F. 3-(4-{l-[6-(4-tert-Butyl-phenyl)-pyridin-3-yloxy]-4,4-dimethyl-pentyl}- benzoylamino)-propionic acid 3 -(4- { 1 - [6-(4-tert-Butyl-phenyl)-pyridin-3 -yloxy] -4,4-dimethyl-pentyl } - benzoylamino)-propionic acid methyl ester (isomer 1, 80 mg, 0.15 mmol) is dissolved in the tettahydrofuran (1 mL) and sodium hydroxide solution (5 M, 1.0 mL, 5 mmol) is added. The reaction is monitored by HPLC, and upon complete conversion, the reaction is neutralized with 5N HCl, diluted with diethyl ether and water. The two phases are separated, and the organic layer is washed, dried, and concentrated. The title compound is used without further purification. MS (ES): 515.2 [M-H]", the structure was also confirmed by proton NMR. Example 63 Racemic 3-(4-{l-[6-(4-Trifluoromethyl-phenyl)-pyridin-3-yloxy]-heptyl}- benzoylamino)-propionic acid
Figure imgf000074_0001
This compound is made by the general method as exemplified in Example 62 using pentylmagnesium chloride in step B and 4-trifluromethyl phenyl boronic acid in step D as starting materials, without chiral separation in step E. MS (ES): 527.3 [M-H]", the structure was also confirmed by proton NMR. Example 64 Racemic 3-(4-{4,4,4-Trifluoro-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- butyl}-benzoylamino)-propionic acid
Figure imgf000074_0002
This compound is made by the general method as exemplified in Example 62 using 3,3,3-trifluropropylmagnesium bromide in step B and 4-trifluromethyl phenyl boronic acid in step D as starting materials, without chiral separation in step E. MS (ES): 539.2 [M-H]", the structure was also confirmed by proton NMR. Example 65 Racemic 3-(4-{3-Methyl-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-butyl}- benzoylamino)-propionic acid
Figure imgf000075_0001
This compound is made by the general method as exemplified in Example 62 using isobutylmagnesium chloride in step B and 4-trifluromethyl phenyl boronic acid in step D as starting materials, and without chiral separation in step E. MS (ES): 499.3 [M-H]", the structure was also confirmed by proton NMR. Example 66 Racemic 3-(4-{4,4-Dimethyl-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- pentyl}-benzoylamino)-propionic acid
Figure imgf000075_0002
This compound is made by the general method as exemplified in Example 62 using 3,3-dimetlιylbutyl magnesium bromide in step B and 4-trifluromethyl phenyl boronic acid in step D as starting materials without chiral separation in step E. MS (ES): 527.2 [M-H]", the structure was also corrfirmed by proton NMR. Example 67 Racemic 3-(4-{l-[6-(4-Trifluoromethyl-phenyl)-pyridin-3-yI]-butoxy}- benzoylamino)-propionic acid
Figure imgf000075_0003
This compound is made by the general method as exemplified in Example 62 using pentylmagnesium chloride in step B and 4-trifluromethyl phenyl boronic acid in step D as starting materials without chiral separation in step E. MS (ES): 485.2 [M-H]", the structure was also confirmed by proton NMR. Example 68 Racemic 3-(4-{l-[6-(4-tert-Butyl-phenyl)-pyridin-3-yloxy]-4,4,4-trifluoro-butyl}- benzoylamino)-propionic acid
Figure imgf000076_0001
This compound is made by the general method as exemplified in Example 62 using 3,3,3-trifluropropylmagnesium chloride in step B and 4-tert-butylphenyl boronic acid in step D as starting materials. MS (ES): 527.3 [M-H]", the structure was also confirmed by proton NMR. Example 69 Racemic 3-(4- {1 - [6-(4-tert-Butyl-phenyl)-pyridin-3-yloxy] -3-methyl-butyl}- benzoylamino)-propionic acid
Figure imgf000076_0002
This compound is made by the general method as exemplified in Example 62 using isobutylmagnesium chloride in step B and 4-tert-butylphenyl boronic acid in step D as starting materials. MS (ES): 487.3 [M-H]", the structure was also confirmed by proton NMR. Example 70 3-(4-{l-[6-(4-tert-Butyl-phenyl)-pyridin-3-yloxy]-4,4-dimethyl-pentyl}- benzoylamino)-propionic acid, enantiomer 2
Figure imgf000076_0003
The racemic 3-(4-{ l-[6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-4,4-dimethyl- pentyl}-benzoylamino)-propionic acid methyl ester (80 mg, 0.15 mmol) is resolved on a Chiralpak AD-H column (0.46 x 15 cm) with a flow rate of 0.6mL/min. and detection at 260nm. Elute with isopropyl alcohol in heptane and concentrate the fractions to provide a purified enantiomer ester (isomer 2, 99.9% ee). Hydrolysis of the enantiomer of the ester provided the title compound as a white solid. MS (ES): 517.3 [M+H]+, 515.2 [M-H]", the structure was also confirmed by proton NMR. Example 71 3-(4- {1 - [6-(4-Trifluoromethyl-phenyl)-py ridin-3-yloxy] -heptyl}-benzoylamino)- propionic acid, Isomer 1 and Example 72 3-(4-{l-[6-(4-Trifluoromethyl-phenyl)-pyridm-3-yloxy]-heptyl}-benzoylamino)- propionic acid, Isomer 2
Figure imgf000077_0001
These compounds are made by the general method as exemplified in Example 70 by resolving racemic 3-(4-{l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-heptyl}- benzoylamino)-propionic acid methyl ester on a Chiralpak AD-H column (4.6 x 150 mm) with a flow rate of 0.6 mL/min. and detection at 260nm. Elute with acetonitrile in 3A alcohol (isomer 2, 99.9% ee). Isomer IMS (ES): 527.2 [M-H]", the structure was also confirmed by proton NMR; Isomer 2 MS (ES): 527.2 [M-H]", the structure was also confirmed by proton NMR. Example 73 3-(4-{4,4,4-Trifluoro-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-butyl}- benzoylamino)-propionic acid, Isomer 1 and Example 74 3-(4-{4,4,4-Trifluoro-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-butyl}- benzoylamino)-propionic acid, Isomer 2
Figure imgf000077_0002
These compounds are made by the general method as exemplified in Example 70 by resolving racemic 3-(4-{4,4,4-frifluoro-l-[6-(4-frifluoromethyl-phenyl)-pyridin-3- yloxy]-butyl}-benzoylamino)-propionic acid methyl ester on a Chiralpak AD-H column (4.6 x 150 mm) with a flow rate of 0.6 mL/min. and detection at 260nm. Elute with acetonitrile in 3A alcohol (isomer 2, 99.8% ee). Isomer IMS (ES): 539.2 [M-H]", the structure was also confirmed by proton NMR; Isomer 2 MS (ES): 539.2 [M-H]", the structure was also confirmed by proton NMR. Example 75 3-(4-{l-[6-(4-tert-Butyl-phenyl)-pyridin-3-yloxy]-butyl}-benzoylamino)-propionic acid, Isomer 1 and Example 76 3-(4-{l-[6-(4-tert-Butyl-phenyl)-pyridin-3-yloxy]-butyl}-benzoylamino)-propionic acid, Isomer 2
Figure imgf000078_0001
These compounds are made by the general method as exemplified in Example 70 by resolving racemic 3-(4-{l-[6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-butyl}- benzoylamino)-propionic acid methyl ester on a Chiralpak AD-H column (0.46 x 15 cm) with a flow rate of 0.6 mL/min. and detection at 260nm. Eluted with isopropyl alcohol in heptane (isomer 2, >99% ee). MS (ES): 473.2 [M-H]", the structure was also confirmed by proton NMR; MS (ES): 473.2 [M-H]", the structure was also confirmed by proton NMR. Example 77 Racemic 3-(4-{l-[6-(4-Isobutyl-phenyl)-pyridin-3-yloxy]-butyl}-benzoylamino)- propionic acid
Figure imgf000078_0002
This compound is made by the general method as exemplified in Example 62 using propylmagnesium chloride in step B and 4-isobuphenyl boronic acid in step D as starting materials, without chiral separation in step E. MS (ES): 473.4 [M-H]", the structure was also confirmed by proton NMR. Example 78 Racemic 3- {4- [l-(3 ' -Trifluoromethyl-biphenyl-4-ylsulf anyl)-heptyl] -benzoylamino}- propionic acid
Figure imgf000079_0001
Step A. 4-[l-(4-Bromo-phenylsulfanyl)-3-methyl-butyl]-benzoic acid To a solution of 4-(l-hydroxy-3-methyl-heptyl)-benzoic acid methyl ester (1760 mg, 7.04 mmol) in toluene (70 mL) is added l,r-(azodicarbonyl)dipiperidine (ADDP, 2664 mg, 10.56 mmol) at 0 °C, followed by the additions of tributylphosphine (2.63 mL, 8.38 mmol) and 4-bromo-benzenethiol (1597 mg, 8.45 mmol). The reaction mixture is warmed up to room temperature and stined overnight. The mixture is loaded on silica gel, eluted with hexanes with a gradient from 0 % of ethyl acetate to 50 % of ethyl acetate giving 4-[l-(4-bromo-phenylsulfanyl)-heptyl]-benzoic acid methyl ester. 1700 mg of the ester product is taken into ethanol (5 mL), treated with sodium hydroxide (5N aqueous, 2 mL) for 3 h at room temperature. The mixture is concentrated, diluted with ethyl acetate, acidified with 5 N HCl (2 mL), and extracted with ethyl acetate. The organic layers are dried and concentrated giving 4- [l-(4-bromo-phenylsulfanyl)-3-methyl-heptyl] -benzoic acid (1700 mg). Step B. Racemic 3-{4-[l-(4-Bromo-phenylsulfanyl)-3-methyl-heptyl]- benzoylamino}-propionic acid methyl ester To a mixture of 4- [l-(4-bromo-phenylsulfanyl)-3-methyl-hepyl] -benzoic acid (1700 mg, 4.18 mmol) in methylene chloride (42 mL) are added triethyl amine (1.75 mL, 12.53 mmol), DMAP (5.0 mg), 3-amino-propionic acid methyl ester (875 mg, 6.27 mmol) and EDCI (2408 mg, 12.53 mmol) at room temperature. The reaction mixture is stined at room temperature overnight, loaded on silica gel, eluted with eluted with hexanes with a gradient from 0 % of ethyl acetate to 100 % of ethyl acetate giving 3-{4-[l-(4-bromo- phenylsulfanyl)-3-methyl-heptyl] -benzoylamino} -propionic acid methyl ester (1640 mg). Step C. Racemic 3-{4-[3-Methyl-l-(4'-trifluoromethoxy-biphenyl-4-ylsulfanyl)- heptyl] -benzoylamino}-propionic acid 3 - {4- [ 1 -(4-bromo-phenylsulfanyl)-3 -methyl-heptyl] -benzoylamino } -propionic acid methyl ester (100 mg, 0.2 mmol), potassium carbonate (83 mg, 0.6 mmol), 3- friflouromethoxylphenyl boronic acid (76 mg, 0.4 mmol) and tetrakis- (triphenylphosphine)palladium (23 mg, 0.02 mmol) are placed in a flask. After the reaction is purged with N2 for several times, THF/H O (20 ml/ 5 ml) is added. The resulting solution is refluxed overnight, concentrated, diluted with ethyl acetate, acidified with 1 N HCl (0.6 mL), extracted with ethyl acetate. The organic layers are dried and purified with reverse phase HPLC to afford the title compound (58 mg). MS (ES): 544.1 [M+H]+. Example 79 Racemic 3-{4-[l-(4'-Acetyl-biphenyl-4-ylsulfanyl)-heptyl]-benzoylamino}-propionic acid
Figure imgf000080_0001
This compound is made in a substantially similar manner as Example 78 using 4- acetylphenyl boronic acid as reagent in step C. MS (ES): 518.3 [M+H]+. Example 80 Racemic 3-{4-[l-(3',4'-dimethyl-biphenyl-4-ylsulfanyl)-heptyl]-benzoylamino}- propionic acid
Figure imgf000080_0002
This compound is made in a substantially similar manner as Example 78 using
3,4-dimethylphenyl boronic acid as reagent in step C. MS (ES): 504.3 [M+H]+. Example 81 Racemic 3-{4-[l-(4'-methylsulfonyl-biphenyl-4-ylsulfanyl)-heptyl]-benzoylamino}- propionic acid
Figure imgf000080_0003
This compound is made in a substantially similar manner as Example 78 using 4- methylsulfonylphenyl boronic acid as reagent in step C. MS (ES): 554.3 [M+H]+. Example 82 Racemic 3-{4-[l-(2',3'-dimethyl-biphenyl-4-ylsulfanyl)-heptyl]-benzoylamino}- propionic acid
Figure imgf000081_0001
This compound is made in a substantially similar manner as Example 78 using 2,3-dimethylphenyl boronic acid as reagent in step C. MS (ES): 504.2 [M+H]+. Example 83 Racemic 3-{4-[l-(2',6'-dimethyl-biphenyl-4-ylsulfanyl)-heptyl]-benzoylamino}- propionic acid
Figure imgf000081_0002
This compound is made in a substantially similar manner as Example 78 using 2,6-dimethylphenyl boronic acid as reagent in step C. MS (ES): 504.2 [M+H]+. Example 84 Racemic 3-{4-[l-(3'-isopropyl-biphenyl-4-ylsulfanyl)-heptyl]-benzoylamino}- propionic acid
Figure imgf000081_0003
This compound is made in a substantially similar manner as Example 78 using 3- isopropylphenyl boronic acid as reagent in step C. MS (ES): 518.3 [M+H]+. Example 85 Racemic 3-{4-[l-(3'-acetyl-biphenyl-4-ylsulfanyl)-heptyl]-benzoylamino}-propionic acid
Figure imgf000082_0001
This compound is made in a substantially similar manner as Example 78 using 3-acetylphenyl boronic acid as reagent in step C. MS (ES): 518.3 [M+H]+. Example 86 Racemic 3-{4-[l-(4'-pentyl-biphenyl-4-ylsulfanyl)-heptyl]-benzoylamino}-propionic acid
Figure imgf000082_0002
This compound is made in a substantially similar manner as Example 78 using 4-pentylphenyl boronic acid as reagent in step C, MS (ES): 546.3 [M+H]+. Example 87 Racemic 3-{4-[l-(4'-cyclohexyl-biphenyl-4-ylsulfanyl)-heptyl]-benzoylamino}- propionic acid
Figure imgf000082_0003
This compound is made in a substantially similar manner as Example 78 using 4- cyclohexylphenyl boronic acid as reagent in step C. MS (ES): 558.3 [M+H]+. Example 88 Racemic 3-{4-[l-(4-Allyloxy-phenoxy)-heptyl]-benzoylamino}-propionic acid
Figure imgf000082_0004
This compound is made in a substantially similar manner as Example 1 using 4- (l-hydroxy-heptyl)-benzoic acid methyl ester and 4-allyloxy-phenol as reagents in step A. MS (ES): 438.3 [M-H]". Example 89 Racemic 3-{4-[l-(2,2,3,3-Tetrafluoro-2,3-dihydro-benzo[l,4]dioxin-6-yIoxy)-heptyl]- benzoylamino}-propionic acid
Figure imgf000083_0001
This compound is made in a substantially similar manner as Example 1 using 4- (l-hydroxy-heptyl)-benzoic acid methyl ester and 2,2,3,3-tetrafluoro-2,3-dihydro- benzo[l,4]dioxin-6-ol as reagents in step A. MS (ES): 514.2 [M+H]+. Example 90 Racemic 3 -(4-{l-[4-(4-Trifluoromethyl-phenoxy)-phenoxy]-heptyl}-benzoylamino)- propionic acid
Figure imgf000083_0002
This compound is made in a substantially similar manner as Example 1 using 4- (l-hydroxy-heptyι)-benzoic acid methyl ester and 4-(4-trifluoromethyl-phenoxy)-phenol as reagents in step A. MS (ES): 544.2 [M+H]+. Example 91 Racemic 3-{4-[l-(4-Pentyl-phenoxy)-heptyl]-benzoylamino}-propionic acid
Figure imgf000083_0003
This compound is made in a substantially similar manner as Example 1 using 4- (l-hydroxy-heptyι)-benzoic acid methyl ester and 4-pentylphenol as reagents in step A. MS (ES): 454.2 [M+H]+. Example 92 Racemic 3-(4-{l-[4-(4-tert-Butyl-benzyloxy)-phenoxy]-heptyl}-benzoylamino)- propionic acid
Figure imgf000084_0001
Step 1. Racemic 3-{4-[l-(4-AUyloxy-phenoxy)-heptyl]-benzoylamino}-propionic acid methyl ester (1.59 g, 3.51 mmol) and triphenyl-phosphine tetrakis palladium(203 mg, 0.18 mmol) are combined with anhydrous tetrahydrofuran (10 mL) in a round bottom flask under nitrogen. Diethyl amine (712 uL, 7.02 mmol) is added and the reaction is allowed to stir under nitrogen at room temperature. The reaction is monitored by HPLC, and upon complete conversion, the reaction is quenched with water. The reaction is diluted with diethyl ether and rinsed with IN HCl, water, and brine. The ether layer is dried over anhydrous sodium sulfate and concentrated. Racemic 3-{4-[l-(4-Allyloxy- phenoxy)-heptyl] -benzoylamino} -propionic acid methyl ester (1.47 g, 3.50 mmol) is obtained pure after column chromatography. Step 2. To 3-{4-[l-(4-Hydroxy-phenoxy)-heptyl]-benzoylamino}-propionic acid methyl ester (70 mg, 0.17 mmol) in anhydrous dimethyl formamide (1.0 mL) is added cesium carbonate (110 mg, 0.34 mmol) in one portion. The mixture is allowed to stir under nitrogen at room temperature and 4-tert-butyl-benzyl bromide is added. The reaction is allowed to stir at room temperature for several hours and is monitored by HPLC. Upon complete consumption of starting material, the reaction is carefully quenched with water, extracted with ethyl acetate, washed, dried, and concentrated. 3-(4-{l-[4-(4-tert-Butyl- benzyloxy)-phenoxy] -heptyl} -benzoylamino)-propionic acid methyl ester is purified by column chromatography. Step 3. The 3 -(4- { 1 - [4-(4-tert-Butyl-benzyloxy)-phenoxy] -heptyl} -benzoylamino)- propionic acid methyl ester is dissolved in the THF (1.0 mL) and 5N NaOH (1.0 mL) is added. The mixture is heated to reflux under nitrogen and monitored by HPLC. Upon complete conversion, the reaction is neutralized with 5N HCl (1.0 mL), diluted with diethyl ether and water. The two phases are separated and the organic layer is washed, dried, and concentrated to provide the title compound (80 mg, 0.15 mmol). MS (ES): 544.2 [M-H]". Example 93 Racemic 3-(4-{l-[4-(3,5-bis trifluoromethyl-benzyloxy)-phenoxy]-heptyl}- benzoylamino)-propionic acid
Figure imgf000085_0001
This compound is made in a manner substantially similar to Example 92 using 3,5-bistrifluoromethyl-benzyl bromide. MS (ES): 624.2 [M-H]". Example 94 Racemic 3-(4-{l-[4-(4-isopropyl-benzyloxy)-phenoxy]-heptyl}-benzoylamino)- propionic acid
Figure imgf000085_0002
This compound is made in a manner substantially similar to Example 92 using 4- isopropylbenzyl bromide. MS (ES): 530.2 [M-H]". Example 95
Racemic 3-(4-{l-[4-(4-chloro-benzyloxy)-phenoxy]-heptyl}-benzoylamino)-propionic acid
Figure imgf000085_0003
This compound is made in a manner substantially similar to Example 92 using 4- chlorobenzyl bromide. MS (ES): 522.2 [M-H]". Example 96 Racemic 3-(4-{l-[4-(4-ethyl-benzyloxy)-phenoxy]-heptyl}-benzoylamino)-propionic acid
Figure imgf000086_0001
This compound is,made in a manner substantially similar to Example 92 using 4- ethylbenzyl bromide. MS (ES): 516.3 [M-H]". Example 97 Racemic 3-(4-{l-[4-(4-bromo-benzyloxy)-phenoxy]-heptyl}-benzoylamino)-propionic acid
Figure imgf000086_0002
This compound is made in a manner substantially similar to Example 92 using 4- bromobenzyl bromide. MS (ES): 566.2 [M-H]". Example 98 Racemic 3-(4-{l-[4-(4-fluoro-benzyloxy)-phenoxy]-heptyl}-benzoylamino)-propionic acid
Figure imgf000086_0003
This compound is made in a manner substantially similar to Example 92 using 4- fluorobenzyl bromide. MS (ES): 506.2 [M-H]". Example 99 Racemic 3-(4-{l-[4-(4-trifluoromethyl-benzyloxy)-phenoxy]-heptyl}-benzoylamino)- propionic acid
Figure imgf000086_0004
This compound is made in a manner substantially similar to Example 92 using 4- trifluoromethylbenzyl bromide. MS (ES): 556.3 [M-H]". Example 100 Racemic 3-(4-{l-[4-(4-phenyl-benzyloxy)-phenoxy]-heptyl}-benzoylamino)-propionic acid
Figure imgf000087_0001
This compound is made in a manner substantially similar to Example 92 using 4- phenylbenzyl bromide. MS (ES): 564.3 [M-H]". Example 101 Racemic 3-(4-{l-[4-(3-chloro-benzyloxy)-phenoxy]-heptyl}-benzoylamino)-propionic acid
Figure imgf000087_0002
This compound is made in a manner substantially similar to Example 92 using 3- chlorobenzyl bromide. MS (ES): 522.2 [M-H]". Example 102 Racemic 3-(4-{l-[4-(3,4-dimethyl-benzyloxy)-phenoxy]-heptyl}-benzoylamino)- propionic acid
Figure imgf000087_0003
This compound is made in a manner substantially similar to Example 92 using 3,4-dimethylbenzyl bromide as reagent. MS (ES): 516.3 [M-H]". Example 103 Racemic 3-(4-{l-[4-(4-isopropoxyphenoxy]-heptyl}-benzoylamino)-propionic acid
Figure imgf000088_0001
This compound is made in a manner substantially similar to Example 92 using 4- isopropyl iodide. MS (ES): 440.2 [M-H]". Example 104 Racemic 3-{4-[l-(3',5'-bistrifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid
Figure imgf000088_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-bromophenol as reagents in Step A and 3,5-bitrifluoromethylphenyl boronic acid in Step C as starting materials. MS (ES): 594.2 [M-H]". Example 105 Racemic 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylaminoj-propionic acid
Figure imgf000088_0003
This compound is made by the general method as exemplified in Example 1 using 4'-tert-butyl-biphenyl-4-ol and 4-(l-hydroxy-4,4-dimethyl-pentyl)-benzoic acid methyl ester in step A as starting materials. MS (ES): 516.3 [M+H]+. Example 106 Racemic 3-{4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylamino}-propionic acid
Figure imgf000089_0001
This compound is made by the general method as exemplified in Example 1 using 4'-frifluoromethyl-biphenyl-4-ol and 4-(l-hydroxy-4,4-dimethyl-pentyl)-benzoic acid methyl ester in step A as starting materials. MS (ES): 526.2 [M-H]". Example 107 Racemic 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-2-methyl-propyl]-benzoylamino}- propionic acid
Figure imgf000089_0002
This compound is made by the general method as exemplified in Example 1 using 4'-tert-butyl-biphenyl-4-ol and 4-(l-hydroxy-2-methyl-propyl)-benzoic acid methyl ester in step A as starting materials. MS (ES): 474.2 [M+H]+. Example 108 Racemic 3-{4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-hexyl]-benzoylamino}- propionic acid
Figure imgf000089_0003
This compound is made by the general method as exemplified in Example 1 using 4'-trifluoromethyl-biphenyl-4-ol and 4-(l-hydroxyhexyl)-benzoic acid methyl ester in step A as starting materials. MS (ES): 512.3 [M-H]". Example 109 3- {4- [1 -(3 ' ,5' -bistrifluoromethyl-biphenyl-4-yloxy)-heptyl] -benzoylamino}-propionic acid, Isomer 1
Figure imgf000090_0001
Chiral Separation: The racemic 3 - {4- [ 1 -(4-benzyloxy-phenoxy)-hexyl] -benzoylamino } -propionic acid methyl ester is resolved on a Chiralpak AD-H column (4.6 x 150 mm). Elute with Isopropyl Alcohol/Heptane (15/85 ) and concentrate the fractions to provide a purified enantiomer ester (isomer 1, >99 % ee). Hydrolysis of the purified enantiomer of the ester provided the title compound as a white solid. MS (ES): 594.2 [M-H]". Example 110 3- {4- [1 -(3 ' ,5 ' -bistrifluoromethyI-biphenyI-4-yloxy)-heptyl] -benzoylamino}-propionic acid, Isomer 2
Figure imgf000090_0002
This compound is made by the general method as exemplified in Example 109 by resolving racemic 3-{4-[l-(3',5'-bistrifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm) eluted with Isopropyl Alcohol/Heptane (15 /85 ). MS (ES): 594.2 [M-H]". Example 111 3-{4-[l-(4-tert-Butyl-phenoxy)-3-methyl-butyl]-benzoylamino}-propionic acid, i Isomer 1 and Example 112 3-{4-[i-(4-tert-Butyl-phenoxy)-3-methyl-butyl]-benzoylamino}-propionic acid, Isomer 2
Figure imgf000091_0001
These compounds are made by the general method as exemplified in Example 109 by resolving racemic 3-{4-[l-(4-tert-butyl-phenoxy)-3-methyl-butyl]-benzoylamino}- propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm) eluted with Methanol (100% ). Isomer 1 MS (ES): 412.3 [M+H]+; Isomer 2 MS (ES): 412.3 [M+H]+. Example 113 3-{4-[l-(4'-tertbutyl-biphenyl-4-yloxy)-2-methyl-propyl]-benzoylamino}-propionic acid, Isomer 1 or Example 114 3- {4- [1 -(4 ' -tertbutyl-biphenyl-4-yloxy)-2-methyl-propyl] -benzoylamino}-propionic acid, Isomer 2
Figure imgf000091_0002
These compounds are made by the general method as exemplified in Example 109 by resolving racemic 3-{4-[l-(4'-tertbutyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm) eluted with Isopropyl Alcohol/Heptane (50 /50 ). Isomer 1 MS (ES): 474.2 [M+H]+. Isomer 2 MS (ES): 474.2 [M+H]+. Example 115 3-{4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]-benzoylamino}- propionic acid, Isomer 1 and Example 116 3-{4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000092_0001
These compounds are made by the general method as exemplified in Example 109 by resolving racemic 3-{4-[l-(4'-trifluoromethyl-biphenyl-4-yioxy)-4,4-dimethyl-pentyl]- benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm) eluted with Propyl Alcohol (100% ). Isomer IMS (ES): 526.2 [M-H]". Isomer 2 MS (ES): 526.2 [M-H]". Example 117 3-{4-[l-(4'-Trifluoromethoxy-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid, Isomer 1
Figure imgf000092_0002
Step A. Racemic 4-[l-(4-Bromo-phenoxyI)-heptyl]-benzoic acid To a solution of 4-(l-hydroxy-heptyl)-benzoic acid methyl ester (1800 mg, 7.2 mmol) in toluene (72 mL) is added l,r-(azodicarbonyl)dipiperidine (ADDP, 2725 mg, 10.8 mmol) at 0 °C, followed by the additions of tributylphosphine (2.69 mL, 10.8 mmol) and 4-bromo-phenol (1503 mg, 8.64 mmol). The reaction mixture is warmed up to room temperature and stined overnight. The mixture is loaded on silica gel, eluted with hexanes with a gradient from 0 % of ethyl acetate to 50 % of ethyl acetate giving 4-[l-(4- bromo-phenoxyl)-heptyl] -benzoic acid methyl ester. 1900 mg of the ester product is taken into ethanol (5 mL), treated with sodium hydroxide (5N aqueous, 2 mL) for 3 h at room temperature. The mixture is concentrated, diluted with ethyl acetate, acidified with 5 N HCl (2 mL), and extracted with ethyl acetate. The organic layers are dried and concentrated giving 4- [l-(4-bromo-phenoxyl)-heptyl] -benzoic acid (1800 mg). Step B. Racemic 3-{4-[l-(4-Bromo-phenoxyl)-heptyl]-benzoylamino}-propionic acid methyl ester To a mixture of 4- [l-(4-bromo-phenoxyl)-heptyl] -benzoic acid (1700 mg, 4.35 mmol) in methylene chloride (43 mL) are added triethyl amine (1.82 mL, 13.4 mmol), DMAP (5.0 mg), 3-amino-propionic acid methyl ester (910 mg, 6.52 mmol) and EDCI (2507 mg, 13.04 mmol) at room temperature. The reaction mixture is stined at room temperature overnight, loaded on silica gel, eluted with eluted with hexanes with a gradient from 0 % of ethyl acetate to 100 % of ethyl acetate giving racemic 3-{4-[l-(4- bromo-phenoxyl)-heptyl] -benzoylamino} -propionic acid methyl ester (1660 mg). Step C. 3-{4-[l-(4-Bromo-phenoxyl)-heptyl]-benzoylamino}-propionic acid methyl ester, isomers 1 and 2 The racemic 3-{4-[l-(4-bromo-phenoxyl)-heptyl]-benzoylamino}-propionic acid methyl ester was resolved on a Chiralpak AD-H column (4.6 x 150 mm). Elute with Isopropyl Alcohol/Heptane (50 /50 ) and concentrated the fractions to provide a purified enantiomer ester (isomer 1, 99.5 % ee, isomer 2, 94.6 % ee).
Step D. 3-{4-[l-(4'-Trifluoromethoxy-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid methyl ester, isomer 1 3-{4-[l-(4-Bromo-phenoxyl)-heptyl]-benzoylamino}-propionic acid methyl ester (isomer 1, 100 mg, 0.21 mmol), potassium carbonate (85 mg, 0.63 mmol), 4-triflouromethoxylphenyl boronic acid (86 mg, 0.42 mmol) and tetrakis- (friphenylphosphine)palladium (24 mg, 0.021 mmol) are place in a flask. After the reaction is purged with N for several times, THF/H O (20 ml/5 ml) is added. The resulting solution is refluxed overnight, concentrated and acidified by 1 N HCl (0.6 mL), extracted with ethyl acetate. Combined organic layers are washed with water and brine, dried over sodium sulfate, purified by reverse phase HPLC to give the title compound (40 mg). MS (ES): 526.2 [M-H]". Example 118 3-{4-[l-(4'-Trifluoromethoxy-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid, Isomer 2
Figure imgf000093_0001
This compound is made in a substantially similar manner as Example 117 using isomer 2 of 3-{4-[l-(4-bromo-phenoxyl)-heptyl]-benzoylamino}-propionic acid methyl ester as starting material in step D. MS (ES): 526.2 [M-H]'. Example 119 3-{4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid, Isomer 1 or Example 120 3-{4-[l-(4,-Trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid, Isomer 2
Figure imgf000094_0001
These compounds are made by the general method as exemplified in Example 117 using isomer 2 of 3-{4-[l-(4-bromo-phenoxyl)-heptyl]-benzoylamino}-propionic acid methyl ester and triflouromethylphenyl boronic acid as starting materials in step D. Isomer 1 MS (ES): 528.3 [M+H]+; Isomer 2 MS (ES): 528.3 [M+H]+. Example 121 3-{4-[l-(2,2,3,3-Tetrafluoro-2,3-dihydro-benzo[l,4]dioxin-6-yloxy)-heptyl]- benzoylamino}-propionic acid, Isomer 1 and Example 122 3-{4-[l-(2,2,3,3-Tetrafluoro-2,3-dihydro-benzo[l,4]dioxin-6-yloxy)-heptyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000094_0002
This compound is made by the general method as exemplified in Example 109 by resolving racemic 3-{4-[l-(2,2,3,3 -tetrafluoro-2,3 -dihydro-benzo [ 1 ,4] dioxin-6-yloxy)- heptyl] -benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm) eluted with Propyl Alcohol/Heptane (15 /85 ). Isomer 1 MS (ES): 512.3 [M-H]"; Isomer 2 MS (ES): 514.2 [M+H]+. Example 123 3-(4-{l-[4-(4-Trifluoromethyl-phenoxy)-phenoxy]-heptyl}-benzoylamino)-propionic acid, Isomer 1 and Example 124 3-(4-{l-[4-(4-Trifluoromethyl-phenoxy)-phenoxy]-heptyl}-benzoylamino)-propionic acid, Isomer 2
Figure imgf000095_0001
These compounds are made by the general method as exemplified in Example 109 by resolving racemic 3 -(4- { 1 - [4-(4-trifluoromethyl-phenoxy)-phenoxy] -heptyl } - benzoylamino)-propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm) eluted with Propyl Alcohol/Heptane (15 /85 ). Isomer 1 MS (ES): 542.3 [M-H]". Isomer 2 MS (ES): 542.3 [M-H]". Example 125 3-{4-[l-(4'-Trifluoromethyl-biphenyI-4-yIoxy)-hexyI]-benzoyIamino}-propionic acid, Isomer 1 and Example 126
3-{4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-hexyl]-benzoylamino}-propionic acid, Isomer 2
Figure imgf000096_0001
These compounds are made by the general method as exemplified in Example 109 by resolving racemic 3-{4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-hexyl]- benzoylamino} -propionic acid methyl ester on Chiralcel OJ-H column (4.6 x 150 mm) eluted with MeOH (100% ). Isomer 1 MS (ES): 512.3 [M-H]". Isomer 2 MS (ES): 512.3 [M-H]". Example 127 3-(4-{l-[4'-isopropyl-biphenyl-4-ylsulfanyl]-butyl}-benzoylamino)-propionic cid, Isomer 1
Figure imgf000096_0002
This compound is made in a substantially similar manner as Example 117 using 4- (l-hydroxy-butyl)-benzoic acid methyl ester as starting material in step A and 4- isopropyphenylboronic acid as reagent in step D. MS (ES): 460.2 [M+H]+. Example 128 Racemic 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-heptyl]- benzoylamino}-propionic acid
Figure imgf000096_0003
Step A. Racemic 4-[l-(4-Bromo-3,5-dimethyl-phenoxyl)~heptyl]-benzoic acid To a solution of 4-(l-hydroxy-heptyl)-benzoic acid methyl ester (1000 mg, 4.0 mmol) in toluene (40 mL) is added l,r-(azodicarbonyl)dipiperidine (ADDP, 1514mg, 6.0 mmol) at 0 °C, followed by the additions of tributylphosphine (1.49 mL, ό.Ommol) and 4- bromo-3,5-dimethyl-phenol (965 mg, 4.8 mmol). The reaction mixture is warmed up to room temperature and stined overnight. The mixture is loaded on silica gel, eluted with hexanes with a gradient from 0 % of ethyl acetate to 50 % of ethyl acetate giving 4-[l-(4- bromo-phenoxyl)-heptyl] -benzoic acid methyl ester. The ester product (1800 mg) is taken into ethanol (5 mL), treated with sodium hydroxide (5N aqueous, 5 mL) for 3 h at room temperature. The mixture is concentrated, diluted with ethyl acetate, acidified with 5 N HCl (5 mL), extract with ethyl acetate. The organic layers are dried and concentrated giving 4-[l-(4-bromo-3,5-dimethyl-phenoxyl)-heptyl]-benzoic acid (1790 mg).
Step B. Racemic 3-{4-[l-(4-Bromo-3,5-dimethyl-phenoxyl)-heptyl]-benzoylamino}- propionic acid methyl ester To a mixture of 4-[l-(4-bromo-3,5-dimethyl-phenoxyl)-heptyl]-benzoic acid (1790 mg, 4.27 mmol) in methylene chloride (43 mL) are added triethyl amine (1.79 mL, 12.82 mmol), DMAP (5.0 mg), 3-amino-propionic acid methyl ester (895 mg, 6.4 mmol) and EDCI (2463 mg, 12.8 mmol) at room temperature. The reaction mixture is stined at room temperature overnight, loaded on silica gel, eluted with eluted with hexanes with a gradient from 0 % of ethyl acetate to 100 % of ethyl acetate giving racemic 3-{4-[l-(4- bromo-3,5-dimethyl-phenoxyl)-heptyl]-benzoylamino}-propionic acid methyl ester (945 mg).
Step C. Racemic 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)- heptyl] -benzoylamino}-propionic acid 3 - { 4- [ 1 -(4-Bromo-3 ,5 -dimethyl-phenoxyl)-heptyl] -benzoylamino} -propionic acid methyl ester (isomer 1, 100 mg, 0.2 mmol), potassium flouride (35 mg, 0.6 mmol), 4- triflouromethoxylphenyl boronic acid (83 mg, 0.4 mmol) and tetrakis(triphenylphosphine)palladium (23 mg, 0.02mmol) are place in a flask. After the reaction is purged with N2 for several times, Toluene/H2O (20 ml/5 ml) is added. The resulting solution is refluxed overnight, loaded on silica gel, eluted with hexane and ethyl acetate to give 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid, (105 mg).
Step D. 3- {4- [1 -(2,6-Dimethyl-4' -trifluoromethoxy-biphenyl-4-yloxy)-heptyl] - benzoylamino}-propionic acid To a mixture of 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)- heptyl] -benzoylamino} -propionic acid methyl ester (105 mg) in methanol (2 mL) is added sodium hydroxide (5 N aqueous, 0.5 mL) and stined for 5 h. The reaction mixture is concentrated and acidified by 5 N HCl (0.5 mL), extracted with ethyl acetate. Combined organic layers are washed with water and brine, dried over sodium sulfate. Concentration gives the title compound (114 mg). MS (ES): 572.3 [M+H]+. Example 129 Racemic 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino}-propionic acid
Figure imgf000098_0001
This compound is made in a substantially similar manner as Example 128 using 4- trifluoromethylphenyl boronic acid as reagent in step C. MS (ES): 554.2 [M-H]". Example 130 Racemic 3-{4-[l-(2,6-Dimethyl-4'-tertbutyl-biphenyl-4-yloxy)-heptyl]- benzoylamino}-propionic acid
Figure imgf000098_0002
This compound is made in a substantially similar manner as Example 128 using 4- tertbutylphenyl boronic acid as reagent in step C. MS (ES): 542.3 [M-H]". Example 131 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}-2 R)- hydroxy-propionic acid
Figure imgf000098_0003
Step A. 4-[l-(4'-tertbutyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoic acid To a solution of racemic 4-(l-hydroxy-3-methyl-butyl)-benzoic acid methyl ester (300 mg, 1.35 mmol) in toluene (14 mL) is added l,r-(azodicarbonyι)dipiperidine (ADDP, 512 mg, 2.03 mmol) at 0 °C, followed by the addition of tributylphosphine (0.5 mL, 2.03 mmol) and 4'-tert butyl-biphenyl-4-ol (367 mg, 1.62 mmol). The reaction mixture is warmed up to room temperature and stined overnight. The mixture is loaded on silica gel, eluted with hexanes with a gradient from 0 % of ethyl acetate to 50 % of ethyl acetate giving 4- [ 1 -(4'-tertbutyl-biphenyl-4-yloxy)-3 -methyl-butyl] -benzoic acid methyl ester. The ester product is taken into ethanol (5 mL), treated with sodium hydroxide (5N aqueous, 1 mL) for 3 h at room temperature. The mixture is concentrated, diluted with ethyl acetate, acidified with 5 N HCl (1 mL), extract with ethyl acetate. The organic layers are dried and concentrated giving 4-[l-(4'-tertbutyl-biphenyl-4-yloxy)-3- methyl-butyl] -benzoic acid (400 mg)..
Step B. 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}- 2(R)-hydroxy-propionic acid methyl ester To a mixture of 4-[l-(4'-tertbutyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoic acid (120 mg) in methylene chloride (3 mL) are added triethyl amine (0.12 mL, 0.87 mmol), DMAP (5 mg), 3-Amino-2( R)-hydroxy-propionic acid methyl ester (67.3 mg, 0.43 mmol) and EDCI (166 mg, 0.87 mmol) at room temperature. The reaction mixture is stined at room temperature overnight, loaded on silica gel, eluted with eluted with hexanes with a gradient from 0 % of ethyl acetate to 100 % of ethyl acetate giving 3-{4- [ 1 -(4'-tert-butyl-biphenyl-4-yloxy)-3 -methyl-butyl] -benzoylamino } -2(R)-hydroxy- propionic acid methyl ester (60 mg).
Step C. 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}- 2(R)-hydroxy-propionic acid To a mixture of 3-{4-[l-(4'-tert-butyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino}-2(R)-hydroxy-propionic acid methyl ester (60 mg, 0.12 mmol) in methanol (2 mL) is added sodium hydroxide (5 N aqueous, 0.5 mL) and stined for 5 h. The reaction mixture is concentrated and acidified by 5 N HCl (0.5 mL), extracted with ethyl acetate. Combined organic layers are washed with water and brine, dried over sodium sulfate. Concentration gives the title compound (63 mg). MS (ES): 504.3 [M+H]+. Example 132 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}-2(S)- hydroxy-propionic acid
Figure imgf000100_0001
This compound is made in a substantially similar manner as Example 131 using 3- amino-2( S)-hydroxy-propionic acid methyl ester as reagent in step B. MS (ES): 504.2 [M+H]+. Example 133
3-{4-[l-(4'-Pentyl-biphenyl-4-yloxy)-butyl]-benzoylamino}-propionic acid, Isomer 1
Figure imgf000100_0002
This compound is made in a substantially similar manner as Example 117 using isomer 1 of 3-{4-[l-(4-bromo-phenoxy)-butyl]-benzoylamino}-propionic acid methyl ester and 4-pentylphenylboronic acid as starting materials in step D. MS (ES): 488.3 [M+H]+. Example 134 3-{4-[l-(4'-Isobutyl-biphenyl-4-yloxy)-butyl]-benzoylamino}-propionic acid, Isomer 1
Figure imgf000100_0003
This compound is made in a substantially similar manner as Example 117 using isomer 1 of 3- { 4- [l-(4-bromo-phenoxy)-butyl] -benzoylamino} -propionic acid methyl ester and 4-isobutylphenylbronic acid as starting materials in step D. MS (ES): 472.2 [M- H]". Example 135 Racemic 3-{4-[l-(6-chloro-pyridin-3-yloxy)-4,4,4-trifluoro-butyl]-benzoylamino}- propionic acid
Figure imgf000101_0001
The title compound is prepared in a manner substantially similar to Example 62 starting from 3-{4-[l-(6-chloro-pyridin-3-yloxy)-4,4,4-trifluoro-butyl]-benzoylamino}- propionic acid methyl ester. MS: 429.2 [M-H]". Example 136 3-{4-[l-(4'-Acetyl-biphenyl-4-yloxy)-butyl]-benzoylamino}-propionic acid, Isomer 1
Figure imgf000101_0002
This compound is made in a substantially similar manner as Example 117 using isomer 1 of 3-{4-[l-(4-bromo-phenoxy)-butyl]-benzoylamino}-propionic acid methyl ester and 4-acetylphenylboronic acid as starting materials in step D. MS (ES): 458.3 [M- H]\ Example 137 3-{4-[l-(3% 5'-dichloro-biphenyl-4-yloxy)-butyl]-benzoylamino}-propionic acid, Isomer 1 and Example 138 3- {4- [1 -(3 ' , 5 ' -dichloro-biphenyl-4-yloxy)-butyl] -benzoy lamino}-propionic acid, Isomer 2
Figure imgf000101_0003
These compounds are made in a manner substantially similar to Example 117 using isomer 1 of 3-{4-[l-(4-bromo-phenoxy)-butyl]-benzoylamino}-propionic acid methyl ester and 3', 5'-dichlorophenylboronic acid as starting materials in step D. Isomer 1 MS (ES): 484.2 [M-H]"; Isomer 2 MS (ES): 486.2 [M+H]+. Example 139 3-{4-[l-(2', 3', 4,-trifluoro-biphenyl-4-yloxy)-butyl]-benzoylamino}-propionic acid, Isomer 1
Figure imgf000102_0001
This compound is made in a substantially similar manner as Example 117 using isomer 1 of3-{4-[l -(4-bromo-phenoxy)-butyl] -benzoylamino } -propionic acid methyl ester and 2', 3', 4'-trifluorophenylboronic acid as starting materials in step D. MS (ES):
Figure imgf000102_0002
Example 140 3- {4- [1 -(2 ' , 4 ' -dimethoxy-biphenyl-4-yloxy)-buty 1] -benzoy lamino}-propionic acid, Isomer 1
Figure imgf000102_0003
This compound is made in a substantially similar manner as Example 117 using isomer 1 of 3- { 4- [l-(4-bromo-phenoxy)-butyl] -benzoy lamino} -propionic acid methyl ester and 2', 4'-dimethoxyphenylboronic acid as starting materials in step D. MS (ES): 478.3 [M+H]+. Example 141 3-{4-[l-(4'-t-butyl-biphenyl-4-yloxy)-hexyl]-benzoylamino}-propionic acid, Isomer 1 and Example 142 3-{4-[l-(4'-t-butyl-biphenyl-4-yloxy)-hexyl]-benzoylamino}-propionic acid, Isomer 2
Figure imgf000102_0004
These compounds are made in a manner substantially similar to Example 30 by resolving racemic 3 - {4- [ 1 -(4' -t-butyl-biphenyl-4-yloxy)-hexyl] -benzoylamino } -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 502.2 [M+H]+; Isomer 2 MS (ES): 502.2 [M+H]+. Example 143 3-{4-[l-(4'-pentylphenyl-4-yloxy)-hexyl]-benzoylamino}-propionic acid, Isomer 1 and Example 144 3-{4-[l-(4'-pentylphenyl-4-yloxy)-hexyl]-benzoylamino}-propionic acid, Isomer 2
Figure imgf000103_0001
These compounds are made in a manner substantially similar to Example 30 by resolving racemic 3-{4-[l-(4' -pentylphenyl-4-yloxy)-hexyl] -benzoylamino } -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer IMS (ES): 454.2
[M+H]+; Isomer 2 MS (ES): 454.2 [M+H]+. Example 145 3-(4-{l-[4-(l-Methyl-l-phenyl-ethyl)-phenoxy]-heptyl}-benzoylamino)-propionic acid, Isomer 1 and Example 146 3-(4-{l-[4-(l-Methyl-l-phenyl-ethyl)-phenoxy]-heptyl}-benzoylamino)-propionic acid, Isomer 2
Figure imgf000103_0002
These compounds are made in a manner substantially similar to Example 30 by resolving racemic 3-(4-{ l-[4-(l-methyl-l-phenyl-ethyl)-phenoxy]-heptyl}- benzoylamino)-propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 502.2 [M+H]+. Isomer 2 MS (ES): 502.2 [M+H]+. Example 147 3-{4-[l-(2', 4', 6'-trimethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid, Isomer 1
Figure imgf000104_0001
This compound is made in a substantially similar manner as Example 117 using isomer 1 of 3-{4-[l-(4-bromo-phenoxy)-heptyl]-benzoylamino}-propionic acid methyl ester and 2', 4', 6'-trimethylphenylboronic acid as starting materials in step D. MS (ES): 502.2 [M+H]+. Example 148 3-{4-[l-(4'-Fluoro-2'-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid, Isomer 1
Figure imgf000104_0002
This compound is made in a substantially similar manner as Example 117 using isomer 1 of 3-{4-[l-(4-bromo-phenoxy)-heptyl]-benzoylamino}-propionic acid methyl ester and 4-fluoro-2-methyl-phenylboronic acid as starting materials in step D. MS (ES): 492.3 [M+H]+. Example 149 3-{4-[l-(4'-Trifluoromethoxy-biphenyl-4-yloxy)-hexyl]-benzoylamino}-propionic acid, Isomer 1
Figure imgf000104_0003
This compound is made in a substantially similar manner to Example 117 using isomer 1 of 3-{4-[l-(4-bromo-phenoxy)-hexyl]-benzoylamino}-propionic acid methyl ester and 4-trifluoromethoxy-phenylboronic acid as starting materials in step D. MS (ES): 530.2 [M+H]+. Example 150
3-{4-[l-(4'-Fluoro-biphenyl-4-ylόxy)-heptyl]-benzoylamino}-propionic acid, Isomer 1
Figure imgf000105_0001
This compound is made in a substantially similar manner to Example 117 using isomer 1 of 3- { 4- [l-(4-bromo-phenoxy)-heptyl] -benzoylamino} -propionic acid methyl ester and 4-trifluoromethoxy-phenylboronic acid as starting materials in step D. MS (ES): 476.2 [M-H]". Example 151 3-{4-[Cyclopropyl-(4'-trifluoromethyl-biphenyl-4-yloxy)-methyl]-benzoylamino}- propionic acid, Isomer 1 and Example 152 3-{4-[Cyclopropyl-(4'-trifluoromethyl-biphenyl-4-yloxy)-methyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000105_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[cyclopropyl-(4'-trifluoromethyl-biphenyl-4-yloxy)-methyl]- benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm).
Isomer 1 MS (ES): 482.2 [M-H]"; Isomer 2 MS (ES): 482.2 [M-H]". Example 153 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-benzoylamino}- propionic acid, Isomer 1 and Example 154 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000106_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3 - {4- [ 1 -(4'-tert-butyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl] - benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 528.3 [M+H]+. Isomer 2 MS (ES): 528.3 [M+H]+. Example 155 3-{4-[l-(4'-Chloro-biphenyl-4-yloxy)-hepryl]-benzoylamino}-propionic acid, Isomer 1
Figure imgf000106_0002
This compound is made in a substantially similar manner to Example 117 using isomer l of3-{4-[l -(4-bromo-phenoxy)-heptyl] -benzoylamino } -propionic acid methyl ester and 4-chlorophenylboronic acid as starting materials in step D. MS (ES): 492.3 [M- H]\ Example 156 3-{4-[l-(4'-tert-Butyl-2-methyl-biphenyl-4-yloxy)-3-methyl-butyl]-3-fluoro- benzoylamino}-propionic acid, Isomer 1 and Example 157 3-{4-[l-(4'-tert-Butyl-2-methyl-biphenyl-4-yloxy)-3-methyl-butyl]-3-fluoro- benzoylamino}-propionic acid, Isomer 2
Figure imgf000107_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-tert-butyl-2-methyl-biphenyl-4-yloxy)-3-methyl-butyl]-3- fluoro-benzoy lamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 520.2 [M+H]+; Isomer 2 MS (ES): 520.2 [M+H]+. Example 158 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-heptyl]-3-fluoro-benzoylamino}-propionic acid, Isomer 1 and Example 159 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-heptyl]-3-fluoro-benzoyIamino}-propionic acid, Isomer 2
Figure imgf000107_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-tert-butyl-biphenyl-4-yloxy)-heptyl]-3-fluoro- benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 534.2 [M+H]+. Isomer 2 MS (ES): 534.2 [M+H]+. Example 160 3-{3-Fluoro-4-[l-(2-methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino}-propionic acid, Isomer 1 and Example 161 3-{3-Fluoro-4-[l-(2-methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000108_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3 - { 3 -fluoro-4- [ 1 -(2-methyl-4,-trifluoromethyl-biphenyl-4-yloxy)- heptyl] -benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 560.2 [M+H]+; Isomer 2 MS (ES): 560.2 [M+H]+. Example 162 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl]-3-fluoro-benzoylamino}- propionic acid, Isomer 1 and Example 163 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl]-3-fluoro-benzoylamino}- propionic acid, Isomer 2
Figure imgf000108_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3 - {4- [ 1 -(4'-tert-butyl-biphenyl-4-yloxy)-3 -methyl-butyl] -3 -fluoro- benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 506.2 [M+H]+; Isomer 2 MS (ES): 506.2 [M+H]+. Example 164 3- {4- [1 -(4' -tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-heptyl] -benzoylamino}- propionic acid, Isomer 1 and Example 165 3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000109_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 544.2 [M+H]+. Isomer 2 MS (ES): 544.2 [M+H]+. Example 166 3-{4-[l-(4'-tert-Butyl-2-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid, Isomer 1 and Example 167 3-{4-[l-(4'-tert-Butyl-2-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid, Isomer 2
Figure imgf000109_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-tert-butyl-2-methyl-biphenyl-4-yloxy)-heptyl]- benzoy lamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 530.5 [M+H]+. Isomer 2 MS (ES): 530.5 [M+H]+. Example 168 3-{4-[l-(2-Methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid, Isomer 1 and Example 169 3-{4-[l-(2-Methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000110_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(2-methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 540.3 [M-H]". Isomer 2 MS (ES): 540.3 [M-H]". Example 170 3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino}-propionic acid, Isomer 1 and Example 171 3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000110_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 516.3 [M+H]+. Isoemr 2 MS (ES): 516.3 [M+H]+. Example 172 3- {4- [1 -(4 ' -Isopropyl-2-methyl-biphenyl-4-yloxy)-heptyl] -benzoylaminoj-propionic acid, Isomer 1 and Example 173 3-{4-[l-(4'-IsopropyI-2-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid, Isomer 2
Figure imgf000111_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3 - {4- [ 1 -(4'-isopropyl-2-methyl-biphenyl-4-yloxy)-heptyl] - benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 514.2 [M-H]". Isomer 2 MS (ES): 516.3 [M+H]+. Example 174 3- {4- [l-(4' -Fluoro-2-methyl-biphenyl-4-yloxy)-heptyl] -benzoylamino} -propionic acid, Isomer 1 and Example 175 3-{4-[l-(4'-Fluoro-2-methyl-biphenyl-4-yloxy)-heptyl]-benzoyIamino}-propionic acid, Isomer 2
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-fluoro-2-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 492.3 [M+H]+. Isomer 2 MS (ES): 490.2 [M-H]". Example 176 3-{4-[l-(4'-Ethyl-2-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid, Isomer 1 and Example 177
3-{4-[l-(4'-Ethyl-2-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid, Isomer 2
Figure imgf000112_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-ethyl-2-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 502.2 [M+H]+; Isomer 2 MS (ES): 502.2 [M+H]+. Example 178 3-{4-[l-(2,6-Dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}-propionic acid, Isomer 1 and Example 179 3- {4- [1 -(2,6-Dimethyl-biphenyl-4-yloxy)-3-methyl-butyl] -benzoylamino}-propionic acid, Isomer 2
Figure imgf000112_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3'{4-[l-(2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid methyl ester on Chiralcel OJ column (4.6 x 250 mm). Isomer 1 MS (ES): 458.3 [M-H]"; Isomer 2 MS (ES): 458.3 [M-H]". Example 180 3-{4-[l-(4'-Ethyl-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}- propionic acid, Isomer 1 and Example 181 3-{4-[l-(4'-Ethyl-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000113_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-ethyl-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid methyl ester on Chiralcel OJ column (4.6 x 250 mm). Isoemr 1 MS (ES): 488.3 [M+H]+; Isomer 2 MS (ES): 488.3 [M+H]+. Example 182 3-{4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino}-propionic acid, Isomer 1 and Example 183 3-{4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000113_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-tert-but l-2-frifluoromethyl-biphenyl-4-yloxy)-3-methyl- butyl] -benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 556.3 [M+H]+. Isomer 2 MS (ES): 556.3 [M+H]+. Example 184 3-{4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid, Isomer 1 and Example 185 3-{4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-heptyI]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000114_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3- {4-[l -(4'-tert-butyl-2-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 584.2 [M+H]+; Isomer 2 MS (ES): 584.2 [M+H]+. Example 186 3-{4-[l-(4'-tert-Buryl-2-trifluoromethyl-biphenyl-4-yloxy)-pentyl]-benzoylamino}- propionic acid, Isomer 1 and Example 187 3-{4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-pentyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000114_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-tert-butyl-2-trifluoromethyl-biphenyl-4-yloxy)-pentyl]- benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 556.3 [M+H]+; Isomer 2 MS (ES): 556.3 [M+H]+. Example 188 3- {4- [1 -(4 ' -tert-Butyl-2-trifluoromethyl-biphenyl-4-y loxy)-2-methyl-propyl] - benzoylamino}-propionic acid, Isomer 1 and Example 189 3-{4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000115_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-tert-butyl-2-trifluoromethyl-biphenyl-4-yloxy)-2-methyl- propyl] -benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 542.3 [M+H]+; Isomer 2 MS (ES): 542.3 [M+H]+. Example 190 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylamino}-propionic acid, Isomer 1 and Example 191 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000115_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4- dimethyl-pentyl] -benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 556.3 [M+H]+; Isomer 2 MS (ES): 556.3 [M+H]+. Example 192 3-{4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylamino}-propionic acid, Isomer 1 and Example 193 3-{4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000116_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4-dimethyl- pentyl] -benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 530.5 [M+H]+; Isomer 2 MS (ES): 530.2 [M+H]+. Example 194 3- {4- [1 -(2-Cy ano-4 ' -isopropyl-biphenyl-4-yloxy)-3-m ethyl-butyl] -benzoylamino}- propionic acid, Isomer 1 andExample 195 3-{4-[l-(2-Cyano-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyI]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000116_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(2-cyano-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 499.2 [M+H]+; Isomer 2 MS (ES): 499.2 [M+H]+. Example 196 3-{4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yIoxy)-2-methyl-propyl]- benzoylamino}-propionic acid, Isomer 1 and Example 197 3-{4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000117_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl- propyl] -benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 488.3 [M+H]+; Isomer 2 MS (ES): 488.3 [M+H]+. Example 198 3- {4- [1 -(2-Ethyl-4' -trifluoromethyl-biphenyl-4-yloxy)-heptyl] -benzoylamino}- propionic acid, Isomer 1 and Example 199 3-{4-[l-(2-Ethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000117_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(2-ethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 556.3 [M+H]+; Isomer 2 MS (ES): 556.3 [M+H]+. Example 200 3-{4-[l-(4'-Chloro-2,6-dimethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylamino}-propionic acid, Isomer 1 and Example 201 3-{4-[l-(4'-Chloro-2,6-dimethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000118_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-chloro-2,6-dimethyl-biphenyl-4-yloxy)-4,4-dimethyl- pentyl] -benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 522.2 [M+H]+; Isomer 2 MS (ES): 522.2 [M+H]+. Example 202 3- {4- [1 -(4' -tert-Butyl-2,6-dimethyl-biphenyl-4-y loxy)-2-methyl-propyl] - benzoylamino}-propionic acid, Isomer 1 and Example 203 3- {4- [1 -(4' -tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl] - benzoylaminoj-propionic acid, Isomer 2
Figure imgf000118_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl- propyl] -benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). MS (ES): 502.2. [M+H]+. MS.(ES): 502.2 [M+H]+. Example 204 3-{4-[2-Methyl-l-(2-methyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-propyl]- benzoylamino}-propionic acid, Isomer 1 and Example 205 3- {4- [2-Methyl-l -(2-methy 1-4 ' -trifluoromethoxy-biphenyl-4-yloxy)-propyl] - benzoy!amino}-propionic acid, Isomer 2
Figure imgf000119_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[2-methyl-l -(2-methyl-4'-trifluoromethoxy-biphenyl-4-yloxy)- propyl] -benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 516.3 [M+H]+; Isomer 2 MS (ES): 516.3 [M+H]+. Example 206 3-{4-[l-(2-Chloro-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}- propionic acid, Isomer 1 and Example 207 3-{4-[l-(2-Chloro-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000119_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(2-chloro-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 508.3 [M+H]+; Isomer 2 MS (ES): 508.3 [M+H]+. Example 208 3- {4- [1 -(2-Chloro-4' -trifluoromethyl-bipheny l-4-yloxy)-3-methyl-buty 1] - benzoylamino}-propionic acid, Isomer 1 and Example 209 3-{4-[l-(2-Chloro-4'-trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000120_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(2-chloro-4'-trifluoromethyl-biphenyl-4-yloxy)-3-methyl- butyl] -benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 534.2 [M+H]+; Isomer 2 MS (ES): 534.2 [M+H]+. Example 210 3-{4-[2-Methyl-l-(2-methyl-4,-trifluoromethyl-biphenyl-4-yloxy)-propyl]- benzoylamino}-propionic acid, Isomer 1 and Example 211 3-{4-[2-Methyl-l-(2-methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000120_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[2-Methyl-l-(2-methyl-4'-trifluoromethyl-biphenyl-4-yloxy)- propyl] -benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 500.3 [M+H]+; Isomer 2 MS (ES): 500.3 [M+H]+. Example 212 3-(4-{3-Methyl-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-butyl}- benzoylamino)-propionic acid, Isomer 1 and Example 213 3-(4-{3-Methyl-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-butyl}- benzoylamino)-propionic acid, Isomer 2
Figure imgf000121_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3 -(4- {3 -methyl-1 -[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3- yloxy]-butyl}-benzoylamino)-propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 515.2 [M+H]+; Isomer 2 MS (ES): 515.2 [M+H]+. Example 214 3-(4-{l-[6-(4-Isopropyl-phenyl)-5-methyl-pyridin-3-yloxy]-3-methyl-butyl}- benzoylamino)-propionic acid, Isomer 1 and Example 215 3-(4-{l-[6-(4-Isopropyl-phenyl)-5-methyl-pyridin-3-yloxy]-3-methyl-butyl}- benzoylamino)-propionic acid, Isomer 2
Figure imgf000121_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-(4-{l-[6-(4-isopropyl-phenyl)-5-methyl-pyridin-3-yloxy]-3-methyl- butyl}-benzoylamino)-propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 489.2 [M+H]+; Isomer 2 MS (ES): 489.2 [M+H]+. Example 216 3-(3-Fluoro-4-{3-methyl-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-butyl}- benzoylamino)-propionic acid, Isomer 1 and Example 217 3-(3-Fluoro-4-{3-methyl-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-butyl}- benzoyIamino)~propionic acid, Isomer 2
Figure imgf000121_0003
These compounds are made by the general method exemplified in Example 30 by resolving racernic 3-(3-fluoro-4-{3.-methyl-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3- yloxy]-butyl}-benzoylamino)-ρropionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 519.2 [M+H]+. Isomer 2 MS (ES): 519.2 [M+H]+. Example 218 3-(4-{3-MethyI-l-[4-(5-trifluoromethyl-pyridin-2-yl)-phenoxy]-butyl}- benzoylamino)-propionic acid, Isomer 1 and Example 219 3-(4-{3-Methyl-l-[4-(5-trifluoromethyl-pyridin-2-yI)-phenoxy]-butyl}- benzoylamino)-propionic acid, Isomer 2
Figure imgf000122_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3 -(4- { 3 -methyl- 1 - [4-(5-trifluoromethyl-pyridin-2-yl)-phenoxy] -butyl } - benzoylamino)-propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). MS (ES): 501.2 [M+H]+; MS (ES): 501.2 [M+H]+. Example 220 3-{4-[l-(4-tert-Butyl-phenoxy)-3-methyl-butyI]-benzoyIamino}-propionic acid, Isomer 1 and Example 221 3-{4-[l-(4-tert-Butyl-phenoxy)-3-methyl-butyl]-benzoyIamino}-propionic acid, Isomer 2
Figure imgf000122_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3 - {4- [ 1 -(4-tert-butyl-phenoxy)-3 -methyl-butyl] -benzoylamino } - propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 412.3 [M+H]+. Isomer 2 MS (ES): 412.3 [M+H]+. Example 222 2-Hydroxy-3-{4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid, Isomer 1 and Example 223 2-Hydroxy-3-{4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000123_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 2-hydroxy-3-{4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 542.3 [M-H]"; Isomer 2 MS (ES): 542.3 [M-H]". Example 224 2-Hydroxy-3-{4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid, Isomer 1 and Example 225 2-Hydroxy-3-{4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000124_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 2-Hydroxy-3-{4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 542.3 [M-H]"; Isomer 2 MS (ES): 542.3 [M-H]". Example 226 3-(4-{l-[4-(l,l,3,3-Tetramethyl-butyl)-phenoxy]-heptyl}-benzoylamino)-propionic acid, Isomer 1 and Example 227 3-(4-{l-[4-(l,l,3,3-Tetramethyl-bu yl)-phenoxy]-heptyl}-benzoylamino)-propionic acid, Isomer 2
Figure imgf000124_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-(4-{l-[4-(l,l,3,3-tetramethyl-butyl)-ρhenoxy]-heptyl}- benzoylamino)-propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 496.5 [M+H]+; Isomer 2 MS (ES): 496.5 [M+H]+. Example 228 3-{4-[l-(2,2,3,3-Tetrafluoro-2,3-dihydro-benzo[l,4]dioxin-6-yloxy)-heptyl]- benzoylamino}-propionic acid, Isomer 1 and Example 229 3-{4.[l.(2,2,3,3-Tetrafluoro-2,3-dihydro-benzo[l,4]dioxin-6-yloxy)-heptyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000125_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(2,2,3,3 -tetrafluoro-2,3 -dihydro-benzo [ 1 ,4] dioxin-6-yloxy)- heptyl] -benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 514.2 [M+H]+; Isomer 2 MS (ES): 514.2 [M+H]+. Example 230 3-{4-[l-(2,6-DimethyI-4'-trifluoromethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino}-propionic acid, Isomer 1 and Example 231 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000125_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3,3- dimethyl-butyl] -benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 540.3 [M-H]"; Isomer 2 MS (ES): 542.3 [M+H]+. Example 232 3-{4-[l-(4'-tert-Buryl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino}-propionic acid, Isomer 1 and Example 233 3-{4-[l-(4,-tert-Buryl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000126_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl- butyl] -benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 528.3 [M-H]"; Isomer 2 MS (ES): 528.3 [M-H]". Example 234 3-{4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino}-propionic acid, Isomer 1 and Example 235 3-{4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000126_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl- butyl] -benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 516.3 [M+H]+; Isomer 2 MS (ES): 516.3 [M+H]+. Example 236 3-(4-{3,3-Dimethyl-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- butyl}-benzoylamino)-propionic acid, Isomer 1 and Example 237 3-(4-{3,3-Dimethyl-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- butyl}-benzoylamino)-propionic acid, Isomer 2
Figure imgf000127_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3 -(4- { 3 ,3 -dimethyl- 1 - [5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin- 3-yloxy]-butyl}-benzoylamino)-propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer IMS (ES): 529.3 [M+H]+; Isomer 2 MS (ES): 529.3 [M+H]+. Example 238 3-{4-[l-(4'-Isopropyl-2-methoxy-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}- propionic acid, Isomer 1 and Example 239 3-{4-[l-(4'-Isopropyl-2-methoxy-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000127_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(4'-isopropyl-2-methoxy-biphenyl-4-yloxy)-3-methyl-butyl]- berizoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 504.2 [M+H]+; Isomer 2 MS (ES): 504.2 [M+H]+. Example 240 3-{4-[l-(4'-Isopropyl-2-methyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}- propionic acid, Isomer 1 and Example 241 3-{4-[l-(4'-Isopropyl-2-methyI-biphenyl-4-yloxy)-3-methyl-butyI]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000128_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3 - {4- [ 1 -(4'~isopropyl-2-methyl-biphenyl-4-yloxy)-3 -methyl-butyl] - benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 488.3 [M+H]+; Isomer 2 MS (ES): 488.3 [M+H]+. Example 242 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoy!amino}-propionic acid, Isomer 1 and Example 243 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000128_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(2,6-dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-3,3- dimethyl-butyl] -benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 558.3 [M+H]+; Isomer 2 MS (ES): 558.3 [M+H]+. Example 244 3-(4-{l-[2-(tert-Butoxyimino-methyl)-4'-trifluoromethyl-biphenyl-4-yloxy]-3-methyl- butyl}-benzoylamino)-propionic acid, Isomer 1 and Example 245
3-(4-{l-[2-(tert-Butoxyimino-methyl)-4'-trifluoromethyl-biphenyl-4-yloxy]-3-methyl- butyl}-benzoylamino)-propionic acid, Isomer 2
Figure imgf000129_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-(4-{ l-[2-(tert-butoxyimino-methyl)-4'-trifluoromethyl-biphenyl-4- yloxy]-3-methyl-butyl}-benzoylamino)-propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 599.2 [M+H]+; Isomer 2 MS (ES): 599.2 [M+H]+. Example 246 3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino}-2-hydroxy-propionic acid, Isomer 1 and Example 247 3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino}-2-hydroxy-propionic acid, Isomer 2
Figure imgf000129_0002
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l -(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-3, 3 -dimethyl- butyl] -benzoylamino }-2-hydroxy-propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 546.3 [M+H]+; Isomer 2 MS (ES): 546.3 [M+H]+. Example 248 3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino}-2-hydroxy-propionic acid, Isomer 1. and Example 249 3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino}-2-hydroxy-propionic acid, Isomer 2
Figure imgf000130_0001
These compounds are made by the general method exemplified in Example 30 by resolving racemic 3-{4-[l-(4,-tert-butyl-256-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl- butyl] -benzoylamino }-2-hydroxy-propionic acid ethyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 546.3 [M+H]+; Isomer 2 MS (ES): 546.3 [M+H]+. Example 250 3-{4-[l-(4'-Fluoro-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}- propionic acid, Isomer 1
Figure imgf000130_0002
This compound is made in a manner substantially similar to Example 117 using isomer 1 of 3-{4-[l-(4-bromo-3,5-dimethyl-phenoxy)-3-methyl-butyl]-benzoylamino}- propionic acid methyl ester and 4-fluorophenylboronic acid as starting materials in step D. MS (ES): 476.2 [M-H]". Example 251 3-{4-[l-(4'-Fluoro-2,6,2'-trimethyl-biphenyl-4-yloxy)-hepryl]-benzoylamino}- propionic acid, Isomer 1
Figure imgf000130_0003
This compound is made in a manner substantially similar to Example 117 using isomer l of3-{4-[l -(4-bromo-3 ,5-dimethyl-phenoxy)-heptyl] -benzoylamino } -propionic acid methyl ester and 4-fluoro-2-methyl-phenylboronic acid as starting materials in step D. MS (ES): 520.2 [M+H]+. Example 252 3-{4-[l-(4'-Chloro-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}- propionic acid, Isomer 1
Figure imgf000131_0001
This compound is made in a manner substantially similar to Example 117 using isomer 1 of 3-{4-[l-(4-bromo-3,5-dimethyl-phenoxy)-3-methyl-butyl]-benzoylamino}- propionic acid methyl ester and 4-chloro-phenylboronic acid as starting materials in step D. MS (ES): 492.3 [M+H]+. Example 253 3-{4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyI-4-yloxy)-3-methyl-butyl]- benzoylamino}-propionic acid, Isomer 1
Figure imgf000131_0002
This compound is made in a manner substantially similar to Example 117 using isomer 1 of 3-{4-[l -(4-bromo-3,5-dimethyl-phenoxy)-3-methyl-butyl]-benzoylamino}- propionic acid methyl ester and 4-isopropylphenylboronic acid as starting materials in step D. MS (ES): 502.2 [M+H]+. Example 254 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino}-propionic acid, Isomer 1 and Example 255 3- {4- [1 -(2,6-Dimethyl-4' -trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl] - benzoylaminoj-propionic acid, Isomer 2
Figure imgf000132_0001
These compounds are made by the general method as exemplified in Example 30 by resolving racemic 3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3- methyl-butyl] -benzoylamino} -propionic acid methyl ester on Chiralpak AD-H column (4.6 x 150 mm). Isomer 1 MS (ES): 528.3 [M+H]+; Isomer 2MS (ES): 528.4 [M+H]+. Example 256 Racemic 3-{4-[l-(4'-tert-Bu yl-biphenyl-4-yloxy)-hexyl]-benzoylamino}-propionic acid
Figure imgf000132_0002
This compound is made by the general method exemplified in Example 1 using 4- (l-hydroxy-hexyl)-benzoic acid methyl ester and 4'-tertbutyl-biphenyl-4-ol as starting materials. MS (ES): 502.2 [M+H]+. Example 257 Racemic 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-heptyl]-3-fluoro-benzoylamino}- propionic acid
Figure imgf000132_0003
This compound is made by the general method as exemplified in Example 1 using 3-fluoro-4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4'-tertbutyl-biphenyl-4-ol as starting materials. MS (ES): 534.2 [M+H]+. Example 258 Racemic 3- {4- [l-(4' -tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl] -3-fluoro- benzoylamino}-propionic acid
Figure imgf000133_0001
This compound is made by the general method as exemplified in Example 1 using 3-fluoro-4-(l-hydroxy-3-methyl-butyl)-benzoic acid methyl ester and 4'-tertbutyl- biphenyl-4-ol as starting materials. MS (ES): 504.2 [M-H]". Example 259 Racemic 3-{4-[l-(2-Cyano-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-buryl]- benzoylaminoj-propionic acid
Figure imgf000133_0002
This compound is made by the general method as exemplified in Example 1 using
4-(l-hydroxy-3-methyl-butyl)-benzoic acid methyl ester and 4-hydroxy-4'-isopropyl- biphenyl-2-carbonitrile as starting materials. MS (ES): 499.2 [M+H]+. Example 260 Racemic 3-{4-[l-(4'-Isopropyl-2-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino}-propionic acid
Figure imgf000133_0003
This compound is made by the general method as exemplified in Example 1 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4,-isopropyl-2-trifluoromethyl- biphenyl-4-ol as starting materials. MS (ES): 570.2 [M+H]+. Example 261 Racemic 3-{4-[l-(2-Ethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylaminoj-propionic acid
Figure imgf000134_0001
This compound is made by the general method as exemplified in Example 1 using 4-(l -hydroxy-heptyl)-benzoic acid methyl ester and 2-ethyl-4,-trifluoromethyl-biphenyl- 4-ol as starting materials. MS (ES): 556.3 [M+H]+. Example 262 3-[4-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxymethyl)-benzoyIamino]-propionic acid
Figure imgf000134_0002
This compound is made by the general method as exemplified in Example 1 using 4-hydroxymethyl-benzoic acid methyl ester and 4'-tert-butyl-2,6-dimethyl-biphenyl-4-ol as starting materials. MS (ES): 460.2 [M+H]+. Example 263 3-[4-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxymethyl)-benzoylamino]-propionic acid
Figure imgf000134_0003
This compound is made by the general method as exemplified in Example 1 using 3 -(4-hydroxymethyl-benzoic acid methyl ester and 4'-trifluoromethyl-2,6-dimethyl- * biphenyl-4-ol as starting materials. MS (ES): 472.2 [M+H]+. Example 264 Racemic 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-ethyl]- benzoylamino}-propionic acid
Figure imgf000135_0001
This compound is made by the general method as exemplified in Example 1 using 4-(l-hydroxy-ethyl)-benzoic acid methyl ester and 4'-trifluoromethyl-2,6-dimethyl- biρhenyl-4-ol as starting materials. MS (ES): 486.2 [M+H]+. Example 265 Racemic 3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-ethyl]-benzoylamino}- propionic acid
Figure imgf000135_0002
This compound is made by the general method as exemplified in Example 1 using 4-(l -hydroxy-ethyl)-benzoic acid methyl ester and 4'-tert-butyl-2,6-dimethyl-biphenyl-4- ol as starting materials. MS (ES): 474.2 [M+H]+. Example 266 Racemic 3-(3-Fluoro-4-{3-methyl-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- butyl}-benzoylamino)-prόpionic acid
Figure imgf000135_0003
This compound is made by the general method as exemplified in Example 1 using 3-fluoro-4-(l-hydroxy-3-methyl-butyl)-benzoic acid methyl ester and 6-(4- trifluoromethyl-phenyl)-pyridin-3-ol as starting materials. MS (ES): 519.2 [M+H]+. Example 267 Racemic 3-(4-{l-[4-(l,l,3,3-Tetramethyl-butyl)-phenoxy]-heptyl}-benzoylamino)- propionic acid
Figure imgf000136_0001
This compound is made by the general method as exemplified in Example 1 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-(l,l,3,3-tetramethyl-butyl)-phenol as starting materials. MS (ES): 494.2 [M-H]". Example 268 Racemic 3-(4-{3-Methyl-l-[4-(5-trifluoromethyl-pyridin-2-yl)-phenoxy]-butyl}- benzoylamino)-propionic acid
Figure imgf000136_0002
This compound is made by the general method as exemplified in Example 1 using 4-(l -hydroxy-3-methyl-butyl)-benzoic acid methyl ester and 4-(5-trifluoromethyl- pyridin-2-yl)-phenol as starting materials. MS (ES): 499.2 [M-H]". Example 269 Racemic 3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylaminoj-propionic acid
Figure imgf000136_0003
This compound is made by the general method as exemplified in Example 1 using
4-(l-hydroxy-3,3-dimethyl-butyl)-benzoic acid methyl ester and 4'-tert-butyl-2,6- dimethyl-biphenyl-4-ol as starting materials. MS (ES): 530.5 [M+H]+. Example 270 Racemic 3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino}-2-hydroxy-propionic acid
Figure imgf000137_0001
This compound is made by the general method as exemplified in Example 1 using 4-(l-hydroxy-3,3-dimethyl-butyl)-benzoic acid methyl ester and 4'-tert-butyl-2,6- dimethyl-biphenyl-4-ol as starting materials. MS (ES): 546.3 [M+H]+. Example 271 Racemic 3-{4-[l-(4'-tert-Buryl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino}-2-hydroxy-propionic acid
Figure imgf000137_0002
This compound is made by the general method as exemplified in Example 1 using 4-(l -hydroxy-3,3-dimethyl-butyl)-benzoic acid methyl ester and 4'-tert-butyl-2,6- dimethyl-biphenyl-4-ol as starting materials. MS (ES): 546.3 [M+H]+. Example 272 Chiral 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino}-2-hydroxy-propionic acid, Isomer 1
Figure imgf000137_0003
This compound is made by the general method as exemplified in Example 1 using chiral 4-(l-hydroxy-3-methyl-butyl)-benzoic acid methyl ester and 2,6-dimethyl-4'- trifluoromethyl-biphenyl-4-ol as starting materials. MS (ES): 544.2 [M+H]+. Example 273 Chiral 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyI-4-yloxy)-3-methyl-butyl]- benzoylamino}-2-hydroxy-propionic acid, Isomer 1
Figure imgf000138_0001
This compound is made by the general method as exemplified in Example 1 using chiral 4-(l-hydroxy-3-methyl-butyl)-benzoic acid methyl ester and 2,6-dimethyl-4'- trifluoromethyl-biphenyl-4-ol as starting materials. MS (ES): 544.2 [M+H]+. Example 274 Racemic 3-{4-[l-(4-Bromo-3-[l,3]dioxan-2-yl-phenoxy)-3-methyl-butyl]- benzoylamino}-propionic acid
Figure imgf000138_0002
This compound is made by the general method as exemplified in Example 1 using 4-(l-hydroxy-3-methyl-butyl)-benzoic acid methyl ester and 4-bromo-3-[l,3]dioxan-2-yl- phenol as starting materials. MS (ES): 521.3 [M+H]+. Example 275 Racemic 3-{4-[l-(4-tert-Butyl-phenoxy)-3-methyl-butyl]-benzoylamino}-propionic acid
Figure imgf000138_0003
This compound is made by the general method as exemplified in Example 1 using
4-(l-hydroxy-3-methyl-butyl)-benzoic acid methyl ester and 4-t-butyl-phenol as starting materials. MS (ES): 412.32 [M+H]+. Example 276 Racemic 3-{4-[l-(4'-tert-ButyI-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}-2- hydroxy-propionic acid
Figure imgf000139_0001
This compound is made by the general method as exemplified in Example 1 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 4' -tertbutyl-biphenol as starting materials. MS (ES): 504.2 [M+H]+. Example 277 Racemic 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}-2- hydroxy-propionic acid
Figure imgf000139_0002
This compound is made by the general method as exemplified in Example 1 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 4 '-tertbutyl-biphenol as starting materials. MS (ES): 504.2 [M+H]+. Example 278 Racemic 3-{4-[l-(4-Pentyl-phenoxy)-heptyl]-benzoylamino}-propionic acid
Figure imgf000139_0003
This compound is made by the general method as exemplified in Example 1 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-pentyl-phenol as starting materials. MS (ES): 454.2 [M+H]+. Example 279 Racemic 3-(4-{l-[4-(l-Methyl-l-phenyl-ethyl)-phenoxy]-heptyl}-benzoylamino)- propionic acid
Figure imgf000140_0001
This compound is made by the general method as exemplified in Example 1 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-(l -methyl-1 -phenyl-ethyl)-phenol as starting materials. MS (ES): 500.3 [M-H]". Example 280 Racemic 2-Hy droxy-3- {4- [l-(4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl] - benzoylamino}-propionic acid
Figure imgf000140_0002
This compound is made by the general method as exemplified in Example 1 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-trifluoromethyl-biphenol as starting materials. MS (ES): 542.3 [M-H]". Example 281 Racemic 2-Hydroxy-3-{4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino}-propionic acid
Figure imgf000140_0003
This compound is made by the general method as exemplified in Example 1 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-trifluoromethyl-biphenol as starting materials. MS (ES): 542.3 [M-H]". Example 282 Racemic 3-{4-[l-(4'-Isopropyl-2-methyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino}-propionic acid
Figure imgf000141_0001
This compound is made by the general method as exemplified in Example 1 using 4-(l-hydroxy-3-methyl-butyl)-benzoic acid methyl ester and 4'-isopropyl-2-methyl- biphenyl-4-ol as starting materials. MS (ES): 488.3 [M+H]+. Example 283 Racemic 3-{4-[l-(4-Chloro-3-trifluoromethyl-phenoxy)-heptyl]-benzoylamino}-2- hydroxy-propionic acid
Figure imgf000141_0002
This compound is made by the general method as exemplified in Example 1 using 4-(l-hydroxy-heptyι)-benzoic acid methyl ester and 4-chloro-3-trifluoromethyl-phenol as starting materials. MS (ES): 486.2 [M+H]+. Example 284 Racemic 3-{4-[l-(3-ChIoro-4-methyl-phenoxy)-3-methyl-butyl]-benzoylamino}- propionic acid
Figure imgf000141_0003
This compound is made by the general method as exemplified in Example 1 using
4-(l-hydroxy-3-methyl-butyl)-benzoic acid methyl ester and 3-chloro-4-methyl-phenol as starting materials. MS (ES): 404.2 [M+H]+. Example 285 Racemic 3-{4-[l-(2,2,3,3-Tetrafluoro-2,3-dihydro-benzo[l,4]dioxin-6-yloxy)-heptyl]- benzoylamino}-propionic acid
Figure imgf000142_0001
This compound is made by the general method as exemplified in Example 1 using 4-(l-hydroxy-heptyι)-benzoic acid methyl ester and 2,2,3 ,3-tetrafluoro-2,3-dihydro- benzo[l,4]dioxin-6-ol as starting materials. MS (ES): 514.2 [M+H]+. Example 286 Racemic 3- {4- [Cy clopropyl-(4' -trifluoromethyl-biphenyl-4-yloxy)-methyl] - benzoylamino}-propionic acid
Figure imgf000142_0002
This compound is made by the general method as exemplified in Example 1 using 4-(cyclopropyl-hydroxy-methyl)-benzoic acid methyl ester and 4'-trifluoromethyl- biphenyl-4-ol as starting materials. MS (ES): 482.2 [M-H]". Example 287 Racemic 3-{4-[l-(4'-IsopropyI-2,6-dimethyI-biphenyl-4~yloxy)-heptyl]- benzoylaminoj-propionic acid
Figure imgf000142_0003
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy~heptyl)~benzoic acid methyl ester and 4-bromo-3, 5-dimethylphenol as reagents in step A and 4-isopropylphenyl boronic acid in step C as starting materials. MS (ES): 530.5 [M+H]+. Example 288 Racemic 3-{4-[l -(4'-Acetyl-2,6-dimethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid
Figure imgf000143_0001
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-bromo-3, 5-dimethylphenol as reagents in step A and 4-acetylphenyl boronic acid in step C as starting materials. MS (ES): 530.2 [M+H]+. Example 289 Racemic 3-{4-[l-(4'-tert-Buryl-2-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid
Figure imgf000143_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-bromo-3-methylphenol as reagents in step A and 4-tertbutylphenyl boronic acid in step C as starting materials. MS (ES): 528.3 [M-H]". Example 290 Racemic 3-{4-[l-(2-Methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino}-propionic acid
Figure imgf000143_0003
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-bromo-3-methylphenol as reagents in step A and 4-trifluoromethylphenyl boronic acid in step C as starting materials. MS (ES): 540.3 [M-H]". Example 291 Racemic 3-(4-{l-[6-(4-Isopropyl-phenyl)-5-methyl-pyridin-3-yloxy]-4,4-dimethyl- pentyl}-benzoylamino)-propionic acid
Figure imgf000144_0001
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-4,4-dimethyl-pentyl)-benzoic acid methyl ester and 6-chloro-5- methyl-pyridin-3-ol as reagents in step A and 4-isopropylphenyl boronic acid in step C as starting materials. MS (ES): 517.3 [M+H]+. Example 292 Racemic 3-(4-{4,4-Dimethyl-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3- yloxy]-pentyl}-benzoylamino)-propionic acid
Figure imgf000144_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-4,4-dimethyl-pentyl)-benzoic acid methyl ester and 6-chloro-5- methyl-pyridin-3-ol as reagents in step A and 4-trifluoromethylphenyl boronic acid in step C as starting materials. MS (ES): 529.3 [M+H]+. Example 293 Racemic 3-(4- {4,4-Dimethyl-l- [5-methyl-6-(4-trifluoromethoxy-phenyI)-pyridin-3- yloxy]-pentyl}-benzoylamino)-propionic acid
Figure imgf000145_0001
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-4,4-dimethyl-pentyl)-benzoic acid methyl ester and 6-chloro-5- methyl-pyridin-3-ol as reagents in step A and 4-trifluoromethoxyphenyl boronic acid in step C as starting materials. MS (ES): 545.3 [M+H]+. Example 294 Racemic 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-3,3-dimethyl- butyl]-benzoylamino}-propionic acid
Figure imgf000145_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3, 3 -dimethyl-butyl)-benzoic acid methyl ester and 4-bromo-3,5- dimethyl-phenol as reagents in step A and 4-trifluoromethoxyphenyl boronic acid in step C as starting materials. MS (ES): 558.3 [M+H]+. Example 295 Racemic 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3,3-dimethyl- butyl] -benzoylamino}-2-hydroxy-propionic acid
Figure imgf000145_0003
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 ,3 -dimethyl-butyl)-benzoic acid methyl ester and 4~bromo-3,5- dimethyl-phenol as reagents in step A and 4-trifluoromethylphenyl boronic acid in step C as starting materials. MS (ES): 558.3 [M+H]+. Example 296 Racemic 3-{4-[l-(2,6-Dϊmethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3,3-dimethyI- butyl]-benzoylamino}-2-hydroxy-propionic acid
Figure imgf000146_0001
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-3,3-dimethyl-butyl)-benzoic acid methyl ester and 4-bromo-3,5- dimethyl-phenol as reagents in step A and 4-trifluoromethylphenyl boronic acid in step C as starting materials. MS (ES): 558.3 [M+H]+. Example 297 Racemic 2-Hydroxy-3-{4-[l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3- dimethyl-butyl]-benzoylamino}-propionic acid
Figure imgf000146_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-3,3-dimethyl-butyl)-benzoic acid methyl ester and 4-bromo-3,5- dimethyl-phenol as reagents in step A and 4-trifluoromethylphenyl boronic acid in step C as starting materials. MS (ES): 532.3 [M+H]+. Example 298 Racemic 3-{4-[l-(4'-Isopropyl-2-methoxy-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino}-propionic acid
Figure imgf000146_0003
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 4-bromo-3 -methoxy- phenol as reagents in step A and 4-isopropylphenyl boronic acid in step C as starting materials. MS (ES): 504.2 [M+H]+. Example 299 Racemic 3-{3-Fluoro-4-[l-(2-methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino}-propionic acid
Figure imgf000147_0001
This compound is made by the general method as exemplified in Example 24 using 3-fluoro-4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-bromo-3- methylphenol as reagents in step A and 4-trifluoromethylphenyl boronic acid in step C as starting materials. MS (ES): 516.3 [M+H]+. Example 300 Racemic 3-{4-[l-(4'-tert-Butyl-2-chloro-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid
Figure imgf000147_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-bromo-3-chloro-phenol as reagents in step A and 4-tertbutylphenyl boronic acid in step C as starting materials. MS (ES): 548.3 [M-H]". Example 301 Racemic 3-{4-[l-(4'-trifluoromethyl-2-chloro-biphenyl-4-yloxy)-heptyl]- benzoylamino}-propionic acid
Figure imgf000148_0001
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-bromo-3-chloro-phenol as reagents in step A and 4-trifluoromethylphenyl boronic acid in step C as starting materials. MS (ES): 560.2 [M-H]". Example 302 Racemic 3-{4-[l-(2', 4'-bistrifluoromethyl-2-chloro-biphenyl-4-yloxy)-heptyl]- benzoylaminoj-propionic acid
Figure imgf000148_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-bromo-3-chloro-phenol as reagents in step A and 2,4-bistrifluoromethylphenyl boronic acid in step C as starting materials. MS (ES): 628.3 [M-H]". Example 303 Racemic 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3-methyl- butyl] -benzoylaminoj-propionic acid
Figure imgf000148_0003
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 4-bromo-3,5- dimethyl-phenol as reagents in step A and 4-trifluoromethylphenyl boronic acid in step C as starting materials. MS (ES): 526.2 [M-H]". Example 304 Racemic 3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino}-propionic acid
Figure imgf000149_0001
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 4~bromo-3,5- dimethyl-phenol as reagents in step A and 4-t-butylphenyl boronic acid in step C as starting materials. MS (ES): 516.3 [M+H]+. Example 305 Racemic 3- {4- [l-(2-Hy droxy-4 ' -isopropyl-biphenyl-4-yloxy)-3-methyl-butyl] - benzoylamino}-propionic acid
Figure imgf000149_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-3-methyl-butyl)-benzoic acid methyl ester and 4-bromo-benzene-l,3- diol as reagents in step A and 4-isopropylphenyl boronic acid in step C as starting materials. MS (ES): 490.2 [M+H]+. Example 306 Racemic 3-{4-[l-(2-[l,3]Dioxan-2-yl-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino}-propionic acid
Figure imgf000150_0001
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 4-bromo-3- [l,3]dioxan-2-yl-phenol as reagents in step A and 4-isopropylphenyl boronic acid in step C as starting materials. MS (ES): 560.2 [M+H]+. Example 307 Racemic 3-(4-{l-[2-(tert-Butoxyimino-methyl)-4'-isopropyl-biphenyl-4-yloxy]-3- methyl-butyl}-benzoylamino)-propionic acid
Figure imgf000150_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 2-bromo-5-hydroxy- benzaldehyde O-tert-butyl-oxime as reagents in step A and 4-isopropylphenyl boronic acid in step C as starting materials. MS (ES): 573.3 [M+H]+. Example 308
Racemic 3-(4-{l-[2-(tert-Butoxyimino-methyl)-4'-trifluoromethyl-biphenyl-4-yloxy]- 3-methyl-butyl}-benzoylamino)-propionic acid
Figure imgf000150_0003
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 2-bromo-5~hydroxy- benzaldehyde O-tert-butyl-oxime as reagents in step A and 4-trifluoromethylphenyl boronic acid in step C as starting materials. MS (ES): 599.2 [M+H]-. Example 309 Racemic 3-{4-[l-(2,6-Dimethyl-biphenyl-4-yloxy)-3-methyl-buryl]-benzoylamino}- propionic acid
Figure imgf000151_0001
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 4-bromo-3,5- dimethyl-phenol as reagents in step A and phenyl boronic acid in step C as starting materials. MS (ES): 460.2 [M+H]+. Example 310 Racemic 3-{4-[l-(4'-Ethyl-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylaminoj-propionic acid
Figure imgf000151_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 4-bromo-3,5- dimethyl-phenol as reagents in step A and 4-ethyl-phenyl boronic acid in step C as starting materials. MS (ES): 486.2 [M-H]". Example 311 Racemic 3- {4- [1 -(2-Methyl-4 ' -trifluoromethoxy-biphenyl-4-yloxy)-heptyl] - benzoylamino}-propionic acid
Figure imgf000151_0003
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-bromo-3 -methyl-phenol as reagents in step A and 4-trifluoromethoxy-phenyl boronic acid in step C as starting materials. MS (ES): 556.3 [M-H]". Example 312 Racemic 3-{4-[l-(4'-Isopropyl-2-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid
Figure imgf000152_0001
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-bromo-3 -methyl-phenol as reagents in step A and 4-isopropyl-phenyl boronic acid in step C as starting materials. MS (ES): 516.3 [M+H]+. Example 313 Racemic 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-3-methyl- butyl]-benzoylamino}-propionic acid
Figure imgf000152_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 4-bromo-3,5- dimethyl-phenol as reagents in step A and 4-trifluoromethoxy -phenyl boronic acid in step C as starting materials. MS (ES): 542.3 [M-H]". Example 314 Racemic 3-{4-[l-(4'-ethyl-2-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid
Figure imgf000152_0003
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-bromo-3 -methyl-phenol as reagents in step A and 4-ethyl-phenyl boronic acid in step C as starting materials. MS (ES): 502.2 [M+H]+. Example 315 Racemic 3-{4- [l-(4'-acetyl-2-methyl~biphenyl-4-yloxy)-heptyl] -benzoylamino}- propionic acid
Figure imgf000153_0001
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-bromo-3 -methyl-phenol as reagents in step A and 4-acetyl-phenyl boronic acid in step C as starting materials. MS (ES): 514.2 [M-H]". Example 316 Racemic 3-{4-[l-(4'-fluoro-2-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid
Figure imgf000153_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l- hydroxy-heptyl)-benzoic acid methyl ester and 4-bromo-3 -methyl-phenol as reagents in step A and 4-fluoro-phenyl boronic acid in step C as starting materials. MS (ES): 490.2 [M-H]". Example 317 Racemic 3-{4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino}-propionic acid
Figure imgf000153_0003
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-chloro-3 -trifluoromethyl- phenol as reagents in step A and 4-tertbutyl-phenyl boronic acid in step C as starting materials. MS (ES): 582.2 [M-H]". Example 318 Racemic 3-{4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yIoxy)-pentyI]- benzoylamino}-propionic acid
Figure imgf000154_0001
This compound is made by the general method as exemplified in Example 24 using 4-( 1 -hydroxy-pentyl)-benzoic acid methyl ester and 4-chloro-3 -trifluoromethyl- phenol as reagents in step A and 4-tertbutyl-phenyl boronic acid in step C as starting materials. MS (ES): 554.2 [M-H]". Example 319 Racemic 3-{4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-2-methyl- propyl] -benzoylamino}-propionic acid
Figure imgf000154_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-2-methyl-propyl)-benzoic acid methyl ester and 4-chloro-3- trifluoromethyl-phenol as reagents in step A and 4-t-butyl-phenyl boronic acid in step C as starting materials. MS (ES): 540.3 [M-H]". Example 320 Racemic 3-{4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylaminoj-propionic acid
Figure imgf000154_0003
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 4-chloro-3- tnfluoromethyl-phenol as reagents in step A and 4-tertbutyl-phenyl boronic acid in step C as starting materials. MS (ES): 554.2 [M-H]". Example 321 Racemic 3-{4-[l-(3,5-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino}-propionic acid
Figure imgf000155_0001
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-bromo-3,5-dimethyl-phenol as reagents in step A and 4-trifluoromethyl-phenyl boronic acid in step C as starting materials. MS (ES): 554.2 [M-H]". Example 322 Racemic 3-{4-[l-(4'-Chloro-3,5-dimethyl-biphenyl-4-yloxy)-hepryl]-benzoylamino}- propionic acid
Figure imgf000155_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-bromo-3,5-dimethyl-phenol as reagents in step A and 4-chloro-phenyl boronic acid in step C as starting materials. MS (ES): 522.2 [M+H]+. Example 323 Racemic 3-{4-[l-(4'-Chloro-3-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid
Figure imgf000156_0001
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4-bromo-3-dimethyl-phenol as reagents in step A and 4-chloro-phenyl boronic acid in step C as starting materials. MS (ES): 506.2 [M-H]". Example 324 Racemic 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3,3-dimethyl- butyl]-benzoylamino}-propionic acid
Figure imgf000156_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 ,3 -dimethyl-butyl)-benzoic acid methyl ester and 4-bromo-3,5- dimethyl-phenol as reagents in step A and 4-fluoromethyl-phenyl boronic acid in step C as starting materials. MS (ES): 540.3 [M-H]". Example 325 Racemic 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4-dimethyl- pentyl]-benzoylamino}-propionic acid
Figure imgf000156_0003
This compound is made by the general method as exemplified in Example 24 using 4-(l~hydroxy-4,4-dimethyl-pentyl)-benzoic acid methyl ester and 4-bromo-3,5: dimethyl-phenol as reagents in step A and 4-fluoromethyl-phenyl boronic acid in step C as starting materials. MS (ES): 554.2 [M-H]". Example 326 Racemic 3-{4-[l-(2,6-Dimethyl-4'-isopropyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylamino}-propionic acid
Figure imgf000157_0001
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-4,4-dimethyl-pentyl)-benzoic acid methyl ester and 4-bromo-3,5- dimethyl-phenol as reagents in step A and 4-isopropyl-phenyl boronic acid in step C as starting materials. MS (ES): 530.2 [M+H]+. Example 327 Racemic 3-{4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino}-propionic acid
Figure imgf000157_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-2-methyl-propyl)-benzoic acid methyl ester and 4-bromo-3,5- dimethyl-phenol as reagents in step A and 4-isopropyl-phenyl boronic acid in step C as starting materials. MS (ES): 488.3 [M+H]+. Example 328 Racemic 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-methyl- propyl] -benzoylamino}-propionic acid
Figure imgf000157_0003
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-2-methyl-propyl)-benzoic acid methyl ester and 4-bromo-3,5- dimethyl-phenol as reagents in step A and 4-trifluoromethyl-phenyl boronic acid in step C as starting materials. MS (ES): 514.2 [M+H]+. Example 329 Racemic 3-{4-[2-Methyl-l-(2-methyl-4'-trifluoromethyl-biphenyI-4-yloxy)-propyl]- benzoylamino}-propionic acid
Figure imgf000158_0001
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-2-methyl-propyl)-benzoic acid methyl ester and 4-bromo-3 -methyl- phenol as reagents in step A and 4-trifluoromethyl-phenyl boronic acid in step C as starting materials. MS (ES): 500.3 [M+H]+. Example 330 Racemic 3-{4-[l-(2,6-Dimethyl-4'-chloro-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylaminoj-propionic acid
Figure imgf000158_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy ~4,4-dimethyl-pentyl)-benzoic acid methyl ester and 4-bromo-3,5- dimethyl-phenol as reagents in step A and 4-chloro-phenyl boronic acid in step C as starting materials. MS (ES): 522.2 [M+H]+. Example 331 Racemic 3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino}-propionic acid
Figure imgf000158_0003
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-2-methyl-propyl)-benzoic acid methyl ester and 4-bromo-3 -methyl- phenol as reagents in step A and 4-tertbutyl-phenyl boronic acid in step C as starting materials. MS (ES): 502.2 [M+H]+. Example 332 Racemic 3-{4-[l-(4'-Isopropyl-2-methyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino}-propionic acid
Figure imgf000159_0001
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-2-methyl-propyl)-benzoic acid methyl ester and 4-bromo-3 -methyl- phenol as reagents in step A and 4-isopropyl-phenyl boronic acid in step C as starting materials. MS (ES): 474.2 [M+H]+. Example 333 Racemic 3-{4-[l-(2,6-Difluoro-4'-trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylaminoj-propionic acid
Figure imgf000159_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 4-bromo-3,5-difluoro- phenol as reagents in step A and 4-trifluoromethyl-phenyl boronic acid in step C as starting materials. MS (ES): 536.2 [M+H]+. Example 334 Racemic 3-{4-[l-(2,6-Difluoro-4'-isopropyl-biphenyl-4-yIoxy)-3-methyl-buryl]- benzoylamino}-propionic acid
Figure imgf000159_0003
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 4-bromo-3,5-difluoro- phenol as reagents in step A and 4-isopropyl-phenyl boronic acid in step C as starting materials. MS (ES): 510.2 [M+H]+. Example 335 Racemic 3-{4-[l-(2-Chloro-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino}-propionic acid
Figure imgf000160_0001
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3-methyl-butyl)-benzoic acid methyl ester and 4-bromo-3-chloro- phenol as reagents in step A and 4-isopropyl-phenyl boronic acid in step C as starting materials. MS (ES): 508.3 [M+H]+. Example 336 Racemic 3-{4-[l-(2-Chloro-4'-trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino}-propionic acid
Figure imgf000160_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 4-bromo-3-chloro- phenol as reagents in step A and 4-trifluoromethyl-phenyl boronic acid in step C as starting materials. MS (ES): 534.2 [M+H]+. Example 337 Racemic 3-(4-{3-Methyl-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- butyl}-benzoylamino)-propionic acid
Figure imgf000160_0003
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-3-methyl-butyl)-benzoic acid methyl ester and 6-chloro-5-methyl- pyridin-3-ol as reagents in step A and 4-trifluoro-phenyl boronic acid in step C as starting materials. MS (ES): 515.2 [M+H]+. Example 338 Racemic 3-(4-{l-[6-(4-Isopropyl-phenyl)-5-methyl-pyridin-3-yloxy]-3-methyl-butyl}- benzoylamino)-propionic acid
Figure imgf000161_0001
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3-methyl-butyl)-benzoic acid methyl ester and 6-chloro-5-methyl- pyridin-3-ol as reagents in step A and 4-isopropyl-phenyl boronic acid in step C as starting materials. MS (ES): 489.2 [M+H]+. Example 339 Racemic 3-{4-[l-(4'-tert-Butyl-biphenyl-3-yloxy)-3-methyl-butyl]-benzoylamino}- propionic acid
Figure imgf000161_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 3-bromo-phenol as reagents in step A and 4-tertbutyl-phenyl boronic acid in step C as starting materials. MS (ES): 488.3 [M+H]+. Example 340 Racemic 3-{4-[3-Methyl-l-(4'-trifluoromethyl-biphenyl-3-yloxy)-butyl]- benzoylamino}-propionic acid
Figure imgf000161_0003
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 3-bromo-phenol as reagents in step A and 4-trifluoromethyl-phenyl boronic acid in step C as starting materials. MS (ES): 500.3 [M+H]+. Example 341 Racemic 3-{4-[l-(4'-Isopropyl-biphenyl-3-yloxy)-3-methyl-buryl]-benzoylamino}- propionic acid
Figure imgf000162_0001
Tins compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 3-bromo-phenol as reagents in step A and 4-isopropyl-phenyl boronic acid in step C as starting materials. MS (ES): 474.2 [M+H]+. Example 342 Racemic 3-{4-[3-Methyl-l-(4'-trifluoromethoxy-biphenyl-3-yloxy)-butyl]- benzoylamino}-propionic acid
Figure imgf000162_0002
This compound is made by the general method as exemplified in Example 24 using 4-(l-hydroxy-3-methyl-butyl)-benzoic acid methyl ester and 3-bromo-phenol as reagents in step A and 4-trifluoromethoxy-phenyl boronic acid in step C as starting materials. MS (ES): 516.3 [M+H]+. Example 343 Racemic 3-{4-[3-Methyl-l-(6-methyl-4'-trifluoromethyl-biphenyl-3-yloxy)-butyl]- benzoylamino}-propionic acid
Figure imgf000162_0003
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 3-bromo-4-methyl- phenol as reagents in step A and 4-trifluoromethyl-phenyl boronic acid in step C as starting materials. MS (ES): 514.2 [M+H]+. Example 344 Racemic 3-{4-[l-(4'-tert-Butyl-6-methyl-biphenyl-3-yloxy)-3-methyl-butyI]- benzoyIamino}-propionic acid
Figure imgf000163_0001
This compound is made by the general method as exemplified in Example 24 using 4-(l -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester and 3-bromo-4-methyl- phenol as reagents in step A and 4-t-butyl-phenyl boronic acid in step C as starting materials. MS (ES): 502.2 [M+H]+. Example 345 Racemic 3-{4-[l-(2-Hydroxymethyl-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino}-propionic acid
Figure imgf000163_0002
and Example 346 Racemic 3-{4-[l-(2-Formyl-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino}-propionic acid
Figure imgf000163_0003
Step A. 4-[l-(4-Bromo-3-[l,3]dioxan-2-yl-phenoxy)-3-methyl-butyl]-benzoic acid methyl ester To a solution of 4-( 1 -hydroxy-3 -methyl-butyl)-benzoic acid methyl ester (1600 mg, 7.21 mmol) in toluene (72 mL) is added l, -(azodicarbonyl)dipiperidine (ADDP, 2728 mg, 10.81 mmol) at 0°C, followed by the additions of tributylphosphine (2.69 mL, 10.81 mmol) and 4-bromo-3-[l,3]dioxan-2-yl-phenol (2240 mg, 8.65 mmol). The reaction mixture is warmed up to room temperature and stined overnight. The mixture is loaded on silica gel, eluted with hexanes with a gradient from 0 % of ethyl acetate to 50
% of ethyl acetate giving the titled compound (1000 mg).
Step B. 4-[l-(4-Bromo-3-[l,3]dioxan-2-yl-phenoxy)-3-methyl-butyl]-benzoic acid To the solution of 4-[l-(4-bromo-3-[l,3]dioxan-2-yl-phenoxy)-3-methyl-butyl]- benzoic acid methyl ester (1000 mg) in methanol (20 mL) is added sodium hydroxide (5
N aqueous, 2 mL) and stined for 4 h. The reaction mixture is concentrated and acidified by 5 N HCl (2 mL), extracted with ethyl acetate. Combined organic layers are washed with water and brine, dried over sodium sulfate. Concentration gives the title compound (940 mg) as a white solid.
Step C. 3-{4-[l-(4-Bromo-3-[l,3]dioxan-2-yl-phenoxy)-3-methyl-butyl]- benzoylaminoj-propionic acid methyl ester To a mixture of 4-[l-(4-bromo-3-[l,3]dioxan-2-yl-phenoxy)-3-methyl-butyl]- benzoic acid (940 mg, 2.09 mmol) in methylene chloride (21 mL) is added triethyl amine (0.88mL, 6.28 mmol), DMAP (5.0 mg), 3-Amino-propionic acid methyl ester hydrochloride (438 mg, 3.14 mmol) and EDCI (1207 mg, 6.28mmol) at room temperature. The reaction mixture is stined at room temperature overnight, loaded on silica gel, eluted with eluted with hexanes with a gradient from 0 % of ethyl acetate to
100 % of ethyl acetate giving the titled compound (670mg). Step D. 3-{4-[l-(2-[l,3]Dioxan-2-yl-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylaminoj-propionic acid methyl ester 3 - { 4- [ 1 -(4-Bromo-3 -[1,3] dioxan-2-yl-phenoxy)-3 -methyl-butyl] -benzoylamino } - propionic acid methyl ester (560 mg, 1.05 mmol), potassium Fluoride (183 mg, 3.15 mmol), 4-isopropylphenyl boronic acid (344 mg, 2.1 mmol) and tetrakis(triphenylphosphine)palladium (121 mg, 0.105 mmol) are placed in a flask. After the reaction is purged with N2 for several times, THF/H2O (20ml/5ml) is added. The resulting solution is refluxed overnight, loaded on silica gel, eluted with hexane and ethyl acetate to give the titled compound (570 mg).
Step E. Racemic 3-{4-[l-(2-Formyl-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoy laminoj-propionic acid methyl ester, and
Racemic 3-{4-[l-(2-Formyl-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino}-propionic acid 3-{4-[l-(2-[l,3]Dioxan-2-yl-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid methyl ester (570mg) is taken into THF (10ml), treated with 5N HCl for 5h, neutralfied with 5N NaOH, extracted with ethyl actate, dried over MgSO4 and concentrated. The residue is purified by column chromatography to afford 3- {4- [ 1 -(2-formyl-4'-isopropyl-biphenyl-4-yloxy)-3 -methyl-butyl] -benzoylamino } - propionic acid methyl ester (36mg) and 3-{4-[l-(2-formyl-4'-isopropyl-biphenyl-4- yloxy)-3-methyl-butyl]-benzoylamino}-ρroρionic acid (228mg). MS (ES): 502.2 [M+H]+. Step F. 3-{4-[l-(2-Hydroxymethyl-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino}-propionic acid To the solution of 3-{4-[l-(2-formyl-4'-isopropyl-biphenyl-4-yloxy)-3-methyl- butyl] -benzoylamino} -propionic acid methyl ester (36mg, 0.07mmol) in methanol (5ml) is added NaBH4 (3mg, 0.07mmol). After 2h, the mixture is diluted with ethyl actate, washed with IN HCl, water, brine, dried over MgSO4, and concentrated. The residue is taken into methanol (20 mL), followed by the addition of sodium hydroxide (5 N aqueous, 1 mL), stined for 4 h. The reaction mixture is concentrated and acidified by 5 N HCl (1 mL), extracted with ethyl acetate. Combined organic layers are washed with water and brine, dried over sodium sulfate. Concentration gives the title compound (93 mg) as a white solid. MS (ES): 502.2 [M-H]". Example 347 Racemic 3-(4-{l-[2-(Hydroxyimino-methyl)-4'-isopropyl-biphenyl-4-yIoxy]-3- methyl-butyl}-benzoylamino)-propionic acid
Figure imgf000165_0001
To the solution of 3-{4-[l-(2-formyl-4'-isopropyl-biphenyl~4-yloxy)-3-methyl~ butyl] -benzoylamino} -propionic acid (75mg, 0.15mmol) in methanol (10ml) is added hydroxylamine hydrochloride (104mg, 1.5mmol). After 4h, the mixture is diluted with ethyl actate, washed with IN HCl, water, brine, dried over MgSO4, and concentrated. The residue is purified by column chromatography to afford 38mg of 3~(4-{l-[2- (hydroxyimino-methyl)-4'-isopropyl-biphenyl-4-yloxy]-3-methyl-butyl}-benzoylamino)- propionic acid methyl ester, which is hydrolyzed by 5N NaOH to afford the titled compound (36mg). MS (ES): 517.2 [M+H]+. Example 348 Racemic 3-{4-[l-(4'-Isopropyl-2-morpholin-4-ylmethyl-biphenyl-4-yloxy)-3-methyl- butyl]-benzoylamino}-propionic acid
Figure imgf000166_0001
To the solution of 3-{4-[l-(2-formyl-4'-isopropyl-biphenyl-4-yloxy)-3-methyl- butyl]-benzoylamino}-propionic acid (240mg, 0.48mmol) and Morpholine (84 mg, 0.96mmol) in dichlorometane (20ml) is added NaBH(OAc)3 (143mg, 0.67mmol) and acetic acid (58mg, 0.96mmol). The resulting mixture is stined overnight, diluted with ethyl actate, washed with IN HCl, water, brine, dried over MgSO4, and concentrated. The residue is purified by column chromatography to afford 80mg of the titled compound as a white solid. MS (ES): 573.5 [M+H]+. Example 349 3-(4-{3,3-Dimethyl-l-[5-methyl-l-oxy-6-(4-trifluoromethoxy-phenyl)-pyridin-3- yloxy] -butyl}-benzoylamino)-propionic acid
Figure imgf000166_0002
Step A. 4-[l-(6-Chloro-5-methyl-pyridin-3-yloxy)-3,3-dimethyl-butyl]-benzoic acid methyl ester To a solution of 4-(l -hydroxy-3 ,3 -dimethyl-butyl)-benzoic acid methyl ester (450 mg, 1.91 mmol) in toluene (19 mL) is added l,r-(azodicarbonyl)dipiperidine (ADDP, 722 mg, 2.86 mmol) at 0°C, followed by the additions of tributylphosphine (0.71 mL, 2.86 mmol) and 6-chloro-5-methyl-pyridin-3-ol (327 mg, 2.29 mmol). The reaction mixture is warmed up to room temperature and stined overnight. The mixture is loaded on silica gel, eluted with hexanes with a gradient from 0 % of ethyl acetate to 50 % of ethyl acetate giving the titled compound (440 mg).
Step B. 4-[l-(6-Chloro-5-methyl-pyridin-3-yloxy)-3,3-dimethyl-butyl]-benzoic acid To the solution of 4-[l-(6-cUoro-5-methyl-pyridin-3-yloxy)-3,3-dimethyl-butyl]-benzoic acid methyl ester (440 mg) in methanol (30 mL) is added sodium hydroxide (5 N aqueous, 2 mL) and stined for 5 h. The reaction mixture is concentrated and acidified by 5 N HCl (2 mL), extracted with ethyl acetate. Combined organic layers are washed with water and brine, dried over sodium sulfate. Concentration gives the titled compound (414 mg). Step C. 3-{4-[l-(6-Chloro-5-methyl-pyridin-3-yloxy)-3,3-dimethyl-butyl]- benzoylamino}-propionic acid methyl ester To a mixture of 4-[l-(6-chloro-5-methyl-pyridin-3-yloxy)-3,3-dimethyl-butyl]- benzoic acid (414 mg, 1.19 mmol) in methylene chloride (12 mL) is added triethyl amine (0. 5mL, 3.6 mmol), DMAP (5.0 mg), 3-Amino-propionic acid methyl ester hydrochloride (250 mg, l.Smmol) and EDCI (688 mg, 3.6 mmol) at room temperature. The reaction mixture is stined at room temperature overnight, loaded on silica gel, eluted with eluted with hexanes with a gradient from 0 % of ethyl acetate to 100 % of ethyl acetate giving the titled compound (400mg). Step D. 3-(4-{3,3-Dimethyl-l-[5-methyl-6-(4-trifluoromethoxy-phenyl)-pyridin-3- yloxy]-butyl}-benzoylamino)-propionic acid methyl ester 3 - {4-[ 1 -(6-Chloro-5-methyl-pyridin-3 -yloxy)-3 ,3 -dimethyl-butyl] - benzoylamino} -propionic acid methyl ester (200 mg, 0.46 mmol), potassium fluoride (80 mg, 1.38 mmol), 4-trifluoromethoxyphenyl boronic acid (190 mg, 0.92 mmol) and tetrakis(triphenylphosphine)palladium (53 mg, 0.046 mmol) are placed in a flask. After the reaction is purged with N2 for several times, THF/H2O (20ml/5ml) is added. The resulting solution is refluxed overnight, loaded on silica gel, eluted with hexane and ethyl acetate to give the titled compound (220 mg).
Step F. 3-(4-{3,3-Dimethyl-l-[5-methyl-l-oxy-6-(4-trifluoromethoxy-phenyl)- pyridin-3-yloxy] -butyl}-benzoylamino)-propionic acid To the solution of 3 -(4- {3, 3 -Dimethyl- 1 -[5-methyl-6-(4-trifluoromethoxy- phenyl)-pyridin-3-yloxy] -butyl }-benzoylamino)-propionic acid methyl ester (200 mg, 0.36mmol) in chloroform (20 mL) is added the solution of mCPBA (247 mg, 1.43mmol) in chloroform (10ml) dropwise. The resulting mixture is stined overnight. K2CO3 (200mg) and MeOH (1ml) are added. The mixture is stined for 30min, filtrated. The solid residue is washed with dichloromethane/MeOH(9/l). The filtrate is concentrated and purified by column chromatography to afford 3-(4-{3,3-dimethyl-l-[5-methyl-l-oxy-6- (4-trifluoromethoxy-phenyl)-pyridin-3 -yloxy] -butyl } -benzoylamino)-propionic acid methyl ester (80mg), which is hydrolyzed by sodium hydroxide (5 N aqueous, 1 mL) giving the title compound (55 mg). MS (ES): 561.3 [M+H]+. Example 350 2-Hydroxy-3-{4-[l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino}-propionic acid, Isomer 1
Figure imgf000168_0001
Step A. 4-[l-(4-Bromo-3,5-dimethyl-phenoxy)-2-methyl-propyl]-benzoic acid methyl ester To a solution of 4-(l-hydroxy-2-methyl-propyl)-benzoic acid methyl ester (5000 mg, 24.04 mmol) in toluene (240 mL) is added l,r-(azodicarbonyl)dipiperidine (ADDP,
9098 mg, 36.06 mmol) at 0°C, followed by the additions of tributylphosphine (8.98 mL,
36.06 mmol) and 4-bromo-3,5-dimethyl-phenol (5798 mg, 28.85 mmol). The reaction mixture is warmed up to room temperature and stined overnight. The mixture is loaded on silica gel, eluted with hexanes with a gradient from 0 % of ethyl acetate to 50 % of ethyl acetate giving the titled compound (5540 mg).
Step B. 4-[l-(4-Bromo-3,5-dimethyl-phenoxy)-2-methyl-propyl]-benzoic acid methyl ester, isomers 1 and 2 The racemic 4- [ 1 -(4-bromo-3 ,5 -dimethyl-phenoxy)-2-methyl-propyl] -benzoic acid methyl ester was resolved on a Chiralcel OJ-H column (4.6 x 150 mm). Eluted with Methanol/DMEA (98/2) and concentrated the fractions to provide a purified enantiomer ester (isomer 1, 98.4 % ee, isomer 2, >99% ee).
Step C. 4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]-benzoic acid methyl ester, isomer 1 Isomer 1 of 4-[l-(4-bromo-3,5-dimethyl-phenoxy)-2-methyl-propyl]-benzoic acid methyl ester (500 mg, 1.28 mmol), potassium fluoride (223 mg, 3.84 mmol), 4- isopropylphenyl boronic acid (419 mg, 2.56 mmol) and tetrakis-
(triphenylphosplιine)palladium (148 mg, 0.128 mmol) are placed in a flask. After the reaction is purged with N for several times, THF/H2O (20ml/5ml) is added. The resulting solution is refluxed overnight, loaded on silica gel, eluted with hexane and ethyl acetate to give the titled compound (510 mg).
Step D. 4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]-benzoic acid, isomers 1 To the solution of isomer 1 of 4-[l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-
2-methyl-propyl] -benzoic acid methyl ester (510 mg) in methanol (10 mL) is added sodium hydroxide (5 N aqueous, 2 mL) and stined for 4 h. The reaction mixture is concentrated and acidified by 5 N HCl (2 mL), extracted with ethyl acetate. Combined organic layers are washed with water and brine, dried over sodium sulfate. Concentration gives the title compound (450 mg) as a white solid.
Step E. 2-Hydroxy-3-{4-[l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl- propyl]-benzoylamino}-propionic acid methyl ester, isomer 1 To a mixture of 4-[l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl- propyl] -benzoic acid (150 mg, 0.36 mmol) in methylene chloride (4 mL) is added triethyl amine (0.15mL, 1.08 mmol), DMAP (5.0 mg), 3-Amino-2-hydroxy-propionic acid methyl ester (83 mg, 0.54 mmol) and EDCI (208 mg, 1.08 mmol) at room temperature.
The reaction mixture is stined at room temperature overnight, loaded on silica gel, eluted with eluted with hexanes with a gradient from 0 % of ethyl acetate to 100 % of ethyl acetate giving the titled compound (150mg). Step F. 2-Hydroxy-3-{4-[l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl- propyl]-benzoylamino}-propionic acid, isomer 1 To the solution of isomer 1 of 2-Hydroxy-3-{4-[l-(4'-isopropyl-2,6-dimethyl- biphenyl-4-yloxy)-2-methyl-propyl]-benzoylamino}-propionic acid methyl ester (150 mg) in methanol (10 mL) is added sodium hydroxide (5 N aqueous, 1 mL) and stined for 4 h. The reaction mixture is concentrated and acidified by 5 N HCl (1 mL), extracted with ethyl acetate. Combined organic layers are washed with water and brine, dried over sodium sulfate. Concentration gives the title compound (93 mg) as a white solid. MS (ES): 504.2 [M+H]+.
The following compounds are made in a manner substantially similar to Example 350 using appropriate starting materials: Example 351 2-Hydroxy-3-{4-[l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000170_0001
Chiral MS (ES): 504.2 [M+H]+. Example 352 2-Hydroxy-3-{4-[l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino}-propionic acid, Isomer 1
Figure imgf000170_0002
MS (ES): 504.2 [M+H]+. Example 353
2-Hydroxy-3-{4-[l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000170_0003
MS (ES): 504.2 [M+H]4 Example 354 -{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino}-2-hydroxy-propionic acid, Isomer 1
Figure imgf000171_0001
ES): 530.2 [M+H]+. Example 355-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino}-2-hydroxy-propionic acid, Isomer 2
Figure imgf000171_0002
ES): 530.2 [M+H]+. Example 356-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino}-2-hydroxy-propionic acid, Isomer 1
Figure imgf000171_0003
ES): 530.2 [M+H]+. Example 357-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino}-2-hydroxy-propionic acid, Isomer 2
Figure imgf000171_0004
ES): 530.2 [M+H]+. Example 358 Racemic 3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulf anyl)-5,5,5- trifluoro-pentyl]-benzoylamino}-propionic acid
Figure imgf000172_0001
Step A. Racemic 4-[l-(4-Bromo-3,5-dimethyl-phenyIsulfanyl)-5,5,5-trifluoro- pentyl] -benzoic acid methyl ester A solution of the 4-bromo-3,5-dimethyl-benzenethiol (0.572 g, 2.26 mmol) and (R,S) 4-(5,5,5-trifluoro-l-hydroxy-pentyι)-benzoic acid methyl ester (0.500 g, 1.81 mmol) in toluene(10 mL) is degassed and filled with nitrogen three times. Tributylphosphine (0.670 mL, 2.72 mmol) is added to the reaction mixture under nitrogen at 0 °C, followed by addition of l,r-(azodicarbonyl)-dipiperidine (0.685 g, 2.72 mmol). The reaction mixture is allowed to warm to room temperature and stined overnight, the mixture is concentrated and purified by flash column chromatography (0.424 g, 0.89 mmol). Step B. Racemic 4-[l-(4-Bromo-3,5-dimethyl-phenylsulfanyl)-5,5,5-trifluoro- pentyl] -benzoic acid Racemic 4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-5,5,5-trifluoro-pentyl]- benzoic acid methyl ester (0.424 g, 0.890 mmol) is dissolved in the tetrahydrofuran (2.5 mL) and sodium hydroxide (2.5 mL, 5N) is added. The reaction is monitored by HPLC, and upon complete conversion, the reaction is neutralized with hydrochloric acid (2.5 mL, 5N) and diluted with diethyl ether and water. The two phases are separated, and the organic layer is washed, dried, and concentrated. The title compound (0.380 g, 0.826 mmol) is used without further purification. Step C. Racemic 3-{4-[l-(4-Bromo-3,5-dimethyl-phenylsulfanyl)-5,5,5-trifluoro- pentyl]-benzoylamino}-propionic acid ethyl ester Racemic 4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-5,5,5-trifluoro-pentyl]- benzoic acid(0.190 g, 0.410 mmol), 2-chloro-4,6-dimethoxy-l,3,5-triazine (0.0747 g, 0.430 mmol) and 4-methylmorpholine (0.050 mL, 0.430 mmol) are combined in anhydrous dichloromethane(2.0 mL) under nitrogen. The reaction is allowed to stir under nitrogen at room temperature overnight. The beta alanine ethyl ester hydrochloride (0.0695 g, 0.450 mmol) and 4-methylmorpholine (0.100 mL, 0.860 mmol) is added to the reaction mixture and allowed to stir at room temperature. Some water (<10% volume) is added to help solubility. The reaction is monitored by HPLC, and upon complete consumption of the acid, the reaction is diluted with dichloromethane. The reaction is diluted with water and rinsed with IN hydrochloric acid. Upon acidification, the two layers are separated. The organic layer is washed with brine, dried over anhydrous sodium sulfate, and concentrated. Flash column chromatography gave the title compound (0.200 g, 0.360 mmol). Step D. Racemic 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)- 5,5,5-trifluoro-pentyl]-benzoylamino}-propionic acid ethyl ester To a solution of racemic 3-{4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-5,5,5- trifluoro-pentyl] -benzoylamino} -propionic acid ethyl ester (0.200 g, 0.360 mmol) in toluene(2 mL) is added palladium tetrakis triphenylphosphine (0.0267 g, 0.020 mmol), 4- trifluoromethyl phenyl boronic acid(0.135 g, 0.720 mmol), and potassium fluoride
(0.0416 g, 0.720 mmol). The reaction is purged with nitrogen three times and heated to reflux under nitrogen. At reflux, water (1.0 mL) is added to the reaction and the reaction is allowed to reflux under nitrogen. The reaction is monitored by HPLC, and upon completion, allowed to cool to room temperature. The reaction is diluted with ethyl acetate and celite is added, followed by water. This mixture is then filtered through a pad of celite. The solution is poured into a separatory funnel and the organic layer is washed with water and brine. The organic layer is dried over anhydrous sodium sulfate and concentrated. The product is purified by flash column chromatography (0.150 g, 0.240 mmol). Step E. Racemic 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)- 5,5,5-trifluoro-pentyl]-benzoylamino}-propionic acid Racemic 3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-5,5,5- trifluoro-pentyl] -benzoylamino} -propionic acid ethyl ester (0.150 g, 0.240 mmol) is dissolved in tetrahydrofuran(l .0 mL) and sodium hydroxide(l .0 mL, 5N) is added. The reaction is monitored by HPLC, and upon complete conversion, the reaction is neutralized with hydrochloric acid (1.0 mL, 5N) and diluted with diethyl ether and water. The two phases are separated, and the organic layer is washed, dried, and concentrated. The title compound is used without further purification. MS (ES): 596.3 [M-H]". Example 359 Racemic 3-{4-[l-(2,4,6-tri-t-butyl-phenoxy)-5,5,5-trifluoro-pentyl]-benzoylamino}- propionic acid,
Figure imgf000174_0001
Step A. Racemic 4-[l-(4-Bromo-phenoxy)-5,5,5-trifluoro-pentyl]-benzoic acid methyl ester A solution of the 4-bromo-phenol (2.36 g, 13.61 mmol) and (R,S) 4-(5,5,5- trifluoro-l-hydroxy-pentyl)-benzoic acid methyl ester (3.00 g, 10.89 mmol) in toluene (50 mL) is degassed and filled with nitrogen three times. Tributylphosphine (4.03 mL, 16.34 mmol) is added to the reaction mixture under nitrogen at 0°C, followed by addition of l, -(azodicarbonyl)-dipiperidine (4.12 g, 16.34 mmol). The reaction mixture is allowed to warm to room temperature and stined overnight; the mixture is concentrated and purified by flash column chromatography (3.0 g, 6.96 mmol).
Step B. Racemic 4-[l-(4-Bromo-phenoxy)-5,5,5-trifluoro-pentyl]-benzoic acid Racemic 4-[l-(4-bromo-phenoxy)-5,5,5-trifluoro-pentyl]-benzoic acid methyl ester (7.80 g, 18.1 mmol) is dissolved in the tetrahydrofuran (75 mL) and sodium hydroxide(25 mL, 5N) is added. The reaction is heated to reflux under nitrogen. The reaction is monitored by HPLC, and upon complete conversion, the reaction is neutralized with hydrochloric acid (25 mL, 5N) and diluted with diethyl ether and water. The two phases are separated, and the organic layer is washed, dried, and concentrated. The title compound (7.46 g, 16.24 mmol) is used without further purification. Step C. Racemic 3-{4-[l-(4-Bromo-phenoxy)-5,5,5-trifluoro-pentyl]-benzoylamino}- propionic acid methyl ester Racemic 4-[l-(4-bromo-phenoxy)-5,5,5-trifluoro-pentyl]-benzoic acid (7.46 g, 17.89 mmol), 2-chloro-4,6-dimethoxy-l,3,5-triazine (3.23 g, 18.43 mmol) and 4- methylmorpholine (2.07 mL, 18.78 mmol) are combined in anhydrous dichloromethane (100 mL) under nitrogen. The reaction is allowed to stir under nitrogen at room temperature overnight. Beta alanine methyl ester hydrochloride (2.76 g, 19.68 mmol) and 4-methylmorpholine (4.14 mL, 37.56 mmol) is added to the reaction mixture and allowed to stir at room temperature. Some water (<10% volume) is added to help solubility. The reaction is monitored by HPLC, and upon complete consumption of the acid, the reaction is diluted with dichloromethane. The reaction is diluted with water and rinsed with IN hydrochloric acid. Upon acidification, the two layers are separated. The organic layer is washed with brine, dried over anhydrous sodium sulfate, and concentrated. Flash column chromatography gave the title compound (7.07 g, 14.1 mmol). Step D. Racemic 3-(4-{5,5,5-Trifluoro-l-[4-(4,4,5,5-tetramethyl-
[l,3,2]dioxaborolan-2-yl)-phenoxy]-pentyl}-benzoylamino)-propionic acid methyl ester To a solution of racemic 3-{4-[l-(4-bromo-phenoxy)-5,5,5-trifluoro-pentyl]- benzoylamino} -propionic acid methyl ester (2.20 g, 4.38 mmol) in dimethyl sulfoxide(15 mL) is added [l,r-bis(diphenylphosphino)fenocene]dichloropalladium(II), complex with dichloromethane (1:1) (0.178 g, 0.022 mmol), bis(pinnocalado)diborane (2.22 g, 8.76 mmol), and potassium acetate(0.860 g, 8.76 mmol). The reaction is purged with nitrogen three times and heated to reflux under nitrogen. The reaction is monitored by HPLC, and upon completion, allowed to cool to room temperature. The reaction is diluted with ethyl acetate and celite is added, followed by water. This mixture is then filtered through a pad of celite. The solution is poured into a separatory funnel and the organic layer is washed with water and brine. The organic layer is dried over anhydrous sodium sulfate and concentrated. The product is purified by flash column chromatography (1.78 g, 3.24 mmol). Step E. Racemic 3-{4-[l-(2,4,6-tri-t-butyl-phenoxy)-5,5,5-trifluoro-pentyl]- benzoylamino}-propionic acid methyl ester To a solution of racemic 3-(4-{5,5,5-Trifluoro-l-[4-(4,4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl)-phenoxy] -pentyl } -benzoylamino)-propionic acid methyl ester(0.300 g, 0.550 mmol) in toluene(3.0 mL) is added palladium tetrakis triphenylphosphine(0.0316 g, 0.030 mmol), 2-bromo-l ,3,5-tri-tert-butyl-benzene (0.353 g, 1.09 mmol), and potassium fluoride(0.063 g, 1.09 mmol). The reaction is purged with nitrogen three times and heated to reflux under nitrogen. At reflux, water (1.0 mL) is added to the reaction and the reaction is allowed to reflux under nitrogen. The reaction is monitored by HPLC, and upon completion, allowed to cool to room temperature. The reaction is diluted with ethyl acetate and celite is added, followed by water. This mixture is then filtered through a pad of celite. The solution is poured into a separatory funnel and the organic layer is washed with water and brine. The organic layer is dried over anhydrous sodium sulfate and concentrated. The product is purified by flash column chromatography (0.333 g, 0.500 mmol).
Step F. Racemic 3-{4-[l-(2,4,6-tri-t-butyl-phenoxy)-5,5,5-trifluoro-pen yl]- benzoylamino}-propionic acid Racemic 3-{4-[l-(2,4,6-tri-t-butyl-phenoxy)-5,5,5-trifluoro-pentyl]- berizoy lamino} -propionic acid methyl ester (0.333 g, 0.500 mmol) is dissolved in tehahydrofuran(3.0 mL) and sodium hydroxide(3.0 mL, 5N) is added. The reaction is monitored by HPLC, and upon complete conversion, the reaction is neutralized with hydrochloric acid(3.0 mL, 5N) and diluted with diethyl ether and water. The two phases are separated, and the organic layer is washed, dried, and concentrated. The title compound is used without further purification. MS (ES): 652.2 [M-H]". Example 360 3-(4-{5,5,5-trifluoro-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- pentyl}-benzoylamino)-propionic acid, Isomer 1 and Example 361 3-(4-{5,5,5-trifluoro-l-[5-methyl-6-(4-trifluoromethyl-phenyI)-pyridin-3-yloxy]- pentyl}-benzoylamino)-propionic acid, Isomer 2
Figure imgf000176_0001
The title compounds are prepared in a manner substantially similar to Example 1 starting from 4-(5,5,5-trifluoro-l-hydroxy-pentyl)-benzoic acid methyl ester and 5- methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-ol (Preparation 34). The isomers are resovled by methods described herein or known to one skilled in the art. Isomer 1 MS: 567.3 [M-H]"; Isomer 2 MS: 567.3 [M-H]". Example 362 Racemic 3-(4-{l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-pentyl}- benzoy!amino)-propionic acid
Figure imgf000177_0001
The title compound is prepared in a manner substantially similar to Example 62 starting from 3-{4-[l-(6-chloro-pyridin-3-yloxy)-pentyl]-benzoylamino}-propionic acid methyl ester and 4-trifluoromethyl phenyl boronic acid. MS: 499.2 [M-H]". Example 363 Racemic 3-{4-[l-(4'-tert-buryl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-5,5,5-trifluoro- pentyl] -benzoylamino}-propionic acid
Figure imgf000177_0002
The title compound is prepared in a manner substantially similar to Example 358 starting from 3-{4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-5,5,5-trifluoro-pentyl]- benzoylamino} -propionic acid methyl ester and 4-tert-butyl phenyl boronic acid. MS: , . 584.2 [M-H]". Example 364 , Racemic 3-{4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-5,5,5-trifluoro-pentyl]- benzoylamino}-propionic acid
Figure imgf000177_0003
The title compound is prepared in a manner substantially similar to Example 358 starting from 3-{4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-5,5,5-trifluoro-pentyl]- benzoylamino} -propionic acid methyl ester. MS: 531.2 [M-H]". Example 365 Racemic 3-(4- {5,5,5-trifluoro-l- [5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3- yloxy] -penryl}-benzoylamino)-propionic acid
Figure imgf000178_0001
The title compound is prepared in a manner substantially similar to Example 1 starting from 4-(5,5,5-trifluoro-l-hydroxy-pentyl)-benzoic acid methyl ester and 5- methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-ol (Preparation 34). MS: 567.3 [M-H]". Example 366 Racemic 3-(4-{4,4,4-trifluoro-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3- yloxy]-butyl}-benzoylamino)-propionic acid
Figure imgf000178_0002
The title compound is prepared in a manner substantially similar to Example 1 starting from 3-[4-(4,4,4-trifluoro-l-hydroxy-butyl)-benzoylamino]-propionic acid methyl ester and 5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-ol(Preparaton 34). MS: 553.3 [M-H]". Example 367 3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-3-methyl-butyl]- benzoylamino}-propionic acid, Isomer 1 and Example 368 3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-3-methyl-butyI]- benzoyIamino}-propionic acid, Isomer 2
Figure imgf000178_0003
The title compound is prepared in a manner substantially similar to Example 358 starting from enatiomerically purified 3-{4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-3- methyl-butyl] -benzoylamino} -propionic acid methyl ester and 4-trifluoromethyl phenyl boronic acid. Isomer 1 MS: 542.2 [M-H]"; Isomer 2 MS: 542.2 [M-H]". Example 369 3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-3-methyl-butyl]- benzoylamino}-propionic acid, Isomer 1 and Example 370 3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-3-methyl-butyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000179_0001
The title compound is prepared in a manner substantially similar to Example 367 starting from 3 - {4- [ 1 -(4-bromo-3 ,5-dimethyl-phenylsulfanyl)-3 -methyl-butyl] - benzoylamino} -propionic acid methyl ester and 4-tert-butyl phenyl boronic acid. Isomer 1 MS: 530.2 [M-H]"; Isomer 2 MS: 530.2 [M-H]". Example 371 3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-4,4,4-trifluoro-butyl]- benzoylamino}-propionic acid, Isomer 1 and Example 372 3-{4-[i-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-4,4,4-trifluoro-buryl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000179_0002
The title compounds are prepared in a manner substantially similar to Example 367 starting from 3-{4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-4,4,4-trifluoro-butyl]- benzoylamino} -propionic acid methyl ester and 4-tert-butyl phenyl boronic acid. Isomer 1 MS: 570.2 [M-H]"; Isomer 2 MS: 570.2 [M-H]". Example 373 3-{4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-4,4,4-trifluoro-butyl]-benzoylamino}- propionic acid, Isomer 1 and Example 374 3-{4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-4,4,4-trifluoro-butyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000180_0001
The title compounds are prepared in a manner substantially similar to Example 358 starting from 3-{4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-4,4,4-trifluoro-butyl]- benzoylamino} -propionic acid methyl ester. Isomer 1 MS: 517.3 [M-H]"; Isomer 2 MS: 517.3 [M-H]". Example 375 3-{4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-3-methyl-butyl]-benzoylamino}- propionic acid, Isomer 1 and Example 376 3-{4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-3-methyl-butyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000180_0002
The title compounds are prepared in a manner substantially similar to Example
358 starting from enatiomers of 3-{4-[l-(4-bromo-3,5-dimetliyl-phenylsulfanyl)-3- methyl-butyl] -benzoylamino} -propionic acid methyl ester. Isomer 1 MS: 477.2 [M-H]"; Isomer 2 MS: 477.2 [M-H]". Example 377 3-{4-[l-(2,6-dimethyl-4,-trifluoromethyl-biphenyl-4-yloxy)-5,5,5-trifluoro-pentyl]- benzoylamino}-propionic acid, Isomer 1 and Example 378 3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-5,5,5-trifluoro-pentyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000181_0001
The title compounds are prepared in a manner substantially similar to Example 1 starting from 4-(6,6,6-trifluoro-l-hydroxy-hexyl)-benzoic acid methyl ester and 4'-tert- butyl-2,6-dimethyl-biphenyl-4-ol. The isomers are resovled by methods described herein or known to one skilled in the art. Isomer 1 MS: 580.2 [M-H]"; Isomer 2 MS: 580.2 [M- H]\ Example 379 3-{4-[4,4,4-trifluoro-l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-butyl]- benzoylamino}-propionic acid, Isomer 1 and Example 380 3-{4-[4,4,4-trifluoro-l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-butyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000181_0002
The title compounds are prepared in a manner substantially similar to Example 128 starting from enatiomers of 3-{4-[l-(4-bromo-3,5-dimethyl-phenoxy)-4,4,4-trifluoro- butyl] -benzoylamino} -propionic acid methyl ester and 4-isopropyl phenyl boronic acid. Isomer 1 MS: 540.2 [M-H]", Isomer 2 MS: 540.2 [M-H]". Example 381 Racemic 3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-4,4,4- trifluoro-butyl]-benzoylamino}-propionic acid
Figure imgf000182_0001
The title compound is prepared in a manner substantially similar to Example 358 starting from 3-{4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-4,4,4-trifluoro-butyl]- benzoylamino} -propionic acid methyl ester and 4-trifluoromethyl phenyl boronic acid. MS: 582.3 [M-H]". Example 382 Racemic 3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-4,4,4-trifluoro- butyl]-benzoylamino}-propionic acid
Figure imgf000182_0002
The title compound is prepared in a manner substantially similar to Example 358 starting from 3-{4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-4,4,4-trifluoro-butyl]- benzoylamino} -propionic acid methyl ester and 4-tert-butyl phenyl boronic acid. MS: 570.2 [M-H]". Example 383
Figure imgf000182_0003
The title compound is prepared in a manner substantially similar to Example 358 starting from 3- {4- [ 1 -(4-bromo-3 ,5-dimethyl-phenylsulfanyl)-3 -methyl-butyl] - benzoylamino} -propionic acid methyl ester and 4-trifluoromethyl phenyl boronic acid.
MS: 542.2 [M-H]". Example 384 Racemic 3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-3-methyl-butyl]- benzoylaminoj-propionic acid
Figure imgf000183_0001
The title compound is prepared in a manner substantially similar to Example 358 starting from 3 - {4-[ 1 -(4-bromo-3 ,5-dimethyl-phenylsulfanyl)-3 -methyl-butyl] - benzoylamino} -propionic acid methyl ester and 4-tert-butyl phenyl boronic acid. MS: 530.2 [M-H]". Example 385 Racemic 3-{4-[l-(4-bromo-3,5-dimethyI-phenylsulfanyl)-4,4,4-trifluoro-butyl]- benzoylamino}-propionic acid
Figure imgf000183_0002
The title compound is prepared in a manner substantially similar to Example 358 startmg from 3-{4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-4,4,4-trifluoro-butyl]- benzoylamino}-propionic acid methyl ester. MS: 517.3 [M-H]". Example 386 Racemic 3-{4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-3-methyl-butyl]- benzoylamino}-propionic acid
Figure imgf000183_0003
. The title compound is prepared in a manner substantially similar to Example 358 starting from 3 - {4- [ 1 -(4-bromo-3 ,5 -dimethyl-phenylsulfanyl)-3 -methyl-butyl] - benzoylamino} -propionic acid methyl ester. MS: 477.2 [M-H]". Example 387 3-{4-[l-(2,6-dimethyI-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid, Isomer 1 and Example 388 3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000184_0001
The title compounds are prepared in a manner substantially similar to Example 1 starting from 4-(l-hydroxy-heptyl)-benzoic acid methyl ester and 4'-tert-butyl-2,6- dimethyl-biphenyl-4-ol. The isomers are resovled by methods described herein or known to one skilled in the art. Isomer 1 MS: 554.3 [M-H]"; Isomer 2 MS: 554.3 [M-H]". Example 389 3-{4-[3-methyl-l-(2,2',4'-trichloro-biphenyl-4-yloxy)-butyl]-benzoylamino}- propionic acid, Isomer 1 and Example 390 3-{4-[3-methyl-l-(2,2',4'-trichloro-biphenyl-4-yloxy)-buryl]-benzoylamino}- propionic acid, isomer 2
Figure imgf000184_0002
The title compounds are prepared in a manner substantially similar to Example 24 starting from 3 - {4- [ 1 -(4-bromo-3 -chloro-phenoxy)-3 -methyl-butyl] -benzoylamino } - propionic acid methyl ester and 2,4-dichlorophenyl boronic acid. The isomers are resovled by methods described herein or known to one skilled in the art. Isomer 1 MS: 533.2 [M-H]"; Isomer 2 MS: 533.2 [M-H]". Example 391 3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]- benzoylamino}-propionic acid, Isomer 1 and Example 392 3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000185_0001
The title compounds are prepared in a manner substantially similar to Example 1 starting from 4-(4,4,4-trifluoro-l-hychOxy-butyl)-benzoic acid methyl ester and 2,6- dimethyl-4'-trifluoromethyl-biphenyl-4-ol. The isomers are resovled by methods described herein or known to one skilled in the art. Isomer 1 MS: 566.3 [M-H]"; Isomer 2 MS: 566.3 [M-H]". Example 393 3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-buryl]- benzoylamino}-propionic acid, Isomer 1 and Example 394 3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyI]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000185_0002
The title compounds are prepared in a manner substantially similar to Example 1 starting from 4-(4,4,4-trifluoro-l-hydroxy-butyl)-benzoic acid methyl ester and 4'-tert-butyl-2,6- dimethyl-biphenyl-4-ol. The isomers are resovled by methods described herein or known to one skilled in the art. Isomer 1 MS: 554.2 [M-H]"; Isomer 2 MS: 554.2 [M-H]". Example 395 3-{4-[5,5,5-trifluoro-l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-pentyl]- benzoylamino}-propionic acid, Isomer 1 and Example 396 3-{4-[5,5,5-trifluoro-l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-pentyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000186_0001
The title compounds are prepared in a manner substantially similar to Example
128 starting from 3-{4-[l-(4-bromo-3,5-dimethyl-phenoxy)-5,5,5-trifluoro-pentyl]- benzoylamino} -propionic acid methyl ester and 4-isopropyl phenyl boronic acid. Isomer 1 MS: 554.2 [M-H]"; Isomer 2 MS: 554.2 [M-H]". Example 397 Racemic 3-{4-[5,5,5-trifluoro-l-(4'-isopropyl-2,6-dimethyI-biphenyl-4-yloxy)-pentyl]- benzoylamino}-propionic acid
Figure imgf000186_0002
The title compound is prepared in a manner substantially similar to Example 128 starting from 3-{4-[l-(4-bromo-3,5-dimethyl-phenoxy)-5,5,5-trifluoro-pentyl]- benzoylamino} -propionic acid methyl ester and 4-isopropyl phenyl boronic acid. MS: 554.2 [M-H]". Example 398 3- {4- [1 -(2,6~dimethyl-4' -trifluoromethyl-biphenyl-4-yloxy)-5-methyl-hexyl] - benzoylamino}-propionic acid, Isomer 1 and Example 399 3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-5-methyl-hexyl]- benzoylamino}-propionic acid, Isomer 2
Figure imgf000187_0001
The title compounds are prepared in a manner substantially similar to Example 1 starting from 4-(l-hydroxy-5-methyl-hexyl)-benzoic acid methyl ester and 2,6-dimethyl- 4'-trifluoromethyl-biphenyl-4-ol. The isomers are resovled by methods described herein or known to one skilled in the art. Isomer 1 MS:554.2 [M-H]"; Isomer 2 MS:554.2[M-H]". Example 400 3-{4-[5-methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-hexyl]-benzoylamino}- propionic acid, Isomer 1 and Example 401 3-{4-[5-methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-hexyl]-beιιzoylammo}- propionic acid, Isomer 2
Figure imgf000187_0002
The title compounds are prepared in a manner substantially similar to Example 1 starting from 4-(l -hydroxy-5-methyl-hexyl)-benzoic acid methyl ester and 4'- trifluoromethyl-biphenyl-4-ol. The isomers are resovled by methods described herein or known to one skilled in the art. Isomer 1 MS: 526.2 [M-H]"; Isomer 2 MS: 526.2 [M-H]". Example 402 3-(4-{l7[6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-5-methyl-hexyl}-benzoylamino)- propionic acid, Isomer 1 and Example 403 3-(4- {1 - [6-(4-tert-butyl-phenyl)-py ridin-3-yloxy] -5-methyl-hexyl}-benzoylamino)- propionic acid, Isomer 2
Figure imgf000188_0001
The title compounds are prepared in a manner substantially similar to Example 62 starting from 3 - {4- [ 1 -(6-chloro-pyridin-3 -yloxy)-5 -methyl-hexyl] -benzoylamino } - propionic acid methyl ester and 4-tert-butyl phenyl boronic acid. Isomer 1 MS: 515.2 [M- H]"; Isomer 2 MS: 515.2 [M-H]". Example 404 Racemic 3-(4-{5-methyl-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-hexyl}- benzoyIamino)-propionic acid
Figure imgf000188_0002
The title compound is prepared in a manner substantially similar to Example 62 starting from 3-{4-[l-(6-chloro-pyridin-3-yloxy)-5-methyl-hexyl]-benzoylamino}- propionic acid metliyl ester and 4-trifluoromethyl phenyl boronic acid. MS: 527.2[M-H]" Example 405 Racemic 3-{4-[l-(6-chloro-pyridin-3-yloxy)-5-methyl-hexyl]-benzoylamino}- propionic acid
Figure imgf000188_0003
The title compound is prepared in a manner substantially similar to Example 62 starting from 3 - {4-[ 1 -(6-chloro~pyridin-3 -yloxy)-5-methyl-hexyl] -benzoylamino } - propionic acid methyl ester. MS: 417.3 [M-H]". Example 406
Racemic 3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-5-methyl-hexyl]- benzoylamino}-propionic acid
Figure imgf000189_0001
The title compound is prepared in a manner substantially similar to Example 1 starting from 4-(l-hydroxy-5-methyl-hexyl)-benzoic acid methyl ester and 2,6-dimethyl- 4'-trifluoromethyl-biphenyl-4-ol. MS: 554.2 [M-H]". Example 407 Racemic 3-(4-{l-[6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-5-methyl-hexyl}- benzoylamino)-propionic acid
Figure imgf000189_0002
The title compound is prepared in a manner substantially similar to Example 62 starting from 3 - {4- [ 1 -(6-chloro-pyridin-3 -yloxy)-5 -methyl-hexyl] -benzoylamino } - propionic acid methyl ester and 4-tert-butyl phenyl boronic acid. MS: 515.2 [M-H]". Example 408 Racemic 3-{4-[5-methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-hexyl]- benzoylamino}-propionic acid
Figure imgf000189_0003
The title compound is prepared in a manner substantially similar to Example 1 starting from 4-(l-hydroxy-5-methyl-hexyl)-benzoic acid methyl ester and 4'- trifluoromethyl-biρhenyl-4-ol. MS: 526.2 [M-H]". Example 409 Racemic 3-{4-[l-(4'-tert-butyl-biphenyl-4-yloxy)-5-methyl-hexyl]-benzoylamino}- propionic acid
Figure imgf000190_0001
The title compound is prepared in a manner substantially similar to Example 1 starting from 4-(l-hydroxy-5-methyl-hexyl)-benzoic acid methyl ester and 4'-tert-butyl- biphenyl-4-ol. MS: 514.2 [M-H]". Example 410 3-(4-{l-[6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-5,5,5-trifluoro-pentyl}- benzoylamino)-propionic acid, Isomer 1 and Example 411 3-(4-{l-[6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-5,5,5-trifluoro-pentyl}- benzoylamino)-propionic acid, Isomer 2
Figure imgf000190_0002
The title compounds are prepared in a manner substantially similar to Example 62 starting from 4-[l-(6-chloro-pyridin-3-yloxy)-5,5,5-trifluoro-pentyl]-benzoic acid methyl ester and 4-tert-butyl phenyl boromc acid. Isomer 1 MS: 541.3 [M-H]"; Isomer 2 MS: 541.3 [M-H]". j Example 412 3-(4-{l-[6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-4,4,4-trifluoro-butyl}- benzoylamino)-propionic acid, Isomer 1 and Example 413 3-(4-{l-[6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-4,4,4-trifluoro-butyl}- benzoylamino)-propionic acid, Isomer 2
Figure imgf000190_0003
The title compounds are prepared in a manner substantially similar to Example 62 starting from 4-[l-(6-chloro-pyridin-3-yloxy)-4,4,4-trifluoro-butyl]-benzoic acid methyl ester and 4-tert-butyl phenyl boronic acid. Isomer 1 MS: 527.2 [M-H]"; Isomer 2 MS: 527.2 [M-H]". Example 414 Racemic 3-{4-[(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-cyclohexyl-methyl]- benzoylamino}-propionic acid
Figure imgf000191_0001
The title compound is prepared in a manner substantially similar to Example 1 starting from 4-(cyclohexyl-hydroxy-methyl)-benzoic acid methyl ester and 4'-tert-butyl- biphenyl-4-ol. MS: 540.3 [M-H]". Example 415 Racemic 3- {4- [l-(4 ' -tert-butyl-2,6-dimethyl-biphenyl-4-y loxy)-4,4,4-trifluoro-buty 1] - benzoylamino}-propionic acid
Figure imgf000191_0002
The title compound is prepared in a manner substantially similar to Example 1 starting from 4-(4,4,4-trifluoro-l-hydroxy-butyl)-benzoic acid methyl ester and 4'-tert- butyl-biphenyl-4-ol. MS: 554.2 [M-H]". Example 416 3-{4-[4,4,4-trifluoro-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]-benzoylamino}- propionic acid, Isomer 1 and Example 417 3-{4-[4,4,4-trifluoro-l-(4'-trifluoromethyI-biphenyI-4-yIoxy)-butyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000192_0001
The title compounds are prepared in a manner substantially similar to Example 1 starting from 4-(4,4,4-trifluoro-l-hydroxy-butyl)-benzoic acid methyl ester and 4'- trifluoromethyl-biphenyl-4-ol. The isomers are resovled by methods described herein or known to one skilled in the art. Isomer 1 MS: 538.3 [M-H]"; Isomer 2 MS: 538.3 [M-H]". Example 418 Racemic 3-(4-{4,4,4-trifluoro-l-[6-(4-isopropyl-phenyl)-pyridin-3-yloxy]-butyl}- benzoylamino)-propionic acid
Figure imgf000192_0002
The title compound is prepared in a manner substantially similar to Example 62 starting from 4-[l-(6-chloro-pyridin-3-yloxy)-4,4,4-trifluoro-butyl]-benzoic acid methyl ester and 4-isopropyl phenyl boronic acid. MS: 513.2 [M-H]". Example 419 Racemic 3-(4-{5,5,5-trifluoro-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- pentyl}-benzoylamino)-propionic acid
Figure imgf000192_0003
The title compound is prepared in a manner substantially similar to Example 62 starting from 4-[l-(6-chloro-pyridin-3-yloxy)-5,5,5-trifluoro-pentyl]-benzoic acid methyl ester and 4-trifluoromethyl phenyl boronic acid. MS: 553.3 [M-H]". Example 420 Racemic 3-(4-{[6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-cyclohexyl-methyl}- benzoylamino)-propionic acid
Figure imgf000193_0001
The title compoxind is prepared in a manner substantially similar to Example 62 starting from 4- [(6-chloro-pyridin-3-yloxy)-cyclohexyl-methyl] -benzoic acid methyl ester and 4-tert-butyl phenyl boronic acid. MS: 513.2 [M-H]". Example 421 Racemic 3-(4-{5,5,5-trifluoro-l-[6-(4-isopropyl-phenyl)-pyridin-3-yloxy]-pentyl}- benzoylamino)-propionic acid
Figure imgf000193_0002
The title compound is prepared in a manner substantially similar to Example 62 starting from 4-[l-(6-chloro-pyridin-3-yloxy)-5,5,5-trifluoro-pentyl]-benzoic acid methyl ester and 4-isopropyl phenyl boronic acid. MS: 527.2 [M-H]". Example 422 Racemic 3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4,4-trifluoro- butyl]-benzoylamino}-propionic acid
Figure imgf000193_0003
The title compound is prepared in a manner substantially similar to Example 128 starting from 3-{4-[l -(4-bromo-3,5-dimethyl-phenoxy)-4,4,4-trifluoro-butyl]- benzoylamino} -propionic acid methyl ester and 4-trifluoromethyl phenyl boronic acid. MS: 566.2 [M-H]". Example 423 Racemic 3-(4-{cyclohexyl-[6-(4-isopropyl-phenyl)-pyridin-3-yIoxy]-methyl}- benzoylamino)-propionic acid
Figure imgf000194_0001
The title compound is prepared in a manner substantially similar to Example 62 starting from 4- [(6-chloro-pyridin-3-yloxy)-cyclohexyl-methyl] -benzoic acid methyl ester and 4-isopropyl phenyl boronic acid. MS: 499.2 [M-H]". Example 424 Racemic 3-{4-[cyclohexyl-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-methyI]- benzoylamino}-propionic acid
Figure imgf000194_0002
The title compound is prepared in a manner substantially similar to Example 128 starting from 3-{4-[(4-bromo-3,5-dimethyl-phenoxy)-cyclohexyl-methyl]- benzoylamino} -propionic acid methyl ester and 4-isopropyl phenyl boronic acid. MS: 526.2 [M-H]". Example 425 Racemic 3-{4- [4,4,4-trifluoro-l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-butyl] - benzoyIamino}-propionic acid
Figure imgf000194_0003
The title compound is prepared in a manner substantially similar to Example 128 starting from 3-{4-[l-(4-bromo-3,5-dimethyl-phenoxy)-4,4,4-trifluoro-butyl]- benzoylamino} -propionic acid methyl ester and 4-isopropyl phenyl boronic acid. MS: 540.3 [M-H]". Example 426 3-{4-[cyclohexyl-(4,-trifluoromethyl-biphenyl-4-yloxy)-methyl]-benzoylamino}- propionic acid, Isomer 1 and Example 427 3-{4-[cyclohexyl-(4'-trifluoromethyl-biphenyl-4-yloxy)-methyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000195_0001
H The title compound is prepared in a manner substantially similar to Example 128 starting from 3 - {4- [(4-bromo-ρhenoxy)-cyclohexyl-methyl] -benzoylamino } -propionic acid methyl ester and 4-trifluoromethyl phenyl boronic acid. The isomers are resovled by methods described herein or known to one skilled in the art. Isomer 1 MS: 524.3 [M-H]"; Isomer 2 MS: 524.3 [M-H]". Example 428 3-{4-[5,5,5-trifluoro-l-(4'-isopropyl-biphenyl-4-yloxy)-pentyl]-benzoylamino}- propionic acid, Isomer 1 and Example 429 3-{4-[5,5,5-trifluorθ l-(4'-isopropyl-biphenyl-4-yloxy)-pentyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000195_0002
The title compound is prepared in a manner substantially similar to Example 128 starting from 3 - {4-[ 1 -(4-bromo-phenoxy)-5,5,5-trifluoro-pentyl]-benzoylamino } - propionic acid methyl ester and 4-isopropyl phenyl boronic acid. The isomers are resovled by methods described herein or known to one skilled in the art. Isomer 1 MS: 526.2 [M-H]"; Isomer 2 MS: 526.2 [M-H]". Example 430 Racemic 3- {4- [(4' -tert-butyl-biphenyl-4-yloxy)-cy clohexyl-methyl] -benzoylamino} - propionic acid
Figure imgf000196_0001
The title compound is prepared in a manner substantially similar to Example 128 starting from 3 - {4- [(4-bromo-phenoxy)-cyclohexyl-methyl] -benzoylamino } -propionic acid methyl ester and 4-tert-butyl phenyl boronic acid. MS: 512.3 [M-H]". Example 431 Racemic 3-{4-[5,5,5-trifluoro-l-(2,-3'-fluoro-4,-trifluoromethyl-biphenyl-4-yloxy)- pentyl] -benzoylamino}-propionic acid
Figure imgf000196_0002
The title compound is prepared in a manner substantially similar to Example 359 starting from 3-(4-{5,5,5-trifluoro-l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- phenoxy]-pentyl}-benzoylamino)-propionic acid methyl ester and l-bromo-2,3-difluoro- 4-trifluoromethyl-benzene. MS: 588.3 [M-H]". Example 432 Racemic 3-{4-[cyclohexyl-(4'-trifluoromethyl-biphenyl-4-yloxy)-methyl]- benzoylamino}-propionic acid
Figure imgf000196_0003
The title compound is prepared in a manner substantially similar to Example 128 starting from 3 - {4- [(4-bromo-phenoxy)-cyclohexyl-methyl] -benzoylamino } -propionic acid methyl ester and 4-trifluoromethyl phenyl boronic acid. MS: 524.3 [M-H]". Example 433 Racemic 3-{4-[5,5,5-trifluoro-l-(4'-isopropyl-biphenyl-4-yloxy)-pentyl]- benzoylamino}-propionic acid
Figure imgf000197_0001
The title compound is prepared in a manner substantially similar to Example 128 starting from 3 - {4- [ 1 -(4-bromo-phenoxy)-5 ,5 ,5 -trifluoro-pentyl] -benzoylamino } - propionic acid methyl ester and 4-isopropyl phenyl boronic acid. MS: 526.2 [M-H]". Example 434 Racemic 3-{4-[l-(4'-ethyl-biphenyl-4-yloxy)-5,5,5-trifluoro-pentyl]-benzoylamino}- propionic acid
Figure imgf000197_0002
The title compound is prepared in a manner substantially similar to Example 128 starting from 3 - {4- [ 1 -(4-bromo~phenoxy)-5 ,5 ,5 -trifluoro-pentyl] -benzoylamino } -propionic acid methyl ester and 4-ethyl phenyl boronic acid. MS: 572.3 [M-H]". Example 435 Racemic 3-{4-[5,5,5-trifluoro-l-(3'-fluoro-4'-trifluoromethyl-biphenyl-4-yloxy)- pentyl] -benzoylaminoj-propionic acid
Figure imgf000197_0003
The title compound is prepared in a manner substantially similar to Example 359 starting from 3-(4-{5,5,5-trifluoro-l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- phenoxy]-pentyl}-benzoylamino)-propionic acid methyl ester and 4-bromo-2-fluoro-l- frifluoromethyl-benzene. MS: 570.2 [M-H]". Example 436 Racemic 3-{4-[l-(2,4,6-triisopropyl-phenoxy)-5,5,5-trifluoro-pentyl]-benzoylamino}- propionic acid
Figure imgf000198_0001
The title compound is prepared in a manner substantially similar to Example 359 starting from 3-(4-{5,5,5-trifluoro-l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- phenoxy]-pentyl}-benzoylamino)-propionic acid methyl ester and 2-bromo- 1,3,5- triisopropyl-benzene. MS: 610.2 [M-H]". Example 437 Racemic 3-{4-[l-(2,3,4,5,6-pentamethyI-phenoxy)-5,5,5-trifluoro-pentyl]- benzoylamino}-propionic acid
Figure imgf000198_0002
The title compound is prepared in a manner substantially similar to Example 359 starting from 3-(4-{5,5,5-trifluoro-l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- phenoxy] -pentyl} -benzoylamino)-propionic acid methyl ester and l-bromo-2,3,4,5,6- pentamethyl-benzene. MS: 554.2 [M-H]". Example 438 Racemic 3-{4-[l-(2,4,6-tri-t-butyl-phenoxy)-5,5,5-trifluoro-pentyl]-benzoylamino}- propionic acid
Figure imgf000198_0003
The title compound is prepared in a manner substantially similar to Example 359 starting from 3-(4-{5,5,5-trifluoro-l-[4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)- phenoxy] -pentyl} -benzoylamino)-propionic acid methyl ester and 2-bromo-l,3,5-tri-tert- butyl-benzene. MS: 652.2 [M-H]". Example 439 Racemic 3-{4-[l-(3,5-dimethyl-phenoxy)-5,5,5-trifluoro-pentyl]-benzoylamino}- propionic acid
Figure imgf000199_0001
The title compound is prepared in a manner substantially similar to Example 128 starting from 3-{4-[l-(4-bromo-phenoxy)-5,5,5-trifluoro-pentyl]-benzoylamino}- propionic acid methyl ester. MS: 436.2 [M-H]". Example 440 3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-5,5,5-trifluoro-pentyl]- benzoylamino}-propionic acid, Isomer 1 and Example 441 3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyI-4-yloxy)-5,5,5-trifluoro-pentyI]- benzoylamino}-propionic acid, isomer 2
Figure imgf000199_0002
The title compounds are prepared in a manner substantially similar to Example
128 starting from 3-{4-[l-(4-bromo-3,5-dimethyl-phenoxy)-5,5,5-trifluoro-pentyl]- benzoylamino} -propionic acid methyl ester and 4-tert-butyl phenyl boronic acid. Isomer 1 MS: 568.2 [M-H]"; Isomer 2 MS: 568.2 [M-H]". Example 442 Racemic 3-{4-[l-(4-ethyl-3, 5-dimethyl-phenoxy)-5,5,5-trifluoro-pentyl]- benzoylamino}-propionic acid
Figure imgf000199_0003
The title compound is prepared in a manner substantially similar to Example 128 starting from 3 - { 4- [ 1 -(4-bromo-3 ,5 -dimethyl-phenoxy)-5,5 ,5 -trifluoro-pentyl] - benzoylamino} -propionic acid methyl ester and ethyl boronic acid. MS: 464.2 [M-H]". Example 443 Racemic 3-{4-[l -(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-5,5,5-trifluoro- pentyl]-benzoylamino}-propionic acid
Figure imgf000200_0001
The title compound is prepared in a manner substantially similar to Example 128 starting from 3-{4-[l-(4-bromo-3,5-dimethyl-phenoxy)-5,5,5-trifluoro-pentyl]- benzoylamino} -propionic acid methyl ester and 4-trifluoromethyl phenyl boronic acid. MS: 580.3 [M-H]". Example 444 Racemic 3-(4-{l-[4-(4-methyl-pentyloxy)-phenoxy]-heptyl}-benzoylamino)-propionic acid
Figure imgf000200_0002
The title compound is prepared in a manner substantially similar to Example 92 starting from 3-{4-[l-(4-hydroxy-ρhenoxy)-heptyl]-benzoylamino}-proρionic acid methyl ester and l-bromo-4-methyl-pentane. MS: 484.2 [M-H]". Example 445 Racemic 3-{4-[l-(4-pentyloxy-phenoxy)-heptyl]-benzoylamino}-propionic acid
Figure imgf000200_0003
The title compound is prepared in a manner substantially similar to Example 92 starting from 3-{4-[l-(4-hydroxy-phenoxy)-heptyl]-benzoylamino}-propionic acid methyl ester and 1-bromo-pentane. MS: 468.2 [M-H]". Example 446 3-{4-[5,5,5-trifluoro-l-(4,-trifluoromethyl-biphenyl-4-yloxy)-pentyl]-benzoylamino}- propionic acid, Isomer 1 and Example 447
3-{4-[5,5,5-trifluoro-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-pentyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000201_0001
The title compound is prepared in a manner substantially similar to Example 128 starting from 3 - {4- [ 1 -(4-bromo-phenoxy)-5 ,5 ,5 -trifluoro-pentyl] -benzoylamino } - propionic acid methyl ester and 4-trifluoromethyl phenyl boronic acid. Isomer 1 MS: 552.2 [M-H]"; Isomer 2 MS: 552.2 [M-H]". Example 448 Racemic 3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-5,5,5-trifluoro- pentyl] -benzoylamino} -propionic acid
Figure imgf000201_0002
The title compound is prepared in a manner substantially similar to Example 128 starting from 3-{4-[l-(4-bromo-3,5-dimethyl-phenoxy)-5,5,5-trifluoro-pentyl]- benzoylamino} -propionic acid methyl ester and 4-tert-butyl phenyl boronic acid. MS:
568.2 [M-H]". Example 449 Racemic 3-{4-[l-(4-bromo-3,5-dimethyl-phenoxy)-5,5,5-trifluoro-pentyl]- benzoylamino}-propionic acid
Figure imgf000202_0001
The title compound is prepared in a manner substantially similar to Example 128 starting from 3-{4-[l-(4-bromo-3,5-dimethyl-phenoxy)-5,5,5-trifluoro-pentyl]- benzoylamino} -propionic acid methyl ester. MS: 516 [M-H]". Example 450 3-{4-[l-(4'-tert-butyl-biphenyl-4-yloxy)-5,5,5-trifluoro-pentyl]-benzoylamino}- propionic acid, Isomer 1 and Example 451 3-{4-[l-(4'-tert-butyl-biphenyl-4-yloxy)-5,5,5-trifluoro-pentyl]-benzoylamino}- propionic acid, Isomer 2
Figure imgf000202_0002
The title compounds are prepared in a manner substantially similar to Example 128 starting from 3-{4-[l-(4-bromo-phenoxy)-5,5,5-trifluoro-pentyl]-benzoylamino}- propionic acid methyl ester and 4-tert-butyl phenyl boronic acid. Isomer 1 MS: 540.3 [M- H]"; Isomer 2 MS: 540.3 [M-H]". Example 452 3-(4-{l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-hexyl}-benzoylamino)- propionic acid, Isomer 1 and Example 453 3-(4-{l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-hexyl}-benzoylamino)- propionic acid, Isomer 2
Figure imgf000203_0001
The title compounds are prepared in a manner substantially similar to Example 62 starting from 3 - {4- [l-(6-chloro-pyridin-3-yloxy)-hexyl] -benzoylamino} -propionic acid methyl ester and 4-trifluoromethyl phenyl boronic acid. Isomer 1 MS: 513.3 [M-H]"; Isomer 2 MS: 513.3 [M-H]". Example 454 3-(4-{l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-pentyl}-benzoylamino)- propionic acid, Isomer 1 and Example 455 3-(4-{l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-pentyl}-benzoylamino)- propionic acid, Isomer 2
Figure imgf000203_0002
The title compounds are prepared in a manner substantially similar to Example 62 starting from 3-{4-[l-(6-chloro-pyridin-3-yloxy)-pentyl]-benzoylamino}-propionic acid methyl ester and 4-trifluoromethyl phenyl boronic acid. Isomer 1 MS: 499.2 [M-H]"; Isomer 2 MS: 499.2 [M-H]". Example 456 Racemic 3-{4-[5,5,5-trifluoro-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-pentyl]- benzoylamino}-propionic acid
Figure imgf000203_0003
The title compound is prepared in a manner substantially similar to Example 128 starting from 3-{4-[l-(4-bromo-phenoxy)-5,5,5-trifluoro-pentyl]-benzoylamino}- propionic acid methyl ester and 4-trifluoromethyl phenyl boronic acid. MS: 552.2[M-H]", Example 457 Racemic 3-{4-[l-(4'-tert-butyl-biphenyl-4-yloxy)-5,5,5-trifluoro-pentyl]- benzoylamino}-propionic acid
Figure imgf000204_0001
The title compound is prepared in a manner substantially similar to Example 128 starting from 3 - {4- [ 1 -(4-bromo-phenoxy)-5 , 5 ,5 -trifluoro-pentyl] -benzoylamino } - propionic acid methyl ester and 4-tert-butyl phenyl boronic acid. MS : 540.3 [M-H]". Example 458 Racemic 3-{4-[l-(4-bromo-phenoxy)-5,5,5-trifluoro-pentyl]-benzoylamino}- propionic acid
Figure imgf000204_0002
The title compound is prepared in a manner substantially similar to Example 128 starting from 3-{4-[l-(4-bromo-phenoxy)-5,5,5-trifluoro-pentyl]-benzoylamino}- propionic acid methyl ester. MS: 488 [M-H]". Example 459 Racemic 3-{4-[l-(4-hydroxy-phenoxy)-heptyl]-benzoylamino}-propionic acid
Figure imgf000204_0003
The title compound is prepared in a manner substantially similar to Example 92 starting from 3-{4-[l-(4-hydroxy-phenoxy)-heptyl]-benzoylamino}-propionic acid methyl ester. MS: 398.3 [M-H]". Example 460 3- (4- [1 -(2,6-Dimethyl-4' -trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl] - benzoylamino}-propionic acid, isomer 1 Example 461 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino}-propionic acid, isomer 1
Figure imgf000205_0001
The racemic 3- {4-[l -(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2- methyl-propyl] -benzoylamino} -propionic acid is resolved on a Chiralpak OJ-H column (0.46 x 15 cm) with a flow rate of 0.6mL/min. and detection at 250nm. Elute with Methanol and concentrate the fractions to provide a purified enantiomer ester isomer 1 (100 % ee) and enantiomer ester isomer 2 (99.3 % ee). Hydrolysis of the purified enantiomer of the ester provided the title compound as a white solid. The structure was confirmed by proton NMR. Example 462 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid, isomer 1 Example 463
3-{4-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid, isomer 1
Figure imgf000205_0002
The racemic 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)- heptyl] -benzoylamino} -propionic acid is resolved on a Chiralpak OJ-H column (0.46 x 15 cm) with a flow rate of 0.6mL/min. and detection at 250nm. Elute with Methanol and concentrate the fractions to provide a purified enantiomer ester isomer 1 (100 % ee) and enantiomer ester isomer 2 (99.2 % ee). Hydrolysis of the purified enantiomer of the ester provided the title compound as a white solid. The structure was confirmed by proton NMR. The compound of Formula I is preferably formulated in a unit dosage form prior to administration. Therefore, yet another embodiment of the present invention is a pharmaceutical composition comprising a compound of Formula I and one or more pharmaceutically acceptable earners, diluents or excipients. The present pharmaceutical compositions are prepared by known procedures using well-known and readily available ingredients. In making the formulations of the present invention, the active ingredient (Formula I compound) will usually be mixed with a canier, or diluted by a canier, or enclosed within a canier which may be in the form of a capsule, sachet, paper or other container. When the canier serves as a diluent, it may be a solid, semisolid or liquid material that acts as a vehicle, excipient, or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosol (as a solid or in a liquid medium), soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders. Some examples of suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpynolidone, cellulose, water syrup, methyl cellulose, methyl and propylhydroxybenzoates, talc, magnesium stearate and mineral oil. The formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents. The compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient. The compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimize the therapeutic effects, i.e., antihistaminic activity and the like. Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices. Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injections or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration. Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier such as inert compressed gas, e.g. nitrogen. For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides such as cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein by stirring or similar mixing. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration, Such liquid forms include solutions, suspensions and emulsions. The compounds of the invention may also be deliverable transdermally. The transdermal compositions may take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as a re conventional in the art for this purpose. Preferably the compound is administered orally. Preferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose. The quantity of the inventive active composition in a unit dose of preparation may be generally varied or adjusted from about 0.01 milligrams to about 1,000 milligrams, preferably from about 0.01 to about 950 milligrams, more preferably from about 0.01 to about 500 milligrams, and typically from about 1 to about 250 milligrams, according to the particular application. The actual dosage employed may be varied depending upon the patient's age, sex, weight and severity of the condition being treated. Such techniques are well known to those skilled in the art. Generally, the human oral dosage form containing the active ingredients can be administered 1 or 2 times per day. There is increasing evidence that glucagon plays an important role in glucose homeostasis. Compounds of Formula I are effective as antagonists or inverse agonists of the glucagon receptor, and thus inhibit the activity of the glucagon receptor. More particularly, these compounds are selective antagonists or inverse agonists of the glucagon receptor. As selective antagonists or inverse agonists, the compounds of Formula I are useful in the treatment of diseases, disorders, or conditions responsive to the inactivation of the glucagon receptor, including but not limited to diabetic and other glucagon related disorder. It is postulated that selective antagonists or inverse agonists of the glucagon receptor will lower plasma glucose levels and thus prevent or treat diabetic and other glucagon related metabolic disorders. PHARMACOLOGICAL METHODS In the following section binding assays as well as functional assays useful for evaluating the efficiency of the compounds of the invention are described. Binding of compounds to the glucagon receptor may be determined in a competition binding assay using the cloned human glucagon receptor, and selectivity against the hGlpl receptor. Antagonism may be determined as the ability of the compounds to inhibit the amount of cAMP formed in in the assay in the presence of 5 nM glucagon.
Glucagon Receptor (hGlucR) Binding Assay
The receptor binding assay used cloned human glucagon receptor (Lok S, Kuijper JL, Jelinek LJ, Kramer JM, Whitmore TE, Sprecher CA, Mathewes S, Grant FJ, Biggs SH, Rosenberg GB, et al.Gene 140 (2), 203-209 (1994)) isolated from 293HEK membranes. The hGlucR cDNA was subcloned into the expression plasmid phD (Trans-activated expression of fully gamma-carboxylated recombinant human protein C, an antithrombotic factor. Grinnell, B.W., Berg, D.T., Walls, J. and Yan, S.B. Bio/Technology 5: 1189-1192 (1987)). This plasmid DNA was transfected into 293 HEK cells and selected with 200 ug/mL Hygromycin. Crude plasma membranes are prepared using cells from suspension culture. The cells are lysed on ice in hypotonic buffer containing 25 mM Tris HCL, pH 7.5, 1 mM ■ MgC12, DNAsel, 20 u/mL, and Roche Complete Inhibitors-without EDTA. The cell suspension is homogenized with a glass dounce homogenizer using a Teflon pestle for 25 strokes. The homogenate is centrifuged at 4 degrees C at 1800 x g for 15 mins. The supernate is collected and the pellet is resuspended in hypotonic buffer and rehomogenized. The mixture is centrifuged at 1800 x g for 15 mins. The second supernate is combined with the first supernate. The combined supemates are recentrifuged at 1800 x g for 15 mins to clarify. The clarified supernate is transfened to high speed tubes and centrifuged at 25000 x g for 30 minutes at 4 degrees C. The membrane pellet is resuspended in homogenization buffer and stored as frozen aliquots at -80 degree C freezer until needed. Glucagon is radioiodinated by I-125-lactoperoxidase procedure and purified by reversed phase HPLC at Perkin-Elmer/NEN (NEX207). The specific activity is 2200 Ci/mmol. Kd determination is performed by homologous competition instead of saturation binding due to high propanol content in the 1-125 glucagon material. The Kd is estimated to be 3 nM and is used to calculate Ki values for all compounds tested. The binding assays are carried out using a Scintillation Proximity Assay
(Amersham) with WGA beads previously blocked with 1% fatty acid free BSA (ICN). The binding buffer contains 25 mM Hepes, pH 7.4, 2.5 mM CaC12, 1 mM MgC12, 0.1% fatty acid free BSA, (ICN), 0.003% tween-20, and Roche Complete Inhibitors without EDTA. Glucagon is dissolved in 0.01 N HCl at 1 mg/mL and immediately frozen at -80 degrees C in 30 ul aliquots. The glucagon aliquot is diluted and used in binding assays within an hour. Test compounds are dissolved in DMSO and serially diluted in DMSO. 10 ul diluted compounds or DMSO is transfened into Corning 3632, opaque clear bottom assay plates containing 90 ul assay binding buffer or cold glucagon (NSB at 1 uM final). 50 ul of 1-125 glucagon (0.15 nM final in reaction), 50 ul of membranes (300 ug/well), and 40 ul of WGA beads (150 ugs/well) are added, covered, and mixed end over end. Plates are read with a MicroBeta after 14 hours of settling time at room temp. Results are calculated as a percent of specific I-125-glucagon binding in the presence of compound. The absolute EC50 dose of compound is derived by non-linear regression of percent specific binding of I-125-glucagon vs. the dose of compound added. The EC50 dose is converted to Ki using the Cheng-Prusoff equation (Cheng Y., Prusoff W. H., Biochem. Pharmacol. 22, 3099-3108, 1973). Glucagon -Like - Peptide 1 (Glpl-R) Receptor Binding Assay The receptor binding assay used cloned human glucagon-like peptide 1 receptor (hGlpl-R). (Graziano MP, Hey PJ, Borkowski D, Chicchi GG, Strader CD, Biochem Biophys Res Commun. 1993 Oct 15;196(l):141-6) isolated from 293HEK membranes. The hGlpl-R cDNA was subcloned into the expression plasmid phD (Trans-activated expression of fully gamma-carboxylated recombinant human protein C, an antithrombotic factor. Grinnell, B.W., Berg, D.T., Walls, J. and Yan, S.B. Bio/Technology 5: 1189- 1192 (1987)). This plasmid DNA was transfected into 293 HEK cells and selected with 200 ug/mL Hygromycin. Crude plasma membrane is prepared using cells from suspension culture. The cells are lysed on ice in hypotonic buffer containing 25 mM Tris HCl, pH 7.5, 1 mM MgC12, DNAse, 20 u/mL, and Roche Complete Inhibitors without EDTA. The cell suspension is homogenized with a glass dounce homogenizer using a Teflon pestle for 25 strokes. The homogenate is centrifuged at 4 degrees C at 1800 x g for 15 mins. The supernate is collected and the pellet is resuspended in hypotonic buffer and rehomogenized. The mixture is centrifuged at 1800 x g for 15 mins. The second supernate is combined with the first supernate. The combined supemates are recentrifuged at 1800 x g for 15 mins to clarify. The clarified supernate is transfened to high speed tubes and centrifuged at 25000 x g for 30 minutes at 4 degrees C. The membrane pellet is resuspended in homogenization buffer and stored as frozen aliquots in -80 degree C freezer until use. Glucagaon-like peptide 1 (Glp-1) is radioiodinated by the I-125-lactoperoxidase procedure and purified by reversed phase HPLC at Perkin-Elmer/NEN (NEX308). The specific activity is 2200 Ci/mmol. Kd determination is performed by homologous competition instead of saturation binding due to high propanol content in the 1-125 Glp-1 material. The Kd is estimated to be 3 nM and is used to calculate Ki values for all compounds tested. The binding assays are canied out using a Scintillation Proximity Assay (Amersham) with wheat germ agglutinin (WGA) beads previously blocked with 1% fatty acid free BSA (ICN). The binding buffer contains 25 mM Hepes, pH 7.4, 2.5 mM CaC12, 1 mM MgC12, 0.1% fatty acid free BSA, (ICN), 0.003% rween-20, and Roche Complete Inhibitors without EDTA. Glucagon-like peptide 1 is dissolved in PBS at 1 mg/mL and immediately frozen at -80 degrees C in 30 ul aliquots. The glucagon-like peptide aliquot is diluted and used in binding assays within an hour. Test compounds are dissolved in DMSO and serially diluted in DMSO. 10 ul diluted compounds or DMSO is transfened into Corning 3632, opaque clear bottom assay plates containing 90 ul assay binding buffer or cold glucagon-like peptide 1 (NSB at 1 uM final). 50 ul of 1-125 glucagon-like peptide 1 (0.15 nM final in reaction), 50 ul of membranes (600 ug/well), and 40 ul of WGA beads (150 ugs/well) are added, covered, and mixed end over end. Plates are read with a MicroBeta after 14 hours of settling time at room temp. Results are calculated as a percent of specific I-125-glucagon-like peptide 1 binding in the presence of compound. The absolute EC50 dose of compound is derived by non-linear regression of percent specific binding of I-125-glucagon-like peptide 1 vs. the dose of compound added. The EC50 dose is converted to Ki using the Cheng-Prusoff equation (Cheng Y., Prusoff W. H., Biochem. Pharmacol. 22, 3099-3108, 1973).
Glucagon-Stimulated cAMP Functional Antagonist Assay The cAMP functional assay uses the same cloned human glucagon receptor cell line isolated for the hGlucR binding assay described above. Cells are stimulated with a mixture of an EC80 dose of glucagon in the presence of compound. The cAMP generated within the cell is quantitated using an Amplified Luminescent Proximity Homogeneous Assay, Alpha Screen, from Perkin Elmer (6760625R).
Briefly, cAMP within the cell competes for binding of biotinylated cAMP from the kit to a coated anti-cAMP antibody Acceptor bead and a strepavidin coated Donor bead. As the cAMP level within the cell increases, a disruption of the Acceptor bead-biotinlyated cAMP -Donor bead complex occurs and decreases the signal.
Glucagon is dissolved in 0.01 N HCl at 1 mg/mL and immediately frozen at -80 degrees C in 30 ul aliquots. The glucagon aliquot is diluted and used in the functional assay within an hour. Cells are harvested from sub-confluent tissue culture dishes with Enzyme-Free Cell Dissociation Solution, (Specialty Media 5-004-B). The cells are pelleted at low speed and washed 3 times with assay buffer [25 mM Hepes in HBSS-with Mg and Ca (GIBCO, 14025-092) with 0.1% Fatty Acid Free BSA (ICN)] then diluted to a final concentration of 250,000 cells per mL. Compounds are serially diluted into DMSO then diluted into assay buffer with a 3X concentration of glucagon and 3% DMSO. The EC80 of glucagon is pre-determined from a full glucagon dose response and represents the dose at which glucagons produces an 80% of the maximal glucagon response. A mixture of biotinylated cAMP (1 unit/well final) from the Alpha Screen Kit and 3X IBMX (1500 uM) is prepared in Assay Buffer.
The functional assay is performed in 96 well, low- volume, white, poylstyrene Costar Plates (3688). The biotinylated cAMP/IBMX mixture, 0.02 mLs, is placed into each well, followed by addition of 0.02 mLs of glucagon dose response, cAMP standard curve, or compound/glucagon mixtures. The reaction is started by addition of 0.02 mLs of cells (5000/well final). After 60 minutes at room temperature, the reaction is stopped by the addition of 0.03 mLs of Lysis Buffer [10 mM Hepes, pH 7.4, 1% NP40, and 0.01% fatty acid free BSA (ICN) containing 1 unit each well of Acceptor and Donor beads from the Alpha Screen Kit]. Lysis Buffer addition is performed under a green light to prevent bleaching of the detection beads. The plates are wrapped in foil and left to equilibrate overnight at room temperature. The plates are read on a Packard Fusion™- D Instrument. Alpha screen units are converted to pmoles cAMP generated per well based upon the cAMP standard curve. The pmoles cAMP produced in the presence of compound are converted to % of a maximal response with the EC80 dose of glucagon alone. With each experiment, the dose of glucagon needed to produce a 50% response of pmoles cAMP is determined. This EC50 dose is used to normalize results to a Kb using a modified Cheng-Prusoff equation (Cheng Y., Prusoff W. H., Biochem. Pharmacol. 22, 3099-3108, 1973), where Kb = (EC50 compound)/ [1 + (pM glucagon used/ EC50 inpM for glucagon dose response)]. The compounds according to the invention preferably have a Ki value of no greater than 50μM as determined by the Glucagon Receptor (hGlucR) Binding Assay disclosed herein. More preferably, the compounds according to the invention have a Ki value of less than 5μM, preferably of less than 500 nM and even more prefened of less than 100 nM as determined by the Glucagon Receptor (hGlucR) Binding Assay disclosed herein. Generally, the compounds according to the invention show a higher affinity for the glucagon receptor compared to the GLP-1 receptor, and preferably have a higher binding affinity to the glucagon receptor than to the GLP-1 receptor. The results are given below for the indicated compound. Table 1:
Figure imgf000213_0001
From the above description, one skilled in the art can ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, other embodiments are also within the claims.

Claims

WHAT IS CLAIMED IS: A compound structurally represented by Formula I
Figure imgf000214_0001
R11 ( I ) or a pharmaceutically acceptable salt thereof wherein: Y is -O- or -S-; Q, D, X, and T independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein), or nitrogen (optionally substituted with oxygen), provided that no more than two of Q, D, X, and T are nitrogen; RI is -H, -OH, or -halogen; R2 is -H or -(d-C3) alkyl (optionally substituted with 1 to 3 halogens); R3 and R4 are independently - H, -halogen, -CN, -OH, -(C C7) alkoxy, -(C1-C7) alkyl(optionally substituted with 1 to 3 halogens), or -(C2-C7) alkenyl; R5 is selected from the group consisting of -H, -(CrC12) alkyl(optionally substituted with 1 to 3 halogens), -(C3-C12)cycloalkyl, -phenyl, -phenyl-phenyl-(Ci-C12)alkyl, -aryl, -aryl-(C1-C12)alkyl, -heteroaryl, -heteroaryl-(C1-C12)alkyl, -(C2~ C12)alkenyl, -(C3-C1 )cycloalkenyl, -heterocycloalkyl, -aryl-(C2-C10)alkenyl, -heteroaryl-(C2-C10)alkenyl, ~(C ~C1 )alkynyl, -(C3-C12)cycloalkynyl, -aryl-(C2-C12)alkynyl, and -heteroaryl-(C2-C12)alkynyl, and wherein -( - C12)alkyl, -(C3-C12)cycloalkyl, -phenyl, -phenyl-phenyl-(C1-C12)alkyl, -aryl, -aryl-(C1-C12)alkyl, -heteroaryl, -heteroaryl-(C1-C12)alkyl, -heterocycloalkyl, -(C2-C12)alkenyl, -(C3-C12)cycloalkenyl, -aryl-(C2- C10)alkenyl, -heteroaryl-(C2-C10)alkenyl, -(C2-C12)alkynyl, -(C3-C12) cycloalkynyl, -aryl-(C2-C1 )alkynyl, -heteroaryl-(C2-C12)alkynyl, are each optionally substituted with from one to three substituents each independently selected from the group consisting of -hydrogen, -hydroxy, -cyano, -nitro, -halo, -oxo, -(C1-C7)alkyl (optionally substituted with 1 to 3 halogens), -(C1-C7)alkyl-C(O)OR12, -(Ci-C7)alkoxy, -(C3-C7)cycloalkyl, -C(O)R12, -C(O)OR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O)R12, -NR12SO2R12, -SR12, -S(O)R12, -S(O)2R12, and -S(O)2N(R12)2; R6 and R7 are independently at each occunence selected from the group consisting of -H, -halogen, -hydroxy, -CN, -(C^C?) alkoxy, -(C2-C7)alkenyl, -( - C10)alkyl (optionally substituted with 1 to 3 halogens), -(C3-C1 )cycloalkyl, tert-butoxyiminomethyl, l,3-dioxan-2-yl, hydroxymethyl, formyl, hydroxyiminomethyl, morphylino-4-yl-methyl, 4-methylpentyloxy, and pentyloxy; provided however that wherein D is nitrogen, then R6 or R7 are not attached to D, and provided that wherein T is nitrogen, then R6 or R7 are not attached to T, and provided that wherein Q is nitrogen, then R6 or R7 are not attached to Q, and provided that wherein X is nitrogen, then R6 or R7 are not attached to X; wherein R6 and R7 may optionally form a six membered ring with the atoms to which they are attached, and the ring so formed may optionally contain up to two oxygens, and further the ring so formed may optionally be substituted with up to four halogens;
R8 and R9 are independently at each occunence selected from the group consisting of -hydrogen, -hydroxy, -CN, -nitro, -halo, -(C1-C7)alkyl(optionally substituted with 1 to 3 halogens), -(C1-C7)alkoxy, -(C3-C7)cycloalkyl, -aryl, -aryl-(C1-C7)alkyl, -heteroaryl, -heteroaryl-(C1-C7)alkyl, -aryloxy, -C(O)R12, -COOR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O)R12, -NR12SO2 R12, -SR12, -S(O)R12, -S(O)2R12, -O(C2- C7)alkenyl, and -S(O)2N(R12)2; and wherein -(C1-C7)alkyl, -(C1-C7)alkoxy, -(C3-C7)cycloalkyl, -aryl, -aryl-(C1-C7)alkyl, -heteroaryl, -heteroaryl-(C1-C7)alkyl, -aryloxy, and -O(C2-C7)alkenyl are each optionally substituted with from one to three substituents independently selected from the group consisting of -hydrogen, -hydroxy, -cyano, -nitro, -halo, -oxo, -(CrC7)alkyl, -(C1-C7)alkyl-C(O)OR12, -(C1-C7)alkoxyl, -(C3-C7)cycloalkyl, -heterocycloalkyl, -C(O)R12, -COOR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O)R12, -NR12SO2 R12, -SR12, -S(O)R12, -S(O)2R12, and -S(O)2N(R12)2; RIO is selected from the group consisting of -H, halogen, -(C1-C12)alkyl(optionally substituted with 1 to 3 halogens), -cycloalkyl, -aryl, -aryl-(C1-C )alkyl, -heteroaryl, -heteroaryl -(Q- C7)alkyl, -(C2-C12)alkenyl, -(C3-C12)cycloalkenyl, -aryl-(C2-C10)alkenyl, -heteroaryl-(C -C1o)alkenyl, -(C2-C12)alkynyl, -(C3-C1 )cycloalkynyl, -aryl-(C2-C12)alkynyl, and -heteroaryl-(C -C12)alkynyl;
Rll is independently at each occunence selected from the group consisting of -H, -halogen,
Figure imgf000216_0001
, wherein the zig-zag mark shows the point of attachment to the parent molecule, wherein A, G, and E independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein) or nitrogen, provided that no more than two of A, G, and E are nitrogen; provided however that wherein A is nitrogen, then R8, R9, and R14 are not attached to A, and provided that wherein G is nitrogen, then R8, R9, and R14 are not attached to G, and provided that wherein E is nitrogen, then R8, R9, and R14 are not attached to E,
Figure imgf000217_0001
, wherein the zig-zag mark shows the point of attachment to the parent molecule, wherein m is an integer of 0, 1, 2, or 3, and when m is 0 then (CH )m is a bond, and
Figure imgf000217_0002
, wherein the zig-zag mark shows the point of attachment to the parent molecule, provided however that wherein D is nitrogen, then Rll is not attached to D, and provided that wherein T is nitrogen, then RI 1 is not attached to T, and provided that wherein Q is nitrogen, then RI 1 is not attached to Q, and provided that wherein X is nitrogen, then Rll is not attached to X; R12 is independently at each occunence selected from the group consisting of -hydrogen, -(Q-C7) alkyl(optionally substituted with 1 to 3 halogens), and -aryl; R13 is independently at each occunence selected from the group consisting of -hydrogen, -halogen, -( -C ) alkyl(optionally substituted with 1 to 3 halogens), phenyl, and -(C2-C7)alkenyl; and R14 is independently at each occunence -H, halogen, or -(C1-C ) alkyl (optionally substituted with 1 to 3 halogens). 2. A compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: Y is -O- or -S-; Q, D, X, and T independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein), or nitrogen, provided that no more than two of Q, D, X, and T are nitrogen; RI is -H, -OH, or -halogen; R2 is -H or -(Cι-C3) alkyl (optionally substituted with 1 to 3 halogens); R3 and R4 are independently - H, -halogen, -CN, -( -C7) alkoxy, -( -C7) alkyl(optionally substituted with 1 to 3 halogens), or -(C -C7)alkenyl; R5 is selected from the group consisting of -(Cι-Cι2) alkyl(optionally substituted with 1 to 3 halogens), -(C3-C12)cycloalkyl, -phenyl, -phenyl-phenyl-(C1-C12)alkyl,-(C2- C12)alkenyl, -(C3-C12)cycloalkenyl, -heterocycloalkyl, -(C2-C12)alkynyl, and -(C3- C1 )cycloalkynyl, and wherein -(C1-C12)alkyl, -(C3-C12)cycloalkyl, -phenyl, -ρhenyl-phenyl-(CrC12)alkyl, -heterocycloalkyl, -(C2- C12)alkenyl, -(C3-C12)cycloalkenyl, -(C2-C12)alkynyl, and -(C3-C12) cycloalkynyl, are each optionally substituted with from one to three substituents each independently selected from the group consisting of -hydrogen, -hydroxy, -cyano, -nitro, -halo, -oxo, -(C1-C7)alkyl (optionally substituted with 1 to 3 halogens); R6 and R7 are independently at each occunence selected from the group consisting of -H, -halogen, -hydroxy, -CN, -( -C7) alkoxy, -(C2-C7)alkenyl, -(Ci- Cio)alkyl (optionally substituted with 1 to 3 halogens), -(C3-C12)cycloalkyl, tert-butoxyiminomethyl, l,3-dioxan-2-yl, hydroxymethyl, formyl, hydroxyiminomethyl, morphylino-4-yl-methyl, 4-methylpentyloxy, and pentyloxy; provided however that wherein D is nitrogen, then R6 or R7 are not attached to D, and provided that wherein T is nitrogen, then R6 or R7 are not attached to T, and provided that wherein Q is nitrogen, then R6 or R7 are not attached to Q, and provided that wherein X is nitrogen, then R6 or R7 are not attached to X; wherein R6 and R7 may optionally form a six membered ring with the atoms to which they are attached, and the ring so formed may optionally contain up to two oxygens, and further the ring so formed may optionally be substituted with up to four halogens;
R8 and R9 are independently at each occunence selected from the group consisting of -hydrogen, -hydroxy, -CN, -nitro, -halo, -(C1-C7)alkyl(optionally substituted with 1 to 3 halogens), -(C1-C7)alkoxy, -(C3-C7)cycloalkyl, - C(O)R12, -C(O)OR12, -OC(O)R12, -OS(O)2R12, -N(R12)2, -NR12C(O) R12, -NR12SO2 R12, -SR12, -S(O)R12, -S(O)2R12, -O(C2-C7)alkenyl, and -S(O)2N(R12)2; and wherein -(C1-C7)alkyl, -(C1-C7)alkoxy, -(C3- C7)cycloalkyl, and -O(C2~C7)alkenyl are each optionally substituted with from one to three substituents independently selected from the group consisting of -hydrogen, -hydroxy, -cyano, -nitro, -halo, -oxo, and -( - C7)alkyl; RIO is selected from the group consisting of -H, halogen, and -(C1-C12)alkyl(optionally substituted with 1 to 3 halogens);
Rll is independently at each occunence selected from the group consisting of -H, -halogen,
Figure imgf000219_0001
, wherein the zig-zag mark shows the point of attachment to the parent molecule, wherein A, G, and E independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein) or nitrogen, provided that no more than two of A, G, and E are nitrogen; provided however that wherein A is nitrogen, then R8, R9, and R14 are not attached to A, and provided that wherein G is nitrogen, then R8, R9, and R14 are not attached to G, and provided that wherein E is nitrogen, then R8, R9, and R14 are not attached to E,
Figure imgf000219_0002
, wherein the zig-zag mark shows the point of attachment to the parent molecule, wherein m is an integer of 0, 1,
2, or 3, and when m is 0 then (CH2)m is a bond, and
Figure imgf000220_0001
, wherein the zig-zag mark shows the point of attachment to the parent molecule, provided however that wherein D is nitrogen, then Rll is not attached to D, and provided that wherein T is nitrogen, then RI 1 is not attached to T, and provided that wherein Q is nitrogen, then RI 1 is not attached to Q, and provided that wherein X is nitrogen, then RI 1 is not attached to X; R12 is independently at each occunence selected from the group consisting of -hydrogen, and -(C1-C7) alkyl(optionally substituted with 1 to 3 halogens); R13 is independently at each occunence selected from the group consisting of -hydrogen, -halogen, -(C1-C7) alkyl(optionally substituted with 1 to 3 halogens), phenyl, and -(C -C7)alkenyl; and R14 is independently at each occunence -H, halogen, or -(Ci-C ) alkyl (optionally substituted with 1 to 3 halogens). 3. A compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: Y is -O-, or -S-; Q, D, X, and T independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein); RI is -H, -OH, or -halogen; R2 is -H; R3 and R4 are independently -H, -halogen, or -( -C6) alkyl(optionally substituted with 1 to 3 halogens); R5 is selected from the group consisting of -(Ci-C1 ) alkyl(optionally substituted with 1 to 3 halogens), and -(C3-C12)cycloalkyl(optionally substituted with 1 to 3 halogens); R6 and R7 are independently at each occunence selected from the group consisting of -H, -halogen, -hydroxy, -CN, -( -C7) alkoxy, -(C2-C7)alkenyl, -(Q- C!o)alkyl (optionally substituted with 1 to 3 halogens), -(C3-C12)cycloalkyl, tert-butoxyiminomethyl, l,
3-dioxan-2-yl, hydroxymethyl, formyl, hydroxyiminomethyl, morphylino-4-yl-methyl, 4-methylpentyloxy, and pentyloxy; provided however that wherein D is nitrogen, then R6 or R7 are not attached to D, and provided that wherein T is nitrogen, then R6 or R7 are not attached to T, and provided that wherein Q is nitrogen, then R6 or R7 are not attached to Q, and provided that wherein X is nitrogen, then R6 or R7 are not attached to X; R8 and R9 are independently at each occunence selected from the group consisting of -hydrogen, -halogen, -(C1-C7)alkyl(optionally substituted with 1 to 3 halogens), -(Cι-C7)al oxy, -(C3-C7)cycloalkyl, -C(O)R12, -C(O)OR12, -OC(O)R12, -OS(O)2R12, -SR12, -S(O)R12, -S(O)2R12, and -O(C2- C7)alkenyl; RIO is -H; RI 1 is independently at each occunence selected from the group consisting of -H, -halogen, and
Figure imgf000221_0001
, wherein the zig-zag mark shows the point of attachment to the parent molecule, wherein A, G, and E independently represent carbon (substituted with hydrogen or the optional substituents as indicated herein), provided however that wherein A is nitrogen, then R8, R9, and R14 are not attached to A, and provided that wherein G is nitrogen, then R8, R9, and R14 are not attached to G, and provided that wherein E is nitrogen, then R8, R9, and R14 are not attached to E; R12 is independently at each occunence selected from the group consisting of -hydrogen, and -(Cx-Q-j) alkyl(optionally substituted with 1 to 3 halogens); R13 is independently at each occunence selected from the group consisting of -hydrogen, -halogen, -( -C7) alkyl(optionally substituted with 1 to 3 halogens), and -(C2-C7)alkenyl; and R14 is independently at each occunence -H, halogen, or -( -C7) alkyl (optionally substituted with 1 to 3 halogens).
4. A compound of any of claims 1, 2, or 3, wherein Y is -O- or -S-; RI is hydrogen or -OH; R2 is hydrogen; R3 and R4 are independently hydrogen or halogen; R5 is methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, octyl, 3,3-dimethylbutyl, 2- methylpropyl, 4-methylpentyl, 2,2-dimethylpropyl, 3-trifluoropropyl, 4-trifluorbutyl, cyclohexyl, or 4-bromo- phenyl; R6 and R7 are independently hydrogen, methyl, ethyl, 1,1,3,3-tetramethylbutyl, tert-butyl, cyclohexyl, pentyl, isopropoxy, chloro, fluoro, bromo, hydoxy, trifluoromethyl, -CN, methoxy, tertbutoxyiminomethyl, l,3-dioxan-2-yl, hydroxymethyl, formyl, hydroxyiminomethyl, morpholino-4-yl-methyl, 4-methylpentyloxy, and 4- pentyloxy, and wherein R6 and R7 combine to form, with the phenyl to which they are attached, a fused benzodioxin moiety; R8 and R9 are independently hydrogen, fluoro, chloro, methyl, ethyl, pentyl, isopropyl, tert-butyl, trifluoromethyl, acetyl, 2-methylpropyl, methoxy, cyclohexyl, allyloxy, or trifluormethoxy; RIO is hydrogen; Rll is hydrogen, halogen, phenyl (substituted, independently at each occunence, once with R8, once with R9, and twice with R14), pyridinyl (substituted, independently at each occunence, once with R8, once with R9, and twice with R14), or benzoxy (substituted twice with R13); R13 is hydrogen, trifluoromethyl, tertbutyl, isopropyl, chloro, fluoro, bromo, methyl, ethyl, or phenyl, T is -CH-, -CR6-, or N; X is -CH- or -CR11-; D is -CH-, -CR6-, -CR11-, or N; and Q is -CH-, -CR6-, or N; R14 is hydrogen, bromo, fluoro, methyl, tertbutyl, or isopropyl.
5. A compound of any of claims 1, 2, 3, or 4 wherein Y is -O-.
6. A compound of any of claims 1, 2, 3, or 4 wherein Y is -S-.
7. The compound of claim 5 or 6 wherein RI, R2, R3, R4, and RIO are -H.
8. The compound of any of claims 1, 2, 3, 4, 5, 6, or 7 wherein D, X, Q, and T are carbon (substituted with hydrogen or the optional substituents. as indicated herein).
9. The compound of any of claims 1, 2, 3, 4, 5, 6, or 7 wherein D is nitrogen, and T, Q, and X are carbon (substituted with hydrogen or the optional substituents as indicated herein).
10. The compound of any of claims 1, 2, 3, 4, 5, 6, or 7 wherein R6 and R7 are independently hydrogen or methyl.
11. The compound of claim 10 wherein X is carbon substituted with Rll.
12. The compound of claim 11 wherein A, G, and E are carbon (substituted with hydrogen or the optional substituents as indicated herein).
13. The compound of claim 12 wherein R5 is -( - 2) alkyl(optionally substituted with 1 to 3 halogens), -(C3-C12)cycloalkyl, -(C -C12)alkenyl, -(C - C12)cycloalkenyl, -heterocycloalkyl, -(C2-C12)alkynyl, or -(C3-C12)cycloalkynyl.
14. The compound of claim 12 wherein R5 is -(Cι-C12) alkyl(optionally substituted with 1 to 3 halogens), or -(C3-C12)cycloalkyl.
15. A compound of claim 1 selected from the group consisting of: Racemic 3-{4- l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-propyl]-benzoylamino}- propionic acid Racemic 3-{4- 3 -Methyl- 1 -(4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]- benzoylamino -propionic acid; Racemic 3-{4- l-(4-tert-Butyl-phenoxy)-3-methyl-butyl]-benzoylamino}- propionic acid Racemic 3-{4- l-(4'-tert-Butyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]- benzoylamino -propionic acid; Racemic 3-{4- 4,4,4-Trifluoro-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]- benzoylamino -propionic acid; Racemic 3-{4- (4-Bromo-phenyl)-(4'-tert-butyl-biphenyl-4-yloxy)-methyl]- benzoylamino -propionic acid; Racemic 3-{4- 2-Methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]- benzoylamino -propionic acid; Racemic 3-{4- l-(4'-tert-Butyl-biphenyl-4-yloxy)-propyl]-benzoylamino}- propionic acid Racemic 3-{4- l-(4'-tert-Butyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid Racemic 3-{4- l-(4'-tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino -propionic acid; Racemic 3-{4- l-(4-Cyclohexyl-phenoxy)-hexyl]-benzoylamino}-propionic acid; Racemic 3 - { 4- [ 1 -(4-B enzyloxy-phenoxy)-hexyl] -benzoylamino } -propionic acid;
Racemic 3-[4-(l-Phenoxy-hexyl)-benzoylamino]-propionic acid;
Racemic 3-{4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid; Racemic 3 - { 4- [ 1 -(4'-Trifluoromethyl-biphenyl-4-ylsulf anyl)-heptyl] - benzoylamino} -propionic acid;
Racemic 3- {4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-pentyl]-benzoylamino }- propionic acid;
Racemic 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-pentyl]-benzoylamino}- propionic acid;
Racemic 3 - { 4- [ 1 -(4'-Trifluoromethyl-biphenyl-4-yloxy)-butyl] -benzoylamino } - propionic acid;
Racemic 3- { 4- [ 1 -(4'-tert-Butyl-biphenyl-4-yloxy)-butyl] -benzoylamino } - propionic acid; Racemic 3-{4-[3-Methyl-l-(4 '-trifluoromethyl-biphenyl-4-ylsulfanyl)-butyl]- benzoylamino} -propionic acid;
Racemic 3 - { 4- [ 1 -(4'-Trifluoromethyl-biphenyl-4-yloxy)-nonyl] -benzoylamino } - propionic acid;
Racemic 3 -(4- { 3 -Methyl- 1 - [4-(6-trifluoromethyl-pyridin-3 -yl)-phenoxy] -butyl } - benzoylamino)-propionic acid;
Racemic 3-(4- { 2-Methyl- 1 - [4-(6-trifluoromethyl-pyridin-3 -yl)-phenoxy]-propyl } - benzoylamino)-propionic acid;
Racemic 3-(4-{ l-[4'-trifluoromethoxy-biphenyl-4-ylsulfanyl]-3-methyl-butyl}- benzoylamino)-propionic acid; Racemic 3- {4-[l-(3',4'-dimethyl-biρhenyl-4-ylsulfanyl)-3-methyl-butyl]- benzoylamino} -propionic acid;
Racemic 3- { 4-[ l-(4'-cyano-biphenyl-4-ylsulfanyl)-3-methyl-butyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(4'-Isobutyl-biphenyl-4-ylsulfanyl)-3-methyl-butyl]- benzoylamino} -propionic acid;
Racemic 3-(4-{ l-[4-(6-Methoxy-pyridin-3-yl)-phenylsulfanyl]-3-methyl-butyl}- benzoylamino)-propionic acid; Racemic 3-{4-[l-(4'-Ethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid;
3-{4-[l-(4-Benzyloxy-phenoxy)-hexyl]-benzoylamino}-propionic acid, Isomer 1;
3-{4-[l-(4-Benzyloxy-phenoxy)-hexyl]-benzoylamino}-propionic acid, Isomer 2; 3- {4-[3-Methyl- 1 -(4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]-benzoylamino } - propionic acid, Isomer 1;
3- { 4- [3-Methyl- 1 -(4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]-benzoylamino } - propionic acid, Isomer 2;
3- { 4-[ 1 -(4'-Trifluoromethyl-biphenyl-4-yloxy)-propyl] -benzoylamino } -propionic acid, Isomer 1 ;
3 - { 4- [ 1 -(4'-Trifluoromethyl-biphenyl-4-yloxy)-propyl] -benzoylamino } -propionic acid, Isomer 2;
3- { 4-[ l-(4'-tert-Butyl-biphenyl-4-yloxy)-propyl]-benzoylamino } -propionic acid,
Isomer 1; 3- { 4- [ 1 -(4'-tert-Butyl-biphenyl-4-yloxy)-propyl]-benzoylamino } -propionic acid,
Isomer 2;
3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid,
Isomer 1 ;
3- { 4- [ 1 ~(4'-tert-Butyl-biphenyl-4-yloxy)-heptyl] -benzoylamino } -propionic acid, Isomer 2;
3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}- propionic acid, Isomer 1;
3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}- propionic acid, Isomer 2; 3 - { 4- [ 1 -(4'-Trifluoromethyl-biphenyl-4-ylsulf anyl)-heptyl] -benzoylamino } - propionic acid, Isomer 1;
3 - { 4- [ 1 -(4'-Trifluoromethyl-biphenyl-4-ylsulf anyl)-heptyl] -benzoylamino } - propionic acid, Isomer 2;
3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-pentyl]-benzoylamino}-propionic acid, Isomer 1;
3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-pentyl]-benzoylamino}-propionic acid,
Isomer 2; 3- { 4-[2-Methyl- 1 -(4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]-benzoylamino }- propionic acid, Isomer 1;
3- { 4-[2-Methyl-l -(4,-trifluoromethyl-biphenyl-4-yloxy)-propyl]-benzoylamino } - propionic acid, Isomer 2; 3-{4-[l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-pentyl]-benzoylamino}-propionic acid, Isomer 1 ;
3 - { 4- [ 1 -(4'-Trifluoromethyl-biphenyl-4-yloxy)-pentyl] -benzoylamino } -propionic acid, Isomer 2;
3- { 4-[ 1 -(4'-Trifluoromethyl-biphenyl-4-yloxy)-butyl] -benzoylamino } -propionic acid, Isomer 1;
3 - { 4- [ 1 -(4'-Trifluoromethyl-biphenyl-4-yloxy)-butyl] -benzoylamino } -propionic acid, Isomer 2;
3- { 4- [ 1 -(4'-tert-Butyl-biphenyl-4-yloxy)-butyl]-benzoylamino } -propionic acid,
Isomer 1; 3- { 4- [ 1 -(4'-tert-Butyl-biphenyl-4-yloxy)-butyl]-benzoylamino } -propionic acid,
Isomer 2;
3-(4-{ l-[4'-(l-Fluoro-l-methyl-ethyl)-biphenyl-4-ylsulfanyl]-3-methyl-butyl}- benzoylamino)-propionic acid, Isomer 1;
3-(4-{ l-[4'-(l-Fluoro-l-methyl-ethyl)-biphenyl-4-ylsulfanyl]-3-methyl-butyl}- benzoylamino)-propionic acid, Isomer 2;
3 -(4- { 3 -Methyl- 1 - [4-(6-trifluoromethyl-pyridin-3 -yl)-phenoxy] -butyl } - benzoylamino)-propionic acid, Isomer 1 ;
3 -(4- { 3 -Methyl- 1 - [4-(6-trifluoromethyl-pyridin-3 -yl)-phenoxy] -butyl } - benzoylamino)-propionic acid, Isomer 2; 3- { 4-[ l-(4'-Trifluoromethyl-biphenyl-4-yloxy)-nonyl]-benzoylamino } -propionic acid, Isomer 1;
3- { 4- [ 1 -(4'-Trifluoromethyl-biphenyl-4-yloxy)-nonyl]-benzoylamino } -propionic acid, Isomer 2;
3-{4-[l-(4'-Ethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid, Isomer 1;
3-{4-[l-(4'-Ethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid,
Isomer 2; 3-(4-{ l-[6-(4-tert-Butyl-phenyl)-pyridin-3-yloxy]-4,4-dimethyl-pentyl}- benzoylamino)-propionic acid, Isomer 1;
Racemic 3-(4-{ l-[6-(4-Trifluoromethyl-phenyl)-pyridin-3-yloxy]-heptyl}- benzoylamino)~propionic acid; Racemic 3-(4-{4,4,4-Trifluoro-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- butyl } -benzoylamino)-propionic acid;
Racemic 3-(4-{3-Methyl-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- butyl } -benzoylamino)-propionic acid;
Racemic 3-(4-{4,4-Dimethyl-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- pentyl }-benzoylamino)-propionic acid;
Racemic 3-(4- { l-[6-(4-Trifluoromethyl-phenyl)-pyridin-3-yl]-butoxy }- benzoylamino)-propionic acid;
Racemic 3-(4- { l-[6-(4-tert-Butyl-phenyl)-pyridin-3-yloxy]-4,4,4-trifluoro-butyl }- benzoylamino)-propionic acid; Racemic 3-(4-{ l-[6-(4-tert-Butyl-phenyl)-pyridin-3-yloxy]-3-methyl-butyl}- benzoylamino)-propionic acid;
3-(4- { 1 - [6-(4-tert-Butyl-phenyl)-pyridin-3 -yloxy] -4,4-dimethyl-pentyl } - benzoylamino)-propionic acid, Isomer 2;
3 -(4- { 1 - [6-(4-Trifluoromethyl-phenyl)-pyridin-3 -yloxy] -heptyl } -benzoylamino)- propionic acid, Isomer 1;
3-(4-{ l-[6-(4-Trifluoromethyl-phenyl)-pyridin-3-yloxy]-heptyl}-benzoylamino)- propionic acid, Isomer 2;
3 -(4- { 4,4,4-Trifluoro- 1 - [6-(4-trifluoromethyl-phenyl)-pyridin-3 -yloxy]-butyl } - benzoylamino)-propionic acid, Isomer 1; 3-(4- { 4,4,4-Trifluoro- l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-butyl } - benzoylamino)-propionic acid, Isomer 2;
3-(4-{ l-[6-(4-tert-Butyl-phenyl)-pyridin-3-yloxy]-butyl}-benzoylamino)- propionic acid, Isomer 1;
3-(4-{ l-[6-(4-tert-Butyl-phenyl)-pyridin-3-yloxy]-butyl}-benzoylamino)- propionic acid, Isomer 2;
Racemic 3 -(4- { 1 - [6-(4-Isobutyl-phenyl)-pyridin-3 -yloxy] -butyl } -benzoylamino)- propionic acid; Racemic 3- { 4-[ l-(3 '-Trifluoromethyl-biphenyl-4-ylsulfanyl)-heptyl]- benzoylamino} -propionic acid;
Racemic 3 - { 4- [ 1 -(4'- Acetyl-biphenyl-4-ylsulf anyl)-heptyl] -benzoylamino } - propionic acid; Racemic 3-{4-[l-(3',4'-dimethyl-biphenyl-4-ylsulfanyl)-heptyl]-benzoylamino}- propionic acid;
Racemic 3-{4-[l-(4'-methylsulfonyl-biphenyl-4- ylsulf anyl)-heptyl]- benzoylamino} -propionic acid;
Racemic 3- { 4- [ 1 -(2 ' ,3 ' -dimethyl-biphenyl-4-ylsulfanyl)-heptyl]-benzoylamino } - propionic acid;
Racemic 3- {4-[ 1 -(2' ,6' -dimethyl-biphenyl-4-ylsulfanyl)-heptyl]-benzoylamino } - propionic acid;
Racemic 3- { 4- [ 1 -(3 ' -isopropyl-biphenyl-4-ylsulfanyl)-heptyl]-benzoylamino } - propionic acid; Racemic 3-{4-[l-(3'-acetyl-biphenyl-4-ylsulfanyl)-heptyl]-benzoylamino}- propionic acid;
Racemic 3 - { 4- [ 1 -(4 ' -pentyl-biphenyl-4-ylsulf anyl)-heptyl] -benzoylamino } - propionic acid;
Racemic 3-{4-[l-(4'-cyclohexyl-biphenyl-4- ylsulf anyl)-heptyl]-benzoylamino}- propionic acid;
Racemic 3 - { 4- [ 1 -(4-Allyloxy-phenoxy)-heptyl] -benzoylamino } -propionic acid;
Racemic 3-{4-[l-(2,2,3,3-Tetrafluoro-2,3-dihydro-benzo[l,4]dioxin-6-yloxy)- heptyl] -benzoylamino } -propionic acid;
Racemic 3-(4-{ l-[4-(4-Trifluoromethyl-phenoxy)-phenoxy]-heptyl}- benzoylamino)-propionic acid;
Racemic 3-{4-[l-(4-Pentyl-phenoxy)-heptyl]-benzoylamino}-propionic acid;
Racemic 3-(4-{ l-[4-(4-tert-Butyl-benzyloxy)-phenoxy]-heptyl}-benzoylamino)- propionic acid;
Racemic 3-(4- { l-[4-(3 ,5-bistrifluoromethyl-benzyloxy)-phenoxy]-heptyl } - benzoylamino)-propionic acid;
Racemic 3 -(4- { 1 -[4-(4-isopropyl-benzyloxy)-phenoxy] -heptyl } -benzoylamino)- propionic acid; Racemic 3-(4- { 1 - [4-(4-chloro-beήzyloxy)-phenoxy] -heptyl } -benzoylamino)- propionic acid;
Racemic 3 -(4- { 1 - [4-(4-ethyl-benzyloxy)-phenoxy] -heptyl } -benzoylamino)- propionic acid; Racemic 3-(4-{ l-[4-(4-bromo-benzyloxy)-phenoxy]-heptyl}-benzoylamino)- propionic acid;
Racemic 3-(4-{l-[4-(4-fluoro-benzyloxy)-phenoxy]-heptyl}-benzoylamino)- propionic acid;
Racemic 3 -(4- { 1 - [4-(4-trifluoromethyl-benzyloxy)-phenoxy] -heptyl } - benzoylamino)-propionic acid;
Racemic 3-(4- { 1 - [4-(4-phenyl-benzyloxy)-phenoxy] -heptyl } -benzoylamino)- propionic acid;
Racemic 3 -(4- { 1 - [4-(3 -chloro-benzyloxy)-phenoxy] -heptyl } -benzoylamino)- propionic acid; Racemic 3-(4-{ l-[4-(3,4-dimethyl-benzyloxy)-phenoxy]-heptyl}-benzoylamino)- propionic acid;
Racemic 3-(4-{ l-[4-(4-isopropxyphenoxy]-heptyl}-benzoylamino)-propionic acid;
Racemic 3-{4-[l-(3',5'-bistrifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid;
Racemic 3 - { 4- [ 1 -(4'-tert-Butyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-4 ,4-dimethyl-pentyl]- benzoylamino} -propionic acid; Racemic 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino} -propionic acid;
Racemic 3- { 4- [ 1 -(4'-trifluoromethyl-biphenyl-4-yloxy)-hexyl] -benzoylamino } - propionic acid;
3- { 4-[ l-(3 ' ,5,-bistrifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino } - propionic acid, Isomer 1;
3 - { 4-[ 1 -(3 ' ,5 '-bistrifluoromethyl-biphenyl-4-yloxy)-heptyl] -benzoylamino } - propionic acid, Isomer 2; 3-{4-[l-(4-tert-Butyl-phenoxy)-3-methyl-butyl]-benzoylamino}-propionic acid,
Isomer 1;
3- { 4- [ l-(4-tert-Butyl-phenoxy)-3 -methyl-butyl] -benzoylamino } -propionic acid,
Isomer 2; 3 - { 4-[ 1 ~(4' -tertbutyl-biphenyl-4-yloxy)-2-methyl-propyl]-benzoylamino } - propionic acid, Isomer 1;
3 - { 4- [ 1 -(4 ' -tertbutyl-biphenyl-4-yloxy)-2-methyl-propyl] -benzoylamino } - propionic acid, Isomer 2;
3 - { 4- [ 1 -(4'-trifluoromethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl] - benzoylamino} -propionic acid, Isomer 1;
3 - { 4- [ 1 -(4'-trifluoromethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl] - benzoylamino} -propionic acid, Isomer 2;
3- { 4-[ 1 -(4'-Trifluoromethoxy-biphenyl-4-yloxy)-heptyl] -benzoylamino } - propionic acid, Isomer 1; 3 - { 4-[ 1 -(4'-Trifluoromethoxy-biphenyl-4-yloxy)-heptyl] -benzoylamino } - propionic acid, Isomer 2;
3 - { 4- [ 1 -(4'-Trifluoromethyl-biphenyl-4-yloxy)-heptyl] -benzoylamino } -propionic acid, Isomer 1;
3 - { 4- [ 1 -(4'-Trifluoromethyl-biphenyl-4-yloxy)-heptyl] -benzoylamino } -propionic acid, Isomer 2;
3-{4-[l-(2,2,3,3-Tetrafluoro-2,3-dihydro-benzo[l,4]dioxin-6-yloxy)-heρtyl]- benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(2,2,3,3-Tetrafluoro-2,3-dihydro-benzo[l,4]dioxin-6-yloxy)-heptyl]- benzoylamino} -propionic acid, Isomer 2; 3-(4-{ l-[4-(4-Trifluoromethyl-phenoxy)-phenoxy]-heptyl}-benzoylamino)- propionic acid, Isomer 1;
3-(4-{ l-[4-(4-Trifluoromethyl-phenoxy)-phenoxy]-heptyl}-benzoylamino)- propionic acid, Isomer 2;
3 - { 4- [ 1 -(4'-Trifluoromethyl-biphenyl-4-yloxy)-hexyl] -benzoylamino } -propionic acid, Isomer 1;
3-{4-[l-(4'-Trifluorometlιyl-biphenyl-4-yloxy)-hexyl]-benzoylamino}-propionic acid, Isomer 2; 3 -(4- { 1 - [4'-isopropyl-biphenyl-4-ylsulf anyl] -butyl } -benzoylamino)-propionic acid, Isomer 1;
Racemic 3-{4-[l-(2,6-Dimethyl-4 '-trifluoromethoxy-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid; Racemic 3-{4-[l-(2,6-Dimethyl-4 '-trifluoromethyl-biphenyl-4- yloxy)-heptyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(2,6-Dimethyl-4 '-tertbutyl-biphenyl-4- yloxy)-heptyl]- benzoylamino} -propionic acid;
3 - { 4- [ 1 -(4'-tert-Butyl-biphenyl-4-yloxy)-3 -methyl-butyl] -benzoylamino } -2(R)- hydroxy-propionic acid;
3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino}-2(S)- hydroxy-propionic acid;
3-{4-[l-(4'-Pentyl-biphenyl-4-yloxy)-butyl]-benzoylamino}-propionic acid,
Isomer 1 ; 3- { 4-[ 1 -(4'-Isobutyl-biphenyl-4-yloxy)-butyl] -benzoylamino } -propionic acid, Isomer 1;
Racemic 3-{4-[l-(6-chloro-pyridin-3-yloxy)-4 ,4 ,4-trifluoro-butyl]- benzoylamino} -propionic acid;
3- { 4-[ l-(4'-Acetyl-biphenyl-4-yloxy)-butyl]-benzoylamino } -propionic acid, Isomer 1;
3 - { 4- [ 1 -(3 ' , 5 ' -dichloro-biphenyl-4-yloxy)-butyl] -benzoylamino } -propionic acid,
Isomer 1;
3 - { 4-[ 1 -(3 ' , 5 ' -dichloro-biphenyl-4-yloxy)-butyl]-benzoylamino } -propionic acid,
Isomer 2; 3-{4-[l-(2', 3', 4' -trifluoro-biphenyl-4-yloxy)-butyl]-benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(2', 4'-dimethoxy-biphenyl-4-yloxy)-butyl]-benzoylamino}-propionic acid, Isomer 1 ;
3-{4-[l-(4' -t-butyl-biphenyl-4-yloxy)-hexyl] -benzoylamino } -propionic acid, Isomer 1;
3 - { 4- [ 1 -(4' -t-butyl-biphenyl-4-yloxy)-hexyl] -benzoylamino } -propionic acid,
Isomer 2; 3 - { 4- [ 1 -(4' -pentylphenyl-4-yloxy)-hexyl] -benzoylamino } -propionic acid, Isomer l;
3 - { 4-[ 1 -(4' -pentylphenyl-4-yloxy)-hexyl] -benzoylamino } -propionic acid, Isomer
2; 3-(4-{ l-[4-(l-Methyl-l-phenyl-ethyl)-phenoxy]-heptyl}-benzoylamino)-propionic acid, Isomer 1;
3-(4-{ l-[4-(l-Methyl-l-phenyl-ethyl)-phenoxy]-heptyl}-benzoylamino)-propionic acid, Isomer 2;
3 - { 4- [ 1 -(2 ' , 4 ' , 6 ' -trimethyl-biphenyl-4-yloxy)-heptyl] -benzoylamino } -propionic acid, Isomer 1;
3 - { 4- [ 1 -(4'-Fluoro-2'-methyl-biphenyl-4-yloxy)-heptyl] -benzoylamino } -propionic acid, Isomer 1;
3 - { 4- [ 1 -(4'-Trifluoromethoxy-biphenyl-4-yloxy)-hexyl] -benzoylamino } -propionic acid, Isomer 1; 3- { 4- [ 1 -(4'-Fluoro-biphenyl-4-yloxy)-heptyl] -benzoylamino } -propionic acid,
Isomer 1;
3 - { 4- [Cyclopropyl- (4'-trifluoromethyl-biphenyl-4-yloxy)-methyl] - benzoylamino} -propionic acid, Isomer 1;
3- { 4-[Cyclopropyl-(4'-trifluoromethyl-biphenyl-4-yloxy)-methyl]- benzoylamino} -propionic acid, Isomer 2;
3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-benzoylamino}- propionic acid, Isomer 1;
3- { 4- [ 1 -(4'-tert-Butyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-benzoylamino } - propionic acid, Isomer 2; 3- { 4-[ 1 -(4'-Chloro-biphenyl-4-yloxy)-heptyl] -benzoylamino } -propionic acid,
Isomer 1;
3-{4-[l-(4'-tert-Butyl-2-methyl-biphenyl-4-yloxy)-3-methyl-butyl]-3-fluoro- benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(4'-tert-Butyl-2-methyl-biphenyl-4-yloxy)-3-methyl-butyl]-3-fluoro- benzoylamino} -propionic acid, Isomer 2;
3 - { 4- [ 1 -(4'-tert-Butyl-biphenyl-4-yloxy)-heptyl] -3 -fluoro-benzoylamino } - propionic acid, Isomer 1; 3-{4-[l-(4'-tert-Butyl-biphenyl-4-yloxy)-heptyl]-3-fluoro-benzoylamino}- propionic acid, Isomer 2;
3-{3-Fluoro-4-[l-(2-methyl-4 -trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid, Isomer 1; 3-{3-Fluoro-4-[l-(2-methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid, Isomer 2;
3-{4-[l-(4'-tert-Butyl-biρhenyl-4-yloxy)-3-methyl-butyl]-3-fluoro- benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(4'-tert-Butyl-biρhenyl-4-yloxy)-3-methyl-butyl]-3-fluoro- benzoylamino} -propionic acid, Isomer 2;
3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid, Isomer 1;
3- { 4-[ 1 -(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-heptyl] -benzoylamino } - propionic acid, Isomer 2; 3- {4-[ l-(4'-tert-Butyl-2-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino } - propionic acid, Isomer 1 ;
3 - { 4-[ 1 -(4'-tert-Butyl-2-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino } - propionic acid, Isomer 2;
3 - { 4- [ 1 -(2-Metlιyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl] -benzoylamino } - propionic acid, Isomer 1;
3 - { 4- [ 1 -(2-Methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl] -benzoylamino } - propionic acid, Isomer 2;
3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 1; 3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 2;
3 - {4-[ 1 -(4'-Isopropyl-2-methyl-biphenyl-4-yloxy)-heptyl] -benzoylamino } - propionic acid, Isomer 1;
3 - { 4- [ 1 -(4'-Isopropyl-2-methyl-biphenyl-4-yloxy)-heptyl] -benzoylamino } - propionic acid, Isomer 2;
3-{4-[l-(4'-Fluoro-2-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid, Isomer 1; 3- { 4- [ 1 -(4'-Fluoro-2-methyl-biphenyl-4-yloxy)-heptyl] -benzoylamino } -propionic acid, Isomer 2;
3-{4-[l-(4'-Ethyl-2-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}-propionic acid, Isomer 1; 3 - { 4- [ 1 -(4'-Ethyl-2-methyl-biphenyl-4-yloxy)-heptyl] -benzoylamino } -propionic acid, Isomer 2;
3 - { 4- [ 1 -(2,6-Dimethyl-biphenyl-4-yloxy)-3 -methyl-butyl] -benzoylamino } - propionic acid, Isomer 1;
3- { 4-[ l-(2,6-Dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]-benzoylamino } - propionic acid, Isomer 2;
3-{4-[l-(4'-Ethyl-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 1;
3- { 4- [ 1 -(4'-Ethyl-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl] - benzoylamino} -propionic acid, Isomer 2; 3-{4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 2;
3- { 4-[ 1 -(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-heptyl] - benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid, Isomer 2;
3-{4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-pentyl]- benzoylamino} -propionic acid, Isomer 1; 3-{4-[l-(4'-tert-Butyl-2-trifluoromethyl-biρhenyl-4-yloxy)-pentyl]- benzoylamino} -propionic acid, Isomer 2;
3-{4-[l-(4'-tert-Butyl-2-triflιioromethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino} -propionic acid, Isomer 1;
3-{4-['l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-2-metlιyl-propyl]- benzoylamino} -propionic acid, Isomer 2;
3- { 4- [ 1 -(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl] - benzoylamino} -propionic acid, Isomer 1; 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylamino} -propionic acid, Isomer 2;
3-{4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylamino} -propionic acid, Isomer 1; 3-{4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylamino} -propionic acid, Isomer 2;
3-{4-[l-(2-Cyano-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(2-Cyano-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 2;
3-{4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino} -propionic acid, Isomer 2; 3- { 4-[ 1 -(2-Ethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl] -benzoylamino } - propionic acid, Isomer 1;
3 - { 4- [ 1 -(2-Ethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl] -benzoylamino } - propionic acid, Isomer 2;
3-{4-[l-(4'-Chloro-2,6-dimethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylamino} -propionic acid, Isomer 1;
3 - { 4- [ 1 -(4'-Chloro-2,6-dimethyl-biphenyl-4-yloxy)-4,4-dimethyl-pentyl]- benzoylamino} -propionic acid, Isomer 2;
3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino} -propionic acid, Isomer 1; 3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino} -propionic acid, Isomer 2;
3 - { 4- [2-Methyl- 1 -(2-methyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-propyl] - benzoylamino} -propionic acid, Isomer 1;
3-{4-[2-Methyl-l-(2-methyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-propyl]- benzoylamino } -propionic acid, Isomer 2 ;
3-{4-[l-(2-Chloro-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 1; 3-{4-[l-(2-Chloro-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 2;
3-{4-[l-(2-Chloro-4'-trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 1; 3-{4-[l-(2-Chloro-4'-trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 2;
3-{4-[2-Methyl-l-(2-methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-propyl]- benzoylamino} -propionic acid, Isomer 1;
3- { 4- [2-Methyl- 1 -(2-methyl-4'-trifluoromethyl-biphenyl-4-yloxy)-propyl] - benzoylamino} -propionic acid, Isomer 2;
3-(4-{3-Methyl-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- butyl }-benzoylamino)-propionic acid, Isomer 1;
3-(4-{3-Methyl-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- butyl}-benzoylamino)-propionic acid, Isomer 2; 3-(4- { l-[6-(4-Isopropyl-phenyl)-5-methyl-pyridin-3-yloxy]-3-methyl-butyl }- benzoylamino)-propionic acid, Isomer 1;
3-(4-{ l-[6-(4-Isopropyl-phenyl)-5-methyl-pyridin-3-yloxy]-3-methyl-butyl}- benzoylamino)-propionic acid, Isomer 2;
3 -(3 -Fluoro-4- { 3 -methyl- 1 - [6-(4-trifluoromethyl-phenyl)-pyridin-3 -yloxy] -butyl } - benzoylamino)-propionic acid, Isomer 1;
3-(3-Fluoro-4-{3-methyl-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-butyl}- benzoylamino)-propionic acid, Isomer 2;
3-(4-{3-Metl yl-l-[4-(5-trifluoromethyl-pyridin-2-yl)-phenoxy]-butyl}- benzoylamino)-propionic acid, Isomer 1; 3-(4-{3-Methyl-l-[4-(5-trifluoromethyl-pyridin-2-yl)-phenoxy]-butyl}- benzoylamino)-propionic acid, Isomer 2;
3 - { 4- [ 1 -(4-tert-Butyl-phenoxy)-3 -methyl-butyl] -benzoylamino } -propionic acid,
Isomer 1;
3 - { 4- [ 1 -(4-tert-Butyl-phenoxy)-3 -methyl-butyl] -benzoylamino } -propionic acid, Isomer 2;
2-Hydroxy-3- { 4-[ l-(4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino } - propionic acid, Isomer 1; 2-Hydroxy-3-{4-[l-(4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid, Isomer 2;
2-Hydroxy-3 - { 4- [ 1 -(4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl] -benzoylamino } - propionic acid, Isomer 1; 2-Hydroxy-3 - { 4- [ 1 -(4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl] -benzoylamino } - propionic acid, Isomer 2;
3-(4- { 1 - [4-(l , 1 ,3 ,3 -Tetramethyl-butyl)-phenoxy]-heptyl } -benzoylamino)- propionic acid, Isomer 1;
3 -(4- { 1 - [4-(l , 1 ,3 ,3 -Tetramethyl-butyl)-phenoxy]-heptyl } -benzoylamino)- propionic acid, Isomer 2;
3-{4-[l-(2,2,3,3-Tetrafluoro-2,3-dihydro-benzo[l,4]dioxin-6-yloxy)-heρtyl]- benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(2,2,3,3-Tetrafluoro-2,3-dihydro-benzo[l,4]dioxin-6-yloxy)-heptyl]- benzoylamino} -propionic acid, Isomer 2; 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino} -propionic acid, Isomer 2;
3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino} -propionic acid, Isomer 2;
3-{4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino} -propionic acid, Isomer 1; 3-{4-[l-(4'-Isopropyl-2,6-dimetlιyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino} -propionic acid, Isomer 2;
3-(4-{3,3-Dimethyl-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- butyl}-benzoylamino)-propionic acid, Isomer 1;
3-(4-{3,3-Dimethyl-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- butyl }-benzoylamino)-propionic acid, Isomer 2;
3-{4-[l-(4'-Isopropyl-2-methoxy-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 1; 3 - { 4- [ 1 -(4'-Isopropyl-2-methoxy-biphenyl-4-yloxy)-3 -methyl-butyl] - benzoylamino} -propionic acid, Isomer 2;
3-{4-[l-(4'-Isopropyl-2-methyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 1; 3-{4-[l-(4'-Isopropyl-2-methyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 2;
3-{4-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-3,3-dimethyl- butyl]-benzoylamino}-propionic acid, Isomer 1;
3-{4-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-3,3-dimethyl- butyl] -benzoylamino} -propionic acid, Isomer 2;
3-(4-{ l-[2-(tert-Butoxyimino-methyl)-4'-trifluoromethyl-biphenyl-4-yloxy]-3- methyl-butyl}-benzoylamino)-propionic acid, Isomer 1;
3-(4-{l-[2-(tert-Butoxyimino-methyl)-4'-trifluoromethyl-biphenyl-4-yloxy]-3- methyl-butyl }-benzoylamino)-propionic acid, Isomer 2; 3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino}-2-hydroxy-propionic acid, Isomer 1;
3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino}-2-hydroxy-propionic acid, Isomer 2;
3- { 4- [ 1 -(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3 ,3-dimethyl-butyl] - benzoylamino }-2-hydroxy-propionic acid, Isomer 1;
3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl-butyl]- benzoylamino}-2-hydroxy-propionic acid, Isomer 2;
3-{4-[l-(4'-Fluoro-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 1; 3-{4-[l-(4'-Fluoro-2,6,2'-trimethyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid, Isomer 1;
3-{4-[l-(4'-Chloro-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(2,6-Dimethyl-4,-trifluoromethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 1; 3-{4-[l-(2,6-Dimethyl-4'-trifluoromeιhyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 2;
Racemic 3 - { 4- [ 1 -(4'-tert-Butyl-biphenyl-4-yloxy)-hexyl] -benzoylamino } - propionic acid; Racemic 3-{4-[l-(4 '-tert-Butyl-biphenyl-4- yloxy)-heptyl]-3-fluoro- benzoylamino} -propionic acid;
Racemic 3 - { 4- [ 1 -(4'-tert-Butyl-biphenyl-4-yloxy)-3 -methyl-butyl] -3 -fluoro- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(2-Cyano-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(4 '-Isopropyl-2-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(2-Ethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid; 3-[4-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxymethyl)-benzoylamino]- propionic acid;
3-[4-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxymethyl)-benzoylamino]- propionic acid;
Racemic 3 - { 4- [ 1 -(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-ethyl]- benzoylamino} -propionic acid;
Racemic 3- { 4-[ l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-ethyl]- benzoylamino} -propionic acid;
Racemic 3-(3-Fluoro-4-{3-methyl-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3- yloxy]-butyl } -benzoylamino)-propionic acid; Racemic 3-(4-{ l-[4-(l,l,3,3-Tetramethyl-butyl)-phenoxy]-heptyl}- benzoylamino)-propionic acid;
Racemic 3-(4-{3-Methyl-l-[4-(5-trifluoromethyl-pyridin-2-yl)-phenoxy]-butyl}- benzoylamino)-propionic acid;
Racemic 3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl- butyl] -benzoylamino} -propionic acid;
Racemic 3- { 4-[ l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3 ,3-dimethyl- butyl] -benzoylamino } -2-hydroxy-propionic acid; Racemic 3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3-dimethyl- butyl] -benzoylamino } -2-hydroxy-propionic acid;
Chiral 3-{4-[l-(2,6-Dimethyl-4,-trifluoromethyl-biphenyl-4-yloxy)-3-methyl- butyl] -benzoylamino} -2-hydroxy-propionic acid, Isomer 1; Chiral 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3-methyl- butyl] -benzoylamino} -2-hydroxy-propionic acid, Isomer 1;
Racemic 3-{4-[l-(4-Bromo-3-[l,3]dioxan-2-yl-phenoxy)-3-methyl-butyl]- benzoylamino} -propionic acid;
Racemic 3 - { 4- [ 1 -(4-tert-B utyl-phenoxy)-3 -methyl-butyl] -benzoylamino } - propionic acid;
Racemic 3-{4-[l-(4'-tert-Butyl-biρhenyl-4-yloxy)-3-methyl-butyl]- benzoylamino } -2-hydroxy-propionic acid;
Racemic 3-{4-[l-(4'-tert-Butyl-biρhenyl-4-yloxy)-3-methyl-butyl]- benzoylamino } -2-hydroxy-propionic acid; Racemic 3-{4-[l-(4-Pentyl-phenoxy)-heptyl]-benzoylamino}-propionic acid;
Racemic 3 -(4- { 1 - [4-( 1 -Methyl- 1 -phenyl-ethyl)-phenoxy] -heptyl } -benzoylamino)- propionic acid;
Racemic 2-Hydroxy-3- { 4-[ 1 -(4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl] - benzoylamino} -propionic acid; Racemic 2-Hydroxy-3 - { 4- [ 1 -(4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl] - benzoylamino} -propionic acid;
Racemic 3-{4-[l-(4'-Isopropyl-2-methyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(4-Chloro-3-trifluoromethyl-phenoxy)-heptyl]-benzoylamino}- 2-hydroxy-propionic acid;
Racemic 3-{4-[l-(3-Chloro-4-methyl-phenoxy)-3-methyl-butyl]-benzoylamino}- propionic acid;
Racemic 3-{4-[l-(2,2,3,3-Tetrafluoro-2,3-dihydro-benzo[l,4]dioxin-6-yloxy)- heptyl] -benzoylamino } -propionic acid; Racemic 3- { 4-[Cyclopropyl-(4'-trifluoromethyl-biphenyl-4-yloxy)-methyl]- benzoylamino} -propionic acid; Racemic 3-{4-[l-(4'-Isoρroρyl-2,6-dimethyl-biρhenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(4'-Acetyl-2,6-dimethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid; Racemic 3-{4-[l-(4'-tert-Butyl-2-methyl-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid;
Racemic 3 - { 4- [ 1 -(2-Methyl-4'-trifluorόmethyl-biphenyl-4-yloxy)-heptyl] - benzoylamino} -propionic acid;
Racemic 3-(4-{ l-[6-(4-Isopropyl-phenyl)-5-methyl-pyridin-3-yloxy]-4,4- dimethyl-pentyl}-benzoylamino)-propionic acid;
Racemic 3-(4-{4,4-Dimethyl-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3- yloxy]-pentyl } -benzoylamino)-propionic acid;
Racemic 3-(4- {4,4-Dimethyl- l-[5-methyl-6-(4-trifluoromethoxy-phenyl)-pyridin-
3 -yloxy] -pentyl } -benzoylamino)-propionic acid; Racemic 3 - { 4- [ 1 -(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-3 ,3 - dimethyl-butyl] -benzoylamino } -propionic acid;
Racemic 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3,3- dimethyl-butyl] -benzoylamino } -2-hydroxy-propionic acid;
Racemic 3 - { 4-[ 1 -(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3 ,3 - dimethyl-butyl] -benzoylamino } -2-hydroxy-propionic acid;
Racemic 2-Hydroxy-3-{4-[l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-3,3- dimethyl-butyl] -benzoylamino } -propionic acid;
Racemic 3-{4-[l-(4'-Isopropyl-2 -methoxy-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid; Racemic 3- { 3-Fluoro-4-[ l-(2-methyl-4'-trifluoromethyl-biphenyl-4-yloxy)- heptyl]-benzoylamino}-propionic acid;
Racemic 3-{4-[l-(4'-tert-Butyl-2-chloro-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(4'-trifluoromethyl-2-chloro-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(2', 4'-bistrifluoromethyl-2-chloro-biphenyl-4- yloxy)-heptyl]- benzoylamino} -propionic acid; Racemic 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3-methyl- butyl] -benzoylamino} -propionic acid;
Racemic 3-{4-[l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid; Racemic 3-{4-[l-(2-Hydroxy-4'-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(2-[l,3]Dioxan-2-yl-4'-isopropyl-biphenyl-4-yloxy)-3-methyl- butyl]-benzoylamino}-propionic acid;
Racemic 3-(4- { l-[2-(tert-Butoxyimino-methyl)-4'-isopropyl-biphenyl-4-yloxy]-3- methyl-butyl }-benzoylamino)-propionic acid;
Racemic 3-(4-{ l-[2-(tert-Butoxyimino-metlιyl)-4'-trifluoromethyl-biphenyl-4- yloxy]-3-methyl-butyl}-benzoylamino)-propionic acid;
Racemic 3-{4-[l-(2,6-Dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid; Racemic 3-{4-[l-(4'-Ethyl-2,6-dimethyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(2-Methyl-4 '-trifluoromethoxy-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(4'-Isopropyl-2-methyl-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-3-methyl- butyl] -benzoylamino } -propionic acid;
Racemic 3 - { 4- [ 1 -(4'-ethyl-2-methyl-biphenyl-4-yloxy)-heptyl] -benzoylamino } - propionic acid; Racemic 3- { 4-[ l-(4'-acetyl-2-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino } - propionic acid;
Racemic 3-{4-[l-(4'-fluoro-2-methyl-biphenyl-4-yloxy)-heptyl]-benzoylamino}- propionic acid;
Racemic 3-{4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino } -propionic acid;
Racemic 3-{4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-ρentyl]- benzoylamino} -propionic acid; Racemic 3-{4-[l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-2-methyl- propyl] -benzoylamino } -propionic acid;
Racemic 3- { 4-[ l-(4'-tert-Butyl-2-trifluoromethyl-biphenyl-4-yloxy)-3-methyl- butyl] -benzoylamino } -propionic acid; Racemic 3-{4-[l-(3,5-Dimethyl-4l-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(4'-Chloro-3,5-dimethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid;
Racemic 3- { 4- [ 1 -(4'-Chloro-3-methyl-biphenyl-4-yloxy)-heptyl] -benzoylamino } - propionic acid;
Racemic 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-3,3- dimethyl-butyl]-benzoylamino }-propionic acid;
Racemic 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4 ,4- dimethyl-pentyl] -benzoylamino } -propionic acid; Racemic 3- { 4- [ 1 -(2,6-Dimethyl-4'-isopropyl-biphenyl-4-yloxy)-4,4-dimethyl- pentyl] -benzoylamino } -propionic acid;
Racemic 3-{4-[l-(4'-Isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-methyl- propyl] -benzoylamino} -propionic acid;
Racemic 3-{4-[2-Methyl-l-(2-methyl-4'-trifluoromethyl-biphenyl-4-yloxy)- propyl] -benzoylamino } -propionic acid;
Racemic 3-{4-[l-(2,6-Dimethyl-4 '-chloro-biphenyl-4-yloxy)-4 ,4-dimethyl- pentyl] -benzoylamino } -propionic acid; Racemic 3- { 4-[ l-(4'-tert-Butyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino} -propionic acid;
Racemic 3- { 4-[ l-(4'-Isoproρyl-2-methyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(2,6-Difluoro-4'-trifluoromethyl-biphenyl-4-yloxy)-3-methyl- butyl] -benzoylamino} -propionic acid;
Racemic 3-{4-[l-(2,6-Difluoro-4'-isopropyl-biphenyl-4- yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid; Racemic 3-{4-[l-(2-Chloro-4 '-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid;
Racemic 3- { 4- [ 1 -(2-Chloro-4'-trifluoiOmethyl-biphenyl-4-yloxy)-3 -methyl-butyl] - benzoylamino} -propionic acid; Racemic 3-(4-{3-Methyl-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3- yloxy]-butyl } -benzoylamino)-propionic acid;
Racemic 3-(4-{ l-[6-(4-Isopropyl-phenyl)-5-methyl-pyridin-3-yloxy]-3-methyl- butyl } -benzoylamino)-propionic acid;
Racemic 3-{4-[l-(4'-tert-Butyl-biphenyl-3-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[3-Methyl-l-(4 '-trifluoromethyl-biphenyl-3-yloxy)-butyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(4'-Isopropyl-biphenyl-3-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid; Racemic 3-{4-[3-Methyl-l-(4 '-trifluoromethoxy-biphenyl-3-yloxy)-butyl]- benzoylamino} -propionic acid;
Racemic 3- { 4- [3-Methyl- 1 -(6-methyl-4'-trifluoromethyl-biphenyl-3 -yloxy)- butyl] -benzoylamino } -propionic acid;
Racemic 3-{4-[l-(4'-tert-Butyl-6-methyl-biphenyl-3-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(2 -Hydroxymethyl-4'-isopropyl-biphenyl-4-yloxy)-3-methyl- butyl] -benzoylamino} -propionic acid;
Racemic 3-{4-[l-(2-Formyl-4 '-isopropyl-biphenyl-4-yloxy)-3-methyl-butyl]- benzoylamino} -propionic acid; Racemic 3-(4-{ l-[2-(Hydroxyimino-methyl)-4'-isopropyl-biphenyl-4-yloxy]-3- methyl-butyl } -benzoylamino)-propionic acid;
Racemic 3-{4-[l-(4'-Isopropyl-2-morpholin-4-ylmethyl-biphenyl-4-yloxy)-3- methyl-butyl] -benzoylamino } -propionic acid;
3 -(4- { 3 ,3 -Dimethyl- 1 - [5-methyl- 1 -oxy-6-(4-trifluoromethoxy-phenyl)-pyridin-3 - yloxy]-butyl}-benzoylamino)-propionic acid;
2-Hydroxy-3-{4-[l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl- propyl]-benzoylamino}-propionic acid, Isomer 1; 2-Hydroxy-3-{4-[l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl- propyl]-benzoylamino}-propionic acid, Isomer 2;
2-Hydroxy-3-{4-[l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl- propyl]-benzoylamino} -propionic acid, Isomer 1; 2-Hydroxy-3-{4-[l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-2-methyl- propyl] -benzoylamino} -propionic acid, Isomer 2;
3 - { 4- [ 1 -(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl] - benzoylamino} -2-hydroxy-propionic acid, Isomer 1;
3 - { 4-[ 1 -(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl] - benzoylamino} -2-hydroxy-propionic acid, Isomer 2;
3-{4-[l-(2,6-Dimethyl-4'-trifluorometliyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino} -2-hydroxy-propionic acid, Isomer 1;
3 - { 4-[ 1 -(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl] - benzoylamino} -2-hydroxy-propionic acid, Isomer 2; Racemic 3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-5,5,5- trifluoro-pentyl] -benzoylamino } -propionic acid;
Racemic 3 - { 4-[ 1 -(2,4,6-tri-t-butyl-phenoxy)-5,5,5-trifluoro-pentyl] - benzoylamino} -propionic acid;
3-(4-{5,5,5-trifluoro-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- pentyl }-benzoylamino)-propionic acid, Isomer 1;
3-(4-{5,5,5-trifluoro-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- pentyl }-benzoylamino)-propionic acid, Isomer 2;
Racemic 3- { 4- [ 1 -(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulf anyl)-5 ,5,5- trifluoro-pentyl]-benzoylamino } -propionic acid; Racemic 3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-5,5,5- trifluoro-pentyl] -benzoylamino } -propionic acid;
Racemic 3-{4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-5,5,5-trifluoro-pentyl]- benzoylamino} -propionic acid;
Racemic 3-(4-{5,5,5-trifluoro-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin- 3 -yloxy] -pentyl } -benzoylamino)-propionic acid;
Racemic 3-(4-{4,4 ,4-trifluoro-l-[5-methyl-6-(4-trifluoromethyl-phenyl)-pyridin-
3-yloxy]-butyl}-benzoylamino)-propionic acid; 3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 2; 3- { 4- [ 1 -(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-3 -methyl-butyl] - benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-3-methyl-butyl]- benzoylamino} -propionic acid, Isomer 2;
3 - { 4- [ 1 -(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulf anyl)-4,4,4-trifluoro-butyl]- benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulfanyl)-4,4,4-trifluoro-butyl]- benzoylamino} -propionic acid, Isomer 2;
3-{4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-4,4,4-trifluoro-butyl]- benzoylamino} -propionic acid, Isomer 1; 3- { 4- [ 1 -(4-bromo-3 ,5-dimethyl-phenylsulf anyl)-4,4,4-trifluoro-butyl] - benzoylamino} -propionic acid, Isomer 2;
3-{4-[l-(4-bromo-3,5-dimethyl-phenylsulfanyl)-3-methyl-butyl]-benzoylamino}- propionic acid, Isomer 1;
3- { 4- [ 1 -(4-bromo-3 ,5-dimethyl-phenylsulf anyl)-3 -methyl-butyl] -benzoylamino } - propionic acid, Isomer 2;
3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-5,5,5-trifluoro- pentyl] -benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-5,5,5-trifluoro- pentyl] -benzoylamino} -propionic acid, Isomer 2; 3 - { 4- [4,4,4-trifluoro- l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-butyl] - benzoylamino} -propionic acid, Isomer 1;
3-{4-[4,4,4-trifluoro-l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-butyl]- benzoylamino} -propionic acid, Isomer 2;
Racemic 3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-ylsulfanyl)-4,4,4- trifluoro-butyl] -benzoylamino} -propionic acid;
Racemic 3- { 4- [ 1 -(4'-tert-butyl-2,6-dimethyl-biphenyl-4-ylsulf anyl)-4,4,4- trifluoro-butyl]-benzoylamino } -propionic acid; Racemic 3-{4-[l-(4'-tert-butyl-2,6-dimetlιyl-biphenyl-4-ylsulfanyl)-3-methyl- butyl] -benzoylamino } -propionic acid;
Racemic 3-{4-[l-(4-bromo-3 ,5-dimethyl-phenylsulf anyl)-4,4,4-trifluoro-butyl]- benzoylamino} -propionic acid; Racemic 3-{4-[l-(4-bromo-3 ,5-dimethyl-phenylsulfanyl)-3-methyl-butyl]- benzoylamino} -propionic acid;
3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-heptyl]- benzoylamino } -propionic acid, Isomer 2 ;
3-{4-[3-methyl-l-(2,2',4'-trichloro-biphenyl-4-yloxy)-butyl]-benzoylamino}- propionic acid, Isomer 1;
3-{4-[3-methyl-l-(2,2',4'-trichloro-biphenyl-4-yloxy)-butyl]-benzoylamino}- propionic acid, isomer 2; 3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]- benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]- benzoylamino} -propionic acid, Isomer 2;
3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]- benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]- benzoylamino} -propionic acid, Isomer 2;
3-{4-[5,5,5-trifluoro-l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-pentyl]- benzoylamino} -propionic acid, Isomer 1; 3-{4-[5,5,5-trifluoro-l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-pentyl]- benzoylamino} -propionic acid, Isomer 2;
Racemic 3-{4-[5,5,5-trifluoro-l-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)- pentyl] -benzoylamino } -propionic acid;
3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-5-methyl-hexyl]- benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-5-methyl-hexyl]- benzoylamino} -propionic acid, Isomer 2; 3-{4-[5-methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-hexyl]-benzoylamino}- propionic acid, Isomer 1;
3-{4-[5-methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-hexyl]-benzoylamino}- propionic acid, Isomer 2; 3-(4-{l-[6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-5-methyl-hexyl}- benzoylamino)-propionic acid, Isomer 1;
3-(4-{l-[6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-5-methyl-hexyl}- benzoylamino)-propionic acid, Isomer 2;
Racemic 3-(4-{5-methyl-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- hexyl }-benzoylamino)-propionic acid;
Racemic 3 - { 4- [ 1 -(6-chloro-pyridin-3-yloxy)-5-methyl-hexyl]-benzoylamino } - propionic acid;
Racemic 3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-bipheήyl-4-yloxy)-5-methyl- hexyl] -benzoylamino } -propionic acid; Racemic 3-(4-{ l-[6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-5-methyl-hexyl}- benzoylamino)-propionic acid;
Racemic 3-{4-[5-methyl-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-hexyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(4'-tert-butyl-biphenyl-4-yloxy)-5-methyl-hexyl]- benzoylamino} -propionic acid;
3-(4-{ l-[6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-5,5,5-trifluoro-pentyl}- benzoylamino)-propionic acid, Isomer 1;
3-(4- { l-[6-(4-tert-butyl-phenyl)-pyf idin-3-yloxy]-5,5,5-trifluoro-pentyl } - benzoylamino)-propionic acid, Isomer 2; 3-(4-{ l-[6-(4-tert-butyl-phenyl)-ρyridin-3-yloxy]-4,4,4-trifluoro-butyl}- benzoylamino)-propionic acid, Isomer 1;
3-(4-{ l-[6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-4,4,4-trifluoro-butyl}- benzoylamino)-propionic acid, Isomer 2;
Racemic 3-{4-[(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-cyclohexyl-methyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro- butyl]-benzoylamino}-propionic acid; 3-{4-[4,4,4-trifluoro-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]- benzoylamino} -propionic acid, Isomer 1;
3-{4-[4,4,4-trifluoro-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-butyl]- benzoylamino} -propionic acid, Isomer 2; Racemic 3 -(4- {4,4,4-trifluoro- 1 - [6-(4-isopropyl-phenyl)-pyridin-3 -yloxy] -butyl } - benzoylamino)-propionic acid;
Racemic 3-(4-{5,5,5-trifluoro-l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]- pentyl}-benzoylamino)-propionic acid;
Racemic 3-(4-{[6-(4-tert-butyl-phenyl)-pyridin-3-yloxy]-cyclohexyl-methyl}- benzoylamino)-propionic acid;
Racemic 3-(4-{5,5,5-trifluoro-l-[6-(4-isopropyl-phenyl)-pyridin-3-yloxy]- pentyl } -benzoylamino)-propionic acid;
Racemic 3-{4-[l-(2,6-dimethyl-4 '-trifluoromethyl-biphenyl-4-yloxy)-4,4,4- trifluoro-butyl]-benzoylamino}-propionic acid; Racemic 3-(4-{cyclohexyl-[6-(4-isopropyl-phenyl)-pyridin-3-yloxy]-methyl}- benzoylamino)-propionic acid;
Racemic 3-{4-[cyclohexyl-(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)-methyl]- benzoylamino} -propionic acid;
Racemic 3 -{ 4-[4,4,4-trifluoro- 1 -(4'-isopropyl-2,6-dimethyl-biphenyl-4-yloxy)- butyl] -benzoylamino} -propionic acid;
3-{4-[cyclohexyl-(4'-trifluoromethyl-biphenyl-4-yloxy)-methyl]-benzoylamino}- propionic acid, Isomer 1;
3-{4-[cyclohexyl-(4'-trifluoromethyl-biphenyl-4-yloxy)-methyl]-benzoylamino}- propionic acid, Isomer 2; 3-{4-[5,5,5-trifluoro-l-(4'-isopropyl-biphenyl-4-yloxy)-pentyl]-benzoylamino}- propionic acid, Isomer 1;
3-{4-[5,5,5-trifluoro-l-(4'-isopropyl-biphenyl-4-yloxy)-pentyl]-benzoylamino}- propionic acid, Isomer 2;
Racemic 3-{4-[(4'-tert-butyl-biphenyl-4-yloxy)-cyclohexyl-methyl]- benzoylamino } -propionic acid;
Racemic 3-{4-[5,5,5-trifluoro-l-(2,-3'-fluoro-4'-trifluoromethyl-biphenyl-4- yloxy)-pentyl]-benzoylamino } -propionic acid; Racemic 3-{4-[cyclohexyl-(4'-trifluoromethyl-biphenyl-4-yloxy)-methyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[5,5,5-trifluoro-l-(4'-isopropyl-biphenyl-4-yloxy)-pentyl]- benzoylamino} -propionic acid; Racemic 3-{4-[l-(4'-ethyl-biphenyl-4-yloxy)-5,5,5-trifluoro-pentyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[5,5,5-trifluoro-l-(3'-fluoro-4'-trifluoromethyl-biphenyl-4-yloxy)- pentyl]-benzoylamino}-propionic acid;
Racemic 3-{4-[l-(2,4,6-triisopropyl-phenoxy)-5,5,5-trifluoro-pentyl]- benzoylamino } -propionic acid;
Racemic 3-{4-[l-(2,3,4,5,6-pentamethyl-phenoxy)-5,5,5-trifluoro-pentyl]- benzoylamino } -propionic acid;
Racemic 3-{4-[l-(2,4,6-tri-t-butyl-phenoxy)-5,5,5-trifluoro-pentyl]- benzoylamino} -propionic acid; Racemic 3-{4-[l-(3,5-dimethyl-phenoxy)-5,5,5-trifluoro-pentyl]-benzoylamino}- propionic acid;
3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-5,5,5-trifluoro-pentyl]- benzoylamino} -propionic acid, Isomer 1;
3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-5,5,5-trifluoro-pentyl]- benzoylamino} -propionic acid, isomer 2;
Racemic 3-{4-[l-(4-ethyl-3, 5-dimethyl-phenoxy)-5,5,5-trifluoro-pentyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-5,5,5- trifluoro-pentyl] -benzoylamino } -propionic acid; Racemic 3-(4-{ l-[4-(4-methyl-pentyloxy)-phenoxy]-heptyl}-benzoylamino)- propionic acid;
Racemic 3 - { 4- [ 1 -(4-pentyloxy-phenoxy)-heptyl] -benzoylamino } -propionic acid;
3-{4-[5,5,5-trifluoro-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-pentyl]- benzoylamino} -propionic acid, Isomer 1; 3-{4-[5,5,5-trifluoro-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-pentyl]- benzoylamino} -propionic acid, Isomer 2; Racemic 3-{4-[l-(4'-tert-butyl-2,6-dimethyl-biphenyl-4- yloxy)-5,5,5-trifluoro- pentyl]-benzoylamino} -propionic acid;
Racemic 3-{4-[l-(4-bromo-3,5-dimethyl-phenoxy)-5,5,5-trifluoro-pentyl]- benzoylamino} -propionic acid; 3-{4-[l-(4'-tert-butyl-biphenyl-4-yloxy)-5,5,5-trifluoro-ρentyl]-benzoylamino}- propionic acid, Isomer 1;
3-{4-[l-(4'-tert-butyl-biphenyl-4-yloxy)-5,5,5-trifluoro-pentyl]-benzoylamino}- propionic acid, Isomer 2;
3 -(4- { 1 - [6-(4-trifluoromethyl-phenyl)-pyridin-3 -yloxy] -hexyl } -benzoylamino)- propionic acid, Isomer 1;
3-(4- { l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-hexyl }-benzoylamino)- propionic acid, Isomer 2;
3-(4-{ l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-pentyl}-benzoylamino)- propionic acid, Isomer 1; 3-(4-{ l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-pentyl}-benzoylamino)- propionic acid, Isomer 2;
Racemic 3-{4-[5,5,5-trifluoro-l-(4'-trifluoromethyl-biphenyl-4-yloxy)-pentyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(4'-tert-butyl-biphenyl-4-yloxy)-5,5,5-trifluoro-pentyl]- benzoylamino} -propionic acid;
Racemic 3-{4-[l-(4-bromo-phenoxy)-5,5,5-trifluoro-pentyl]-benzoylamino}- propionic acid;
Racemic 3-{4-[l-(4-hydroxy-phenoxy)-heptyl]-benzoylamino}-propionic acid; Racemic 3-(4-{ l-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-pentyl}- benzoylamino)-propionic acid;
3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino} -propionic acid, isomer 1;
3-{4-[l-(2,6-Dimethyl-4'-trifluoromethyl-biphenyl-4-yloxy)-2-methyl-propyl]- benzoylamino} -propionic acid, isomer 1;
3-{4-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid, isomer 1; and 3-{4-[l-(2,6-Dimethyl-4'-trifluoromethoxy-biphenyl-4-yloxy)-heptyl]- benzoylamino} -propionic acid, isomer 1, or a pharmaceutically acceptable salt thereof.
16. A pharmaceutical composition which comprises a compound of any of claims 1- 15 and a pharmaceutically acceptable canier.
17. A method of inhibiting the glucagon receptor in a mammal comprising administering to a mammal in need thereof a glucagon receptor inhibiting dose of a compound of formula I, or a salt thereof, as described in claim 1.
18. A method of selectively reducing the glycemic level in a mammal comprising administering to a mammal in need thereof a glucagon receptor inhibiting dose of a compound of formula I, or a salt thereof, as described in claim 1.
19. A method for treatment of a diabetic or other glucagon related metabolic disorder which comprises administering to a mammal in need of such treatment or prevention an effective amount of a compound of any of claims 1-15.
20. A method for treatment of a diabetic or other glucagon related metabolic disorder which comprises administering to a mammal in need of such treatment or prevention an effective amount of a pharmaceutical composition of claim 16.
21. A method for treatment of a disorder or disease in which inhibition of the glucagon receptor has a beneficial effect which comprises administering to a subject in need of such treatment an effective amount of a compound of any of claims 1-15.
22. A method for treatment or prevention of a disorder or disease in which inhibition of the glucagon receptor has a beneficial effect which comprises administering to a subject in need of such treatment or prevention an effective amount of a pharmaceutical composition of claim 16.
23. A compound of formula I, or a salt thereof, as claimed in any one of claims 1-15, for use in treating a diabetic or other glucagon related metabolic disorder.
24. The use of a compound of formula I, or a salt thereof, as claimed in any one of claims 1-15, for the manufacture of a medicament for treatment of a diabetic or other glucagon related metabolic disorder.
PCT/US2005/019901 2004-06-14 2005-06-08 Glucagon receptor antagonists, preparation and therapeutic uses WO2005123668A1 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
NZ551015A NZ551015A (en) 2004-06-14 2005-06-08 Glucagon receptor antagonists, preparation and therapeutic uses
EA200700027A EA013003B1 (en) 2004-06-14 2005-06-08 Glucagon receptor antagonists, preparation and therapeutic uses
PL05757998T PL1758853T3 (en) 2004-06-14 2005-06-08 Glucagon receptor antagonists, preparation and therapeutic uses
CN2005800194966A CN1968921B (en) 2004-06-14 2005-06-08 Glucagon receptor antagonists, preparation and therapeutic uses
CA2569459A CA2569459C (en) 2004-06-14 2005-06-08 Glucagon receptor antagonists, preparation and therapeutic uses
RSP-2010/0134A RS51202B (en) 2004-06-14 2005-06-08 Glucagon receptor antagonists, preparation and therapeutic uses
US11/570,449 US7816557B2 (en) 2004-06-14 2005-06-08 Glucagon receptor antagonists, preparation and therapeutic uses
JP2007516542A JP5000492B2 (en) 2004-06-14 2005-06-08 Glucagon receptor antagonist, its preparation and therapeutic use
DE602005019043T DE602005019043D1 (en) 2004-06-14 2005-06-08 Glucagonone receptor agonists, their preparation and their therapeutic use
EP05757998A EP1758853B1 (en) 2004-06-14 2005-06-08 Glucagon receptor antagonists, preparation and therapeutic uses
MXPA06014426A MXPA06014426A (en) 2004-06-14 2005-06-08 Glucagon receptor antagonists, preparation and therapeutic uses.
DK05757998.9T DK1758853T3 (en) 2004-06-14 2005-06-08 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses
AT05757998T ATE455756T1 (en) 2004-06-14 2005-06-08 GLUCAGON RECEPTOR ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE
BRPI0512058-6A BRPI0512058A (en) 2004-06-14 2005-06-08 compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and use of a compound
AU2005254950A AU2005254950B2 (en) 2004-06-14 2005-06-08 Glucagon receptor antagonists, preparation and therapeutic uses
IL179599A IL179599A (en) 2004-06-14 2006-11-27 Glucagon receptor antagonists, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments for treating diabetic or other glucagon related metabolic disorders
NO20070213A NO341028B1 (en) 2004-06-14 2007-01-12 Glucagon Receptor Antagonists, Pharmaceutical Compositions and Therapeutic Uses
HK07108943.4A HK1104174A1 (en) 2004-06-14 2007-08-16 Glucagon receptor antagonists, preparation and therapeutic uses
HR20100148T HRP20100148T1 (en) 2004-06-14 2010-03-15 Glucagon receptor antagonists, preparation and therapeutic uses
US12/868,773 US20100324140A1 (en) 2004-06-14 2010-08-26 Glucagon receptor antagonists, preparation and therapeutic uses
AU2010246329A AU2010246329A1 (en) 2004-06-14 2010-11-19 Glucagon receptor antagonists, preparation and therapeutic uses
US13/013,280 US8609892B2 (en) 2004-06-14 2011-01-25 Glucagon receptor antagonists, preparation and therapeutic uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57936204P 2004-06-14 2004-06-14
US60/579,362 2004-06-14

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/570,449 A-371-Of-International US7816557B2 (en) 2004-06-14 2005-06-08 Glucagon receptor antagonists, preparation and therapeutic uses
US12/868,773 Continuation US20100324140A1 (en) 2004-06-14 2010-08-26 Glucagon receptor antagonists, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
WO2005123668A1 true WO2005123668A1 (en) 2005-12-29

Family

ID=35219490

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/019901 WO2005123668A1 (en) 2004-06-14 2005-06-08 Glucagon receptor antagonists, preparation and therapeutic uses

Country Status (29)

Country Link
US (3) US7816557B2 (en)
EP (2) EP1758853B1 (en)
JP (1) JP5000492B2 (en)
KR (1) KR100835496B1 (en)
CN (1) CN1968921B (en)
AT (1) ATE455756T1 (en)
AU (2) AU2005254950B2 (en)
BR (1) BRPI0512058A (en)
CA (1) CA2569459C (en)
CY (1) CY1109787T1 (en)
DE (1) DE602005019043D1 (en)
DK (1) DK1758853T3 (en)
EA (1) EA013003B1 (en)
EC (1) ECSP067082A (en)
ES (1) ES2337596T3 (en)
HK (1) HK1104174A1 (en)
HR (1) HRP20100148T1 (en)
IL (1) IL179599A (en)
MA (1) MA28706B1 (en)
MX (1) MXPA06014426A (en)
NO (1) NO341028B1 (en)
NZ (1) NZ551015A (en)
PL (1) PL1758853T3 (en)
PT (1) PT1758853E (en)
RS (1) RS51202B (en)
SI (1) SI1758853T1 (en)
UA (1) UA86621C2 (en)
WO (1) WO2005123668A1 (en)
ZA (1) ZA200610298B (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006058648A2 (en) * 2004-12-03 2006-06-08 F. Hoffmann-La Roche Ag Biaryloxymethylarene carboxylic acids
WO2006086488A2 (en) * 2005-02-11 2006-08-17 Eli Lilly And Company Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
WO2007120270A3 (en) * 2005-11-22 2008-02-28 Lilly Co Eli Glucagon receptor antagonists, preparation and therapeutic uses
WO2011058154A1 (en) * 2009-11-16 2011-05-19 F. Hoffmann-La Roche Ag Biphenyl carboxylic acids and bioisosteres as glycogen synthase activators
WO2012085745A1 (en) 2010-12-23 2012-06-28 Pfizer Inc. Glucagon receptor modulators
WO2012107850A1 (en) 2011-02-08 2012-08-16 Pfizer Inc. Glucagon receptor modulator
WO2013014569A1 (en) 2011-07-22 2013-01-31 Pfizer Inc. Quinolinyl glucagon receptor modulators
WO2013081993A1 (en) 2011-12-02 2013-06-06 Eli Lilly And Company Anti-glucagon antibodies and uses thereof
US8710236B2 (en) 2007-02-09 2014-04-29 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
EP2799428A2 (en) 2008-08-13 2014-11-05 Metabasis Therapeutics, Inc. Glucagon antagonists
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2017093120A1 (en) 2015-12-01 2017-06-08 Basf Se Pyridine compounds as fungicides
WO2017093167A1 (en) 2015-12-01 2017-06-08 Basf Se Pyridine compounds as fungicides
US10076504B2 (en) 2014-06-12 2018-09-18 Ligand Pharmaceuticals, Inc. Glucagon antagonists
WO2018219725A1 (en) 2017-05-30 2018-12-06 Basf Se Pyridine and pyrazine compounds
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA86621C2 (en) * 2004-06-14 2009-05-12 Эли Лилли Энд Компани Glucagon receptor antagonists, preparation and therapeutic uses
AU2006227435A1 (en) * 2005-03-21 2006-09-28 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives
US7935713B2 (en) 2006-05-16 2011-05-03 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010098948A1 (en) * 2009-02-13 2010-09-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containin such compounds and methods of use
US20140210770A1 (en) * 2012-10-04 2014-07-31 Corning Incorporated Pressure sensing touch systems and methods
TW201427658A (en) * 2012-12-10 2014-07-16 Merck Sharp & Dohme Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor
CN111184706B (en) * 2020-03-05 2020-11-17 牡丹江医学院 Active medicine for preventing and treating cholecystitis and application thereof
KR102606541B1 (en) * 2021-04-23 2023-11-29 가천대학교 산학협력단 Biphenylsulfonamide derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating glucagon Receptor activity related diseases containing the same as an active ingredient

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048109A1 (en) * 2001-12-03 2003-06-12 Novo Nordisk A/S Novel glucagon antagonists
WO2004002480A1 (en) * 2002-06-27 2004-01-08 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973731A (en) 1987-04-23 1990-11-27 Riker Laboratories, Inc. Di-t-butylphenyl alkyl and benzyl ether nitriles
GB9420557D0 (en) * 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
EP1054871A2 (en) * 1998-04-01 2000-11-29 Du Pont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
MXPA01011757A (en) * 1999-05-17 2002-06-04 Novo Nordisk As Glucagon antagonists/inverse agonists.
EP1296942A1 (en) * 2000-06-23 2003-04-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6706744B2 (en) * 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU2003291959A1 (en) 2002-12-20 2004-07-14 Novo Nordisk A/S Novel glucagon antagonists
US20080254182A1 (en) 2004-04-26 2008-10-16 Laurens Last Packaged Flowable Ice Product, Such as a Milk Shake
EP1758859B1 (en) * 2004-05-28 2013-07-17 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
UA86621C2 (en) * 2004-06-14 2009-05-12 Эли Лилли Энд Компани Glucagon receptor antagonists, preparation and therapeutic uses
ES2332470T3 (en) * 2005-02-11 2010-02-05 Eli Lilly And Company THIOPHEN DERIVATIVES REPLACED AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES.
AU2006227435A1 (en) 2005-03-21 2006-09-28 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives
WO2007106181A2 (en) * 2005-11-17 2007-09-20 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
PT1951658E (en) * 2005-11-17 2012-11-12 Lilly Co Eli Glucagon receptor antagonists, preparation and therapeutic uses
WO2007114855A2 (en) * 2005-11-18 2007-10-11 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
BRPI0618140A2 (en) * 2005-11-22 2011-08-16 Lilly Co Eli pharmaceutically acceptable compound or salt thereof, pharmaceutical composition, and use of a compound or salt thereof
WO2007120284A2 (en) * 2005-11-23 2007-10-25 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048109A1 (en) * 2001-12-03 2003-06-12 Novo Nordisk A/S Novel glucagon antagonists
WO2004002480A1 (en) * 2002-06-27 2004-01-08 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KURUKULASURIYA ET AL: "Biaryl amide glucagon receptor antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 14, no. 9, 2004, pages 2047 - 2050, XP002339903, ISSN: 0960-894X *

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006058648A3 (en) * 2004-12-03 2006-12-28 Hoffmann La Roche Biaryloxymethylarene carboxylic acids
WO2006058648A2 (en) * 2004-12-03 2006-06-08 F. Hoffmann-La Roche Ag Biaryloxymethylarene carboxylic acids
US7524870B2 (en) 2004-12-03 2009-04-28 Hoffmann-La Roche Inc. Biaryloxymethylarenecarboxylic acids as glycogen synthase activators
US8084489B2 (en) 2005-02-11 2011-12-27 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
WO2006086488A2 (en) * 2005-02-11 2006-08-17 Eli Lilly And Company Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
WO2006086488A3 (en) * 2005-02-11 2006-12-14 Lilly Co Eli Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
JP2008530102A (en) * 2005-02-11 2008-08-07 イーライ リリー アンド カンパニー Substituted thiophene derivatives as glucagon receptor antagonists, their preparation and therapeutic use
US8691856B2 (en) * 2005-11-22 2014-04-08 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
WO2007120270A3 (en) * 2005-11-22 2008-02-28 Lilly Co Eli Glucagon receptor antagonists, preparation and therapeutic uses
US9701626B2 (en) 2007-02-09 2017-07-11 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
US10807946B2 (en) 2007-02-09 2020-10-20 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
US10239829B2 (en) 2007-02-09 2019-03-26 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
US9169201B2 (en) 2007-02-09 2015-10-27 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
US8710236B2 (en) 2007-02-09 2014-04-29 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
US8907103B2 (en) 2008-08-13 2014-12-09 Metabasis Therapeutics, Inc. Glucagon antagonists
US11352321B2 (en) 2008-08-13 2022-06-07 Metabasis Therapeutics, Inc. Glucagon antagonists
US10221130B2 (en) 2008-08-13 2019-03-05 Metabasis Therapeutics, Inc. Glucagon antagonists
US9783494B2 (en) 2008-08-13 2017-10-10 Metabasis Therapeutics, Inc. Glucagon antagonists
EP2799428A2 (en) 2008-08-13 2014-11-05 Metabasis Therapeutics, Inc. Glucagon antagonists
WO2011058154A1 (en) * 2009-11-16 2011-05-19 F. Hoffmann-La Roche Ag Biphenyl carboxylic acids and bioisosteres as glycogen synthase activators
JP2014500306A (en) * 2010-12-23 2014-01-09 ファイザー・インク Glucagon receptor modulator
US8809342B2 (en) 2010-12-23 2014-08-19 Pfizer Inc. Glucagon receptor modulators
WO2012085745A1 (en) 2010-12-23 2012-06-28 Pfizer Inc. Glucagon receptor modulators
US8859591B2 (en) 2011-02-08 2014-10-14 Pfizer Inc. Glucagon receptor modulators
US9073871B2 (en) 2011-02-08 2015-07-07 Pfizer Inc. Glucagon receptor modulators
US9452999B2 (en) 2011-02-08 2016-09-27 Pfizer Inc. Glucagon receptor modulators
WO2012107850A1 (en) 2011-02-08 2012-08-16 Pfizer Inc. Glucagon receptor modulator
US8507533B2 (en) 2011-02-08 2013-08-13 Pfizer Inc. Glucagon receptor modulators
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
US9139538B2 (en) 2011-07-22 2015-09-22 Pfizer Inc. Quinolinyl glucagon receptor modulators
WO2013014569A1 (en) 2011-07-22 2013-01-31 Pfizer Inc. Quinolinyl glucagon receptor modulators
WO2013081993A1 (en) 2011-12-02 2013-06-06 Eli Lilly And Company Anti-glucagon antibodies and uses thereof
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US10076504B2 (en) 2014-06-12 2018-09-18 Ligand Pharmaceuticals, Inc. Glucagon antagonists
WO2017093167A1 (en) 2015-12-01 2017-06-08 Basf Se Pyridine compounds as fungicides
WO2017093120A1 (en) 2015-12-01 2017-06-08 Basf Se Pyridine compounds as fungicides
WO2018219725A1 (en) 2017-05-30 2018-12-06 Basf Se Pyridine and pyrazine compounds
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists

Also Published As

Publication number Publication date
JP5000492B2 (en) 2012-08-15
HRP20100148T1 (en) 2010-04-30
PL1758853T3 (en) 2010-06-30
IL179599A0 (en) 2007-05-15
US7816557B2 (en) 2010-10-19
UA86621C2 (en) 2009-05-12
PT1758853E (en) 2010-03-02
IL179599A (en) 2011-11-30
EP1758853B1 (en) 2010-01-20
US20070249688A1 (en) 2007-10-25
EA200700027A1 (en) 2007-06-29
MXPA06014426A (en) 2007-03-01
AU2005254950A1 (en) 2005-12-29
BRPI0512058A (en) 2008-02-06
HK1104174A1 (en) 2008-01-04
CA2569459C (en) 2013-01-29
ES2337596T3 (en) 2010-04-27
NZ551015A (en) 2010-07-30
CN1968921A (en) 2007-05-23
EA013003B1 (en) 2010-02-26
AU2010246329A1 (en) 2010-12-09
JP2008502683A (en) 2008-01-31
ECSP067082A (en) 2007-01-26
CA2569459A1 (en) 2005-12-29
EP2159221A1 (en) 2010-03-03
CN1968921B (en) 2011-11-23
MA28706B1 (en) 2007-06-01
US20100324140A1 (en) 2010-12-23
DK1758853T3 (en) 2010-04-06
CY1109787T1 (en) 2014-09-10
RS51202B (en) 2010-12-31
ZA200610298B (en) 2008-02-27
EP1758853A1 (en) 2007-03-07
ATE455756T1 (en) 2010-02-15
NO20070213L (en) 2007-03-12
US8609892B2 (en) 2013-12-17
SI1758853T1 (en) 2010-05-31
NO341028B1 (en) 2017-08-07
AU2005254950B2 (en) 2010-08-19
DE602005019043D1 (en) 2010-03-11
US20110124648A1 (en) 2011-05-26
KR100835496B1 (en) 2008-06-09
KR20070026585A (en) 2007-03-08

Similar Documents

Publication Publication Date Title
CA2569459C (en) Glucagon receptor antagonists, preparation and therapeutic uses
EP1758859B1 (en) Glucagon receptor antagonists, preparation and therapeutic uses
JP4988604B2 (en) Substituted thiophene derivatives as glucagon receptor antagonists, their preparation and therapeutic use
CA2629223C (en) Glucagon receptor antagonists, preparation and therapeutic uses
EP1951661B1 (en) Glucagon receptor antagonists, preparation and therapeutic uses
CA2629311C (en) Glucagon receptor antagonists, preparation and therapeutic uses
CA2629172C (en) Glucagon receptor antagonists, preparation and therapeutic uses
CA2629321C (en) Glucagon receptor antagonists, preparation and therapeutic uses
EP1951659B1 (en) Glucagon receptor antagonists, preparation and therapeutic uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 551015

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005254950

Country of ref document: AU

Ref document number: 3511/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 179599

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2569459

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 06122207

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2006/10298

Country of ref document: ZA

Ref document number: PA/a/2006/014426

Country of ref document: MX

Ref document number: 200610298

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2005757998

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11570449

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020067026229

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007516542

Country of ref document: JP

Ref document number: 12006502520

Country of ref document: PH

Ref document number: 200580019496.6

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: CR2006-008830

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 2005254950

Country of ref document: AU

Date of ref document: 20050608

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005254950

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: DZP2007000018

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 200700027

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2005757998

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067026229

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 11570449

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0512058

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: P-2010/0134

Country of ref document: RS